<?xml version="1.0" encoding="UTF-8"?>
<rss  version="2.0">
    <channel>
        <title>Parent Project Muscular Dystrophy</title>
        <description>The latest news in Duchenne research, advocacy, care, community, and education. </description>
        <link>http://www.parentprojectmd.org/site/PageServer?pagename=Connect_news</link>
        <docs>http://blogs.law.harvard.edu/tech/rss</docs>
        <lastBuildDate>Tue, 22 Aug 2017 16:25:59 -0400</lastBuildDate>
        <pubDate>Tue, 22 Aug 2017 16:25:49 -0400</pubDate>
        <generator>FeedForAll Mac v2.1 (2.1.0.1); http://www.FeedForAll.com/</generator>
        <item>
            <title>Duchenne Action Month Needs YOU!</title>
            <description>This September, we are asking you, our community, to participate in Duchenne Action Month in order to create awareness, raise money, and make an impact in the fight to #endDuchenne. Check out 10 simple and powerful actions you can take to make an impact this September: www.parentprojectmd.org/actionmonth</description>
            <link>http://www.parentprojectmd.org/actionmonth</link>
            <guid isPermaLink="false">67E2F394-CB0E-4201-AD9C-1D2BA8A6A1C9-3832-000034093FBF2B83-FFA</guid>
            <pubDate>Thu, 03 Aug 2017 16:25:51 -0400</pubDate>
        </item>

        <item>
            <title>How You Can Participate in the Ataluren Ad Comm</title>
            <description>The FDA has announced the scheduling of a September 28th Advisory Committee Meeting for PTC’s therapy ataluren. Whether submitting written testimony and/or attending the Ad Comm in person, there are multiple ways for Duchenne community members in the U.S. and abroad to have an impact and share your personal experience with the Advisory Committee reviewing this product. Visit our blog to learn how you can participate.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/how-you-can-participate-in-the-ataluren-ad-comm</link>
            <guid isPermaLink="false">04BF4215-ACF9-4372-8677-2D068651749B-3832-000032DEF5595507-FFA</guid>
            <pubDate>Tue, 22 Aug 2017 16:06:11 -0400</pubDate>
        </item>

        <item>
            <title>PPMD's Bone Health Workshop Published</title>
            <description>Bone health has long been a confusing and often neglected aspect of Duchenne care. There is very little knowledge of underlying bone health in Duchenne, which is further complicated by the possible effects of glucocorticoids on both bone development and bone density/strength. We applaud the incredible work of this group of experts who participated in PPMD's Bone Health Workshop, and hope that, with increased awareness, further work to prevent osteoporosis and enhance bone health in people living with Duchenne will continue.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-s-bone-health-workshop-published</link>
            <guid isPermaLink="false">DD3ECB2A-E4A9-47C0-891C-517A727C6A79-3832-000033D28A9E08DF-FFA</guid>
            <pubDate>Fri, 18 Aug 2017 16:22:06 -0400</pubDate>
        </item>

        <item>
            <title>PPMD's Every Single [One] Tour: Charleston, WV</title>
            <description>Registration for the next stop on PPMD's Every Single [One] Tour is now open! Combining each of the pillars that make up PPMD's mission -- To #EndDuchenne -- the Every Single [One] Tour brings free day-long meetings featuring updates on research, advocacy, and care to the Duchenne community across the country. We hope to see you in Charleston, WV on September 9!</description>
            <link>http://www.parentprojectmd.org/ESOCharleston</link>
            <guid isPermaLink="false">432CC966-B12D-48E6-A7C1-D76354F31741-3832-000033D7DB7C9484-FFA</guid>
            <pubDate>Thu, 17 Aug 2017 16:22:54 -0400</pubDate>
        </item>

        <item>
            <title>[Webinar] Gene Therapy for Duchenne - August 2017</title>
            <description>Last week, PPMD hosted a webinar focused on understanding the different therapies that are being developed that are commonly referred to as gene therapy, including micro-dystrophin and CRISPR/Cas9, how are they similar and different, and what are the challenges and limitations for each of them. If you missed it, the recording of the webinar is now available!&lt;br /&gt;
COMING SOON: This fall PPMD will be hosting additional webinars with companies and institutions who are developing gene therapies and/or CRISPR/Cas9 for Duchenne. Stay tuned for more details!</description>
            <link>https://youtu.be/N7JYTLMDQhM</link>
            <guid isPermaLink="false">907FE017-85DC-456E-B3E1-19555164D413-3832-000033E762522269-FFA</guid>
            <pubDate>Tue, 22 Aug 2017 16:24:47 -0400</pubDate>
        </item>

        <item>
            <title>Understanding Clinical Trials in Duchenne</title>
            <description>Did you know that there are over 50 clinical trials going on in the US focused on Duchenne &amp; Becker? While having so many clinical trials is exciting, it can also be overwhelming when you are trying to make a decision about if you want to be in a study and if so, which study is the best fit for you and your family. Learn more about the current clinical trial landscape &amp; the PPMD resources that can help you explore clinical trial options.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/celebrating-hope-clinical-trials-in-duchenne?xg_source=facebook</link>
            <guid isPermaLink="false">B4316CCA-446B-4DDA-A618-E177CCB5C14B-3832-000033FD2789C0BA-FFA</guid>
            <pubDate>Mon, 07 Aug 2017 16:25:19 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Nationwide Children’s Hospital Carrier Study</title>
            <description>PPMD recently hosted a webinar for a discussion on the Nationwide Children’s Hospital Carrier Study. </description>
            <link>https://www.youtube.com/watch?v=fGh7gvySU5Q&amp;feature=youtu.be</link>
            <guid isPermaLink="false">0349A2BB-1BF2-49F4-A8BE-B2280229BCBC-14628-0000A110C7B4517F-FFA</guid>
            <pubDate>Tue, 23 May 2017 11:18:12 -0400</pubDate>
        </item>

        <item>
            <title>FDA Pediatric Advisory Committee Unanimously Votes YES — Now Moves to Commissioner</title>
            <description>Today’s Pediatric Advisory Committee Meeting resulted in a unanimous decision from committee members to recommend the use of in-dwelling ports in Sarepta's ESSENCE clinical trial. A final decision will be announced once the Commissioner has reviewed the summary report. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/fda-pediatric-advisory-committee-unanimously-votes-yes-now-moves</link>
            <guid isPermaLink="false">7118F008-27C6-4C4F-BC9C-97C8BC93FC97-14628-0000A0EE73FC1545-FFA</guid>
            <pubDate>Thu, 18 May 2017 11:15:40 -0400</pubDate>
        </item>

        <item>
            <title>Deciphering What We Know About EMFLAZA</title>
            <description>Deciphering What We Know About EMFLAZA</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/deciphering-what-we-know-about-emflaza?xg_source=facebook</link>
            <guid isPermaLink="false">37E7E146-1504-4BD6-856E-7B0AD0D9E447-14628-0000A0EA7128DE9E-FFA</guid>
            <pubDate>Mon, 15 May 2017 11:15:24 -0400</pubDate>
        </item>

        <item>
            <title>ACTION ALERT: Urge Your Senators to Sign the FY18 Duchenne Funding Letter</title>
            <description>ACTION ALERT: Urge Your Senators to Sign the FY18 Duchenne Funding Letter</description>
            <link>http://www.parentprojectmd.org/site/Advocacy?cmd=display&amp;page=UserAction&amp;id=249</link>
            <guid isPermaLink="false">64542FE1-D3AF-4A4E-9B0C-1D03F16CAB32-14628-0000A0E6E9AA7DBD-FFA</guid>
            <pubDate>Mon, 15 May 2017 11:15:10 -0400</pubDate>
        </item>

        <item>
            <title>In Honor of Moms</title>
            <description>This Mother’s Day, thank someone for their role in the fight to end Duchenne. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/in-honor-of-moms?xg_source=activity</link>
            <guid isPermaLink="false">80ED1C37-DCC0-40DC-831A-86FD094FED73-14628-0000A0E360E3C844-FFA</guid>
            <pubDate>Wed, 10 May 2017 11:14:54 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Results from Phase I/II HOPE Clinical Trial of CAP-1002</title>
            <description>PPMD, Coalition Duchenne, and Capricor recently hosted a webinar to hear a community update on the six-month results from Capricor's randomized Phase I/II HOPE Clinical Trial of CAP-1002. </description>
            <link>https://www.youtube.com/watch?v=moxUKI0XIuQ</link>
            <guid isPermaLink="false">87C6F57A-8854-4C78-B29A-A8799C62E0B4-14628-0000A0DF5E8C25D3-FFA</guid>
            <pubDate>Tue, 09 May 2017 11:14:37 -0400</pubDate>
        </item>

        <item>
            <title>PPMD's Response to PTC Announcement of EMFLAZA (deflazacort) Pricing &amp; Access</title>
            <description>Today, PTC Therapeutics provided a community update on EMFLAZA (deflazacort) which they acquired earlier in the year from Marathon Pharmaceuticals. PPMD will continue to monitor and remain engaged in the access environment in order to understand the impact of every new approval, including EMFLAZA, and will update our online Access Resource as information becomes available.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-s-response-to-ptc-announcement-of-emflaza-deflazacort-pricin</link>
            <guid isPermaLink="false">7C96837D-C875-42AF-9E0A-7A5BF8A768F7-14628-0000A0D26E342030-FFA</guid>
            <pubDate>Mon, 08 May 2017 11:13:46 -0400</pubDate>
        </item>

        <item>
            <title>Meet the Race to End Duchenne .1K!</title>
            <description>September is Duchenne Action Month, and now is the time for you to start planning an event than can raise awareness and money, while providing people with an amazing experience that is fun and rewarding…the Race to End Duchenne .1K! </description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Fundraise_wdad_point1k</link>
            <guid isPermaLink="false">B99F40B3-E062-4435-AD01-BD82FCDAEF88-14628-0000A0CA0FB9C5D5-FFA</guid>
            <pubDate>Fri, 05 May 2017 11:13:13 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Givinostat in Duchenne</title>
            <description>PPMD and Italfarmaco recently hosted a webinar to discuss Italfarmaco's investigational drug Givinostat and how it works in Duchenne. </description>
            <link>https://www.youtube.com/watch?v=eWpKTbs4XBM&amp;feature=youtu.be</link>
            <guid isPermaLink="false">C4569EDE-C284-442B-9588-911619106352-14628-0000A0C17C618E1E-FFA</guid>
            <pubDate>Mon, 01 May 2017 11:12:40 -0400</pubDate>
        </item>

        <item>
            <title>FDA Announces Pediatric Advisory Committee Meeting</title>
            <description>On May 18, FDA's Pediatric Advisory Committee will convene to consider the issue of allowing in-dwelling ports in Sarepta’s Essence trial. Details including instructions on submitting both written and oral testimony have now been posted by the FDA. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/fda-announces-pediatric-advisory-committee-meeting-on-may-18</link>
            <guid isPermaLink="false">4BE76B27-C90E-44B1-85F3-4C77D6572838-14628-0000A0BE275F28C7-FFA</guid>
            <pubDate>Mon, 24 Apr 2017 11:12:11 -0400</pubDate>
        </item>

        <item>
            <title>September is Duchenne Action Month!</title>
            <description>Mark your calendars…This year, PPMD is calling on the Duchenne community to save the month of September for Duchenne Action Month! That’s right, this September will be packed full of simple and powerful actions you can take to help raise awareness and support PPMD’s work in the fight to end Duchenne. </description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Connect_wdad</link>
            <guid isPermaLink="false">BB137B75-3443-4C55-BD2A-18F9172E4F5B-14628-0000A0B8094D002F-FFA</guid>
            <pubDate>Wed, 19 Apr 2017 11:11:49 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Designates UC Davis a Certified Duchenne Care Center</title>
            <description>PPMD is excited to announce our 15th Certified Duchenne Care Center  -- UC Davis Department of Physical Medicine and Rehabilitation Neuromuscular Disease Clinic (UC Davis)! </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-designates-uc-davis-a-certified-duchenne-care-center</link>
            <guid isPermaLink="false">08ABA252-950C-4CD3-B47E-350C7F095AED-14628-0000A0B40340FD64-FFA</guid>
            <pubDate>Thu, 06 Apr 2017 11:11:29 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Working with FDA to Plan Landmark Pediatric Advisory Committee Meeting to Improve Clinical Trial Experience</title>
            <description>Later this spring, FDA’s Pediatric Advisory Committee will convene to consider amending the protocol in Sarepta’s Essence trial to allow the use of ports at the discretion of trial participants. If you have experience to lend we will be asking you in the coming weeks to submit your written testimony or join us in person at this Pediatric Ad Comm. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-working-with-fda-to-plan-landmark-pediatric-advisory</link>
            <guid isPermaLink="false">A0BAD7EE-033B-496A-9F79-654FE8817B1C-14628-0000A0AF9855D2EB-FFA</guid>
            <pubDate>Wed, 05 Apr 2017 11:11:11 -0400</pubDate>
        </item>

        <item>
            <title>PPMD's Duchenne Drug Development Roundtable Meeting Series, Part 3: Clinical Trial Readiness from the Viewpoint of Clinicians and Infrastructure</title>
            <description>Our hope is that this meeting, combined with the direction the first two meetings provided, will help us chart a new course and ensure that Duchenne clinical trials are optimized and available to every single one. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-s-duchenne-drug-development-roundtable-meeting-series-part-3</link>
            <guid isPermaLink="false">90C9CE86-67BE-4979-ADB3-F8A70EA22A4F-14628-0000A0A934E73E69-FFA</guid>
            <pubDate>Wed, 05 Apr 2017 11:10:41 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Akashi Provides Update on HT-100</title>
            <description>PPMD and Akashi Therapeutics recently hosted a webinar to discuss HT-100 and next steps for the clinical program.</description>
            <link>https://www.youtube.com/watch?v=PQb-FXrwynI&amp;feature=youtu.be</link>
            <guid isPermaLink="false">0BF5714C-0790-4587-BAB9-91AAFBE98096-14628-0000A0894B1F7609-FFA</guid>
            <pubDate>Wed, 29 Mar 2017 11:08:45 -0400</pubDate>
        </item>

        <item>
            <title>Upcoming Webinar: Akashi Provides Update on HT-100</title>
            <description>Join PPMD and Akashi Therapeutics as we host a webinar Monday, March 27 at 1:30 PM ET to discuss HT-100 and next steps for the clinical program.</description>
            <link>http://community.parentprojectmd.org/events/upcoming-webinar-akashi-provides-update-on-ht-100</link>
            <guid isPermaLink="false">0D9D069E-61AF-434F-88F1-0DED2D7718CC-22732-00009EC4BD62448B-FFA</guid>
            <pubDate>Thu, 23 Mar 2017 11:54:57 -0400</pubDate>
        </item>

        <item>
            <title>Action Alert: Make Your Voice Heard on New Healthcare Proposal</title>
            <description>Urge Congress to protect the Duchenne community's healthcare priorities.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/action-alert-make-your-voice-heard-on-new-healthcare-proposal</link>
            <guid isPermaLink="false">7545A917-69D7-4013-B189-F277A271A32B-22732-00009EC1685AF11D-FFA</guid>
            <pubDate>Tue, 28 Mar 2017 11:54:47 -0400</pubDate>
        </item>

        <item>
            <title>Action Alert: Urge Your Representative to Sign the FY 18 Duchenne Appropriations Letter</title>
            <description>This action is critical to help ensure the agencies that impact Duchenne receive the funding they need to concentrate on the needs of our community.</description>
            <link>http://www.parentprojectmd.org/site/Advocacy?cmd=display&amp;page=UserAction&amp;id=244</link>
            <guid isPermaLink="false">5D773F53-028E-4A9D-A54A-4EB36DEB104B-22732-00009EBBF8A11958-FFA</guid>
            <pubDate>Mon, 20 Mar 2017 11:54:26 -0400</pubDate>
        </item>

        <item>
            <title>PTC Therapeutics Announces Agreement to Acquire Emflaza™ (deflazacort)</title>
            <description>Today we learned that PTC Therapeutics has entered into an asset purchase agreement with Marathon Pharmaceuticals, LLC to acquire all rights to Emflaza™ (deflazacort). Emflaza is the first treatment approved in the United States for all Duchenne patients five years and older, regardless of their genetic mutation.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ptc-therapeutics-announces-agreement-to-acquire-emflazam-deflazac</link>
            <guid isPermaLink="false">D01BC023-5568-443E-8B38-614962218F85-22732-00009EB8E296CCAF-FFA</guid>
            <pubDate>Thu, 16 Mar 2017 11:54:05 -0400</pubDate>
        </item>

        <item>
            <title>Registration Now Open for PPMD's 2017 Connect Conference in Chicago, June 29 - July 2!</title>
            <description></description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_2017</link>
            <guid isPermaLink="false">292B17CC-81A2-4DAB-98B0-ABA469FFABE4-22732-00009EB6BB613E29-FFA</guid>
            <pubDate>Tue, 14 Mar 2017 11:53:52 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Idebenone Clinical Trials in Duchenne</title>
            <description>PPMD and Santhera Pharmaceuticals recently hosted a webinar to discuss idebenone clinical trials in Duchenne.</description>
            <link>https://www.youtube.com/watch?v=1hrtoDDncrM</link>
            <guid isPermaLink="false">2D1D2B71-C6B9-4B7B-ADA0-C3A5C8EAAE93-22732-00009EB2F5F3F8BF-FFA</guid>
            <pubDate>Mon, 13 Mar 2017 11:53:38 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: NS Pharma's Exon 53 Skipping Program</title>
            <description>PPMD and NS Pharma recently hosted a webinar to provide an update on trial recruitment for NS Pharma's Exon 53 Skipping Program.</description>
            <link>https://www.youtube.com/watch?v=iVnZ-PLoDfs</link>
            <guid isPermaLink="false">EFA63D6B-4AD7-4199-8965-6FE381953C74-22732-00009EADD1A46A22-FFA</guid>
            <pubDate>Mon, 27 Feb 2017 10:53:20 -0500</pubDate>
        </item>

        <item>
            <title>Duchenne Research Update: February 2017</title>
            <description>Take a closer look at some of the incredible progress Duchenne research has made only two months into 2017. PPMD's SVP of Research Strategy, Abby Bronson, provides a snapshot of the Duchenne pipeline, including updates on therapies in development and PPMD's latest funding news.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/duchenne-research-update-february-2017</link>
            <guid isPermaLink="false">2860CCE6-D0DA-492C-8525-BAD29B0CBE07-22732-00009EAAAA924CA4-FFA</guid>
            <pubDate>Fri, 24 Feb 2017 10:53:03 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Designates Lurie Children's a Certified Duchenne Care Center</title>
            <description>PPMD is excited to announce our 14th Certified Duchenne Care Center -- Ann &amp; Robert H. Lurie Children’s Hospital of Chicago! </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-designates-ann-robert-h-lurie-children-s-hospital-of-chicago</link>
            <guid isPermaLink="false">D9EA5E32-683B-4C42-9294-68DBBD14EF3E-22732-00009EA615C17A05-FFA</guid>
            <pubDate>Thu, 16 Feb 2017 10:52:46 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Recommends Marathon Convene Broad Array of Duchenne Stakeholders to Discuss Re-evaluation of Deflazacort Pricing</title>
            <description>In light of the pause in commercialization of EMFLAZA™ (deflazacort) by Marathon Pharmaceuticals earlier this week, PPMD recommends that Marathon seek input from a broad array of stakeholders including Duchenne clinicians, health insurance plans, pharmacy benefit managers, and Duchenne advocacy groups. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-recommends-marathon-convene-broad-array-of-duchenne-stakehol</link>
            <guid isPermaLink="false">62678FAD-4FF8-4A36-A6C1-DB04916B84FA-22732-00009EA2AB03A25B-FFA</guid>
            <pubDate>Wed, 15 Feb 2017 10:52:29 -0500</pubDate>
        </item>

        <item>
            <title>Urge Congress to Protect Duchenne Community's Healthcare Priorities</title>
            <description>This week, PPMD advocates from across the country are storming Capitol Hill to ensure legislators make Duchenne and rare disease a priority. This year’s agenda includes urging Congress NOT to repeal the Patient Protection and Affordable Care Act until there is a guarantee that people with Duchenne will continue to have access to equal or better coverage. Please take a moment today to tell Congress why this matters so much to our community!</description>
            <link>http://www.parentprojectmd.org/takeaction</link>
            <guid isPermaLink="false">A201F424-70B5-434C-B2E4-3B3305170522-22732-00009E9DB020F052-FFA</guid>
            <pubDate>Tue, 14 Feb 2017 10:52:11 -0500</pubDate>
        </item>

        <item>
            <title>Marathon Pharmaceuticals Update on EMFLAZA™ (deflazacort)</title>
            <description>Marathon has announced that they will pause the commercialization of their recently FDA-approved steroid EMFLAZA™ (deflazacort). This pause will allow Marathon to consider the feedback they have received from the community since last week’s announcement regarding pricing and potential for combining this therapy with other approved drugs in the future. Marathon has assured families that during this pause, access to deflazacort will not be disrupted.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/marathon-pharmaceuticals-update-on-emflazam-deflazacort?xg_source=nws_index</link>
            <guid isPermaLink="false">EA6F1559-B3B0-4BF6-B802-BF97FD8B4821-22732-00009E98637C4422-FFA</guid>
            <pubDate>Mon, 13 Feb 2017 10:51:49 -0500</pubDate>
        </item>

        <item>
            <title>Deflazacort Approved in the U.S. for Duchenne</title>
            <description>Today, the FDA approved EMFLAZA™ (deflazacort) for Duchenne. This is the first approval of a steroid for Duchenne and a therapy that applies to people with Duchenne 5 years of age and older, regardless of genetic mutation. Representatives from Marathon Pharmaceuticals will be joining us for a webinar Friday, February 10th at 12 PM EST to provide information about EMFLAZA’s FDA-approved label, patient support services, and access to this medication.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/deflazacort-approved-in-the-u-s-for-duchenne?xg_source=nws_index</link>
            <guid isPermaLink="false">894BAB2C-589C-4D2F-B39D-A51B66B544D5-22732-00009E94EE7FCB50-FFA</guid>
            <pubDate>Thu, 09 Feb 2017 10:51:29 -0500</pubDate>
        </item>

        <item>
            <title>PPMD to Host Forum on Access to Emerging Therapies on February 13th, 2017</title>
            <description>Following decades of strategic advocacy, research investment, and biopharmaceutical development, the U.S. Duchenne community recently arrived in the post-approval space and is poised to receive additional novel therapies from a robust innovation pipeline. PPMD is engaged on behalf of families nationwide as industry sponsors work with the FDA to navigate the critical regulatory steps. We are also working now within the access environment to help ensure that families have timely access to these disease-modifying medications. It is our hope that this Forum will be an important step in helping to continue to empower our Duchenne community and our partners to navigate the regulatory and approval pathways necessary to achieve desired levels of clinical treatments and care appropriate for themselves/their children.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-to-host-forum-on-access-to-emerging-therapies-on-february-13?xg_source=rss</link>
            <guid isPermaLink="false">7EC7F38C-6AC8-4CE0-A3EF-DD6F36D3E1D8-6396-0000371F63C26304-FFA</guid>
            <pubDate>Tue, 07 Feb 2017 16:05:30 -0500</pubDate>
        </item>

        <item>
            <title>[Webinar Recording] MoveDMD Trial: Catabasis Provides Update</title>
            <description>The Catabasis team recently joined us to discuss what they have learned from Part B of the MoveDMD® trial of edasalonexent (CAT-1004) in Duchenne and what comes next in the MoveDMD program.</description>
            <link>https://www.youtube.com/watch?v=eoiJHVcDuqw</link>
            <guid isPermaLink="false">E24B4A92-CC21-4B2B-B4F4-836C2F6D714D-31716-0000E8D3FF778CD2-FFA</guid>
            <pubDate>Mon, 06 Feb 2017 13:11:08 -0500</pubDate>
        </item>

        <item>
            <title>[Webinar Recording] Mission DMD: FibroGen’s Anti-Fibrosis Program</title>
            <description>FibroGen recently joined us for a webinar discussion on the company's investigational drug Pamrevlumab (FG-3019), along with FibroGen’s Mission DMD program that is currently being conducted to investigate Pamrevlumab in Duchenne.</description>
            <link>https://www.youtube.com/watch?v=fk9GHdBeLuA</link>
            <guid isPermaLink="false">19417D6B-3DDB-4917-BF8D-81E57D36E05A-31716-0000E8CFA7FD2A19-FFA</guid>
            <pubDate>Fri, 03 Feb 2017 01:10:48 -0500</pubDate>
        </item>

        <item>
            <title>Registration for our 2018 Walt Disney World Marathon Weekend team is now open!</title>
            <description>2018 marks the 25th anniversary of the Full Marathon, with lots of other fun race distances available too. It's the biggest and best marathon weekend of the year for our Run For Our Sons team, and spots are filling up fast. Don't miss out on this magical weekend!</description>
            <link>http://www.parentprojectmd.org/disneyworld2018</link>
            <guid isPermaLink="false">B4E6958B-5757-4016-966D-95D82F494895-31716-0000E8C9A0F97FA9-FFA</guid>
            <pubDate>Thu, 02 Feb 2017 13:10:28 -0500</pubDate>
        </item>

        <item>
            <title>PPMD’s Duchenne Drug Development Roundtable: Bringing Industry Together to Accelerate Research</title>
            <description>Today is the first of PPMD's Duchenne Drug Development Roundtable (DDDR) three-meeting series to address clinical trial challenges and opportunities within our Duchenne space.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-s-duchenne-drug-development-roundtable-bringing-industry?xg_source=nws_index</link>
            <guid isPermaLink="false">5359CC37-EFE5-4197-B295-90BBBFF1BF1A-31716-0000E8BC3155C2DC-FFA</guid>
            <pubDate>Wed, 01 Feb 2017 13:09:59 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Awards $250,000 Grant to UT Southwestern Medical Center to Explore CRISPR/Cas9 Technology</title>
            <description>This grant, part of PPMD’s Gene Transfer Initiative, will support Dr. Olson’s ongoing study of CRISPR/Cas9 technology as a potential treatment for Duchenne</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-awards-250-000-grant-to-ut-southwestern-medical-center-to?xg_source=nws_index</link>
            <guid isPermaLink="false">31BC6939-F8BA-4338-8F08-DC63544767D2-13214-00007543DF1AACB1-FFA</guid>
            <pubDate>Mon, 30 Jan 2017 13:45:22 -0500</pubDate>
        </item>

        <item>
            <title>[Webinar Recording] Summit's Utrophin Modulation Program</title>
            <description>Summit joined us earlier this week for an educational webinar on utrophin modulation, an approach for Duchenne that has the potential to treat all patients.</description>
            <link>https://www.youtube.com/watch?v=PajrkndUgPQ</link>
            <guid isPermaLink="false">F7B47F98-EE56-49B6-B5E1-11B73E7A047E-13214-0000753AE3BD25F1-FFA</guid>
            <pubDate>Fri, 27 Jan 2017 13:44:47 -0500</pubDate>
        </item>

        <item>
            <title>[Webinar Recording] Vamorolone (VBP15) Clinical Trials in Duchenne</title>
            <description>ReveraGen BioPharma CEO Dr. Eric Hoffman joined us earlier this week for a webinar discussion on vamorolone (VBP15) clinical trials in Duchenne. </description>
            <link>https://www.youtube.com/watch?v=h1owg21J0Wc</link>
            <guid isPermaLink="false">89BFD8CF-07B0-428B-B44E-35CFA6148F51-13214-0000752D5B6ED887-FFA</guid>
            <pubDate>Fri, 20 Jan 2017 13:43:50 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Designates Yale New Haven Children's Hospital a Certified Duchenne Care Center</title>
            <description>PPMD is excited to announce our 13th Certified Duchenne Care Center (CDCC) the Yale New Haven Children's Hospital's Muscular Dystrophy Program! </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-designates-yale-new-haven-children-s-hospital-a-certified-du?xg_source=nws_index</link>
            <guid isPermaLink="false">707BDBC1-FE46-4A84-8567-7EE3B9B92EC7-13214-0000752961CFE5DF-FFA</guid>
            <pubDate>Thu, 19 Jan 2017 13:43:32 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Awards $600,000 Grant to NJIT &amp; Talem for Next Phase of Upper Extremity Exoskeleton</title>
            <description>PPMD has awarded a $600,000 grant to the New Jersey Institute of Technology (NJIT) and Talem Technologies as part of our ongoing exploration of robotic technology to assist people living with Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-awards-njit-and-talem-technologies-600-000-grant-exoskeleton</link>
            <guid isPermaLink="false">D0B311ED-DE9A-4DAB-B3E4-26A9640D53A9-13214-000075242A672935-FFA</guid>
            <pubDate>Wed, 18 Jan 2017 13:43:14 -0500</pubDate>
        </item>

        <item>
            <title>New Resource to Help Navigate EXONDYS 51 Access</title>
            <description>Dr. Craig McDonald of UC Davis has shared data and an accompanying presentation to serve as a resource for families who have received an EXONDYS 51 denial from their insurance company and are working to appeal the decision. You should insist that both your clinician and insurance company review this data and presentation.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/new-resource-to-help-navigate-exondys-51-access?xg_source=nws_index</link>
            <guid isPermaLink="false">F96C5CAC-2F31-47D4-B353-158D397D1848-13214-00007520E180B4F8-FFA</guid>
            <pubDate>Fri, 13 Jan 2017 13:42:55 -0500</pubDate>
        </item>

        <item>
            <title>New Research &amp; Clinical Trial Tools on DuchenneConnect</title>
            <description>We are excited to announce three new tools now available on PPMD's DuchenneConnect! These tools are meant to help you in your journey as you gather information around potential research studies and potential new exon skipping therapies.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/new-research-clinical-trial-tools-on-ppmd-s-duchenneconnect?xg_source=nws_index</link>
            <guid isPermaLink="false">99037FEE-66E0-4889-98FE-1235E142115A-13214-00007511FFAB9499-FFA</guid>
            <pubDate>Thu, 12 Jan 2017 13:42:11 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Awards $2.2 Million Grant to Explore Gene Therapy in Duchenne</title>
            <description>PPMD has announced a $2.2 million dollar grant to Dr. Jerry Mendell, Dr. Louise Rodino-Klapac (co-PI), and Nationwide Children’s Hospital. This grant is the first project of a new Gene Transfer Initiative PPMD is launching this month that will include the work Dr. Mendell and Dr. Rodino-Klapac are doing, as well as a deeper exploration of CRISPR/Cas9 technology as a potential therapeutic approach to treating Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-awards-nationwide-children-s-hospital-2-2-million-grant-to?xg_source=nws_index</link>
            <guid isPermaLink="false">A074A4CF-94DB-4149-8E88-0165A12638FA-13214-0000750B8361C5F5-FFA</guid>
            <pubDate>Fri, 06 Jan 2017 13:41:31 -0500</pubDate>
        </item>

        <item>
            <title>Two simple words...THANK YOU!</title>
            <description>We could not be more overwhelmed by the incredible response to our holiday campaign. Thanks to this community, we head into 2017 with incredible momentum—and the funds to move CRISPR/Cas9 research forward. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/two-simple-words-thank-you?xg_source=nws_index</link>
            <guid isPermaLink="false">8DA42803-8960-449B-9115-A435FE0DAE6F-28178-0000F814DA5A7452-FFA</guid>
            <pubDate>Wed, 04 Jan 2017 15:58:17 -0500</pubDate>
        </item>

        <item>
            <title>What You Need to Know about Duchenne and Viral Gastroenteritis (That Horrible Stomach Bug!)</title>
            <description>Viral gastroenteritis — often called the stomach flu — isn't fun for anyone, but it is especially worrisome for a person living with Duchenne muscular dystrophy. Our latest blog explains what you should do if a person with Duchenne contracts the virus, as well as what you can do to stay as healthy as possible. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/duchenne-and-viral-gastroenteritis-that-horrible-stomach-bug</link>
            <guid isPermaLink="false">1C291F0F-9744-46C1-A740-B0A43BE5E8F2-27442-0000F4AF84162FA3-FFA</guid>
            <pubDate>Wed, 04 Jan 2017 15:58:05 -0500</pubDate>
        </item>

        <item>
            <title>How PPMD’s Certified Duchenne Care Centers Are Improving Quality &amp; Access to Care</title>
            <description>People with Duchenne are being cared for by clinics both near and far. Every one of them deserves the best care and treatment possible. Learn how PPMD’s Certified Duchenne Care Center program is making comprehensive Duchenne care more accessible and available for our families.&lt;br /&gt;
</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/how-ppmd-s-certified-duchenne-care-centers-are-improving-quality</link>
            <guid isPermaLink="false">1D51A4F1-373C-4377-BFBB-0E06EC5A2F32-27442-0000F4AB4C59C124-FFA</guid>
            <pubDate>Wed, 28 Dec 2016 14:55:48 -0500</pubDate>
        </item>

        <item>
            <title>Understanding the Path to Access -- Resources for Families</title>
            <description>We have all had frustrations getting healthcare paid for. Coverage can be especially difficult when new medicines or procedures are recommended. PPMD has assembled resources to help families and medical providers at each stage of the healthcare access process. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/understanding-the-path-to-access-resources-for-families</link>
            <guid isPermaLink="false">9B75F384-B363-40C6-B77A-F350E9A3FBBB-27442-0000F4A7A27259BF-FFA</guid>
            <pubDate>Mon, 19 Dec 2016 14:55:29 -0500</pubDate>
        </item>

        <item>
            <title>Webinar Recording: A Closer Look at the Potential of CRISPR/Cas9 in Duchenne</title>
            <description>PPMD recently hosted a webinar with Dr. Eric Olson from the Department of Molecular Biology at UT Southwestern Medical Center to review the basics of gene editing and next steps in the research and development potential of CRISPR/Cas9 in Duchenne. </description>
            <link>https://youtu.be/JixhyD1MrYg</link>
            <guid isPermaLink="false">AFDE475D-09B5-4183-849D-4B3EB86C7AF5-27442-0000F4A3E23A2423-FFA</guid>
            <pubDate>Mon, 19 Dec 2016 14:55:12 -0500</pubDate>
        </item>

        <item>
            <title>The Killian Family Will Match Your Gift!</title>
            <description>The Killian family is matching every online donation to PPMD until we’ve raised $250,000! Your gift will help PPMD fund important research into CRISPR/Cas9, but we have to reach this goal by 12/31—please donate today!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/i-will-match-your-gift</link>
            <guid isPermaLink="false">9B6256DB-B280-475B-AC90-C24F71BF7700-27442-0000F49FAD9182B9-FFA</guid>
            <pubDate>Tue, 13 Dec 2016 14:54:56 -0500</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Seizing the moment</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=25905.0</link>
            <guid isPermaLink="false">5CEDB62A-B6A8-4839-83C7-3ADE0BC9E9B9-27442-0000F49BDCC52354-FFA</guid>
            <pubDate>Fri, 09 Dec 2016 14:54:39 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Is Seizing This Moment to Explore the Potential of CRISPR/Cas9 in Duchenne</title>
            <description>CRISPR/Cas9 gene-editing technology shows incredible promise to target and modify DNA. PPMD is working with researchers to better understand the potential of CRISPR/Cas9 technology in Duchenne. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/crispr?xg_source=nws_index</link>
            <guid isPermaLink="false">95C07AA1-4E73-40A3-BF1F-4F38EC17F549-27442-0000F495ABB59F9B-FFA</guid>
            <pubDate>Fri, 09 Dec 2016 14:54:13 -0500</pubDate>
        </item>

        <item>
            <title>BREAKING NEWS: 21st Century Cures Crossed Over the Finish Line!</title>
            <description>To everyone in our PPMD community who called, reached out, emailed, and met with your elected officials -- WE DID IT!! We are thrilled that Congress has passed the 21st Century Cures bill which includes almost every provision that our Duchenne community championed and led throughout this process.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/breaking-news-21st-century-cures-crossed-over-the-finish-line</link>
            <guid isPermaLink="false">31598333-7959-4E20-B6AE-0E3CCCAC762E-27442-0000F48F5D6951F7-FFA</guid>
            <pubDate>Wed, 07 Dec 2016 14:54:00 -0500</pubDate>
        </item>

        <item>
            <title>[Upcoming Webinar] A Closer Look at the Potential of CRISPR/Cas9 in Duchenne</title>
            <description>Building on our introductory webinar on CRISPR/Cas9 that we held over the summer, join us Thursday, December 15 at 2:00 PM ET for our second webinar on this exciting technology.</description>
            <link>http://community.parentprojectmd.org/events/upcoming-webinar-a-closer-look-at-the-potential-of-crispr-cas9-in?xg_source=nws_index</link>
            <guid isPermaLink="false">7C88A5FD-5407-43B0-B65C-FF4B5819D6DA-56381-0001765CA332E20B-FFA</guid>
            <pubDate>Tue, 06 Dec 2016 11:42:20 -0500</pubDate>
        </item>

        <item>
            <title>Your gift to CRISPR will be Matched!</title>
            <description>There has never been so much momentum in this community. Help us seize this moment by donating toward CRISPR/CAS9 research-- every gift will be doubled! </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/your-gift-to-crispr-will-be-matched?xg_source=nws_index</link>
            <guid isPermaLink="false">21824387-B1EC-4E88-8D76-C1AEB21EC234-56381-00017659B44FBDC9-FFA</guid>
            <pubDate>Thu, 01 Dec 2016 11:42:05 -0500</pubDate>
        </item>

        <item>
            <title>Action Alert: Urge Senate to Vote ‘YES’ on 21st Century Cures Act!</title>
            <description>Please contact your two US Senators today with one simple message—vote YES on 21st Century Cures!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/light-up-the-lines-urge-your-senators-to-vote-yes-on-21st-century</link>
            <guid isPermaLink="false">3FF22FF4-3C69-43F9-871F-27D051A60D27-56381-000176529AA0330B-FFA</guid>
            <pubDate>Mon, 05 Dec 2016 11:41:40 -0500</pubDate>
        </item>

        <item>
            <title>A truly thankful moment</title>
            <description>A truly thankful moment</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/a-truly-thankful-moment?xg_source=activity</link>
            <guid isPermaLink="false">0BC3C68B-C446-41DF-891B-7BEFF0244371-56381-0001764E09866FA2-FFA</guid>
            <pubDate>Thu, 24 Nov 2016 11:41:19 -0500</pubDate>
        </item>

        <item>
            <title>[Webinar Recording] NS Pharma's Exon 53 Skipping Program</title>
            <description>PPMD recently hosted webinar with NS Pharma (US subsidiary of Nippon Shinyaku, Co.,Ltd) to discuss NS Pharma's Exon 53 Skipping Program.</description>
            <link>https://www.youtube.com/watch?v=qvWtFM_LlWA</link>
            <guid isPermaLink="false">AEA182F4-A929-4AFA-9FAC-5791DC3AC3AC-56381-00017649935086AF-FFA</guid>
            <pubDate>Tue, 22 Nov 2016 11:41:00 -0500</pubDate>
        </item>

        <item>
            <title>[Webinar Recording] Deflazacort Access: Navigating Potential Changes to Your Prescription</title>
            <description>PPMD recently hosted a webinar with Masters Pharmaceuticals to discuss the transition from Masters’ deflazacort to Marathon Pharmaceuticals deflazacort, should Marathon receive FDA approval in the U.S. </description>
            <link>https://www.youtube.com/watch?v=2E6s_lwQ74s</link>
            <guid isPermaLink="false">FF049C97-D264-43C1-AEA5-299504ABF057-56381-0001764648387F73-FFA</guid>
            <pubDate>Fri, 18 Nov 2016 11:40:43 -0500</pubDate>
        </item>

        <item>
            <title>Action Alert: Tell Congress to Pass 21st Century Cures!</title>
            <description>On November 15th, rare disease advocates from across the country will be flooding Congressional inboxes and phone lines with one message: Pass 21st Century Cures in this Congress. Please consider taking action Tuesday and all week! Otherwise the work we’ve done over the past two years will be lost and the process will begin again in a new Congress.</description>
            <link>http://www.parentprojectmd.org/site/Advocacy?cmd=display&amp;page=UserAction&amp;id=231</link>
            <guid isPermaLink="false">654F534A-F8A3-470B-B3B4-89E40B74BEAC-551-000000D6622F9AF5-FFA</guid>
            <pubDate>Tue, 15 Nov 2016 16:57:34 -0500</pubDate>
        </item>

        <item>
            <title>Duchenne Carrier Study at Nationwide Children’s Hospital</title>
            <description>PPMD is excited to support this important study that will evaluate the effects of a lower level of dystrophin in female carriers. We hope the results of this study will help us better understand the implications of being a Duchenne carrier, and possibly apply some of the answers to our understanding of Duchenne in males.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/duchenne-carrier-study-at-nationwide-children-s-hospital</link>
            <guid isPermaLink="false">7262CE38-1BBE-4D24-BC6D-C585D593FD52-551-000000CBB0D96C81-FFA</guid>
            <pubDate>Mon, 14 Nov 2016 16:57:01 -0500</pubDate>
        </item>

        <item>
            <title>Registration for the 2017 Bank of America Chicago Marathon is now open!</title>
            <description>Join PPMD's Run For Our Sons team for the 40th anniversary of this incredible race, on Sunday, November 4, 2017. Our entries are only available until January 18th, so sign up soon! </description>
            <link>http://www.parentprojectmd.org/site/TR?fr_id=4452&amp;pg=entry</link>
            <guid isPermaLink="false">E727BE78-7274-418E-9F21-134C856AD0FB-551-000000C571AE9FC9-FFA</guid>
            <pubDate>Wed, 02 Nov 2016 16:56:30 -0400</pubDate>
        </item>

        <item>
            <title>Understanding Insurance Determinations</title>
            <description>PPMD’s Annie Kennedy provides an update on our Duchenne community’s current access environment, and actions that those who are amenable to exon 51 skipping can take in order to encourage their providers to cover EXONDYS 51. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/understanding-insurance-determinations</link>
            <guid isPermaLink="false">96D24A73-79B7-4715-9CA6-0861E6339376-551-000000C0781A2901-FFA</guid>
            <pubDate>Wed, 02 Nov 2016 16:56:05 -0400</pubDate>
        </item>

        <item>
            <title>Deflazacort Access: Navigating Potential Changes to Your Prescription</title>
            <description>PPMD has put together a resource we hope will answer some of the questions that have arisen regarding the potential FDA approval of deflazacort in the U.S. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/deflazacort-access-navigating-potential-changes-to-your</link>
            <guid isPermaLink="false">864F0A00-B89C-4C8B-8128-9BB88BBB56FC-551-000000BB00DD1AB1-FFA</guid>
            <pubDate>Mon, 31 Oct 2016 17:55:38 -0400</pubDate>
        </item>

        <item>
            <title>The Assistance Fund Launches Duchenne Program to Support Access to Exondys 51</title>
            <description>The Assistance Fund has launched a new program in Duchenne to support access to Exondys 51 after efforts through SareptAssist have been other-wise exhausted. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-assistance-fund-launches-duchenne-program-to-support-access</link>
            <guid isPermaLink="false">B48DEACB-EF1F-4B59-B899-F6EE1D0FC963-551-000000B5F7F38C9C-FFA</guid>
            <pubDate>Fri, 28 Oct 2016 17:55:17 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Designates Center for Duchenne Muscular Dystrophy at UCLA, a Certified Duchenne Care Center</title>
            <description>Our Duchenne families in Los Angeles are extremely fortunate to have this team of dedicated clinicians and researchers at UCLA. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-designates-center-for-duchenne-muscular-dystrophy-at-ucla-a</link>
            <guid isPermaLink="false">C9D038F8-5987-4DE0-97AA-C0143E984248-551-000000B0929D957F-FFA</guid>
            <pubDate>Wed, 26 Oct 2016 17:54:53 -0400</pubDate>
        </item>

        <item>
            <title>The Latest Update on Translarna</title>
            <description>PPMD continues to believe that our Duchenne community deserves a full and fair review of the Translarna data by scientific experts at an Advisory Committee Meeting. If you have any experience on Translarna, or are waiting for access to Translarna, please share your experience with us so that we can translate your story into rigorous data that can be shared with FDA.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-latest-update-from-translarna</link>
            <guid isPermaLink="false">CFB6BF73-0C39-491F-94B2-BDD8228C71D9-551-000000AAB4119805-FFA</guid>
            <pubDate>Wed, 26 Oct 2016 17:54:32 -0400</pubDate>
        </item>

        <item>
            <title>Register for PPMD's 2017 Advocacy Conference</title>
            <description>Your presence in Washington, DC this February is a critical part of the Duchenne community's strength and impact going forward. Please consider joining us February 12-14 as we urge Congress to continue to make Duchenne a priority!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/register-for-ppmd-s-2017-advocacy-conference-february-12-14-in</link>
            <guid isPermaLink="false">0D599F2E-742C-4D39-9479-79ADB3ABF9CD-551-0000009A815F3F44-FFA</guid>
            <pubDate>Thu, 20 Oct 2016 17:53:54 -0400</pubDate>
        </item>

        <item>
            <title>Duchenne Research Update: October 2016</title>
            <description>So much has happened in recent weeks in the Duchenne space that it can be hard to keep up. PPMD’s Abby Bronson, SVP, Research Strategy provides a roundup of the latest Duchenne research news.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/duchenne-research-update-october-2016</link>
            <guid isPermaLink="false">01CBC18B-7F7C-4341-95F1-BC62BB5EAB74-551-00000095213B8306-FFA</guid>
            <pubDate>Tue, 18 Oct 2016 16:53:16 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Demands Anthem Reconsider Coverage of Approved Drug</title>
            <description></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-demands-anthem-reconsider-coverage-of-approved-drug</link>
            <guid isPermaLink="false">720C9179-B0D2-4793-93CD-D5307E225BF4-551-00000090D68F0039-FFA</guid>
            <pubDate>Fri, 14 Oct 2016 17:52:30 -0400</pubDate>
        </item>

        <item>
            <title>Connect with PPMD in 2017</title>
            <description></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/connect-with-ppmd-in-2017</link>
            <guid isPermaLink="false">7F0C3124-450A-43CE-BC41-A3C9A963A323-551-0000008AF87264EA-FFA</guid>
            <pubDate>Fri, 14 Oct 2016 17:52:10 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Awards $239,000 Research Grant to Dr. Terence Partridge of Children’s National Medical Center</title>
            <description></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-awards-239-000-research-grant-to-dr-terence-partridge-of-chi</link>
            <guid isPermaLink="false">E0B6584D-2AE0-430E-97EE-C472E9C5A2FE-551-00000086A080F0FD-FFA</guid>
            <pubDate>Fri, 18 Nov 2016 16:51:56 -0500</pubDate>
        </item>

        <item>
            <title>Calling All Adults with Duchenne/Becker – Join the 2017 PPMD Adult Advisory Committee (PAAC)!</title>
            <description></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/calling-all-adults-with-duchenne-becker-join-the-2017-ppmd-adult</link>
            <guid isPermaLink="false">DD2B3B99-3249-4154-8728-A441DE45B43A-551-000000824320BD74-FFA</guid>
            <pubDate>Fri, 18 Nov 2016 16:51:38 -0500</pubDate>
        </item>

        <item>
            <title>[Webinar Takeaways] Preparing for Access to Approved Therapies</title>
            <description></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/webinar-takeaways-preparing-for-access-to-approved-therapies</link>
            <guid isPermaLink="false">A5B7CCE5-173B-43A6-B55E-1C649C780544-551-0000007E0082433F-FFA</guid>
            <pubDate>Fri, 18 Nov 2016 16:51:19 -0500</pubDate>
        </item>

        <item>
            <title>Anthem and Exondys 51 (Eteplirsen)</title>
            <description></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/anthem-denies-coverage-for-exondys-51-eteplirsen</link>
            <guid isPermaLink="false">8301532B-769F-47E0-B96D-376AE3A833B8-551-00000074779EF893-FFA</guid>
            <pubDate>Fri, 18 Nov 2016 16:51:01 -0500</pubDate>
        </item>

        <item>
            <title>[Webinar Recording] SareptAssist Patient Services Overview</title>
            <description></description>
            <link>https://www.youtube.com/watch?v=yQfWVM-PsTY</link>
            <guid isPermaLink="false">69BAC32F-3889-4D31-AAAA-0C52B9A92B97-551-0000006F4901EC6E-FFA</guid>
            <pubDate>Mon, 03 Oct 2016 17:50:20 -0400</pubDate>
        </item>

        <item>
            <title>FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy!</title>
            <description>PPMD is beyond thrilled at today’s historic news from the FDA announcing the accelerated approval of Sarepta Therapeutic’s eteplirsen, now the first approved drug for Duchenne in the U.S.! Eteplirsen is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/fda-grants-accelerated-approval-to-first-drug-for-duchenne</link>
            <guid isPermaLink="false">CACD2BC1-3D8E-4B1A-A724-B6A4D96EF4E5-21450-0000A12DBAACF664-FFA</guid>
            <pubDate>Mon, 19 Sep 2016 11:38:22 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Continues to Lead Work on Critical Duchenne Access Issues</title>
            <description>With the promise of drug approvals on the horizon, access to these therapies will be critical to our Duchenne community. PPMD has been leading work related to access issues on multiple fronts.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-continues-to-lead-work-on-critical-duchenne-access-issues</link>
            <guid isPermaLink="false">E6CAC582-8670-4D66-8CE3-110F62678817-21450-0000A128F1CBEC7B-FFA</guid>
            <pubDate>Thu, 15 Sep 2016 11:38:03 -0400</pubDate>
        </item>

        <item>
            <title>Action Alert: 21st Century Cures Legislation</title>
            <description>September is THE critical month to get 21st Century Cures/ Senate Innovation legislation over the finish line. Tell Congress why this matters so much to our community.</description>
            <link>http://www.parentprojectmd.org/site/Advocacy?cmd=display&amp;page=UserAction&amp;id=223</link>
            <guid isPermaLink="false">09B30E9A-AD41-4AD3-A043-62AAABBED713-21450-00009C56F3DA7B3A-FFA</guid>
            <pubDate>Wed, 14 Sep 2016 11:37:46 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Awards $200,000 Grant to Joshua Selsby, PhD of Iowa State University</title>
            <description>Dr. Selsby is exploring the potential benefit of combining lisinopril with quercetin to see if the two compounds in combination would be more effective than either alone.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-awards-200-000-grant-to-joshua-selsby-phd-of-iowa-state?xg_source=nws_index</link>
            <guid isPermaLink="false">67E52FA1-C515-41EC-BE53-BB7D158B1DE4-13423-00006E20B3D53912-FFA</guid>
            <pubDate>Thu, 08 Sep 2016 09:51:21 -0400</pubDate>
        </item>

        <item>
            <title>September 7: World Duchenne Awareness Day</title>
            <description>For the third year in a row, the global Duchenne community will come together on September 7 for World Duchenne Awareness Day.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/september-7-world-duchenne-awareness-day</link>
            <guid isPermaLink="false">82308E8C-7412-4D15-B877-976F0E0D490B-13423-00006E1C9E22AC4B-FFA</guid>
            <pubDate>Thu, 01 Sep 2016 09:51:04 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Visits South Africa to Help Spread Global Knowledge of Duchenne Care</title>
            <description></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-mdsa-help-spread-global-knowledge-of-duchenne-care?xg_source=nws_index</link>
            <guid isPermaLink="false">8C51A7F1-E24B-4E39-BCA1-28657385C178-13423-00006E18F1804694-FFA</guid>
            <pubDate>Wed, 31 Aug 2016 09:50:45 -0400</pubDate>
        </item>

        <item>
            <title>Essential Back-To-School Resources for Duchenne</title>
            <description>PPMD has compiled a list of helpful resources you can utilize to help ensure a smooth start to the school year. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/your-essential-back-to-school-toolkit-for-duchenne-families</link>
            <guid isPermaLink="false">BE54D636-821B-4EB6-A9B3-A477016EAC0F-13423-00006E10C7FF1796-FFA</guid>
            <pubDate>Mon, 29 Aug 2016 09:50:13 -0400</pubDate>
        </item>

        <item>
            <title>One Month Away from the 9th Annual Coach To Cure MD!</title>
            <description>Join us September 24th as thousands of coaches from hundreds of universities wear the Coach To Cure MD patch on their sleeve to raise awareness and tackle Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/just-one-month-away-from-the-9th-annual-coach-to-cure-md</link>
            <guid isPermaLink="false">DEDABBE2-727E-4286-8BEC-1BAB59E637E6-13423-00006E0BE0A3FAE1-FFA</guid>
            <pubDate>Wed, 24 Aug 2016 09:49:55 -0400</pubDate>
        </item>

        <item>
            <title>PDUFA VI &amp; Its Impact on Duchenne</title>
            <description>PPMD has submitted comments we hope will ensure that PDUFA VI best reflects the needs of our community. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/pdufa-vi-duchenne</link>
            <guid isPermaLink="false">9E46EC87-CE28-4D37-BF72-25058AF163F7-13423-00006E0800FD6994-FFA</guid>
            <pubDate>Fri, 19 Aug 2016 09:49:33 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Every Single Step</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=25505.0</link>
            <guid isPermaLink="false">3CCD714F-538B-4F12-B551-C733D04C7E00-20304-0000BD9AF6681587-FFA</guid>
            <pubDate>Mon, 15 Aug 2016 10:00:08 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Sends Letter to FDA Regarding Duchenne Therapies</title>
            <description>PPMD has sent a letter to the FDA requesting updates on various regulatory actions of tremendous importance to the Duchenne community. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-sends-letter-to-fda-regarding-duchenne-therapies</link>
            <guid isPermaLink="false">1CB1D3E4-774F-4F0B-BD80-07730D27203C-20304-0000BD977CE6F13B-FFA</guid>
            <pubDate>Fri, 05 Aug 2016 09:59:54 -0400</pubDate>
        </item>

        <item>
            <title>[Webinar Recording] PTC Therapeutics Provides Regulatory Update on Translarna - August 2016</title>
            <description>PPMD recently hosted a webinar with PTC Therapeutics to discuss the latest news regarding Translarna and the path forward for the therapy with the FDA. </description>
            <link>https://www.youtube.com/watch?v=vlu6wj_n160</link>
            <guid isPermaLink="false">44E2E83B-B6CF-4F83-8A16-6060F3DA07E0-20304-0000BD948D93C084-FFA</guid>
            <pubDate>Tue, 16 Aug 2016 09:59:42 -0400</pubDate>
        </item>

        <item>
            <title>Help the Powers Family #TackleDuchenne!</title>
            <description>The 9th Annual Coach To Cure MD on September 24 is shaping up to be our biggest year yet! Duchenne mom Kim Powers shares why this is the year you should get in the game and help us #TackleDuchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/help-the-powers-family-tackleduchenne</link>
            <guid isPermaLink="false">1F83A20E-DF0B-4AAA-A26E-E594696052A3-20304-0000BD90B00CF3D6-FFA</guid>
            <pubDate>Thu, 04 Aug 2016 09:59:26 -0400</pubDate>
        </item>

        <item>
            <title>2016 Connect Conference Resources &amp; Recordings</title>
            <description>We are excited to share with you presentations from PPMD’s 22nd Annual Connect Conference! We will continue to update this page over the coming weeks with slides and video content.</description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_presentations_16</link>
            <guid isPermaLink="false">E399CE53-4F1C-47F0-8467-D762C979AEFE-20304-0000BD8C28F69C27-FFA</guid>
            <pubDate>Tue, 26 Jul 2016 09:59:07 -0400</pubDate>
        </item>

        <item>
            <title>[Webinar Recording] What is CRISPR/Cas9?</title>
            <description>PPMD welcomed Dr. Eric Olson from UT Southwestern Medical Center to discuss the basics of gene editing and the potential permanent correction of Duchenne mutations with CRISPR/Cas9.</description>
            <link>https://www.youtube.com/watch?v=yO7iH39GQdg</link>
            <guid isPermaLink="false">758C8C9F-3F0C-4ABE-AF10-37F1BE173AA4-20304-0000BD8772F20C95-FFA</guid>
            <pubDate>Wed, 20 Jul 2016 09:58:48 -0400</pubDate>
        </item>

        <item>
            <title>[Upcoming Webinar - 7/13] What is CRISPR/Cas9?</title>
            <description>PPMD welcomes Dr. Eric Olson from the Department of Molecular Biology at UT Southwestern Medical Center to discuss the basics of gene editing and the potential permanent correction of Duchenne mutations with CRISPR/Cas9.</description>
            <link>http://community.parentprojectmd.org/events/upcoming-webinar-what-is-crispr-cas9-duchenne</link>
            <guid isPermaLink="false">7FA461B6-BD44-4514-8A7A-29E4A73D50A9-6349-00002BD39AEBE407-FFA</guid>
            <pubDate>Thu, 07 Jul 2016 15:16:46 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Receives Grant from Marathon Pharmaceuticals to Help Support Acclaimed Certified Duchenne Care Center Program</title>
            <description>The grant will enable PPMD to provide additional resources to improve patient care and patient recruitment for clinical trials through the centers.</description>
            <link>http://www.prnewswire.com/news-releases/parent-project-muscular-dystrophy-receives-grant-from-marathon-pharmaceuticals-to-help-support-acclaimed-certified-duchenne-care-center-program-300288948.html</link>
            <guid isPermaLink="false">51C355D2-BDCC-4A21-8BD8-C817C848C13C-5199-00002008F0D9304A-FFA</guid>
            <pubDate>Tue, 28 Jun 2016 09:37:23 -0400</pubDate>
        </item>

        <item>
            <title>Join the 2016 #PPMDConnect Conference Online!</title>
            <description>Unable to attend this year's Annual Connect Conference in Orlando? Join us online! PPMD will be live streaming and our DuchenneConnect team will be live tweeting updates June 26-28.</description>
            <link>http://parentprojectmd.org/livestream</link>
            <guid isPermaLink="false">12978B72-6501-4425-AF29-10FC56E82761-5199-00002004B63DFB97-FFA</guid>
            <pubDate>Thu, 23 Jun 2016 09:37:01 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Awards The Ohio State University Grant to Support Cardiomyopathy Therapy for Duchenne</title>
            <description>Heart issues don't just affect some people with Duchenne; they affect all people with Duchenne. PPMD is so grateful to the work being done at institutes like The Ohio State University and we are proud to support Dr. Guttridge.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/parent-project-muscular-dystrophy-awards-the-ohio-state-universit?xg_source=facebook</link>
            <guid isPermaLink="false">D6EFEE1B-63F2-4752-97B2-44355255E3C7-5199-00001FFEFCECB50D-FFA</guid>
            <pubDate>Wed, 22 Jun 2016 09:36:36 -0400</pubDate>
        </item>

        <item>
            <title>Understanding Gene Therapy &amp; CRISPR/Cas9</title>
            <description>Find out more about the latest in gene therapy, CRISPR/Cas9, and what these technologies could mean for Duchenne during three different opportunities this summer that promise to provide an in-depth analysis.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/understanding-gene-therapy-crispr-cas9</link>
            <guid isPermaLink="false">2B7F5FFC-A6C9-44B5-80CD-D20677BF026C-5199-00001FFB240D4C28-FFA</guid>
            <pubDate>Mon, 20 Jun 2016 09:36:17 -0400</pubDate>
        </item>

        <item>
            <title>[Webinar Recording] MoveDMD: A Clinical Trial of Edasalonexent (CAT-1004) in Duchenne</title>
            <description>PPMD and Dr. Joanne Donovan recently hosted a webinar to review information on edasalonexent (previously known as CAT-1004) and the MoveDMD trial.</description>
            <link>https://www.youtube.com/watch?v=v8Zv3W0BQII</link>
            <guid isPermaLink="false">416ED5B5-309D-4C70-802A-31A4F8FCE9F7-5199-00001FF6EE980763-FFA</guid>
            <pubDate>Sat, 11 Jun 2016 09:36:00 -0400</pubDate>
        </item>

        <item>
            <title>Getting Results: Success from your Advocacy efforts in February!</title>
            <description>Your actions this year have yielded incredible results for Duchenne related funding at the federal level.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/getting-results-success-from-your-advocacy-efforts-in-february</link>
            <guid isPermaLink="false">7924361B-E35A-4E3F-9151-9B5C85E8D685-5199-00001FF360C8186A-FFA</guid>
            <pubDate>Fri, 10 Jun 2016 09:35:45 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Awards University of Washington Grant to Support Technology to Help Optimize Gene Therapy</title>
            <description>PPMD is proud to support Dr. Odom from the University of Washington and we are hopeful that his work will help make gene therapy in Duchenne more effective and long lasting.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-awards-university-of-washington-grant-to-support-technology</link>
            <guid isPermaLink="false">F2F5F0E1-EFD0-49AC-B8F6-0392D99B9C6E-5199-00001FEECFCA8CF1-FFA</guid>
            <pubDate>Thu, 09 Jun 2016 09:35:25 -0400</pubDate>
        </item>

        <item>
            <title>PPMD &amp; BIO Release New Report on the Development of Patient Preference Studies</title>
            <description>PPMD hopes that this report will provide guidance for companies seeking to incorporate the patient perspective at every stage of developing and delivering innovative new treatments.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-bio-release-new-report-on-the-development-of-disease-specifi?xg_source=facebook</link>
            <guid isPermaLink="false">3BC70220-7DCD-406E-9E80-68BB84273A7E-5199-00001FEA3E30D0C0-FFA</guid>
            <pubDate>Wed, 08 Jun 2016 09:35:06 -0400</pubDate>
        </item>

        <item>
            <title>BioMarin Discontinues Clinical Development of Drisapersen</title>
            <description>BioMarin has announced that they were discontinuing the clinical development of drisapersen after interactions with both the FDA and EMA.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/biomarin-discontinues-clinical-development-of-drisapersen</link>
            <guid isPermaLink="false">1723DB1C-FA37-4946-92FF-C6FB3B74AD48-5199-00001FE6023F8AC3-FFA</guid>
            <pubDate>Wed, 01 Jun 2016 09:34:49 -0400</pubDate>
        </item>

        <item>
            <title>PPMD’s Every Single One Tour: Salt Lake City</title>
            <description>With a successful ‪Every Single One‬ tour stop in Baltimore under our belts, PPMD visited Salt Lake City this past weekend. Thank you to all of the families from across Utah and Idaho who joined us!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-s-everysingleone-tour-salt-lake-city</link>
            <guid isPermaLink="false">A559CE86-05DD-462E-A308-AAA8FEB9EEF0-5199-00001FDDCD013D5E-FFA</guid>
            <pubDate>Thu, 26 May 2016 09:34:13 -0400</pubDate>
        </item>

        <item>
            <title>Sarepta Announces FDA Will Not Complete the Review of the Eteplirsen NDA By The PDUFA Date</title>
            <description>The FDA has notified Sarepta that they are continuing their review of eteplirsen and will not be able to complete their work by the PDUFA goal date of May 26. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/sarepta-therapeutics-announces-fda-will-not-complete-the-review-o?xg_source=nws_index</link>
            <guid isPermaLink="false">4526EA9D-61F9-4180-BCD8-1C2AD4BAB5D4-5199-00001FDAEBD521D8-FFA</guid>
            <pubDate>Wed, 25 May 2016 09:33:59 -0400</pubDate>
        </item>

        <item>
            <title>[Webinar Recording] MissionDMD: FibroGen’s Anti-Fibrosis Program</title>
            <description>PPMD and FibroGen recently hosted a webinar to discuss the launch of FibroGen's MissionDMD program that is being conducted to investigate FG-3019 in Duchenne. </description>
            <link>https://youtu.be/KVJSeb0-96Y</link>
            <guid isPermaLink="false">1B4D98B6-05EC-4F22-9A0B-78AEEA0D8EC3-4212-000025809B71D8A4-FFA</guid>
            <pubDate>Fri, 20 May 2016 11:12:34 -0400</pubDate>
        </item>

        <item>
            <title>Next Steps with Newborn Screening</title>
            <description>PPMD is leading a national effort including more than 50 of the world’s top newborn screening and Duchenne experts to build a newborn screening infrastructure for Duchenne in the United States.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/next-steps-with-newborn-screening</link>
            <guid isPermaLink="false">20119429-0100-4548-AFE9-A14273BAC36E-4212-0000257D01847895-FFA</guid>
            <pubDate>Thu, 19 May 2016 11:12:17 -0400</pubDate>
        </item>

        <item>
            <title>DRSC Definitions</title>
            <description>PPMD is undertaking multiple efforts to help improve clinical trial design in order to accelerate clinical trials and find promising therapies for Duchenne. But how does data aggregation really work? Our friends at D-RSC have spelled out some concepts and terms for you to make understanding all that PPMD is doing easier. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/drsc-definitions?xg_source=facebook</link>
            <guid isPermaLink="false">560C02B4-0404-44F8-B0D3-A2D1F547308F-4212-000025629A234FE1-FFA</guid>
            <pubDate>Tue, 17 May 2016 11:12:03 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Names Children’s Mercy Hospital in Kansas City, MO, Certified Duchenne Care Center</title>
            <description>Children’s Mercy Hospital in Kansas City, Missouri became the 11th clinic named a Certified Duchenne Care Center by PPMD.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-names-children-s-mercy-hospital-in-kansas-city-mo-certified-</link>
            <guid isPermaLink="false">69E643E1-BE73-4E14-B3F8-FC42FA729102-4212-0000255D49C74D82-FFA</guid>
            <pubDate>Mon, 16 May 2016 11:10:11 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Every Single Carrier</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=25245.0</link>
            <guid isPermaLink="false">65A97208-A3B3-4891-9F53-3CF27A6AF650-4212-0000255A411BDAD1-FFA</guid>
            <pubDate>Mon, 16 May 2016 11:09:48 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Brings Together Experts to Assess Steroid Effects on Bone Health in Duchenne</title>
            <description>More than 50 international experts in both pediatric and Duchenne bone health have gathered to attend PPMD’s Bone Health and Osteoporosis Workshop today &amp; tomorrow in order to dive deeply into these important topics. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-brings-together-experts-to-assess-steroid-effects-on-bone</link>
            <guid isPermaLink="false">22350800-B1BF-4BE2-8178-FE245CECEC1C-4212-000025569C322095-FFA</guid>
            <pubDate>Thu, 12 May 2016 11:09:33 -0400</pubDate>
        </item>

        <item>
            <title>Every Single Carrier</title>
            <description>PPMD is proud to formally announce our carrier initiative. Like everything we do, PPMD will look at carrier issues from a variety of angles, through a variety of lenses. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/every-single-carrier?xg_source=nws_index</link>
            <guid isPermaLink="false">D7D016E5-9487-413A-AC5B-C56FAC7C8C1F-4212-0000255231EA3D1A-FFA</guid>
            <pubDate>Mon, 09 May 2016 11:09:16 -0400</pubDate>
        </item>

        <item>
            <title>Changing the Paradigm: The Eteplirsen Ad Comm</title>
            <description>There is no way around it, today was hard. Like you, we are dumbfounded by the closing votes and discussion. But a decision has not been made – these were recommendations. And we believe that the number of questions with mixed votes represent opportunities for us to change minds and continue to influence the agency.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-eteplirsen-ad-comm-a-paradigm-shift</link>
            <guid isPermaLink="false">48E30720-D2D1-45D4-8062-5F40E046D30F-4212-0000254E115E04EA-FFA</guid>
            <pubDate>Tue, 26 Apr 2016 11:08:58 -0400</pubDate>
        </item>

        <item>
            <title>April 25: FDA Advisory Committee Meeting for Eteplirsen - Live Webcast Information</title>
            <description>The Center for Drug Evaluation and Research (CDER) plans to provide a free of charge, live webcast of the meeting.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/april-25-fda-advisory-committee-meeting-live-webcast-information</link>
            <guid isPermaLink="false">C44D493F-3DFD-4386-BA57-611F34557C99-4212-000025498D4FB5E5-FFA</guid>
            <pubDate>Fri, 22 Apr 2016 11:08:37 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Advocates Ensure Congress Recognizes Importance of Flexibility in FDA Reviews</title>
            <description>Great news as Congress continues to communicate urgency to the FDA to apply flexibility in review of Duchenne therapies, thanks to our PPMD community!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/congress-continues-to-communicate-urgency-to-the-fda-to-apply-fle</link>
            <guid isPermaLink="false">AA9ACF69-6472-4FBF-B2FB-7E42A863A23A-4212-00002544ED1F7C80-FFA</guid>
            <pubDate>Tue, 19 Apr 2016 11:08:18 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Names Children’s Hospital Los Angeles 10th Certified Duchenne Care Center</title>
            <description>PPMD is thrilled to announce our 10th Certified Duchenne Care Center -- Children's Hospital Los Angeles!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-names-children-s-hospital-los-angeles-certified-duchenne-car?xg_source=facebook</link>
            <guid isPermaLink="false">D50CB856-1EF2-4E67-B0A1-80295EE7405B-4212-000025417195F81B-FFA</guid>
            <pubDate>Tue, 19 Apr 2016 11:08:02 -0400</pubDate>
        </item>

        <item>
            <title>PPMD's Every Single [One] Tour Launched in Baltimore!</title>
            <description>On Saturday, Duchenne community members from six states gathered together at Kennedy Krieger in Baltimore to hear the latest developments on clinical trials, clinical care practices, carrier programs, legislative and regulatory efforts, IEPs and school advocacy, physical therapy, genetic testing and more.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-s-every-single-one-tour-launched-in-baltimore</link>
            <guid isPermaLink="false">2FCE3327-4402-4441-9FF7-1E8F940C8CFA-4212-0000253A56460230-FFA</guid>
            <pubDate>Mon, 18 Apr 2016 11:07:33 -0400</pubDate>
        </item>

        <item>
            <title>Senate Sends Strong Letter to FDA about Duchenne Therapies</title>
            <description>With this letter now sent, both the House &amp; Senate have communicated a strong message to the FDA about the need to use every possible tool at their disposal to speed access to promising Duchenne therapies.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/duchenne-champions-senators-wicker-klobuchar-lead-letter-to-fda</link>
            <guid isPermaLink="false">FED82861-C2B2-4EC7-B8DD-1F3397D5EE51-4212-000025365EBF8FAC-FFA</guid>
            <pubDate>Mon, 18 Apr 2016 11:07:17 -0400</pubDate>
        </item>

        <item>
            <title>PPMD’s Patient Preference Study about Pulmonary Outcomes – What we learned and why it matters</title>
            <description>We are pleased to release the Community Report for this study, which takes a deeper look into the results. Later this year, an extended version of the report data will be published in multiple publications.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-s-patient-preference-study-about-pulmonary-outcomes-what-we-</link>
            <guid isPermaLink="false">E55B0624-7924-4AB4-904D-13EA856A7A85-4212-00002532B1DF4139-FFA</guid>
            <pubDate>Wed, 13 Apr 2016 11:07:00 -0400</pubDate>
        </item>

        <item>
            <title>PPMD's 2016 Connect Conference Agenda Now Available</title>
            <description>PPMD is excited to unveil the agenda for the 22nd Annual Connect Conference in Orlando, June 26-29. Make sure you register you and your family before the Early Bird Registration Rate ends April 15th!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-s-2016-connect-conference-agenda-now-available?xg_source=nws_index</link>
            <guid isPermaLink="false">A5DF8D0E-5979-4B07-9071-155090A3BD3E-4212-0000252EFFAC32A3-FFA</guid>
            <pubDate>Mon, 11 Apr 2016 11:06:45 -0400</pubDate>
        </item>

        <item>
            <title>ACTION ALERT: Please urge Your Senators to Sign Letter to FDA</title>
            <description>Please urge your Senators to sign this important letter. Patients need and deserve therapeutic options and the FDA must use the tools they have been given to expedite these options. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/please-urge-your-senators-to-sign-letter-to-fda-applying-fdasia?xg_source=nws_index</link>
            <guid isPermaLink="false">DFDAF89D-815B-47CE-9FB3-BDA13BF13D4D-4212-0000252BBFDB9857-FFA</guid>
            <pubDate>Tue, 05 Apr 2016 11:06:29 -0400</pubDate>
        </item>

        <item>
            <title>How You Can Help with the Upcoming Ad Comm for Eteplirsen</title>
            <description>We are just a few short weeks from the FDA Advisory Committee Meeting for eteplirsen on April 25th. The momentum is tremendous but we need YOU to take action leading up to the big day. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/how-you-can-help-with-the-upcoming-ad-comm-for-eteplirsen-every?xg_source=nws_index</link>
            <guid isPermaLink="false">A1FCA22D-AFD1-4C67-A3C6-12D0002F772C-4212-00002526D1330AB1-FFA</guid>
            <pubDate>Mon, 04 Apr 2016 11:06:12 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: BMS Anti-Myostatin Adnectin Program</title>
            <description>PPMD and Bristol-Myers Squibb (BMS) recently hosted a webinar to discuss the BMS Anti-Myostatin Adnectin Program.</description>
            <link>https://www.youtube.com/watch?v=2T3Y7T6Oxts</link>
            <guid isPermaLink="false">9E31501C-5C41-49C2-8054-38A5D7011909-4212-00002522E44F0745-FFA</guid>
            <pubDate>Fri, 01 Apr 2016 11:05:51 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Community Survey about the Akashi HT-100 study</title>
            <description>If you or your child were in the Akashi HT-100 clinical trial that was recently suspended, please take our survey. Responses are needed by April 10th.</description>
            <link>http://survey.az1.qualtrics.com/jfe/form/SV_aaTqvVR5ucbQsmh</link>
            <guid isPermaLink="false">DDD4C39E-6713-436A-B24B-1D6C6BC19124-4212-0000251EE0CD2927-FFA</guid>
            <pubDate>Fri, 01 Apr 2016 11:05:36 -0400</pubDate>
        </item>

        <item>
            <title>Update on Gene Replacement/Repair Strategies for Duchenne Muscular Dystrophy</title>
            <description>There has been a flurry of press recently on gene therapy in Duchenne and CRISPR technology. With this barrage of information, PPMD wanted to take a deeper dive into gene therapy as a potential treatment for Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/update-on-gene-replacement-repair-strategies?xg_source=nws_index</link>
            <guid isPermaLink="false">76E045F9-51CF-4B08-AE04-13E7CFB5E832-4212-00002519C3D33DC0-FFA</guid>
            <pubDate>Fri, 25 Mar 2016 11:05:18 -0400</pubDate>
        </item>

        <item>
            <title>PPMD is Initial Partner in OnPAR</title>
            <description>PPMD is proud to participate in OnPar which provides access to peer-reviewed research proposals that directly relate to Duchenne research. OnPAR will provide us with an efficient way to solicit early stage and translational Duchenne research proposals, see the breadth of research in Duchenne, and gain access to novel research strategies. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-is-initial-partner-in-onpar-online-partnership-to-accelerate</link>
            <guid isPermaLink="false">F48D49F7-B379-4871-84B3-22DCE3437D23-4212-00002515A27604BA-FFA</guid>
            <pubDate>Thu, 24 Mar 2016 11:04:54 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Launches the Every Single [One] Tour</title>
            <description>For 22 years, PPMD has brought together families with leading experts, care providers, and industry partners through our Annual Connect Conference, FACES meetings, and Roundtables. Now, in an effort to reach every single family facing a Duchenne diagnosis in the U.S., PPMD is launching a multi-year community experience called the Every Single [One] Tour. Combining each of the pillars that make up PPMD’s mission – To End Duchenne – the Every Single [One] Tour will bring updates on research, advocacy, and care to half a dozen cities in 2016. We hope you can join us!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-launches-the-every-single-one-tour-1?xg_source=rssfeed</link>
            <guid isPermaLink="false">7B820F95-2737-41A2-A589-842231B40CB0-10245-00006C20CE2473E8-FFA</guid>
            <pubDate>Fri, 04 Mar 2016 14:04:31 -0500</pubDate>
        </item>

        <item>
            <title>Registration for PPMD's 2016 Connect Conference Now Open!</title>
            <description>This year's Connect Conference will be held in Orlando, FL from Sunday, June 26 to Wednesday, June 29, 2016. We can't wait to see you and your family there!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/registration-for-ppmd-s-2016-connect-conference-is-now-open</link>
            <guid isPermaLink="false">C473B371-56E6-4F68-84EB-A46170ACC165-10245-00006C164DCFD123-FFA</guid>
            <pubDate>Tue, 01 Mar 2016 14:04:02 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Partners with AAP &amp; CDC to Develop New Tool to Help Parents Detect Motor Development Delays</title>
            <description>Early diagnosis and intervention have been part of PPMD’s mission since we began and we hope a resource like this will help shorten the timeline it takes for families to receive a diagnosis.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-partners-with-aap-cdc-to-develop-new-tool-to-help-parents-de</link>
            <guid isPermaLink="false">0B9ADF21-2BFA-440D-B19A-2BAC1D08C3E9-10245-00006C120532BDD7-FFA</guid>
            <pubDate>Wed, 24 Feb 2016 14:03:14 -0500</pubDate>
        </item>

        <item>
            <title>ACTION ALERT: Urge House Member - Apply FDASIA Tools to Duchenne</title>
            <description>There has never been a moment like this in our Duchenne community. Today the FDA released briefing documents on the application for eteplirsen. It is clear that we continue to face a serious regulatory challenge as a community. Urge your Representative to take action. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/action-alert-urge-house-member-apply-fdasia-tools-to-duchenne</link>
            <guid isPermaLink="false">D79E4DE3-5DB3-439C-87C8-018841315BE0-22752-00007143199D0202-FFA</guid>
            <pubDate>Fri, 15 Jan 2016 14:03:23 -0500</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: New Year, New Hope</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>https://secure2.convio.net/ppmd/admin/MessageViewer?em_id=24745.0</link>
            <guid isPermaLink="false">93F7D779-8746-45CE-8929-7B31F4C5A96D-22752-0000713F1C373041-FFA</guid>
            <pubDate>Fri, 15 Jan 2016 14:02:51 -0500</pubDate>
        </item>

        <item>
            <title>A Blow to Our Community – But Our Work Continues</title>
            <description>Today our community was dealt a painful blow as the FDA issued a Complete Response letter to BioMarin regarding the company’s New Drug Application (NDA) for Kyndrisa (drisapersen). As stated in BioMarin’s press release, “The FDA issues Complete Response letters to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. FDA has concluded that the standard of substantial evidence of effectiveness has not been met.”</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/a-blow-to-our-community-but-our-work-continues</link>
            <guid isPermaLink="false">84AC1AB8-0760-4336-883B-E08D4259D37A-22752-0000713ADB559FB8-FFA</guid>
            <pubDate>Thu, 14 Jan 2016 14:02:33 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Responds to Revisions to “The Common Rule”</title>
            <description>The Common Rule or the 'Federal Policy for the Protection of Human Subjects' is the policy that determines how you are consented when participating in trials and research, what types of research are considered to be ethical, and how biomedical samples acquired from patients can be used and stored. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-responds-to-revisions-to-the-common-rule</link>
            <guid isPermaLink="false">1DF6D0F1-18BF-4E4A-832D-9CAC588B8E8D-22752-00007136B1F68655-FFA</guid>
            <pubDate>Wed, 13 Jan 2016 14:02:16 -0500</pubDate>
        </item>

        <item>
            <title>Dysphagia in Duchenne: practical recommendations to guide management</title>
            <description>Dysphasia, or difficulty swallowing, effects many patients with Duchenne. Complaints of &quot;something stuck in my throat&quot; are not uncommon. A new article on dysphagia in Duchenne presents a clear step by step plan of care.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/dysphagia-in-duchenne-muscular-dystrophy-practical</link>
            <guid isPermaLink="false">1FAF45A9-B450-476D-AED6-BF7F8E98E5FD-22752-000071327ABFDEF6-FFA</guid>
            <pubDate>Fri, 08 Jan 2016 14:01:56 -0500</pubDate>
        </item>

        <item>
            <title>Webinar 1/13/16: HOPE-Duchenne Trial - Capricor Therapeutics</title>
            <description>Please join PPMD and Capricor as we host a webinar Wednesday, January 13 at 1pm eastern to discuss the HOPE-Duchenne trial which recently opened for enrollment in the US. </description>
            <link>http://community.parentprojectmd.org/events/webinar-hope-duchenne-trial-capricor-therapeutics</link>
            <guid isPermaLink="false">35BCFBB5-D1C3-4029-85F7-056D9B133BC8-22752-0000712E5B4F20CB-FFA</guid>
            <pubDate>Thu, 07 Jan 2016 14:01:39 -0500</pubDate>
        </item>

        <item>
            <title>We did it! Over $270,000 raised to support early-stage research.</title>
            <description>Last month PPMD told you we hoped to raise $200,000 to support new, early-stage research. And how did you respond? By not only hitting our goal, but surpassing it! </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/we-did-it?xg_source=nws_index</link>
            <guid isPermaLink="false">7A1F733E-62F3-4F54-A430-34B6BB0DF2F0-22752-000071291017FBE2-FFA</guid>
            <pubDate>Tue, 05 Jan 2016 14:01:16 -0500</pubDate>
        </item>

        <item>
            <title>Finding Hope in CRISPR/Cas9</title>
            <description>Duchenne made national headlines over the holidays thanks to the latest news on gene editing technology. PPMD wanted to help take a deeper dive into gene editing and CRISPR/Cas9 so that we can better understand the potential of this cutting-edge technology.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/finding-hope-in-crispr-cas9-1</link>
            <guid isPermaLink="false">8F9810F4-C06C-4518-A667-21D0B06222C9-22752-000071246D061293-FFA</guid>
            <pubDate>Mon, 04 Jan 2016 14:00:58 -0500</pubDate>
        </item>

        <item>
            <title>Last chance to have your donation doubled!</title>
            <description>Just a few hours left to match every single gift! We’re so close to hitting our goal—but we need to raise $24,000 more by midnight tonight. Help us take full advantage of the matching gift by making a tax-deductible donation before midnight!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/last-chance-to-have-your-donation-doubled?xg_source=nws_index</link>
            <guid isPermaLink="false">A5E43D76-A9FC-4AB9-80E3-F8DB709EDEC9-22752-0000711FA6E4EDC5-FFA</guid>
            <pubDate>Thu, 31 Dec 2015 14:00:36 -0500</pubDate>
        </item>

        <item>
            <title>Less than 48 hours left!</title>
            <description>We're less than 48 hours away from a New Year and just $36,000 shy of our $200,000 goal to fund early-stage research. We’re so close, but we need your gift to help us get there. Donate now—take advantage of the final hours of our match!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/less-than-48-hours-left?xg_source=activity</link>
            <guid isPermaLink="false">B4CB1694-369F-4AD7-9ECF-4798B55ED286-22752-0000711BB6E376AA-FFA</guid>
            <pubDate>Wed, 30 Dec 2015 14:00:17 -0500</pubDate>
        </item>

        <item>
            <title>Submit Written Testimony for Sarepta's Upcoming FDA Advisory Committee Meeting</title>
            <description>PPMD encourages Duchenne community members to submit written testimonies to the FDA Advisory Committee in advance of the upcoming Sarepta Ad Comm meeting. Testimonies must be submitted by January 7th.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ad-comms-update-how-to-participate</link>
            <guid isPermaLink="false">1FAF0A39-283C-4095-9658-815FAC9B81B1-22752-0000711563A6BE48-FFA</guid>
            <pubDate>Mon, 28 Dec 2015 13:59:53 -0500</pubDate>
        </item>

        <item>
            <title>&quot;My mom and dad will match your donation!&quot;</title>
            <description>John Owen Dumm shares why his family and John Owen's Adventure want to match every gift made to PPMD online this holiday season. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/my-mom-and-dad-will-match-your-donation</link>
            <guid isPermaLink="false">7EDBDD68-C095-4D74-A4F8-C1431FB65DE4-22752-000071110261C9DB-FFA</guid>
            <pubDate>Mon, 28 Dec 2015 13:59:32 -0500</pubDate>
        </item>

        <item>
            <title>EMA Publishes Guidelines on the Clinical Investigation of Medicinal Products for Duchenne</title>
            <description>The EMA is the European equivalent of the FDA in the US. These guidelines are similar in nature to the guidance the FDA published earlier this year.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ema-publishes-guidelines-on-the-clinical-investigation-of-medicin</link>
            <guid isPermaLink="false">6CDD03F7-285B-4A23-927F-EAFE9771DD0C-22752-0000710BDD5642B1-FFA</guid>
            <pubDate>Wed, 23 Dec 2015 13:59:12 -0500</pubDate>
        </item>

        <item>
            <title>Please give now and we'll match your gift!</title>
            <description>The Dumm family is doubling every single gift to support early-stage research that holds hope for every family with Duchenne. Please donate today so that your gift goes twice as far!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/please-give-now-and-we-ll-match-your-gift</link>
            <guid isPermaLink="false">BF98B1A8-FABF-4F4F-983F-FD4F9F56A748-22752-000071077D9AFD17-FFA</guid>
            <pubDate>Tue, 22 Dec 2015 13:58:53 -0500</pubDate>
        </item>

        <item>
            <title>BioCentury Article: How BIO and PPMD plan to create a blueprint for patient preference studies</title>
            <description>Earlier this month, PPMD announced a partnership with BIO to develop a set of general guidelines and recommendations that stakeholders can use to design and execute disease-specific patient preference studies. With PPMD's history designing and conducting patient preferences studies in Duchenne, we believe strongly that our experience will help other diseases capture patient preferences in their communities.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/how-bio-and-ppmd-plan-to-create-a-blueprint-for-patient-preferenc</link>
            <guid isPermaLink="false">80ACB9D3-4FEE-4DD1-8499-79C62E974BBB-22752-0000710256E532A8-FFA</guid>
            <pubDate>Tue, 22 Dec 2015 13:58:30 -0500</pubDate>
        </item>

        <item>
            <title>A New Dog Model for Drug Development in Duchenne</title>
            <description>The UK beagle model is likely to become a valuable tool in the arsenal to discover and develop new drugs to combat Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/a-new-dog-model-for-drug-development-in-duchenne</link>
            <guid isPermaLink="false">44EE27F3-2501-4E09-86E3-0AE17BEA2500-22752-000070FB136E20D7-FFA</guid>
            <pubDate>Mon, 21 Dec 2015 13:58:12 -0500</pubDate>
        </item>

        <item>
            <title>Dystrophin Mutations Affect Not Only Existing Muscle Fibers, but Satellite Cells As Well</title>
            <description>A recently published paper has provided new insights into what we view as the critical targets for therapies in Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/dystrophin-mutations-affect-not-only-existing-muscle-fibers-but</link>
            <guid isPermaLink="false">18739AEB-3E3B-4EE7-9B46-AB352A8026F8-22752-000070F6660F9676-FFA</guid>
            <pubDate>Fri, 18 Dec 2015 13:57:46 -0500</pubDate>
        </item>

        <item>
            <title>How You Can Participate in Sarepta's Upcoming FDA Advisory Committee Meeting</title>
            <description>Sarepta has officially received notification that an Advisory Committee Meeting with the FDA has been scheduled for January 22, 2016. We hope you will join us in January! </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ad-comms-update-how-to-participate</link>
            <guid isPermaLink="false">0A3C68B7-F32E-46E0-8129-641B06429FEE-22752-000070F00EE41DFD-FFA</guid>
            <pubDate>Fri, 18 Dec 2015 13:57:18 -0500</pubDate>
        </item>

        <item>
            <title>BioMarin Announces That FDA Has Advised it Will Not Take Action on Drisapersen New Drug Application by PDUFA Date</title>
            <description>BioMarin has announced that the FDA will not make a decision regarding drisapersen until early January 2016. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/biomarin-announces-that-fda-has-advised-it-will-not-take-action-o</link>
            <guid isPermaLink="false">2F05BAB0-2E81-402D-9363-EFDA2C72373C-22752-000070EB1B53C88B-FFA</guid>
            <pubDate>Fri, 18 Dec 2015 13:56:53 -0500</pubDate>
        </item>

        <item>
            <title>Another matching gift for early-stage research!</title>
            <description>The Dumm family and their foundation John Owen’s Adventure have stepped forward with a match of $43,000! If you give today, your gift will go twice as far to support early-stage research that has the potential to help every single family affected by a Duchenne diagnosis.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/another-matching-gift-for-early-stage-research</link>
            <guid isPermaLink="false">53CC3CA5-E166-4947-A0F5-E43BFFAAE4D1-22752-000070E5C7B14350-FFA</guid>
            <pubDate>Thu, 17 Dec 2015 13:56:31 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Testifies at FDA PDUFA Stakeholder Meeting</title>
            <description>Read PPMD's testimony before the FDA as to our community's experiences under PDUFA V, our innovation related to Patient Focused Drug Development, and some of our recommendations as to how patient-community engagement in drug development could be further enhanced going forward.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-testifies-at-fda-pdufa-stakeholder-meeting</link>
            <guid isPermaLink="false">9F16D466-EF52-4F60-A149-75DC0B7D0420-22752-000070DE5E5DFAEB-FFA</guid>
            <pubDate>Thu, 17 Dec 2015 13:56:01 -0500</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Understanding the Potential of Epicatechin</title>
            <description>PPMD's Pat Furlong interviewed Dr. George Schreiner, President and CSO of Cardero Therapeutics, Inc. to discuss the potential benefits of epicatechin to people with Duchenne. </description>
            <link>https://www.youtube.com/watch?v=dksgER_qVpo&amp;feature=youtu.be</link>
            <guid isPermaLink="false">A65D4513-4475-4EBD-9EC8-83A19D958378-22752-000070D890D6B92F-FFA</guid>
            <pubDate>Wed, 16 Dec 2015 13:55:35 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Advocates Ensure Duchenne Research Pipeline to Benefit from Congress’s “Omnibus Spending Package&quot;</title>
            <description>Thank you to each member of our PPMD community who participated in congressional outreach efforts online, through phone calls, and through visits to your elected officials both in Washington, DC and in your home districts!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/duchenne-research-to-benefit-from-congress-s-massive-omnibus-spen?xg_source=nws_index</link>
            <guid isPermaLink="false">67238E39-9C59-4164-9765-EDE0B7B666D9-22752-000070C49B10D6A0-FFA</guid>
            <pubDate>Wed, 16 Dec 2015 13:55:00 -0500</pubDate>
        </item>

        <item>
            <title>&quot;Why this community matters to me&quot;</title>
            <description>Mary-Lou Weisman reflects on the strength of our community, and shares why her family has decided to match all gifts made to PPMD up to $50,000 this holiday season.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/why-this-community-matters-to-me?xg_source=nws_index</link>
            <guid isPermaLink="false">5BF1B0D6-C550-4D04-B124-186159990741-9428-000045C3C423875B-FFA</guid>
            <pubDate>Tue, 15 Dec 2015 13:18:59 -0500</pubDate>
        </item>

        <item>
            <title>The Drisapersen Ad Comm: Where We Are Today</title>
            <description>Read PPMD’s latest blog to learn where things stand from our perspective since the drisapersen Advisory Committee Meeting as the community waits for a decision.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-drisapersen-ad-comm-where-we-are-today?xg_source=nws_index</link>
            <guid isPermaLink="false">AD5FD6A3-C890-4061-80FC-14D39455EC49-9428-000045C0068E0AC1-FFA</guid>
            <pubDate>Tue, 15 Dec 2015 13:18:44 -0500</pubDate>
        </item>

        <item>
            <title>Marathon Expanded Access Program for Deflazacort: FAQs</title>
            <description>These FAQs explain what we have learned so far regarding Marathon Pharmaceuticals and their expanded access program for deflazacort in the US.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/marathon-deflazacort-extended-access-program-faq?xg_source=nws_index</link>
            <guid isPermaLink="false">6BAFF393-B35F-4760-9611-4DBCEE25C629-9428-000045BA6918139F-FFA</guid>
            <pubDate>Mon, 14 Dec 2015 13:18:27 -0500</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: We're All in This Together</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=24565.0</link>
            <guid isPermaLink="false">48BAF87C-38C3-4852-88B1-C18D1837E410-9428-000045B54A986552-FFA</guid>
            <pubDate>Wed, 16 Dec 2015 13:18:08 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Houston Roundtable: Session Recordings</title>
            <description>In October, PPMD held a FACES Roundtable in Houston that included an incredible line up of global experts in care and research. In an effort to ensure this information reached families beyond Houston, we recorded the sessions</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-houston-roundtable-session-recordings?xg_source=nws_index</link>
            <guid isPermaLink="false">68FBEE3A-D2DD-4CAD-A4DE-BBFFDA23E1FB-9428-000045B028173976-FFA</guid>
            <pubDate>Fri, 11 Dec 2015 13:17:40 -0500</pubDate>
        </item>

        <item>
            <title>PPMD's Pat Furlong Receives FDLI Distinguished Service and Leadership Award</title>
            <description>Congratulations to PPMD President Pat Furlong on being named a recipient of the 2015 FDLI Distinguished Service and Leadership Award!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-s-pat-furlong-receives-fdli-distinguished-service-and-leader?xg_source=nws_index</link>
            <guid isPermaLink="false">F3FD3042-3E69-4B34-ACB6-4EB38E78DA13-9428-000045AA98221F61-FFA</guid>
            <pubDate>Thu, 10 Dec 2015 13:17:11 -0500</pubDate>
        </item>

        <item>
            <title>BIO and PPMD Launch Initiative to Share Best Practices on Patient Preference Studies</title>
            <description>BIO and PPMD Launch Initiative to Share Best Practices on Patient Preference Studies&lt;br /&gt;
PPMD and the Biotechnology Industry Organization (BIO) are proud to announce the launch of a new collaboration designed to share best practices for the development of disease-specific patient preference studies.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/bio-and-ppmd-launch-initiative-to-share-best-practices-on-patient?xg_source=nws_index</link>
            <guid isPermaLink="false">BF7A7E45-E341-4B1E-8485-0CA1C5B6844F-9428-000045A7143101DF-FFA</guid>
            <pubDate>Wed, 09 Dec 2015 13:16:57 -0500</pubDate>
        </item>

        <item>
            <title>Expanding the Duchenne Therapeutic Opportunities by Targeting Myostatin</title>
            <description>Our Duchenne community is well aware of the need for combination therapies. We are all hopeful that by combining several targeted therapies, we could end Duchenne, stop progression for every single individual. Regeneration of muscle and improving muscle fiber size is thought to be an important piece of the puzzle. Learn more about the current status of research &amp; clinical trials targeting Myostatin (one of the regulators of muscle regeneration) in PPMD's blog.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/expanding-the-duchenne-therapeutic-opportunities-by-targeting?xg_source=feed</link>
            <guid isPermaLink="false">8E840A97-129B-47CD-9317-A6CE09CF3ABA-19615-0000C8B058046DD3-FFA</guid>
            <pubDate>Mon, 07 Dec 2015 20:40:25 -0500</pubDate>
        </item>

        <item>
            <title>Register for PPMD's 2016 Advocacy Conference in Washington, DC (February 21-23, 2016)</title>
            <description>PPMD's Annual Advocacy Conference, held in the first quarter of each year, is the only officially organized gathering on Capitol Hill for the Duchenne community. Families affected by Duchenne will storm Capitol Hill on February 22nd and 23rd to meet with members of Congress and their staffers asking them to focus federal resources on Duchenne.  &lt;br /&gt;
</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/register-for-ppmd-s-2016-advocacy-conference-in-washington-dc</link>
            <guid isPermaLink="false">E6EFE5BE-F096-4573-891B-CC09EF9AAD0D-19615-0000C8A4A4EB446C-FFA</guid>
            <pubDate>Thu, 03 Dec 2015 20:39:50 -0500</pubDate>
        </item>

        <item>
            <title>Every gift doubled--for every single family.</title>
            <description>We're all in this together. Every single success. Every single setback. Every single one of you. Donate today and your gift will be matched dollar for dollar -- helping to fund promising early-stage research that has the potential to benefit every single person with a Duchenne diagnosis.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/every-gift-doubled-for-every-single-family?xg_source=nws_index</link>
            <guid isPermaLink="false">2406A444-071A-40D9-A2B6-194EACB7373A-4237-00002F4B99390188-FFA</guid>
            <pubDate>Mon, 30 Nov 2015 14:37:56 -0500</pubDate>
        </item>

        <item>
            <title>Take a moment today</title>
            <description>Today, PPMD is thankful for you and your family, and we promise to continue to do everything possible until we ‪end Duchenne‬ for every single one of you.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/take-a-moment-today</link>
            <guid isPermaLink="false">B22B23D3-56DD-47EF-8024-6111131C885B-4237-00002F4509B9F98B-FFA</guid>
            <pubDate>Thu, 26 Nov 2015 14:37:36 -0500</pubDate>
        </item>

        <item>
            <title>A Historic Day for Duchenne</title>
            <description>PPMD President Pat Furlong reflects on today's Advisory Committee meeting for BioMarin:&lt;br /&gt;
&quot;This community should be proud - proud of every person in this community who stood up at that microphone today in a room full of decision makers and told their story, spoke their truth (and shared their lived experience of this diagnosis). Proud of every person who submitted written testimony asking the agency to consider an approval. But most importantly, we should be proud of the incredibly brave young men and their families who participated in this trial. They are our strength. And they are why we continue to work tirelessly to end Duchenne.&quot;</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/a-historic-day-for-duchenne</link>
            <guid isPermaLink="false">D3787D13-58AC-4427-9F7D-650CE9BFF153-17004-0000A819677B3F19-FFA</guid>
            <pubDate>Tue, 24 Nov 2015 21:41:35 -0500</pubDate>
        </item>

        <item>
            <title>November 24: FDA Advisory Committee Meeting - Live Webcast Information</title>
            <description>November 24th is a historic day for the Duchenne community as we enter into our first Advisory Committee Meeting with the FDA. Make sure to watch a live stream of the Ad Comm, or follow @ParentProjectMD on Twitter, using the hashtag ‪#‎DuchenneApprovals‬ for regular live updates.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/november-24-fda-advisory-committee-meeting-live-webcast-informati</link>
            <guid isPermaLink="false">E914551E-AD51-4DFA-8169-9FE2F81FD64D-12974-0000787DC8F17C60-FFA</guid>
            <pubDate>Mon, 23 Nov 2015 15:56:41 -0500</pubDate>
        </item>

        <item>
            <title>The Big Day is Almost Here!</title>
            <description>Here’s the latest update on next week’s Ad Comm including logistical details for those attending in person, as well as how to watch a live stream from home. If you are attending, PPMD has worked closely with the FDA to make sure people needing extra assistance are comfortable throughout the day.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-big-day-is-almost-here</link>
            <guid isPermaLink="false">79EC19DF-1E61-43EF-9079-18C96F2264D5-12974-00007879E111103A-FFA</guid>
            <pubDate>Wed, 18 Nov 2015 15:56:22 -0500</pubDate>
        </item>

        <item>
            <title>FDA Advisory Committee Scenarios</title>
            <description>Visit our blog to read more about what we have learned about the FDA Advisory Committee process and watch our webinar recording.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/fda-advisory-committee-scenarios</link>
            <guid isPermaLink="false">90B7D2C8-4DF3-42F6-863D-E90DAF9D9D42-12974-000078768C4256B4-FFA</guid>
            <pubDate>Tue, 17 Nov 2015 15:56:07 -0500</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Tackling Duchenne from Every Angle</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=24451.0</link>
            <guid isPermaLink="false">0EA797AA-CF01-4F31-A893-765836E0B219-12974-000078710DCC54AD-FFA</guid>
            <pubDate>Mon, 16 Nov 2015 15:55:47 -0500</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Understanding Myostatin Inhibition</title>
            <description>Watch our webinar recording to learn more about the importance of myostatin inhibition research. Sponsored by educational partners Bristol-Myers Squibb and Pfizer, this webinar helped to put context and clarity around this treatment pathway so families have a better understanding as they see clinical trials in this area. </description>
            <link>https://www.youtube.com/watch?v=3syf02xe45Y&amp;index=1&amp;list=PLTwierE07UcbylUsK0LmFp2ncD6J_pc7l</link>
            <guid isPermaLink="false">00D885F3-489A-4AB6-BAC7-0AED704C046C-12974-0000786E157FCD31-FFA</guid>
            <pubDate>Mon, 23 Nov 2015 15:55:35 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Supports Advancing Targeted Therapies for Rare Diseases Act of 2015 (S. 2030)</title>
            <description>For over a year, PPMD has been working with congressional champions and industry partners to help lead an effort to streamlining the regulatory pathways and review processes for targeted therapeutics (which would include such things as 'follow on exons') by clarifying the FDA’s existing authority to leverage data previously used in the approval of a targeted product when approving a new therapy.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-supports-advancing-targeted-therapies-for-rare-diseases-act-</link>
            <guid isPermaLink="false">05D9DC36-A194-4DCB-913F-7E979D298A15-12974-00007869AC0F760D-FFA</guid>
            <pubDate>Thu, 12 Nov 2015 15:55:18 -0500</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Decode Duchenne Genetic Testing Program</title>
            <description>Watch our webinar recording to learn how the Decode Duchenne program works, who can apply, and why genetic testing is so important for you and your loved ones. </description>
            <link>https://www.youtube.com/watch?v=htWtq6Y-kRg</link>
            <guid isPermaLink="false">2B900B9F-04A1-4C6F-88DF-2FD8DBC3FE24-12974-0000786655F472EC-FFA</guid>
            <pubDate>Thu, 05 Nov 2015 15:54:59 -0500</pubDate>
        </item>

        <item>
            <title>Help Us Protect Your Wheelchair Technology!</title>
            <description>The Centers for Medicare and Medicaid Services (CMS) has announced that it will apply Medicare competitive bid program pricing to Complex Rehab wheelchair accessories effective January 1, 2016; an action that will likely reduce access to wheelchair features many of our families depend on. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/help-us-protect-your-technology-access-act-now-to-close-a-cms</link>
            <guid isPermaLink="false">97D2EF78-A319-4B9C-99A8-C46FF741B1A1-12974-0000786280BA14E2-FFA</guid>
            <pubDate>Tue, 03 Nov 2015 15:54:44 -0500</pubDate>
        </item>

        <item>
            <title>A Paradigm Shift in Drug Discovery</title>
            <description>The Critical Path Hill Briefing that was just held demonstrated the importance of moving from “if and when [scientists and companies] are willing to share data” to an “institutionalized sharing of data.” </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/a-paradigm-shift-in-drug-discovery</link>
            <guid isPermaLink="false">30CE5844-9095-40FD-AE46-120ACBF641D2-12974-0000785EC62F8C5F-FFA</guid>
            <pubDate>Tue, 27 Oct 2015 16:54:27 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Submits Results of Patient-Centered Benefit-Risk Assessment Study in Duchenne &amp; Becker to FDA</title>
            <description>PPMD is pleased to announce that late yesterday we submitted the results of our most recent patient-centered benefit-risk assessment study to the FDA. Based on this study, we are hopeful the FDA will have a better understanding of preferences of Duchenne patients and caregivers in regards to a specific pulmonary therapeutic target.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-submits-results-of-patient-centered-benefit-risk-assessment-</link>
            <guid isPermaLink="false">D95AE1C6-792C-427F-AD83-832074896A7A-12974-00007859E89691E3-FFA</guid>
            <pubDate>Thu, 22 Oct 2015 16:54:07 -0400</pubDate>
        </item>

        <item>
            <title>How You Can Participate in the Upcoming FDA Advisory Committee Meetings</title>
            <description>With the recent announcement of Advisory Committee (Ad Comm) dates for both BioMarin and Sarepta, families in our community are eager to be engaged and understandably have many questions. Here is a quick guide to what information has been confirmed and how you can participate.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ad-comms-update-how-to-participate</link>
            <guid isPermaLink="false">1664B2E4-22CF-483B-90E0-E7342A345D39-12974-000078564ABA36E3-FFA</guid>
            <pubDate>Tue, 20 Oct 2015 16:53:51 -0400</pubDate>
        </item>

        <item>
            <title>Ad Comms Update: Group Letter Submitted to FDA</title>
            <description>PPMD is proud to help author and share the attached letter to Dr. Janet Woodcock at the FDA. Along with CDMD at UCLA, the Duchenne Alliance, and The Race to Yes, PPMD is asking Dr. Woodcock to consider moving Sarepta’s Advisory Committee date to the same week in November as BioMarin’s.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ad-comms-update-group-letter-submitted-to-fda</link>
            <guid isPermaLink="false">E94DB0E1-A6B9-450C-BBBB-04C68B1AD4CC-12974-00007851D5385066-FFA</guid>
            <pubDate>Mon, 19 Oct 2015 16:53:35 -0400</pubDate>
        </item>

        <item>
            <title>Ad Comms Update: An Overwhelming Day</title>
            <description>We all have many questions about what the January Ad Comm date for Sarepta, after the PDUFA date for BioMarin may mean. And PPMD is working with our regulatory experts to seek those answers and to understand how we can continue to work together as a community to ensure that both products are offered regulatory pathways to success so that patients ultimately may have access to either product, if approved.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ad-comms-update-an-overwhelming-day?xg_source=nws_index</link>
            <guid isPermaLink="false">E6082244-44EA-4F99-85EA-506B369EEFFD-12974-0000784ACB0EE549-FFA</guid>
            <pubDate>Wed, 14 Oct 2015 16:53:21 -0400</pubDate>
        </item>

        <item>
            <title>PPMD’s PRO Project: Adding more tools to help with upcoming clinical trials in Duchenne</title>
            <description>Patient-report outcomes (PROs) are an important tool that allow patients and families to provide structured input about their own experiences and can be used in clinical trials and other research to help measure meaningful differences over time. Our community needs more meaningful PROs so that we have as many tools in our toolbox to help with upcoming clinical trials. That’s why PPMD wants to take a deeper dive into what is most important to you --  what would you value and expect as a result of a new therapeutic? </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-s-pro-project-adding-more-tools-to-help-with-upcoming-clinic?xg_source=nws_index</link>
            <guid isPermaLink="false">B0314BC4-B3A4-4FDC-A852-75BA76E2C197-12974-000078458858A909-FFA</guid>
            <pubDate>Tue, 13 Oct 2015 16:52:47 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Urges Senate to Move Forward on #Cures2015 Innovation for Healthier Americans Bill</title>
            <description>PPMD continues to urge Members of Congress to support the Patient-Focused Impact Assessment Act (PFIA) as part of the Innovation for Healthier Americans bill. Please help us ensure that all Senators are aware of PFIA by reaching out today. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-urges-senate-to-move-forward-on-cures2015-innovation-for?xg_source=nws_index</link>
            <guid isPermaLink="false">F4F6B296-53FB-487F-827E-FA3984267FB1-12974-000077CB3CFC6C9C-FFA</guid>
            <pubDate>Fri, 09 Oct 2015 16:52:19 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Launches Next Phase of Genetic Testing Program, Decode Duchenne in collaboration with BioMarin Pharmaceutical, PTC Therapeutics, &amp; Sarepta Therapeutics</title>
            <description>Thanks to the collaboration and generous support of these partners, Decode Duchenne will continue to provide genetic testing, interpretation, and counseling at no cost to eligible patients who are unable to access testing due to barriers such as a lack of insurance or insufficient insurance coverage. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-launches-next-phase-of-genetic-testing-program-decode-duchen</link>
            <guid isPermaLink="false">95857116-D849-41D0-BB05-7AC4346E8CA2-2609-000016D321CB07CB-FFA</guid>
            <pubDate>Wed, 30 Sep 2015 14:57:44 -0400</pubDate>
        </item>

        <item>
            <title>New Publication Demonstrates Improved Value of Cardiac MRI in Duchenne</title>
            <description>The neuromuscular group at Great Ormond Street Hospital, London UK, have recently published their study comparing the effectiveness of echocardiogram with cardiac MRI in the assessment Duchenne cardiomyopathy in patients preparing for surgical procedures. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/new-cardiac-publication-demonstrates-improved-value-of-cardiac?xg_source=facebook</link>
            <guid isPermaLink="false">A179B108-F8B1-4102-8D45-189D471A9751-2609-000016CF499FCB25-FFA</guid>
            <pubDate>Tue, 29 Sep 2015 14:57:24 -0400</pubDate>
        </item>

        <item>
            <title>The Ensuring Access to Clinical Trials Act (EACT) Passes Senate, then House;</title>
            <description>We are thrilled to report that the Ensuring Access to Clinical Trials Act of 2015 (EACT) passed a vote in the House of Representatives (after passing the Senate by unanimous consent in July) and will go to the President for his signature! This a result of everyone who contacted their Representative including over 400 families in this community alone! </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-ensuring-access-to-clinical-trials-act-eact-passes-senate</link>
            <guid isPermaLink="false">29B0590B-27D4-412B-97D2-7178C161317B-2609-000016CB68FCD0DE-FFA</guid>
            <pubDate>Tue, 29 Sep 2015 14:57:09 -0400</pubDate>
        </item>

        <item>
            <title>“Hullabaloo in Duchenne”</title>
            <description>PPMD believes in treatments for ALL. We believe that all safe and effective treatments deserve quick approval. We believe that patients, that our loved ones living with Duchenne, deserve options. Maybe you like Tylenol over Advil you have a choice to take the drug that best treats your symptoms. We need to support companies as they approach the finish line so that the decision on what treatment you or your child is prescribed is a decision you and your physicians make. Not a situation where you have no options.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/hullabaloo-in-duchenne</link>
            <guid isPermaLink="false">267942C4-6BE2-4E70-B41C-5F934EADC894-2609-000016C744FAA55E-FFA</guid>
            <pubDate>Mon, 28 Sep 2015 14:56:52 -0400</pubDate>
        </item>

        <item>
            <title>Update of the Duchenne Care Considerations</title>
            <description>PPMD’s Kathi Kinnett and Annie Kennedy have spent the last two days in Atlanta at the CDC working on an updated edition of the Care Considerations. Read Kathi’s blog to find out what the extraordinary team of Duchenne care experts assembled at the CDC have been focused on and what changes will be in the next iteration of the Care Considerations.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/update-of-the-duchenne-care-considerations</link>
            <guid isPermaLink="false">E5E0B559-F567-493B-891F-C524359552FD-2609-000016C1E74B1B08-FFA</guid>
            <pubDate>Fri, 25 Sep 2015 14:56:27 -0400</pubDate>
        </item>

        <item>
            <title>Don't Let Critical Senate Legislation Stall!</title>
            <description>On Friday, September 25th, patient advocates from across the country will unite in a day of action to urge the Senate to make medical innovation a top priority. Please help us make a difference by calling your Senators and using social media to get their attention. A delay in this legislation is a delay in life-saving treatment for patients.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/action-alert-don-t-let-critical-senate-legislation-stall</link>
            <guid isPermaLink="false">6B2E65CE-85E9-419E-8408-4435F0185EDA-2609-000016BE67331BC3-FFA</guid>
            <pubDate>Fri, 25 Sep 2015 14:56:16 -0400</pubDate>
        </item>

        <item>
            <title>FDA Advisory Committee Meetings: An Overview of the Process &amp; Ways to be Involved</title>
            <description>On September 2nd, PPMD convened a public webinar for the Duchenne community focused on FDA Advisory Committee Meetings (or “Ad Comms”). After working closely with representatives from FDA, we are excited to share some of the FAQs that arise regarding the Ad Comm process, as well as some specifically relevant to our community. As we get closer to possible dates for these meetings, we will add information as it becomes available.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/fda-advisory-committee-meetings-an-overview-of-the-process-ways-t</link>
            <guid isPermaLink="false">BE033162-14F3-4DC7-A358-6B8E4CA65766-2609-000016BAF233FA75-FFA</guid>
            <pubDate>Thu, 24 Sep 2015 14:55:54 -0400</pubDate>
        </item>

        <item>
            <title>Urge your Representative to Pass the Ensuring Access to Clinical Trials Act of 2015 (H.R. 209)</title>
            <description>We need you to encourage your House member to pass the Ensuring Access to Clinical Trials Act of 2015 (H.R. 209), let them know that clinical trial access matters to you and your family, and help us and protect patients who are participating in potentially life-saving clinical studies.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/action-alert-urge-your-representative-to-pass-the-ensuring-access</link>
            <guid isPermaLink="false">E08DEDEE-65BA-4570-97E5-CB61BCA30684-2872-000017410F26EAB5-FFA</guid>
            <pubDate>Fri, 18 Sep 2015 10:55:19 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: We See Strength in Teamwork</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews!</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=24222.0</link>
            <guid isPermaLink="false">1DFB1712-2953-42D9-9863-1112EF53340B-901-0000049666A91557-FFA</guid>
            <pubDate>Thu, 17 Sep 2015 14:34:43 -0400</pubDate>
        </item>

        <item>
            <title>Bennet, Burr, Warren, Hatch Introduce Bill to Help Patients by Facilitating Faster Development of Drugs for Rare Diseases</title>
            <description>We are thrilled to announce that the Advancing Targeted Drugs for Rare Diseases Act bill has dropped in the Senate! PPMD has been working with the Senate HELP Committee and Sarepta for the last several months on this 21st Century Cures provision which morphed into stand-alone legislation. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/bennet-burr-warren-hatch-introduce-bill-to-help-patients-by-facil</link>
            <guid isPermaLink="false">F67C2846-2251-427C-8BE3-D6A893D2C09D-901-000004927D8C8C1C-FFA</guid>
            <pubDate>Tue, 15 Sep 2015 14:34:26 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: What is an Ad Comm?</title>
            <description>PPMD asked the FDA to participate in a public webinar on September 2 – our most attended webinar to date. The webinar recording is now available for replay. Find out basic information about how Ad Comms work and what role you can play. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/webinar-recording-how-fda-ad-comms-work-what-role-you-can-play</link>
            <guid isPermaLink="false">828A4D94-13A8-417E-990F-E6A0ED2F72FF-901-0000048EBC25B253-FFA</guid>
            <pubDate>Mon, 14 Sep 2015 14:34:09 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Receives $30,000 STRIVE Award From PTC Therapeutics</title>
            <description>On the eve of the 2nd Annual World Duchenne Awareness Day, PPMD is excited to be one of five recipients of PTC Therapeutics’ STRIVE Awards! This $30,000 grant will be used to help PPMD launch a campaign for healthcare professionals and at-risk women to raise awareness about carrier issues in the Duchenne community.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-receives-30-000-strive-award-from-ptc-therapeutics</link>
            <guid isPermaLink="false">F0A52EA9-C881-4EE4-B667-E669E23DBA76-901-000004887FDF3060-FFA</guid>
            <pubDate>Thu, 17 Sep 2015 14:33:49 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Getting Involved with Coach to Cure MD!</title>
            <description>PPMD presented a webinar, Getting Involved with Coach to Cure MD on Wednesday, August 26th at 1pm eastern.</description>
            <link>https://cc.readytalk.com/cc/playback/Playback.do?id=om0j1</link>
            <guid isPermaLink="false">9E6C80DD-3936-4AB2-A1A7-5D501B939D3E-901-000004818E03B23B-FFA</guid>
            <pubDate>Wed, 26 Aug 2015 14:33:31 -0400</pubDate>
        </item>

        <item>
            <title>PPMD’s DuchenneConnect to Receive $1.4 Million Funding Award from PCORI</title>
            <description>DuchenneConnect, led by PPMD, has been approved for a three year, $1.4 million funding award by PCORI the Patient Centered Outcomes Research Institute! This funding award allows DuchenneConnect to continue our work as a member of PCORnet, the National Patient-Centered Clinical Research Network. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-s-duchenneconnect-to-receive-1-4-million-funding-award-from</link>
            <guid isPermaLink="false">D4D85B17-BA63-4325-A492-C45542AB28F4-1042-0000061C968C0743-FFA</guid>
            <pubDate>Wed, 12 Aug 2015 21:14:01 -0400</pubDate>
        </item>

        <item>
            <title>What is an Ad Comm?</title>
            <description>Ad Comm. It’s a term our community will be hearing a lot this fall as companies get closer to the possible approval of treatments for Duchenne. But what is an Ad Comm and how does it involve and affect you or your child? PPMD will host a webinar on September 2 at 1pm eastern to discuss this topic in detail. Guests will include FDA staff.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/what-is-an-ad-comm</link>
            <guid isPermaLink="false">2145AD85-18BF-40B3-9D9A-65242243DF5F-1042-0000061850F2552F-FFA</guid>
            <pubDate>Tue, 11 Aug 2015 21:13:40 -0400</pubDate>
        </item>

        <item>
            <title>Imperatives for DUCHENNE MD: A simplified guide to care for Duchenne published in PLOS</title>
            <description>PPMD is proud to present a published version of Imperatives for DUCHENNE MD a one page snapshot of Duchenne care created by a small group of international experts from PPMD, UPPMD, and TREAT-NMD. We hope you continue to find this a useful resource and we thank PLOS for helping us share this information with the medical community.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/imperatives-for-duchenne-md-a-simplified-guide-to-comprehensive?xg_source=nws_index</link>
            <guid isPermaLink="false">5E00EF87-0467-470A-AD59-60534A327528-1042-00000613457882A1-FFA</guid>
            <pubDate>Tue, 11 Aug 2015 21:13:19 -0400</pubDate>
        </item>

        <item>
            <title>One month away from World Duchenne Awareness Day!</title>
            <description>People around the world will help participate in the second annual World Duchenne Awareness Day on September 7th. There are a variety of ways you can get involved with this international effort how will you raise awareness in your community?</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/one-month-away-from-world-duchenne-awareness-day</link>
            <guid isPermaLink="false">2A8A4705-BC0D-45F5-A519-26AEA7B22538-1042-0000060E68D6E247-FFA</guid>
            <pubDate>Fri, 07 Aug 2015 21:12:59 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Submits Comments on FDA's Draft Guidance on Duchenne</title>
            <description>We are coming to the end of the 60 day open comment period for the FDA’s draft guidance on Duchenne. PPMD submitted our comments to the agency yesterday. While we hope you agree with our response, we respect alternate viewpoints. If you disagree with any comments or have other issues you think the guidance needs to address, we urge you to submit your opinions as well through the FDA public comment mechanisms. This community-wide effort continues to be acknowledged as precedent setting and a variety of rare disease groups are following in our footsteps. We have so much to be proud of and look forward to next steps with the FDA.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-submits-comments-on-fda-s-draft-guidance-on-duchenne</link>
            <guid isPermaLink="false">8B472C0E-C199-4DD4-969C-8B12F5B65C50-1042-00000609628D55BF-FFA</guid>
            <pubDate>Thu, 06 Aug 2015 21:12:40 -0400</pubDate>
        </item>

        <item>
            <title>Action ALERT: Urge your Senators to Cosponsor S. 1597, the Patient-Focused Impact Assessment Act</title>
            <description>Call and email your Senators today and urge them to sign on as a cosponsor of S. 1597, the Patient-Focused Impact Assessment Act, before they go on recess on August 8th. This is critical legislation for our community.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/action-alert-urge-your-senators-to-cosponsor-s-1597-the-patient-f</link>
            <guid isPermaLink="false">FE611459-C1CD-42B6-B444-A1B1C2835C9F-1042-00000604D88B206D-FFA</guid>
            <pubDate>Wed, 05 Aug 2015 21:12:18 -0400</pubDate>
        </item>

        <item>
            <title>Different Together: PPMD Announces the Duchenne Regulatory Science Consortium</title>
            <description>PPMD is thrilled to announce the launch of the Duchenne Regulatory Sciences Consortium (D-RSC) with the Critical Path Institute! Each instance of Duchenne seems to be as unique as the person it affects. The D-RSC will begin by aggregating a wide array of clinical data for analysis by consortium members, with the goal of developing a disease progression model that can be used in the development of new treatments, and reduce the amount of time it takes to get them to people living with Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/different-together-ppmd-announces-the-duchenne-regulatory-science</link>
            <guid isPermaLink="false">8DCEFBF1-CDA1-49A7-B1B1-C00662C2548E-1042-000005FF8C221E56-FFA</guid>
            <pubDate>Mon, 03 Aug 2015 21:11:57 -0400</pubDate>
        </item>

        <item>
            <title>Changes to Deflazacort Ordering Process (via Masters Pharmaceuticals)</title>
            <description>Masters now has an increasing supply of Deflazacort (a steroid available to treat Duchenne outside the US). However, due to recent regulatory changes, changes have been made to the ordering process to assure that the company is able to continue to supply Deflazacort to US families.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/masters-deflazacort-personal-importation</link>
            <guid isPermaLink="false">9B8DCD70-412F-416B-A74D-EC269C71E050-1042-000005FB847AC38F-FFA</guid>
            <pubDate>Mon, 27 Jul 2015 21:11:33 -0400</pubDate>
        </item>

        <item>
            <title>PPMD's 2015 Connect Conference Resources &amp; Recordings</title>
            <description>Presentations from PPMD’s 21st Annual Connect Conference in Washington, D.C. are now available for download.  </description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_presentations_15</link>
            <guid isPermaLink="false">9A7C56D7-81B0-476E-8F5C-126C83AA2995-1042-000005F6EE8C4013-FFA</guid>
            <pubDate>Tue, 21 Jul 2015 21:11:16 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Awards $70,000 Grant to Talem Technologies as Part of Robotics Initiative</title>
            <description>PPMD is proud to award Talem Technologies with a grant for over $70,000 to support a pilot study of their X-Ar exoskeletal arm technology. This grant is a direct result of your donation this spring for our Robotics Initiative. We believe in the X-Ar arm and other technologies that we believe will maintain muscle function and foster independence. Thank you for supporting our robotics program and congratulations to Talem Technologies!</description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_presentations_15</link>
            <guid isPermaLink="false">32414B39-AAA5-4E82-816E-4263DCA5D1FB-1042-000005F1331B595F-FFA</guid>
            <pubDate>Wed, 12 Aug 2015 21:11:04 -0400</pubDate>
        </item>

        <item>
            <title>BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Amenable to Exon 51 Skipping</title>
            <description>The Duchenne community should celebrate. Today, Biomarin submitted the rolling NDA on drisapersen. This means we now have a second NDA submitted for Duchenne. Santhera is likely to follow soon. By first quarter 2016, we may see 3 approved drugs with more to follow. This is exactly what we have been working for, hoping for.</description>
            <link>http://investors.bmrn.com/releasedetail.cfm?ReleaseID=908731</link>
            <guid isPermaLink="false">9A2531AD-7B79-4DF8-8918-4F7BA6477FF5-14066-00007080FC86AA1B-FFA</guid>
            <pubDate>Thu, 30 Apr 2015 16:25:55 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Awards $148,000 Grant to University of Washington</title>
            <description>Exon skipping and gene replacement are leading candidate therapeutics in the Duchenne space right now. It is our hope that Dr. Froehner’s project will help improve decision making in the design and targeting of both exon skipping oligonucleotides and gene therapy vectors so that patients receive the best therapy possible and the chances of approvals in a timely manner are increased.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/parent-project-muscular-dystrophy-awards-148-000-grant-to-univers</link>
            <guid isPermaLink="false">B174D413-4EBB-4830-84B0-B11FA4BA586C-14066-0000707D97388203-FFA</guid>
            <pubDate>Thu, 30 Apr 2015 16:25:46 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: FOR-DMD Study</title>
            <description>The recording of our webinar on the FOR-DMD study (developing standardized corticosteroid treatment for Duchenne) is now available. Included in the webinar is an overview of the aims of the FOR-DMD study, along with a discussion of why the study is particularly relevant in regard to current/future Duchenne clinical trials.</description>
            <link>https://www.youtube.com/watch?v=W7B24zpBrDw</link>
            <guid isPermaLink="false">FD94E16C-99C7-40CD-854C-243501DECA4F-14066-0000707AECE7542E-FFA</guid>
            <pubDate>Thu, 30 Apr 2015 16:25:31 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: PPMD Launches Robotics Initiative</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews!</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?dlv_id=19221&amp;em_id=23322.0</link>
            <guid isPermaLink="false">1E756222-61FB-4F23-AF32-4DEAE70F310D-14066-000070758E8FCC7A-FFA</guid>
            <pubDate>Thu, 30 Apr 2015 16:25:09 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording &amp; Summary: Orthopedic Complications in Duchenne</title>
            <description>If you missed our webinar on Orthopedic Complications in Duchenne (covering contractures, scoliosis, &amp; fractures), you can now access a recording of the webinar online. Summary notes and responses to additional questions we received during the webinar are also available. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/orthopedic-complications-in-duchenne-webinar-summary-recording</link>
            <guid isPermaLink="false">640E3D57-BE5D-41F6-9F15-18039205CA96-14066-00007071B7169D7C-FFA</guid>
            <pubDate>Thu, 30 Apr 2015 16:24:53 -0400</pubDate>
        </item>

        <item>
            <title>Recapping the FDA-NIH Dystrophin Methodology Workshop</title>
            <description>PPMD CEO, Dr. John Porter, recaps yesterday's FDA and NIH dystrophin methodology workshop. This was an important moment for the Duchenne community and PPMD was honored to be a part of it. Thank you to all the families who came to the meeting.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/recapping-the-fda-nih-dystrophin-methodology-workshop</link>
            <guid isPermaLink="false">367CC946-DFC8-4453-8529-4FFC985C86BB-1180-000008E4D76FA027-FFA</guid>
            <pubDate>Sat, 21 Mar 2015 18:13:28 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Participating in FDA-NIH Dystrophin Methodology Meeting on Friday, March 20</title>
            <description>PPMD is grateful that the FDA and NIH are willing to discuss dystrophin and have opened their doors to include our community leaders. &lt;br /&gt;
If you would like to attend Friday’s public scientific workshop, see details here: http://1.usa.gov/1GYNSpV. If you cannot attend but would like to watch a live stream of the meeting, view this link Friday morning to attend virtually: http://1.usa.gov/1GYNSpV.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-participating-in-fda-nih-dystrophin-methodology-meeting-on</link>
            <guid isPermaLink="false">9DC5038F-E3BC-4C06-B45D-DE58FECC7331-946-00000891ECF2B201-FFA</guid>
            <pubDate>Wed, 18 Mar 2015 10:22:22 -0400</pubDate>
        </item>

        <item>
            <title>Dollars Destroying Duchenne</title>
            <description>PPMD loves creative, out-of-the-box fundraisers that raise awareness. This new, annual event from Davenport, FL is a great example of something you can do in your community. Read organizer Diana Rodriguez’s story and don’t hesitate to reach out to us with your own ideas. PPMD has all the tools you need to create a truly memorable and important event!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/dollars-destroying-duchenne?xg_source=feed</link>
            <guid isPermaLink="false">1A69735D-46EC-46E7-B191-060B5EEED909-946-00000888C02D9BA5-FFA</guid>
            <pubDate>Wed, 18 Mar 2015 10:33:39 -0400</pubDate>
        </item>

        <item>
            <title>Registration for PPMD's 2015 Connect Conference is Now Open</title>
            <description>Parent Project Muscular Dystrophy’s Annual Connect Conference is a unique convergence of industry partners, scientific leaders, medical providers, people living with Duchenne, and their families. This exceptional meeting has grown to be recognized worldwide as the foremost Duchenne muscular dystrophy meeting. But more than that, it is a way for families affected by Duchenne to connect with each other. To build support networks. To realize no one is on their own in the fight to end Duchenne.&lt;br /&gt;
&lt;br /&gt;
This year, 2015, marks our 21st Connect Conference. With the Duchenne landscape changing in so many ways, this year’s meeting will help you understand the nuances of Duchenne including the latest in research and care, open communication channels between thought leaders in the field, and lay the groundwork for future collaborations. PPMD's Annual Connect Conference shapes our understanding of the Duchenne landscape. It brings together the people living with Duchenne with the people who have dedicated their lives to finding therapies for Duchenne.&lt;br /&gt;
&lt;br /&gt;
- See more at: http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_2015#sthash.5dQa7DAZ.dpuf</description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_2015</link>
            <guid isPermaLink="false">F0796900-F2B4-446C-B910-2427805B2C96-946-0000087DDD9E3D89-FFA</guid>
            <pubDate>Wed, 18 Mar 2015 10:20:45 -0400</pubDate>
        </item>

        <item>
            <title>Spring Forward: Bringing the MD-CARE Act to Life</title>
            <description>Despite great odds in a political climate that was stacked against us – we achieved what was considered to have been impossible. After months of outreach to congressional champions and visits to Capitol Hill, the MD-CARE Act Amendments were passed and signed into law in the end of 2014.&lt;br /&gt;
Now what? Well… now the real work of implementation actually begins. On Tuesday, March 17, the Muscular Dystrophy Coordinating Committee (MDCC) will be taking the first formal step to bring the MD-CARE Act Amendments to life – and our community will officially Spring forward!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/spring-forward-bringing-the-md-care-act-to-life</link>
            <guid isPermaLink="false">9A346095-2262-4342-A76F-44C301C5E788-946-000008765711491C-FFA</guid>
            <pubDate>Wed, 18 Mar 2015 10:19:54 -0400</pubDate>
        </item>

        <item>
            <title>What is Epicatechin?</title>
            <description>Epicatechin. It’s a word that is starting to pop up more and more in the Duchenne community. But was is it? PPMD helps explain this exciting potential therapy now in the early stages of development.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/what-is-epicatechin</link>
            <guid isPermaLink="false">32C7F4EC-F143-433E-9D4C-A4F0F91A57CD-946-00000860F37A03AB-FFA</guid>
            <pubDate>Wed, 18 Mar 2015 10:19:26 -0400</pubDate>
        </item>

        <item>
            <title>Recall Notice for Deflazacort 30mg</title>
            <description>If you receive this recall notice and/or think that you may have an affected batch (J021 [expiry 30/06/2017] or J028 [expiry 30/09/2017]), you should contact your provider and ask them to replace it with a prescription for prednisone to take until you get your new batches of deflazacort. Do not take deflazacort that is part of the affected batch. As more information becomes available, we will share it with the community immediately. If you have any further questions call your neuromuscular provider.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/recall-notice-for-deflazacort-30mg</link>
            <guid isPermaLink="false">75BA714D-5875-40F7-9ED1-1B6139BF8998-870-0000026CB5C0D1A4-FFA</guid>
            <pubDate>Mon, 16 Mar 2015 10:07:46 -0400</pubDate>
        </item>

        <item>
            <title>Urge Congress to Sign Duchenne Funding Letter</title>
            <description>PPMD’s Annual Advocacy Conference in February was a huge success! Now the important follow up needs to happen. Please take one minute to send an important action alert to urge Congress to continue focusing federal resources on Duchenne. The deadline for House members to sign onto the funding letter is March 20, 2015, so please take action today!</description>
            <link>https://secure2.convio.net/ppmd/site/Advocacy?cmd=display&amp;page=UserAction&amp;id=193</link>
            <guid isPermaLink="false">A314B534-FAF4-46E0-B174-9C934A354E5F-870-0000026A10461BB2-FFA</guid>
            <pubDate>Mon, 16 Mar 2015 10:07:55 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Names Stanford Comprehensive Neuromuscular Clinic at Lucile Packard Children’s Hospital a Certified Duchenne Care Center</title>
            <description>Dr. Day has been a longtime partner in the Duchenne community, as an advocate for both optimal care in the patient community and as a leading researcher in muscular dystrophy. The clinical team he has assembled at Stanford is a shining example of the skill, compassion, and understanding we look for in certifying clinics.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-names-stanford-comprehensive-neuromuscular-clinic-at-lucile-</link>
            <guid isPermaLink="false">509B8C0A-2FB5-44AC-AA56-59AB4B5DBB4B-870-000002665FBFD7C8-FFA</guid>
            <pubDate>Mon, 16 Mar 2015 10:07:17 -0400</pubDate>
        </item>

        <item>
            <title>Dystrophin 101 Webinar Recording</title>
            <description>The recording of our &quot;Dystrophin 101&quot; webinar is now available. Watch now to learn more about the basic biology of dystrophin, how dystrophin is measured in both preclinical studies and clinical trials, and the need for and role that dystrophin analysis play in clinical trials of novel agents designed to exert their therapeutic effects through an increase in dystrophin levels. Our speakers also discussed what is required in order to have dystrophin considered as a surrogate.</description>
            <link>https://www.youtube.com/watch?v=3VFIXq_h0VE</link>
            <guid isPermaLink="false">3BE164C0-11AF-431A-BBB8-E4AD832DD16C-870-00000261C00A487F-FFA</guid>
            <pubDate>Mon, 16 Mar 2015 10:07:10 -0400</pubDate>
        </item>

        <item>
            <title>We Need YOU to Help Us With the Development of the Solid Suit</title>
            <description>PPMD is partnering with some really smart folks to develop wearable technology to enhance strength for people with Duchenne and Becker muscular dystrophy. The Solid Suit is envisioned to be a soft, wearable, assistive device. Conceptually, it could be worn under one’s clothing – next to his/her skin (picture Spider-Man’s suit). The Solid Suit team has been hard at work over the last few months, and we are now turning to the experts with our community – YOU – to help inform the design of the project through a community survey.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/we-need-you-to-help-us-with-the-development-of-the-solid-suit</link>
            <guid isPermaLink="false">64C27F2E-37E3-4428-B325-49408AA7A873-437-0000008F8FF954B6-FFA</guid>
            <pubDate>Mon, 02 Mar 2015 16:04:10 -0500</pubDate>
        </item>

        <item>
            <title>Important New Duchenne Steroid Protocol: Download the &quot;PJ Nicholoff Steroid Protocol&quot;</title>
            <description>Families living with Duchenne muscular dystrophy are aware that maintaining regular doses of corticosteroids is important, but “why” and “how” can be confusing. We have worked together with experts to develop a tool that hopes to simplify these issues. Keep this protocol available to you, and your medical providers, in case of a medical emergency or admission.&lt;br /&gt;
Important steroid protocol topics covered: &lt;br /&gt;
- Corticosteroid conversions/equivalent doses&lt;br /&gt;
- Appropriate corticosteroid stress doses&lt;br /&gt;
- Recommendations for corticosteroid withdrawal&lt;br /&gt;
- Symptoms of adrenal crisis&lt;br /&gt;
- Tests that can help diagnose adrenal crisis&lt;br /&gt;
- Defining HPA suppression in a patient using corticosteroids&lt;br /&gt;
- How to test the HPA axis for continued suppression</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/important-new-duchenne-steroid-protocol-make-sure-your-provider?xg_source=facebook</link>
            <guid isPermaLink="false">5F8C8612-44C1-4E86-9A0A-D047F1D700B0-437-00000083599BF2FE-FFA</guid>
            <pubDate>Mon, 02 Mar 2015 16:03:40 -0500</pubDate>
        </item>

        <item>
            <title>PPMD &amp; FED Award $1 Million Grant to ReveraGen BioPharma</title>
            <description>Parent Project Muscular Dystrophy (PPMD) is excited to join forces with Foundation to Eradicate Duchenne (FED) to award ReveraGen BioPharma a $1 million grant to help fund the chronic toxicology program for VBP15, a combined action drug that addresses multiple levels of Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/parent-project-muscular-dystrophy-foundation-to-eradicate-duchenn</link>
            <guid isPermaLink="false">6BCEBA99-BB45-455B-BF3E-91028DE96088-437-0000007EEE865363-FFA</guid>
            <pubDate>Mon, 02 Mar 2015 16:02:46 -0500</pubDate>
        </item>

        <item>
            <title>Upcoming Webinar: Dystrophin 101</title>
            <description>Join us for a webinar on &quot;Dystrophin 101: Everything You Always Wanted to Know About the Duchenne Protein (And Were Not Afraid to Ask)&quot; on March 3, 2015 from 1pm to 2pm ET.</description>
            <link>http://community.parentprojectmd.org/events/dystrophin-101-everything-you-always-wanted-to-know-about-the-duc</link>
            <guid isPermaLink="false">7B07E81A-771C-4ADD-9939-68C3F37EC767-437-000000791FAF61CB-FFA</guid>
            <pubDate>Mon, 02 Mar 2015 16:02:29 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Awards University of Missouri $50,000 Exploratory Grant to Explore SERCA2A in Duchenne Dog Study</title>
            <description>PPMD has awarded a $50,000 Exploratory Grant to University of Missouri to test SERCA2A gene therapy as a potential treatment for dogs with Duchenne. Dr. Dongsheng Duan, a longtime researcher in Duchenne and a member of PPMD’s Scientific Advisory Committee, leads the project.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-awards-university-of-missouri-50-000-exploratory-grant-to-ex</link>
            <guid isPermaLink="false">61DB2DF0-F1D1-4626-9E95-7D9EA677C12E-1449-000010BBF56B2D70-FFA</guid>
            <pubDate>Tue, 17 Feb 2015 14:07:21 -0500</pubDate>
        </item>

        <item>
            <title>Your Action Plan for the Muscular Dystrophies</title>
            <description>The 2015 Action Plan from the Muscular Dystrophy Coordinating Committee (MDCC) is now available for public comment. PPMD encourages all members of the Duchenne community to provide comments, in particular to ensure that the patient and family voice is heard in the Action Plan. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/your-action-plan-for-the-muscular-dystrophies</link>
            <guid isPermaLink="false">AA5F4BFD-591C-4495-95B2-C486ACF18212-1449-000010B8D38779BF-FFA</guid>
            <pubDate>Tue, 17 Feb 2015 14:07:09 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Names University of Iowa Children’s Hospital a Certified Duchenne Care Center</title>
            <description>With this certification, PPMD recognizes the quality of the neuromuscular care for children living with Duchenne provided by the multidisciplinary team led by Katherine Mathews, MD. This team illustrates the dedication to the Duchenne community that the certification program seeks to promote.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-names-university-of-iowa-children-s-hospital-a-certified-duc</link>
            <guid isPermaLink="false">3759FDC3-1AE3-4096-903E-12310A238CD4-1449-000010B4786B0CA2-FFA</guid>
            <pubDate>Tue, 17 Feb 2015 14:06:53 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Awards UCLA $50,000 Exploratory Grant for Evaluation of Exon Skipping Enhancers in Duchenne</title>
            <description>PPMD is excited to award Dr. Carrie Miceli and her team at UCLA’s David Geffen School of Medicine and College of Letters and Science, a $50,000 exploratory grant to continue their evaluation of exon skipping boosters for the treatment of Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/parent-project-muscular-dystrophy-awards-ucla-50-000-exploratory-</link>
            <guid isPermaLink="false">876C9287-4C39-4E3C-AF8A-AFFFD4638B35-1955-00001D9D775A2242-FFA</guid>
            <pubDate>Fri, 30 Jan 2015 16:12:44 -0500</pubDate>
        </item>

        <item>
            <title>Get Active in Advocacy</title>
            <description>2014 was a historic year in our community. 2015 promises to be another critical year in Duchenne and we need you to help keep the momentum going! With such a big year, it is more important than ever to get involved. Our Annual Advocacy Conference is one month away. We urge everyone to lend your voice, your story, to our efforts in Washington. You don’t have to travel to Washington to be an effective advocate.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/get-active-in-advocacy</link>
            <guid isPermaLink="false">F6F701A6-FDA6-4889-B860-4A2EB0301E95-1955-00001D9A754CB7B9-FFA</guid>
            <pubDate>Fri, 30 Jan 2015 16:12:30 -0500</pubDate>
        </item>

        <item>
            <title>FDA Acknowledges the Importance of Benefit-Risk Preferences: Why this Matters to Duchenne</title>
            <description>Recently the FDA approved a device used to treat obesity, based in part on the results of the preferences study that showed that patients would accept uncertainty about benefits. An FDA spokeswoman said that the FDA believes patients and caregivers who live with a condition should have a say when approving a product, and may have a different view about striking the right risk-benefit balance. This could have incredible significance in the Duchenne community and makes our ongoing benefit/risk work all the more critical. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/fda-acknowledges-the-importance-of-benefit-risk-preferences-why</link>
            <guid isPermaLink="false">F9351104-99D5-4014-A348-21C0AF178F08-1955-00001D9763F5ABD4-FFA</guid>
            <pubDate>Fri, 30 Jan 2015 16:12:19 -0500</pubDate>
        </item>

        <item>
            <title>Important Vaccinations Recommendations</title>
            <description>Vaccinations are important to protect us against infection and disease but they are also confusing. Adding Duchenne medications, pulmonary, and cardiac function to the picture adds even more confusion. In order to answer the regularly asked questions, “to give or not to give, when to give, how to give and what to give,” we have teamed up with the CDMD at UCLA to provide recommendations. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/important-vaccinations-recommendations</link>
            <guid isPermaLink="false">4B723B45-7877-4DA1-9312-2E0334909DDA-1955-00001D943B138188-FFA</guid>
            <pubDate>Fri, 30 Jan 2015 16:12:04 -0500</pubDate>
        </item>

        <item>
            <title>BMS &amp; The Voice of the Patient</title>
            <description>It is a good day when a global biopharmaceutical company commits to focusing on Duchenne. We are grateful that Bristol-Myers Squibb (BMS) has added another possibility for our toolbox of hope!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/bms-the-voice-of-the-patient</link>
            <guid isPermaLink="false">687A1E21-EF33-4015-B365-5758BAE3F7EC-1955-00001D8E91FADC31-FFA</guid>
            <pubDate>Fri, 30 Jan 2015 16:11:52 -0500</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: New Year, Same Mission</title>
            <description>End Duchenne eNews: New Year, Same Mission&lt;br /&gt;
Catch up on the latest research and community updates in this month's End Duchenne eNews!</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?dlv_id=19141&amp;em_id=22742.0</link>
            <guid isPermaLink="false">F366BEF5-A6DB-4574-B586-DDA289DC1BAF-661-000000F535DB94E9-FFA</guid>
            <pubDate>Tue, 20 Jan 2015 10:15:06 -0500</pubDate>
        </item>

        <item>
            <title>Meet Our 2015 PPMD Adult Advisory Council</title>
            <description>The PPMD Adult Advisory Council (PAAC) serves to ensure that the voices of adults living with Duchenne and Becker muscular dystrophy are reflected in PPMD’s legislative, policy, and program activities. PAAC members serve in a formal advisory capacity for their respective term and maintain leadership over a PAAC initiative throughout that term; PAAC initiatives are determined by the PAAC membership and PPMD Executive Team. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/meet-our-2015-ppmd-adult-advisory-council</link>
            <guid isPermaLink="false">E78C9B38-D80A-474B-815F-0DA56CFEA68A-661-000000F90D9E4077-FFA</guid>
            <pubDate>Tue, 20 Jan 2015 10:15:21 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Welcomes New CEO, John Porter, PhD</title>
            <description>PPMD is thrilled to welcome our new CEO, Dr. John Porter! As CEO, John will help PPMD continue to integrate programs to maximize impact, building upon current programs and exploring opportunities to expand the research pipeline, with the goal of accelerating progress and approvals. John joins PPMD Founding President Pat Furlong and Chief Operating Officer, Kimberly Galberaith, in leading the organization. As founding president, Pat will continue to provide strategic direction of PPMD in support of the mission she helped set forth 20 years ago in honor of her sons and all families affected by Duchenne. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/welcome</link>
            <guid isPermaLink="false">089D30BF-CD50-4D3B-B23F-5CDA413927A9-661-000000FCA6DCD373-FFA</guid>
            <pubDate>Tue, 20 Jan 2015 10:15:40 -0500</pubDate>
        </item>

        <item>
            <title>Update on the 2015 Flu</title>
            <description>Even after receiving vaccination, many people are still contracting the flu this season. Read an update on the latest flu strains as well as important information on how to treat the flu if you or your child has Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/update-on-the-2015-flu</link>
            <guid isPermaLink="false">8CF11982-CA58-4591-BD3A-9D538B2427BB-661-000001018786F01D-FFA</guid>
            <pubDate>Tue, 20 Jan 2015 10:15:55 -0500</pubDate>
        </item>

        <item>
            <title>Thank You! Strength Happens Together!</title>
            <description>In early December, we asked you to help PPMD raise $400,000 for combination therapies an innovative approach to treating Duchenne. It was an ambitious goal for an ambitious project. And, thanks to YOU, we did it! In fact, we surpassed it, raising more than $430,000. Thank you to everyone who donated, thank you to Cure Dale’s Duchenne, and thank you to Rally for Ryan. Strength happens together. And together, we will end Duchenne.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=22682.0</link>
            <guid isPermaLink="false">C1F3D1F6-C7E0-482E-8D4E-BDB2E4EF7B4E-661-00000104805774D8-FFA</guid>
            <pubDate>Tue, 20 Jan 2015 10:16:12 -0500</pubDate>
        </item>

        <item>
            <title>Heart Failure Drugs Slow Deadly Damage in Duchenne, Offering New Hope</title>
            <description>In a new study led by Dr. Subha Raman of The Ohio State University Wexner Medical Center, researchers were able to dramatically slow the rate of heart damage in patients with Duchenne muscular dystrophy by using a combination of well-established drugs. Thank you for helping PPMD fund this promising research!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/heart-failure-drugs-slow-deadly-damage-in-duchenne-offering-new</link>
            <guid isPermaLink="false">61973659-838D-44E7-BEAF-80CB5F0B254D-661-00000108DD3A8971-FFA</guid>
            <pubDate>Tue, 20 Jan 2015 10:16:27 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Calls for Greater Transparency and Accountability of FDA Patient Engagement Efforts</title>
            <description><![CDATA[Parent Project Muscular Dystrophy (PPMD) is urging Congress to build upon gains in recent years to further strengthen and enhance programs to ensure the patient voice is heeded during the drug development process during a Congressional briefing tomorrow, Tuesday, December 9th at noon.<br />
 <br />
A champion of policies to enhance the voice of the patient within vital Food and Drug Administration (FDA) deliberations, PPMD is advocating for provisions within the 21st Century Cures Initiatives focused on measuring how the agency is or is not using new patient engagement tools. PPMD and other stakeholders will be presenting on the reform proposal during the briefing tomorrow afternoon.<br />
 <br />
Reform Proposals for 21st Century Cures Initiative<br />
We have seen significant progress over the years in how the FDA pays attention to the voice of the patient. PPMD has been focused relentlessly on this issue and has produced several groundbreaking tools intended to achieve this goal. Now, we must know that this work is bearing fruit and that FDA will actually be using these new tools as they review therapies for Duchenne and beyond.<br />
Dubbed the Patient-Impact Assessment Act, PPMD would like to see a simple and publicly accessible measurement tool developed whereby FDA reviews could note how they did or did not take various patient-focused drug development tools and resources into account in evaluating products and making their decisions. Such an assessment tool would shed light into how Patient Focused Drug Development (PFDD) tools and authorities are or are not being used and would help identify gaps or shortcomings in the space.<br />
In addition to PPMD, leaders from FasterCures and the Pharmaceutical Research and Manufacturers of America (PhRMA) will also be presenting on related PFDD efforts and recommendations.<br />
“Across the whole continuum of discovery, development, and delivery a new focus on the patient is changing culture, practice, and policy. PPMD has pioneered a new model for advancing the science of patient input, one that will help transform the way in which patient perspectives are collected and understood. FasterCures champions a broader partnership of patient, industry, and government organizations to further define the science of patient input and use it to inform decision-making at all levels; the 21st Century Cures Initiative has reinforced the potential for this collaborative approach.”<br />
– Kim McCleary, director of strategic initiatives at FasterCures <br />
Invite Your Members of Congress to the Briefing<br />
Please urge your members of Congress and their staff to attend this important briefing hosted by PPMD tomorrow, Tuesday, December 9th on the 21st Century Cures Initiative. We welcome all members of the community to attend as well.<br />
<br />
Via email: Click here to send the invite to your members (it takes less than a minute!)<br />
Via phone: Take it one step further! Make a call. Call your members offices and tell them to send a representative. Ask to speak with the health legislative assistant. You can find you members offices by clicking here. Be sure to call both Senate offices and your House rep.<br />
Remember, the more constituents the members hear from the better – Ask your family and friends to send the invite as well!]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-calls-for-greater-transparency-and-accountability-of-fda</link>
            <guid isPermaLink="false">6ACC0CCA-C9B2-4146-907B-60257FFA86C1-6723-00002B15E561F19A-FFA</guid>
            <pubDate>Mon, 08 Dec 2014 16:52:02 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Awards Akashi Therapeutics, Inc. $500,000 Grant</title>
            <description><![CDATA[Parent Project Muscular Dystrophy (PPMD) has awarded Akashi Therapeutics, Inc. (Akashi) a $500,000 grant to fund clinical trials to test the safety and efficacy of an investigational new drug known as HT-100 (delayed-release halofuginone).<br />
HT-100 is an orally available small molecule drug candidate being developed to reduce fibrosis and inflammation and to promote healthy muscle fiber regeneration in Duchenne patients. The application of HT-100 to Duchenne and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute in Israel. Akashi, led by CEO Marc Blaustein, has been granted orphan designation for Duchenne in both the U.S. and EU, as well as Fast Track designation in the U.S. A phase 1b/2a clinical program is currently underway at five hospitals across the U.S.<br />
 <br />
The grant will be used to evaluate the safety, tolerability and pharmacokinetics of HT-100 in patients with Duchenne in both a phase 1b open-label, single and multiple ascending dose study and a phase 2a extension study.<br />
 <br />
Funding for the project from PPMD has been awarded based on a positive review by PPMD’s Scientific Advisory Committee, composed of key clinicians and scientists in the field and upon the basis of a review by the TREAT-NMD Advisory Committee on Therapeutics (TACT), whose review activities are supported, in part, by PPMD.<br />
 <br />
Preclinical studies in young mice that lack dystrophin demonstrated that HT-100 reduced the amount of fibrosis that accumulates in the heart and diaphragm muscles and improved the ability of the mice to cling to a rotating rod.  In older mice with established fibrosis in the diaphragm muscle the compound was able to reverse fibrosis and improve respiratory and cardiac function.<br />
“Marc Blaustein and the team at Akashi are innovators and leaders in the Duchenne space. We are thrilled to be able to support this next critical step in the journey of HT-100, a therapy that we believe in. PPMD is excited to partner with Akashi and appreciate that, like us, they believe it is as important for a drug to be safe, as it is to be effective.”<br />
-- PPMD’s Founding President and CEO, Pat Furlong <br />
“PPMD was an early supporter of our efforts to develop HT-100 and this funding—following a thorough scientific review—comes at a crucial time as we continue to generate both safety and efficacy data from the HT-100 clinical program in boys with DMD. We are grateful for PPMD’s continued financial support and pleased to build on our already-strong relationship with PPMD and the broader DMD patient community.”<br />
-- Akashi CEO Marc Blaustein<br />
]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/parent-project-muscular-dystrophy-awards-akashi-therapeutics-inc-</link>
            <guid isPermaLink="false">C79A3E7F-4252-4437-B077-F881C92F57ED-6723-00002B10E5405122-FFA</guid>
            <pubDate>Mon, 08 Dec 2014 16:51:42 -0500</pubDate>
        </item>

        <item>
            <title>ABLE Act Changes Disability Landscape –
This just got real!</title>
            <description>Thank you to the House of Representatives for voting in favor of civil rights for Americans with disabilities today by passing the ABLE Act (S. 313/ HR 647)! With legendary bipartisan support in both the House and Senate, the ABLE Act amends Section 529 of the Internal Revenue Service Code of 1986 to create tax-free savings accounts for individuals with disabilities. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/able-act-changes-disability-landscape-this-just-got-real</link>
            <guid isPermaLink="false">D99112F4-D9AE-4C60-8A14-3176F686E67F-6723-00002B0E4DD286E7-FFA</guid>
            <pubDate>Mon, 08 Dec 2014 16:50:46 -0500</pubDate>
        </item>

        <item>
            <title>Webinar Recording &amp; Summary: Duchenne Pulmonary Care for Adults</title>
            <description>A summary and recording of last week's pulmonary care webinar is now available. Thank you to Dr. Daniel Sheehan and Dr. Lisa Wolfe for such an informative discussion.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/duchenne-pulmonary-care-for-adults-webinar-summary-recording</link>
            <guid isPermaLink="false">A8AD2165-66AF-4221-B147-4D1128AE9246-6723-00002B0C0C159B66-FFA</guid>
            <pubDate>Mon, 08 Dec 2014 16:50:35 -0500</pubDate>
        </item>

        <item>
            <title>Combine therapies. Combine forces.</title>
            <description>In 2015, PPMD will invest $600,000 to further the advancement of combination therapies in Duchenne. To start, we need to raise $400,000 this holiday season. We know that sounds big, but thanks to our partners, it’s within reach—every gift today goes twice as far thanks to two Duchenne foundations that, like us, believe in the importance of combined therapies to treat this horrible disease.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/combine-therapies-combine-forces</link>
            <guid isPermaLink="false">B9B74ABD-E7E0-4A1F-A0E6-B92C9503E351-1810-000013EFF4278B04-FFA</guid>
            <pubDate>Mon, 01 Dec 2014 16:18:42 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Names Baltimore’s Kennedy Krieger Institute a Certified Duchenne Care Center</title>
            <description>Kennedy Krieger Institute in Baltimore, Maryland was named a Certified Duchenne Care Center by Parent Project Muscular Dystrophy (PPMD), the leading advocacy organization working to end Duchenne muscular dystrophy (Duchenne). Kennedy Krieger Institute is the fifth center to be certified by PPMD, recognizing the Institute’s dedication to improving care for people living with Duchenne.
</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-names-baltimore-s-kennedy-krieger-institute-a-certified-duch</link>
            <guid isPermaLink="false">6036C463-EF0F-42B5-BB30-44D4D87B367F-1618-000013AF7747418F-FFA</guid>
            <pubDate>Thu, 20 Nov 2014 13:22:37 -0500</pubDate>
        </item>

        <item>
            <title>Patients Are Waiting...</title>
            <description>The FDA is listening and has told us as much. But that doesn’t mean we should stop doing everything we can to educate the Agency.&lt;br /&gt;
&lt;br /&gt;
Thanks to the dozens of you who participated in PPMD’s benefit/risk project and took the time to share your story, we have been able to compile your responses and will be providing the FDA with “Patients Are Waiting…” (download PDF). Collected on our community site, we have referenced these stories in our interactions with the FDA over the last several months but we wanted them to really understand the urgency of our collective voice, the volume of our collective cries.&lt;br /&gt;
&lt;br /&gt;
These are your stories, your messages to the Agency demanding that they use all the tools at their disposal to make decisions efficiently. We don’t have time.&lt;br /&gt;&lt;br /&gt;
We will continue to use these stories as we support our collective cause—faster access to new treatments.
</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/patients-are-waiting</link>
            <guid isPermaLink="false">94AB0670-C5F5-44E6-8423-FD7050ABAA0E-6144-000046E02A7BFF4D-FFA</guid>
            <pubDate>Tue, 04 Nov 2014 08:59:15 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Submits Letter to FDA Regarding Latest Sarepta Update</title>
            <description>Today’s press release and investor call from Sarepta have sent a ripple of angst and sadness through our community. Moments ago, PPMD sent a letter to the FDA that reflects our organization’s belief that safety and rigor have been demonstrated throughout this process. Further, we believe that any strengthening of data packages that causes delays (as is now being requested by the FDA, as articulated in today’s press release and call) should ensure a streamlined, more expeditious approval process for follow-on exons.&lt;br /&gt;
 &lt;br /&gt;
As a community we believe exon-skipping drugs like eteplirsen hold potentially life-altering benefits, and must be moved forward as rapidly as possible. In addition, we believe eteplirsen to be a critical foundational therapy, restoring dystrophin and significantly slowing disease progression. We look forward to the mid-2015 submission and approval of eteplirsen and the consideration of approval of PMO (phosphodiamidate morpholino oligomer) as a class of drugs that will have the ability to slow/halt progression in a great many of the individuals living with Duchenne.&lt;br /&gt;
 &lt;br /&gt;
PPMD has also reached out to leadership at Sarepta to support the pathway forward for these trials and to work to ensure the approval and availability of an effective therapy to our Duchenne community at the earliest moment possible. As always we will report back to you with updates on next steps and anything we as a community can do to help this process.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-submits-letter-to-fda-regarding-latest-sarepta-update?xg_source=activity</link>
            <guid isPermaLink="false">19557428-16F9-4A6F-927D-5DFF97DCED34-4752-00001A5E87EB19F0-FFA</guid>
            <pubDate>Mon, 27 Oct 2014 16:52:32 -0400</pubDate>
        </item>

        <item>
            <title>PPMD-Funded Gene Therapy Study Improves Walking Ability in Muscular Dystrophy</title>
            <description>Dr. Jerry Mendell of Nationwide Children’s Research Institute recently presented data from a ground-breaking PPMD-funded study demonstrating that a modified virus carrying the gene for follistatin can improve performance on the 6 minute walk test in study participants with Becker muscular dystrophy. This is the first time a gene therapy has demonstrated an improvement in function in a muscular dystrophy. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-funded-gene-therapy-study-improves-walking-ability-in-muscul</link>
            <guid isPermaLink="false">80BBD92A-012A-42D9-8546-560D39603335-1082-000008FFFD525C84-FFA</guid>
            <pubDate>Thu, 23 Oct 2014 09:57:42 -0400</pubDate>
        </item>

        <item>
            <title>News from World Muscle Society Meeting (10/8/14)</title>
            <description>Check out news from the 19th International World Muscle Society Congress in our latest blog: http://j.mp/1yPZtVp. &lt;br /&gt;
&lt;br /&gt;
Topics covered:&lt;br /&gt;
► Highlights from Sarepta's symposium on the role of dystrophin production in disease-modifying treatments for Duchenne&lt;br /&gt;
► Becker muscular dystrophy updates&lt;br /&gt;
► Protecting bone health&lt;br /&gt;
► A “one stop” strategy to address mutations that occur before Exon 5&lt;br /&gt;
► Progress in skipping multiple exons&lt;br /&gt;
► A peak at new compounds&lt;br /&gt;
► Next generation utrophin upregulators&lt;br /&gt;
► Drisapersen long-term data</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/news-from-world-muscle-society-meeting-10-8-14</link>
            <guid isPermaLink="false">BE8E0B91-B5AC-4598-A854-E35ED3DC6835-4623-000008E6E4B460B0-FFA</guid>
            <pubDate>Thu, 09 Oct 2014 10:36:46 -0400</pubDate>
        </item>

        <item>
            <title>Upcoming Webinar: Efficacy of Catena®/Raxone® (Idebenone) on Respiratory Outcome in Duchenne</title>
            <description>Santhera will present results from its Phase III study with Catena®/ Raxone® (Idebenone) in Duchenne during a webinar hosted by PPMD on Wednesday, October 15th at 12pm eastern. </description>
            <link>http://community.parentprojectmd.org/events/webinar-efficacy-of-catena-raxone-idebenone-on-respiratory-outcom</link>
            <guid isPermaLink="false">0B3EDDAC-4D33-42C0-BB5D-D292450893E4-1183-000009654E7656EC-FFA</guid>
            <pubDate>Wed, 01 Oct 2014 11:41:54 -0400</pubDate>
        </item>

        <item>
            <title>President Signs MD-CARE Act Amendments Into Law</title>
            <description>Thank you again to everyone in this community who helped advocate for the passage of this critical legislation! We couldn't be more proud to be on your team!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/president-signs-md-care-act-amendments-into-law</link>
            <guid isPermaLink="false">46C6363C-FC63-4B97-97C8-F4000E80B3B8-1183-0000095E0A8B967E-FFA</guid>
            <pubDate>Fri, 26 Sep 2014 11:41:33 -0400</pubDate>
        </item>

        <item>
            <title>The MD-CARE Act: Reflections &amp; Projections</title>
            <description>Sometimes it is worth taking a moment to reflect so that as we continue to plan ahead we can learn from not only our mistakes, but our victories. Our advocacy initiatives continue to grow and we won’t slow down. We can’t. And we hope you’ll join us as we continue to use our voice in D.C.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-md-care-act-reflections-projections</link>
            <guid isPermaLink="false">BAB133E7-567D-45AE-9F09-34FAA53351E4-1183-0000095A60092B34-FFA</guid>
            <pubDate>Wed, 24 Sep 2014 11:41:02 -0400</pubDate>
        </item>

        <item>
            <title>Duchenne Newborn Screening</title>
            <description>Our Duchenne community has therapies in today’s pipeline that will be most effective when administered early. Our formalized efforts to move towards Duchenne newborn screening began several years ago; our community push begins now.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ald-ever-heard-of-it/</link>
            <guid isPermaLink="false">90B8ED79-9FB0-4310-B4C5-0876BBF376EC-1183-0000095516CC53A3-FFA</guid>
            <pubDate>Tue, 23 Sep 2014 11:40:36 -0400</pubDate>
        </item>

        <item>
            <title>Upcoming Webinar: Prosensa Update about Drisapersen &amp; Other Programs</title>
            <description>UPPMD will host a webinar with Prosensa on Thursday, October 2 at 12 pm EDT. During the webinar, Prosensa will answer questions from the Duchenne Community and give an update. </description>
            <link>http://community.parentprojectmd.org/events/webinar-prosensa-update-on-drisapersen-1</link>
            <guid isPermaLink="false">82A11759-D792-432E-9DF4-640B85812E2D-1183-0000095007585782-FFA</guid>
            <pubDate>Mon, 22 Sep 2014 11:40:15 -0400</pubDate>
        </item>

        <item>
            <title>BREAKING NEWS: MD-CARE Act Passed!</title>
            <description>Today – September 18, 2014, our Duchenne community once again made history by demonstrating that nothing can stop us. Today, the MD-CARE Act Amendments of 2014 passed! WE DID IT!!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/md-care-act-passed</link>
            <guid isPermaLink="false">064A30EB-3F91-4D4E-9C01-A0321A10F9E1-1183-0000094772E719D1-FFA</guid>
            <pubDate>Wed, 01 Oct 2014 11:40:01 -0400</pubDate>
        </item>

        <item>
            <title>Action Alert: Tell the Senate to take action on MD-CARE Act!</title>
            <description>Congress has returned from their Summer recess and it is time to re-engage them on the MD-CARE Act! We need each member of our community to reach out to your Senators and urge them to tell leadership to bring the MD-CARE Act to the floor for a vote. Take action now!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/action-alert-tell-the-senate-to-take-action-on-md-care-act</link>
            <guid isPermaLink="false">8912F874-55B3-42E3-BAA3-EADC79C6D2A8-1769-000013621D8DC63D-FFA</guid>
            <pubDate>Wed, 10 Sep 2014 15:26:31 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Welcomes Annie Kennedy as Senior Vice President of Legislation &amp; Public Policy</title>
            <description>We are thrilled to welcome Annie Kennedy, our new Senior Vice President of Legislation and Public Policy! Annie joins PPMD after being with the Muscular Dystrophy Association (MDA) for 25 years, first as a camp volunteer and as an employee for the last 16 years. Annie’s focus will be on advancing public policy, addressing transition issues for people with Duchenne, and working on newborn screening issues.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/operation-duchenne-proud-to-be-serving-in-the-trenches-with-you?xg_source=rss</link>
            <guid isPermaLink="false">4BB31655-8323-4AFE-90BC-7EEF0D6B08F6-1769-0000135C69F2E398-FFA</guid>
            <pubDate>Wed, 10 Sep 2014 15:26:14 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Submits Cardiac Recommendations to FDA</title>
            <description>During discussions at a working group meeting designed to explore contemporary issues in Duchenne cardiology, the FDA indicated interest in receiving recommendations for cardiac surveillance and cardiac markers, to be included in current and future Duchenne clinical trials. In response to those questions, recommendations were developed by the Expert Working Group and submitted to the FDA for consideration for inclusion in the draft guidance. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-submits-cardiac-recommendations-to-fda</link>
            <guid isPermaLink="false">49A05D10-B9CD-4BB9-B11A-06C0C641C893-1769-00001359E86A3FED-FFA</guid>
            <pubDate>Wed, 10 Sep 2014 15:25:57 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Awarding Grants, Recognizing Progress, Welcoming Leadership</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=21683.0</link>
            <guid isPermaLink="false">14111722-7719-4EED-A228-3997477270DD-975-0000075194F25804-FFA</guid>
            <pubDate>Wed, 16 Jul 2014 10:56:09 -0400</pubDate>
        </item>

        <item>
            <title>One Step Closer</title>
            <description>Progress! Today the House Energy &amp; Commerce committee voted unanimously to advance H.R. 594, the MD-CARE Act Amendments of 2014. This action moves the bill to consideration and hopefully passage by the full House of Representatives.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/energy-and-commerce-committee-clears-md-care-act-for-house-vote</link>
            <guid isPermaLink="false">B8DD4B90-9560-412F-A214-AD0A7B1D8B6F-5474-000056D8FCAF4BB9-FFA</guid>
            <pubDate>Tue, 15 Jul 2014 11:30:47 -0400</pubDate>
        </item>

        <item>
            <title>PPMD President Testifies Before Key Congressional Committee</title>
            <description>Pat Furlong, Founding President and CEO of Parent Project Muscular Dystrophy will testify before the House Energy and Commerce Committee’s Subcommittee on Health as part of the committee’s ongoing 21st Century Cures Initiative on July 11 at 9am eastern. She is one of four patient advocacy representatives selected to testify in a hearing entitled “21st Century Cures: Incorporating the Patient Perspective.&quot;  </description>
            <link>http://energycommerce.house.gov/hearing/21st-century-cures-incorporating-patient-perspective</link>
            <guid isPermaLink="false">465AB297-3178-4A6B-BD1C-EDEC4A7C97A0-5474-000056D4A75B6021-FFA</guid>
            <pubDate>Tue, 15 Jul 2014 11:30:31 -0400</pubDate>
        </item>

        <item>
            <title>PPMD and NHLBI Co-Sponsor Duchenne Cardiac Working Group</title>
            <description>PPMD is thrilled to partner with the National Heart, Lung, and Blood Institute (NHLBI) to convene a working group titled “Contemporary Cardiac Issues in Duchenne Muscular Dystrophy.” The group, made up of top pediatric and adult cardiologists as well as clinical researchers, will meet this week to address critical evidence gaps in the understanding of cardiac issues in Duchenne. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-and-nhlbi-co-sponsor-duchenne-cardiac-working-group?xg_source=activity</link>
            <guid isPermaLink="false">C94C22C6-5148-4C4C-B119-46893B032B8F-5474-000056D0D20A24A7-FFA</guid>
            <pubDate>Tue, 15 Jul 2014 11:30:14 -0400</pubDate>
        </item>

        <item>
            <title>Outcomes Meeting: Laying a Foundation for Outcome Measures</title>
            <description>At PPMD's pre-conference meeting, a group of therapists and industry representatives met to discuss the importance of standardizing outcome measures.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/outcomes-meeting-laying-a-foundation-for-outcome-measures</link>
            <guid isPermaLink="false">E1B0A1AF-A0E9-4B4E-BD5C-74E084FD9E2B-5474-000056CAABE1AC8F-FFA</guid>
            <pubDate>Tue, 15 Jul 2014 11:29:57 -0400</pubDate>
        </item>

        <item>
            <title>Conference 20 Recap</title>
            <description>Conference 20 included young men, parents, medical experts, academic researchers and companies, more than 16 companies talking about current trials or trials in development. We discussed compounds that target dystrophin (exon skipping and nonsense suppression) as well as compounds that ‘chip’ away at the downstream pathology- steroid replacement, anti-myostatin, anti-inflammatories, anti-fibrotics as well as new targets. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/conference-20</link>
            <guid isPermaLink="false">9DE9B523-E97D-420F-ABD9-DA9F3F074752-1751-00000A6C7F76C78A-FFA</guid>
            <pubDate>Wed, 02 Jul 2014 12:13:52 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Welcomes John Porter!</title>
            <description>John Porter, PhD is a Program Director at the NIH/NINDS, responsible for managing a portfolio of research grants across neuromuscular disorders. John has agreed to join PPMD officially as of January 2015, to help us build upon current programs, expand the pipeline, and accelerate progress and approvals.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-welcomes-john-porter</link>
            <guid isPermaLink="false">8023DEC6-9832-4CF3-9895-B7DB43CEED19-545-000000A33E3E7F62-FFA</guid>
            <pubDate>Mon, 30 Jun 2014 09:54:41 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Submits FDA Draft Guidance on Duchenne</title>
            <description>Today is a landmark day for PPMD and the entire Duchenne community. We are so pleased that at our organization’s 20 year anniversary after 2 decades of hard work and resolute persistence within the policy, legislative and regulatory arena we are today able to provide to the FDA the first-ever patient-initiated guidance to help accelerate development and review of potential therapies for Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/strength-happens-together</link>
            <guid isPermaLink="false">062A9338-51E3-488B-8929-B7B91746C7EA-986-00000868133EA2AB-FFA</guid>
            <pubDate>Wed, 25 Jun 2014 11:36:54 -0400</pubDate>
        </item>

        <item>
            <title>Illinois Designates Week of June 23 as Duchenne Awareness Week</title>
            <description>The State of Illinois is recognizing PPMD's 20th Annual Connect Conference in Chicago, IL, June 26-29 by declaring the week of June 23 as Duchenne Muscular Dystrophy Awareness Week! To have our community recognized with a Proclamation that will help raise awareness across the whole state is beyond incredible. We are so appreciative!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/illinois-honors-ppmd-s-20th-connect-conference-designates-week-of</link>
            <guid isPermaLink="false">4A9D7BC2-62C2-4381-8ED9-112A285E25E6-1729-000010DAE605EC08-FFA</guid>
            <pubDate>Mon, 23 Jun 2014 14:15:28 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Convenes Outcome Measures Meeting</title>
            <description>This year’s pre-conference meeting will bring together top therapists from clinics around the country and start what we hope will be an ongoing dialogue about standardizing outcome measures. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-convenes-outcome-measures-meeting</link>
            <guid isPermaLink="false">FE71B208-68A1-48C0-8A96-D09BA173A43A-1729-000010D587E88B54-FFA</guid>
            <pubDate>Mon, 23 Jun 2014 14:15:07 -0400</pubDate>
        </item>

        <item>
            <title>House Schedules Critical Markup on MD-CARE Act</title>
            <description>Great news out of D.C.! Following months of meetings and negotiations, a key House committee will be marking up the MD-CARE Act of 2014, legislation we have championed for more than a year and that is cosponsored by more than 100 members of the House of Representatives. This is a significant step forward, one that would not be possible without your hard work! </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/house-schedules-critical-markup-on-md-care-act</link>
            <guid isPermaLink="false">AECA28AB-3B77-4DCA-AF4F-CDB4B9DA3271-1220-000008C0F697823C-FFA</guid>
            <pubDate>Wed, 18 Jun 2014 11:34:48 -0400</pubDate>
        </item>

        <item>
            <title>Parent Project Muscular Dystrophy Names Children's Hospital Colorado a Certified Duchenne Care Center</title>
            <description>Children's Colorado has been a pivotal partner with PPMD in the Transforming Duchenne Care Initiative (TDCI), along with Nationwide Children's Hospital in Columbus, Ohio, which is the only other recipient of the Certified Duchenne Care Center Program. Dennis J. Matthews, MD, a neuromuscular specialist and chair of Pediatric Rehabilitation Medicine at Children's Colorado, has played an integral part in the TDCI. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/parent-project-muscular-dystrophy-names-children-s-hospital-color</link>
            <guid isPermaLink="false">D809ABC2-D769-4CAE-ABAB-FBC813F4094A-1900-0000141F7129EF9A-FFA</guid>
            <pubDate>Tue, 17 Jun 2014 15:14:44 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Time to Connect</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=21502.0</link>
            <guid isPermaLink="false">02BD6B70-476F-4917-8DC9-CDD2F13CB4E4-1506-00000F321353D08F-FFA</guid>
            <pubDate>Mon, 16 Jun 2014 13:45:35 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Ataluren (Translarna) Update with PTC</title>
            <description>In a webinar hosted by UPPMD, PTC Therapeutics presented an overview of the positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency regarding the company’s application for a conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne, and what this decision means for families living in and outside the EU. </description>
            <link>http://community.parentprojectmd.org/events/webinar-ptc-update-on-translarna-ataluren</link>
            <guid isPermaLink="false">560842C6-74A6-4EAE-94FA-BF12B8A4ABD8-1053-0000068E928FC13F-FFA</guid>
            <pubDate>Mon, 16 Jun 2014 11:07:19 -0400</pubDate>
        </item>

        <item>
            <title>DART Therapeutics Continues Clinical Development of HT-100 for Duchenne</title>
            <description>DART Therapeutics Inc. announced that it has resumed clinical development for its lead drug candidate, HT-100 (delayed-release halofuginone) an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with Duchenne. The company will continue to enroll and dose Duchenne patients in this ongoing phase 1b/2a clinical study to evaluate the safety and tolerability of increasing doses of HT-100, and explore trends in a range of efficacy endpoints. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/clinical-development-of-ht-100-for-duchenne-has-resumed</link>
            <guid isPermaLink="false">4CEF391F-31D1-4674-B2DF-A8F731729B3B-1053-000006899B93D597-FFA</guid>
            <pubDate>Mon, 16 Jun 2014 11:06:56 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Benefit/Risk Study Results Published in Clinical Therapeutics</title>
            <description>PPMD is thrilled that results from the recent benefit/risk project our team led have been published in Clinical Therapeutics. The article concludes that caregivers are willing to accept a serious risk when balanced with noncurative slowing or stopping of the progression of muscle weakness, even absent improvement in lifespan. These preferences should inform the FDA’s benefitrisk assessment of emerging Duchenne therapies. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-benefit-risk-study-results-published-in-clinical</link>
            <guid isPermaLink="false">28472E1D-7B7E-43D7-AD9A-B9A60A196993-1065-000007AC9DEC4EB8-FFA</guid>
            <pubDate>Mon, 09 Jun 2014 14:36:52 -0400</pubDate>
        </item>

        <item>
            <title>Lend Your Voice to the FDA Draft Guidance on Duchenne to Speed the Development of Therapies</title>
            <description>For the past four months, over 80 experts in Duchenne have been working hard to produce draft guidance on Duchenne that we believe will ultimately speed the development of therapies. Now we want to hear from you, the Duchenne community, about your thoughts on the guidance content. Please read the first pass of the guidance and submit your comments by Tuesday, June 10th. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/strength-happens-together-lend-your-voice-to-the-fda-draft?xg_source=homepage</link>
            <guid isPermaLink="false">444ECF19-5C88-4692-B698-DD1716E3DD43-1065-000007A74B8D9011-FFA</guid>
            <pubDate>Mon, 09 Jun 2014 14:36:30 -0400</pubDate>
        </item>

        <item>
            <title>Webinar: SMTC1100 Update with Summit PLC</title>
            <description>Action Duchenne will host a webinar on behalf of Summit on Thursday, June 5th, 2014 at 12pm EDT. In this webinar Summit will discuss the results of the Phase 1b trial and their future plans for the SMTC 1100 program. </description>
            <link>http://community.parentprojectmd.org/events/webinar-smtc1100-update-with-summit-plc-hosted-by-action-duchenne?xg_source=shorten_twitter</link>
            <guid isPermaLink="false">8F51C390-A771-421F-B4D7-43E046BFA314-1014-00000996B00E481B-FFA</guid>
            <pubDate>Tue, 03 Jun 2014 11:45:08 -0400</pubDate>
        </item>

        <item>
            <title>Prosensa Announces A Regulatory Path Forward for Drisapersen as a Potential Treatment for Duchenne</title>
            <description>More good news from the FDA! This news from Prosensa continues to demonstrate that FDA recognizes the urgent needs of this community, the importance of the patient voice to understand the benefit/risk assessment, and continues to demonstrate flexibility in the review process.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/a-regulatory-path-forward-for-drisapersen-as-a-potential-treatmen</link>
            <guid isPermaLink="false">84B356A9-050D-43AE-972E-7A49FCAE6871-640-000002FF208730F9-FFA</guid>
            <pubDate>Tue, 03 Jun 2014 09:44:26 -0400</pubDate>
        </item>

        <item>
            <title>Congressional Committee That Funds the FDA Recognizes PPMD-Led Efforts on Benefit/Risk, Draft Guidance; Applauds Collaboration with Agency</title>
            <description>For the first time ever, the appropriations bill that funds the FDA includes report language focused on Duchenne! This is a significant milestone for the Duchenne community that has worked so hard over the years on both the benefit/risk project and draft guidance that we will soon be submitting to FDA for review. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/congressional-committee-that-funds-the-fda-recognizes-ppmd-led</link>
            <guid isPermaLink="false">7E871F6B-90AB-45DE-ADA4-26FDA87DA407-739-00000460D6885265-FFA</guid>
            <pubDate>Mon, 02 Jun 2014 10:19:22 -0400</pubDate>
        </item>

        <item>
            <title>Upcoming Webinar: Ataluren (Translarna) Update with PTC</title>
            <description>United Parent Project Muscular Dystrophy will host a webinar on June 3 with PTC Therapeutics to discuss an overview of the positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency regarding the company’s application for a conditional marketing authorization of ataluren.</description>
            <link>http://community.parentprojectmd.org/events/webinar-ptc-update-on-translarna-ataluren</link>
            <guid isPermaLink="false">61127D64-DC37-4C46-A6EC-B81FBEA9CB01-739-0000045C98174835-FFA</guid>
            <pubDate>Mon, 02 Jun 2014 10:18:58 -0400</pubDate>
        </item>

        <item>
            <title>PPMD’s Pat Furlong will represent the Duchenne community on FasterCures Benefit-Risk Advisory Council</title>
            <description>For FDA to do its job properly, it must have a robust understanding of how patients would weigh alleviation of their disease’s impact (BENEFIT) versus the potential risks of any new treatment (RISK). Our Benefit-Risk work has been embraced by the FDA and industry and it is being used as a model for rare diseases. This is a critical next step in getting therapies approved quickly for Duchenne. &lt;br /&gt;
</description>
            <link>http://fastercures.org/r-and-d-policy/benefit-risk-assessment/benefit-risk-advisory-council</link>
            <guid isPermaLink="false">EECB7C42-3E44-417F-A52D-32DBDC249574-739-000004571E1944F3-FFA</guid>
            <pubDate>Mon, 02 Jun 2014 10:18:38 -0400</pubDate>
        </item>

        <item>
            <title>EMA grants Conditional Approval for Ataluren</title>
            <description>Ataluren, PTC Therapeutics’ nonsense suppression drug received Conditional Approval. This is a big moment for Duchenne, a landmark decision and a sign of hope for all. While Ataluren is targeted at a small subset of patients (13% +/-), the conditional approval is a sign that the EMA worked very hard to understand Duchenne, that they recognize this unmet need, the progressive and debilitating process of Duchenne and the urgent need to treat. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/a-good-day-for-duchenne?xg_source=activity</link>
            <guid isPermaLink="false">858D2CB6-A5DF-417A-94F1-FDF79E412CB5-739-0000044F69BE9619-FFA</guid>
            <pubDate>Mon, 02 Jun 2014 10:18:12 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Congressional Champions Voice the Need for Action on the MD-CARE Act</title>
            <description>During the latest Congressional &quot;21st Century Cures: PCAST” hearing, Representatives Engel and Burgess mentioned the importance of the MD-CARE Act, the impact it has had on potential therapies and the care of patients and stressed the need to utilize the expedited programs within the FDA (programs like accelerated approval and the “breakthrough therapy” designation).</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-champions-voice-the-need-for-action-on-the-md-care-act</link>
            <guid isPermaLink="false">A2C36173-181E-4CA4-8E47-8553CAC8CE90-739-00000449FD413BC6-FFA</guid>
            <pubDate>Mon, 02 Jun 2014 10:17:42 -0400</pubDate>
        </item>

        <item>
            <title>One More Reason to Register for PPMD's 20th Connect Conference</title>
            <description>Every year on the Saturday night of the Connect Conference, PPMD hosts a final dinner. Usually there is a speaker or two, dinner and drinks and a last moment to talk with friends. Not anymore! This year we are hosting a party a celebration for all complete with DJ, photo booth, face painters, tattoo artists, games, and activities.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/one-more-reason-to-register-for-ppmd-s-20th-connect-conference</link>
            <guid isPermaLink="false">B8D57D13-824D-442E-95A0-6BE44F7A4739-560-000000C9EC6D949C-FFA</guid>
            <pubDate>Mon, 19 May 2014 09:23:59 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Strength Happens Together</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=21362.0</link>
            <guid isPermaLink="false">CBC260FE-B595-477D-8246-264FD8C06CEF-560-000000C363E64877-FFA</guid>
            <pubDate>Mon, 19 May 2014 09:23:32 -0400</pubDate>
        </item>

        <item>
            <title>Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in Duchenne</title>
            <description>Santhera Pharmaceuticals reports that its Phase III DELOS study of orally administered Catena®/Raxone® in patients with Duchenne met the primary endpoint and achieved its primary objective of delaying the loss of respiratory function compared to placebo.</description>
            <link>http://www.santhera.com/index.php?docid=212&amp;vid=&amp;lang=en&amp;newsdate=201405&amp;newsid=1784768&amp;newslang=en</link>
            <guid isPermaLink="false">795AADEB-31C6-45AF-A4F8-0E5CB9D5C8CC-881-000007DFB6CB9B13-FFA</guid>
            <pubDate>Tue, 13 May 2014 11:17:39 -0400</pubDate>
        </item>

        <item>
            <title>20th Annual Connect Conference Agenda Now Available</title>
            <description>For the latest research updates from the leaders behind all the exciting projects in the therapeutic pipeline, make sure you register for PPMD's 20th Annual Connect Conference in Chicago, June 26-29, 2014. </description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_2014</link>
            <guid isPermaLink="false">CAF3ED58-4B47-4E3A-8673-53884C184CC4-1241-00000B1D2A3A3FE7-FFA</guid>
            <pubDate>Mon, 12 May 2014 12:23:51 -0400</pubDate>
        </item>

        <item>
            <title>Unprecedented Collection of Duchenne Experts Developing Guidance for FDA</title>
            <description>We have an unprecedented collaboration of experts from all facets of the Duchenne community currently working on this project. Next week, the Draft Guidance will be posted online and made available for full public comment by you, the community at large. Stay tuned for your chance to voice your comments on the guidance.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/unprecedented-collection-of-duchenne-experts-developing-guidance?xg_source=activity</link>
            <guid isPermaLink="false">C988E478-5A50-4FDF-B0E5-BFA3AAC41A40-708-0000062FD434D370-FFA</guid>
            <pubDate>Mon, 12 May 2014 10:53:34 -0400</pubDate>
        </item>

        <item>
            <title>Results of PPMD-Funded Study Prompt Phase III Study of Tadalafil in Duchenne</title>
            <description>Based on the results of a recent PPMD-funded study, Eli Lilly has begun a Phase III study to determine if tadalafil, a drug typically prescribed for erectile dysfunction or increased pressure in the arteries, can slow the progression of Duchenne. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/results-of-ppmd-funded-study-prompts-phase-iii-study-of-tadalafil</link>
            <guid isPermaLink="false">BBC0EEA0-1612-4525-9B20-4D4AB57067C3-708-0000062A112E935B-FFA</guid>
            <pubDate>Mon, 12 May 2014 10:53:10 -0400</pubDate>
        </item>

        <item>
            <title>DuchenneConnect 2013 Annual Report: Registry Growth &amp; Expanded Services</title>
            <description>This past year has brought many new and exciting changes to DuchenneConnect, the robust and cutting-edge registry and resource that connects Duchenne and Becker patients with actively recruiting clinical trials and research studies, and educates patients and families about Duchenne and Becker research. This 2013 Annual Report highlights how we have grown and expanded our services over the past year.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/duchenneconnect-annual-report-registry-growth-expanded-services</link>
            <guid isPermaLink="false">09E4AE5B-9BE4-42F2-A048-FAE6F2E58730-1477-0000144B0920C2BD-FFA</guid>
            <pubDate>Wed, 07 May 2014 15:08:08 -0400</pubDate>
        </item>

        <item>
            <title>Sarepta Webinar</title>
            <description>On Tuesday, May 13th, Sarepta will host a webinar to update the community on its Duchenne development program, including upcoming clinical trials. Questions can be submitted in advance to info@ParentProjectMD.org</description>
            <link>http://community.parentprojectmd.org/events/webinar-sarepta-therapeutics</link>
            <guid isPermaLink="false">00F65D35-9686-499E-8F8F-CCC5C1DCA99C-919-0000072C7341413D-FFA</guid>
            <pubDate>Mon, 28 Apr 2014 11:19:10 -0400</pubDate>
        </item>

        <item>
            <title>New Duchenne Therapies in Development</title>
            <description>Mutation-specific approaches like exon skipping are not our only irons in the fire. Many of these other therapeutic approaches will be entering the clinic by the end of this year or the next, providing a variety of options for participating in trials.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/new-duchenne-therapies-in-development</link>
            <guid isPermaLink="false">BA554E73-1328-4499-BE7E-FDB9BED9909B-919-00000727391E0C40-FFA</guid>
            <pubDate>Mon, 28 Apr 2014 11:18:44 -0400</pubDate>
        </item>

        <item>
            <title>At Long Last, A Victory!</title>
            <description>This brave and beautiful community has demonstrated in various ways, that this one life will be well-spent, focused on changing the landscape for our children. Today was a day we don’t see nearly enough in our community today was a victory! Learn more about what today's news from Sarepta may mean for your child, as well as what we can expect next.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/sarepta-announcement-faqs-1</link>
            <guid isPermaLink="false">A5671540-0AF6-4709-8CDC-D6C968E5389B-919-0000071FBE476B15-FFA</guid>
            <pubDate>Mon, 28 Apr 2014 11:18:21 -0400</pubDate>
        </item>

        <item>
            <title>Sarepta Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne by Year End 2014</title>
            <description>Sarepta Therapeutics today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne. Eteplirsen is Sarepta’s lead exon-skipping drug candidate in development for the treatment of patients with Duchenne who have a genotype amenable to skipping of exon 51.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/sarepta-therapeutics-announces-plans-to-submit-new-drug-applicati</link>
            <guid isPermaLink="false">90D14226-D183-4130-90D5-BF40A1DFCDB4-912-0000064D386FB4B6-FFA</guid>
            <pubDate>Mon, 21 Apr 2014 10:58:00 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Transforming Duchenne Care</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=21242.0</link>
            <guid isPermaLink="false">C7DEE091-BED8-407E-818B-9FF9330206E0-1866-00001512DA8F2B21-FFA</guid>
            <pubDate>Tue, 15 Apr 2014 14:53:18 -0400</pubDate>
        </item>

        <item>
            <title>A New Care Guide to Give to Your Provider – Imperatives for Duchenne Care</title>
            <description>Health care providers care for many people, with many diagnoses – far too many for any one provider to be an expert in them all. Make sure that you are receiving the best possible care by giving your provider this NEW &quot;cheat sheet&quot; guide to comprehensive ‪‎Duchenne care.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/imperatives-for-duchenne-md-a-guide-for-providers?xg_source=activity</link>
            <guid isPermaLink="false">7711920D-DAE0-4B0C-AB67-C5C56EF68813-940-000006949BB2B25F-FFA</guid>
            <pubDate>Tue, 15 Apr 2014 10:27:43 -0400</pubDate>
        </item>

        <item>
            <title>Prosensa Update on Drisapersen (webinar)</title>
            <description>Prosensa presented a status update on Drisapersen and its follow-on compounds in a patient focused webinar hosted by United Parent Projects Muscular Dystrophy (UPPMD) on Tuesday, March 25th at 1 PM ET.</description>
            <link>http://community.parentprojectmd.org/events/webinar-prosensa-update-on-drisapersen</link>
            <guid isPermaLink="false">870D6781-12A8-4151-91DC-D8249A1CD602-8200-00013946CCBB0938-FFA</guid>
            <pubDate>Mon, 31 Mar 2014 12:15:11 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Awards $100,000 in Exploratory Grants</title>
            <description>PPMD is thrilled to award two exploratory grants as part of our ongoing grant program. Peter Arthur of the University of Western Australia was awarded $50,000 to finish testing a molecule called procysteine in animal models in preparation for a human clinical trial. PPMD has also awarded ReveraGen BioPharma an award of $50,000 to determine if small snippets of RNA called &quot;microRNAs&quot; can affect the efficiency of exon-skipping.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-awards-100-000-in-exploratory-grants</link>
            <guid isPermaLink="false">3F9D2544-BFC3-40F2-96FF-260FEA498E0E-8200-00013941E33DD7CB-FFA</guid>
            <pubDate>Mon, 31 Mar 2014 12:14:48 -0400</pubDate>
        </item>

        <item>
            <title>NEW Certified Duchenne Care Center Program</title>
            <description>PPMD is proud to award Nationwide Children’s Hospital as our first Certified Duchenne Care Center. Every person with Duchenne deserves the best care and treatment possible, and has the right to know what clinics meet optimal standards. This program will do just that. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-transforming-duchenne-care-initiative-tdci-and-the-certified?xg_source=homepage</link>
            <guid isPermaLink="false">CA185DDC-B951-4CD2-9C74-02C6DC3C797C-8200-0001393D0416C1B5-FFA</guid>
            <pubDate>Mon, 31 Mar 2014 12:14:27 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: What Do YOU Think?</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=21142.0</link>
            <guid isPermaLink="false">402310EA-E1EE-4BD4-B17C-A64ECA49D79D-527-0000008967729F1B-FFA</guid>
            <pubDate>Tue, 18 Mar 2014 13:54:19 -0400</pubDate>
        </item>

        <item>
            <title>Action Alert: Ensuring Federal Agencies Working on Duchenne Receive Proper Funding</title>
            <description>While the MD-CARE Act remains a top priority, we need to also make sure that federal agencies receive adequate funding and direction for the programs that are so critical to our community. One tool we use to ensure that funding and direction is our Congressional funding letter. The investment to date is over $250 million on Duchenne let's keep adding to that number. It takes less than a minute to send your message to Congress.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/action-alert-ensuring-federal-agencies-working-on-duchenne</link>
            <guid isPermaLink="false">8DF2743C-11BB-4271-ACB8-8B81FF8FD6BC-851-00000430AA73C9CA-FFA</guid>
            <pubDate>Tue, 18 Mar 2014 12:40:18 -0400</pubDate>
        </item>

        <item>
            <title>Registration for PPMD's 20th Annual Connect Conference is now open</title>
            <description>This year marks PPMD's 20th Annual Connect Conference in Chicago, June 26-29, 2014. Join families, physicians, researchers, industry leaders, and experts of all kinds as we gather to speak face-to-face about Duchenne.</description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_2014</link>
            <guid isPermaLink="false">C8E37D0C-B3C7-4018-BB42-5136130B39C0-851-0000042AC21F4433-FFA</guid>
            <pubDate>Tue, 18 Mar 2014 12:39:54 -0400</pubDate>
        </item>

        <item>
            <title>Contemporary Cardiac Issues in Duchenne</title>
            <description>Heart issues don't just affect some people with Duchenne; they affect ALL people with Duchenne and heart failure remains one of the leading causes of death in Duchenne. Cardiac concerns continue to be a top priority for PPMD. One way we have taken action to further explore these heart issues is by joining together with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH) to develop a cardiac working group.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/contemporary-cardiac-issues-in-duchenne-muscular-dystrophy?xg_source=ppmdhomepage</link>
            <guid isPermaLink="false">4CB8B025-4B72-4B40-A874-CDAEB1D9D139-1596-000010FB8A38FF2C-FFA</guid>
            <pubDate>Wed, 05 Mar 2014 15:03:52 -0500</pubDate>
        </item>

        <item>
            <title>Nutrition, Energy, and Duchenne</title>
            <description>During her years of clinical practice, Kathi Kinnett, Vice President of Clinical Care was often asked, “Is there something that I can feed my child to help slow down, or stop, the effects of Duchenne?” The absolute answer is we don’t know. But a new article out this week has endeavored to address this question.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/nutrition-energy-and-duchenne?xg_source=homepage</link>
            <guid isPermaLink="false">B7E4F0C6-6D3D-4E9C-81D2-20E8CFB12893-1404-0000135D333D0B16-FFA</guid>
            <pubDate>Wed, 26 Feb 2014 14:32:30 -0500</pubDate>
        </item>

        <item>
            <title>Take Action Now!</title>
            <description>ONE minute of your time will mean a lifetime for those with Duchenne. As members of the Duchenne community are on Capitol Hill meeting with Members of Congress, we need you to take just ONE minute and take a simple action that will let your Member know how critical their support of this legislation is.</description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Advocate_2014ActionAlert</link>
            <guid isPermaLink="false">AEFFBB35-8797-4F5C-86C1-FB6A1BC99FF5-3281-00000A7261055F23-FFA</guid>
            <pubDate>Mon, 24 Feb 2014 12:29:02 -0500</pubDate>
        </item>

        <item>
            <title>DuchenneConnect Receives $970,000 Grant</title>
            <description>DuchenneConnect will be one of 29 members of PCORnet, the National Patient-Centered Clinical Research Network. The goal of PCORnet is to create a large, highly representative, national network for conducting clinical research. We hope to ask and answer important questions about Duchenne and Becker using the huge, connected network.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/duchenneconnect-receives-large-grant</link>
            <guid isPermaLink="false">DFE09F0A-15D6-4CAE-A901-002488A25D09-1447-0000177E31F04B08-FFA</guid>
            <pubDate>Wed, 19 Feb 2014 15:55:07 -0500</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Raising Our Voices</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=21002.0</link>
            <guid isPermaLink="false">BF490FE9-3B9B-4903-8224-DC949F6A1FF3-823-000004B010AFDEE5-FFA</guid>
            <pubDate>Tue, 18 Feb 2014 10:57:31 -0500</pubDate>
        </item>

        <item>
            <title>Webinar: How You Can Help PPMD’s Advocacy Agenda</title>
            <description>On February 11th, Pat Furlong, Ryan Fischer and Dave Zook (FaegreBD) provided an overview of PPMD’s overarching advocacy strategy, laying out our goals for 2014 and discussing how you can get involved at our Advocacy Conference in Washington, DC and/or advocate from your home.</description>
            <link>http://community.parentprojectmd.org/events/how-you-can-help-ppmd-s-advocacy-agenda</link>
            <guid isPermaLink="false">7DB4ED18-3A33-45C7-9D77-769D84172409-1977-00000FAE8D02C356-FFA</guid>
            <pubDate>Wed, 12 Feb 2014 16:07:51 -0500</pubDate>
        </item>

        <item>
            <title>Webinar: ACT DMD Update with PTC</title>
            <description>On February 5, 2014, Dr. Jay Barth, Vice President for Clinical Development at PTC Therapeutics, presented an update about PTC’s Phase 3 study of ataluren, now known as the Ataluren Confirmatory Trial in DMD (ACT DMD).</description>
            <link>http://community.parentprojectmd.org/events/act-dmd-update-with-ptc-webinar</link>
            <guid isPermaLink="false">9F2ADEF6-31F4-4D2D-9AE1-78F3CDEE3075-1977-00000FA950D2040D-FFA</guid>
            <pubDate>Wed, 12 Feb 2014 16:07:29 -0500</pubDate>
        </item>

        <item>
            <title>Finally, Some Good News!</title>
            <description>Sarepta’s 120 week stability data on both the six minute walk test, as well as, pulmonary function is good news.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/finally-some-good-news?xg_source=ppmdhome</link>
            <guid isPermaLink="false">E32D4396-4A29-408A-B3F9-9EBBC9173EAF-1056-000006EED175F109-FFA</guid>
            <pubDate>Mon, 10 Feb 2014 11:35:00 -0500</pubDate>
        </item>

        <item>
            <title>Register for the 2014 Advocacy Conference (Feb 23-25)</title>
            <description>You are invited to join us in Washington (February 23-25) for what is going to be another critical year in Duchenne advocacy. As you know our efforts last year were focused on collecting cosponsors for the MD-CARE Act (MDCA) reauthorization. To date we stand at 77 cosponsors in the House and 17 in the Senate.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/register-today-for-the-2014-advocacy-conference-feb-23-25</link>
            <guid isPermaLink="false">23B4AB48-61AE-41C2-AEE5-AD475D89BF6E-1008-0000065F300900B0-FFA</guid>
            <pubDate>Mon, 10 Feb 2014 11:24:43 -0500</pubDate>
        </item>

        <item>
            <title>FDA Guidance: Representing the Duchenne Community</title>
            <description>On Monday, February 24, members of the Steering Committee and working groups will provide progress to date and may request additional comments and opinion about particular topics. This will take place in conjunction with our Annual Advocacy Conference.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/guiding-the-fda-toward-faster-drug-reviews-approvals</link>
            <guid isPermaLink="false">A4D9BA74-4ECB-4CE0-8309-3969C8286D20-1008-00000658699A39B3-FFA</guid>
            <pubDate>Mon, 10 Feb 2014 11:24:17 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Funds Kinnect Project</title>
            <description>Recognizing the need to enhance trial participation for those who are non ambulatory, PPMD has invested in the development of endpoints to measure upper body function. One project PPMD is funding uses the Microsoft Kinect system to measure the &quot;functional space&quot; that a person can reach.</description>
            <link>http://iospress.metapress.com/content/m640m7k5736611u5/fulltext.pdf</link>
            <guid isPermaLink="false">6363AE5D-A689-4842-A7A0-DEBD1E421225-660-00000630DB0DB8E1-FFA</guid>
            <pubDate>Mon, 27 Jan 2014 11:22:47 -0500</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: New Year, New Energy</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=20782.0</link>
            <guid isPermaLink="false">555E6159-067D-45B2-AEFC-32C8848C6C86-828-00000CBA822A5860-FFA</guid>
            <pubDate>Mon, 20 Jan 2014 12:53:13 -0500</pubDate>
        </item>

        <item>
            <title>Superheroes Descend on Disney!</title>
            <description>&quot;We will fight for our sons, we will unite for our sons, and yes, we will run for our sons.&quot; With those words, Mike Gaglianone, our parent speaker at our team pasta dinner, kicked off an incredible weekend at the Walt Disney World Marathon Weekend. All together, 171 runners competed in the 5K, 10K, half marathon and full marathon races and raised more than $315,000 to help end Duchenne!</description>
            <link>http://www.parentprojectmd.org/site/R?i=-aLeTtVy6yrZTgEhhhvc4Q</link>
            <guid isPermaLink="false">9B04E200-C208-4689-AD03-500A5B409C0D-828-00000CB48626CA73-FFA</guid>
            <pubDate>Mon, 20 Jan 2014 12:52:55 -0500</pubDate>
        </item>

        <item>
            <title>Clinical Trials in Duchenne: A Behind the Scenes Look (Webinar Recording)</title>
            <description>Understanding clinical trials can be complicated to say the least. On December 19, PPMD hosted a webinar to give you a “behind-the-scenes” look into what goes into planning a successful clinical trial in Duchenne. Discussion topics included challenges faced, best practices, new ideas, etc.</description>
            <link>http://community.parentprojectmd.org/events/clinical-trials-in-duchenne-a-behind-the-scenes-look</link>
            <guid isPermaLink="false">5A9244BD-0E5A-46E8-B7F8-B11B106AAAD7-828-00000CB0DD822AFE-FFA</guid>
            <pubDate>Mon, 20 Jan 2014 12:52:29 -0500</pubDate>
        </item>

        <item>
            <title>Register Today for the 2014 Advocacy Conference</title>
            <description>Thanks to your voice, our advocacy efforts have resulted in the government investing over $250 million in Duchenne-specific research over the past 13 years. We need to keep adding to that investment. Please join us for our 2014 Advocacy Conference (February 23-25 in Washington, DC) to make sure the voice of our community is heard.</description>
            <link>http://www.parentprojectmd.org/site/Calendar?id=104522&amp;view=Detail</link>
            <guid isPermaLink="false">CEA4DB59-68B3-4FDF-A837-EC9C7E363F1B-828-00000CAC9AC86236-FFA</guid>
            <pubDate>Mon, 20 Jan 2014 12:52:13 -0500</pubDate>
        </item>

        <item>
            <title>College Course Offered in Duchenne</title>
            <description>A course on Duchenne is being offered by the Ohio State University College of Medicine and Nationwide Children's Hospital and is open to the public via real-time streaming and podcasts. PPMD President Pat Furlong will be a featured lecturer in April.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/college-course-offered-in-duchenne</link>
            <guid isPermaLink="false">30784DFD-1645-450C-BC17-6145E8E09184-828-00000CA836882D48-FFA</guid>
            <pubDate>Mon, 20 Jan 2014 12:51:54 -0500</pubDate>
        </item>

        <item>
            <title>Understanding Patient Perspective Critical in Benefit-Risk Assessment</title>
            <description>In a recent guest blog on PhRMA, PPMD's Holly Peay and Tim Franson (one of our D.C. partners/experts) explain how new approaches are required to expedite the development of treatments for rare diseases like Duchenne. </description>
            <link>http://www.phrma.org//catalyst/understanding-patient-perspective-critical-in-benefit-risk-assessment</link>
            <guid isPermaLink="false">2B6FC8D0-8001-4887-9290-7C528FA8A979-828-00000CA421CEAF9C-FFA</guid>
            <pubDate>Mon, 20 Jan 2014 12:51:36 -0500</pubDate>
        </item>

        <item>
            <title>Your Simple Action Made It Happen</title>
            <description>Because of you, we not only reached but actually exceeded our ambitious goal of raising $200,000 for the Duchenne Superhighway, an important project that will make clinical trials simpler, faster, and more efficient. This is such a crucial project for the whole Duchenne community, and we’ll be keeping you up-to-date throughout the year on all the developments as they unfold.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=20722.0</link>
            <guid isPermaLink="false">987DE098-6C63-4E46-AF6F-4CB251E83EF9-828-00000C9D51E610D8-FFA</guid>
            <pubDate>Mon, 20 Jan 2014 12:51:17 -0500</pubDate>
        </item>

        <item>
            <title>Upcoming Webinar: A Behind the Scenes Look at Clinical Trials in Duchenne</title>
            <description>Please join us December 19 at 1pm eastern for a webinar that will give you a “behind-the-scenes” look into what goes into planning a successful clinical trial in Duchenne. Participants will be given ample opportunity to ask questions and make suggestions about trial participation from the family point of view.</description>
            <link>http://community.parentprojectmd.org/events/clinical-trials-in-duchenne-a-behind-the-scenes-look</link>
            <guid isPermaLink="false">0E756252-9714-4B22-A93C-94D5C2923BD4-887-00000FEA473668EF-FFA</guid>
            <pubDate>Tue, 17 Dec 2013 14:08:31 -0500</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Simple Actions, Lasting Impact</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=20662.0</link>
            <guid isPermaLink="false">63AC68F4-7D0A-4675-BDBD-F437E26D5E09-887-00000FE6187C6B17-FFA</guid>
            <pubDate>Tue, 17 Dec 2013 14:08:18 -0500</pubDate>
        </item>

        <item>
            <title>Duchenne Policy Forum Recap</title>
            <description>PPMD was proud to host a historical Duchenne Policy Forum on December 12, designed to create a draft guidance for the FDA that reflects the combined experience and wisdom of the Duchenne community. We couldn’t be more happy with the discussion that was started with representatives from FDA and we are grateful to everyone in the community who participated.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/duchenne-policy-forum-recap</link>
            <guid isPermaLink="false">95F738BB-EDA0-4031-AFA4-27396F749258-887-00000FE11A163174-FFA</guid>
            <pubDate>Tue, 17 Dec 2013 14:08:00 -0500</pubDate>
        </item>

        <item>
            <title>Together We Can Make a Difference</title>
            <description>PPMD Board member Lance Hester explains why this week's FDA Policy Forum is important to every Duchenne family – from rare mutations to Exon 51. Whether you are frustrated by recent news of the FDA’s response to Sarepta’s New Drug Application, or whether you want to know how to make your son’s story relevant to the development of future therapies, you can get involved by telling the FDA what matters to you for the long-term good of attacking Duchenne.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/together-we-can-make-a-difference</link>
            <guid isPermaLink="false">4FF35F4F-E4FB-4AA8-BFAA-6E6D2F1FCAFC-1283-000015CFC3AB5C3F-FFA</guid>
            <pubDate>Mon, 09 Dec 2013 15:59:27 -0500</pubDate>
        </item>

        <item>
            <title>Important Updates on the Duchenne Policy Forum</title>
            <description>Due to overwhelming interest in PPMD’s Duchenne Policy Forum on December 12 in Silver Springs, MD, registration is now closed. We are at capacity and unfortunately there will be no onsite registration due to space restrictions. If you did not register in time or are unable to attend, we hope you will watch this historical event via our live webcast.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/important-updates-on-the-duchenne-policy-forum</link>
            <guid isPermaLink="false">C2BE359E-3A27-4927-B30F-45ECE13E97CB-1283-000015CAC0AC204B-FFA</guid>
            <pubDate>Mon, 09 Dec 2013 15:59:05 -0500</pubDate>
        </item>

        <item>
            <title>Move Duchenne research forward faster with one simple action</title>
            <description>Every dollar you give online this holiday season goes toward an important project—the Duchenne Superhighway—that will make the clinical trial process faster and more efficient.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/move-duchenne-research-forward-faster-with-one-simple-action</link>
            <guid isPermaLink="false">586D6212-27A1-415B-B97D-B1D0DCC2FDBA-1283-000015BFA2A820D5-FFA</guid>
            <pubDate>Mon, 09 Dec 2013 15:58:18 -0500</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Update on Natural History Data Study</title>
            <description>On November 19th, PPMD hosted a webinar with Craig McDonald, MD to discuss the natural history study he has been a part of and the data that has been collected.</description>
            <link>http://community.parentprojectmd.org/events/webinar-update-on-natural-history-data-study?xg_source=homepage</link>
            <guid isPermaLink="false">B5A4A1B9-AF67-4C2D-ABE2-B8DF69854FB8-1730-00001260ADA3BBE6-FFA</guid>
            <pubDate>Fri, 22 Nov 2013 15:04:48 -0500</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Time to Unite &amp; Rally</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews. Also meet our Featured Voice for November, 29-year-old Ansel Lurio.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=20402.0</link>
            <guid isPermaLink="false">A7C24969-AD0E-436C-AF91-88044DBDEE56-1730-00001258AC2F22DE-FFA</guid>
            <pubDate>Fri, 22 Nov 2013 15:04:34 -0500</pubDate>
        </item>

        <item>
            <title>Facing Disappointment from FDA's Eteplirsen Response</title>
            <description>The FDA has requested instead that a larger phase III study be conducted before they will consider Sarepta's application for approval. PPMD, which provided travel support to families who participated in the trial, is deeply disappointed in this decision, but hopeful that the FDA will provide clear guidance in the near future on the quantity and quality of data that is required for it to consider an accelerated approval or an application based on phase II data.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/eteplirsen-phase-ii-nda-announcement?xg_source=homepage</link>
            <guid isPermaLink="false">4F87FB7B-34B9-4683-A458-A6DC8C72C3F8-1730-00001255F523DA23-FFA</guid>
            <pubDate>Fri, 22 Nov 2013 15:03:56 -0500</pubDate>
        </item>

        <item>
            <title>Duchenne Policy Forum</title>
            <description>PPMD is proud to host a Policy Forum on clinical trials of experiment agents on December 12, 2013 from 8.30AM until 4.30PM in Silver Springs, MD. We are especially pleased that key Duchenne-community stakeholders, including the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), and review divisions, are committed to the success of this day-long meeting. </description>
            <link>http://www.parentprojectmd.org/site/Calendar?id=104482&amp;view=Detail</link>
            <guid isPermaLink="false">9F6A5F51-6744-42F7-B3B8-7A6F0179A758-1730-0000124E798D0442-FFA</guid>
            <pubDate>Fri, 22 Nov 2013 15:03:48 -0500</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Pushing the FDA to Accelerate Treatments</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews. Also meet our Featured Voice for September, 9-year-old Jake Pritchard.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=20202.0</link>
            <guid isPermaLink="false">6DF50667-2C92-401F-9531-4DAC8687A77F-839-00001154DEE1EA40-FFA</guid>
            <pubDate>Tue, 15 Oct 2013 14:36:56 -0400</pubDate>
        </item>

        <item>
            <title>Pushing the FDA to Accelerate Treatments</title>
            <description>PPMD, together with our partners in Washington, FaegreBD, have delivered a new white paper to the FDA, urging them to change their decision-making process when it pertains to rare disease, especially Duchenne. Read more about our latest efforts and how you can help us push forward.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/pushing-the-fda-to-accelerate-treatments</link>
            <guid isPermaLink="false">2AF9FCA7-265E-4F3C-8E10-195A2100B029-735-00000A1314574B31-FFA</guid>
            <pubDate>Tue, 15 Oct 2013 12:23:44 -0400</pubDate>
        </item>

        <item>
            <title>WMS: Clinical Trial Expectations</title>
            <description>PPMD was privileged to share some of the data we have collected in our Clinical Trial Expectations study at the World Muscle Society poster session. Many clinicians and industry and academic scientists came to the poster to learn about our community thoughts and preferences.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/clinical-trial-expectations</link>
            <guid isPermaLink="false">6B9B9917-711B-42FF-99B0-0224F89F3776-1970-00005F23831593E8-FFA</guid>
            <pubDate>Wed, 09 Oct 2013 14:02:41 -0400</pubDate>
        </item>

        <item>
            <title>WMS Congress: Considering Care</title>
            <description>Care related research was popular at this year's 18th International World Muscle Society Congress. Kathi Kinnett, VP of Clinical Care, summarizes some of the highlights.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/world-muscle-society-congress-considering-care?xg_source=activity</link>
            <guid isPermaLink="false">B1D51BCF-0188-44E4-8616-759C4232596E-1970-00005F16E1ACAF21-FFA</guid>
            <pubDate>Wed, 09 Oct 2013 14:02:24 -0400</pubDate>
        </item>

        <item>
            <title>WMS Congress: Next Generation Exon-Skipping 
and Clinical Trial Updates</title>
            <description>The World Muscle Society Congress saw reports on a number of topics of interest to the community. On Thursday poster sessions covered advances in the next generation of exon-skipping and updates on various clinical trials.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/world-muscle-society-congress-exon-skipping-and-clinical-trial</link>
            <guid isPermaLink="false">D6D9D013-3421-4714-9445-16A9F10751BA-1079-00000C5FB3DB340F-FFA</guid>
            <pubDate>Wed, 09 Oct 2013 13:53:38 -0400</pubDate>
        </item>

        <item>
            <title>Important Flu Vaccination Updates for 2013-14</title>
            <description>Flu season is back and the vaccine is slightly different this year. Nasal spray flu vaccines are not recommended. Injected flu shots are recommended for patients with neuromuscular diseases and patients taking chronic steroids.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/important-update-flu-vaccinations-for-2013-14</link>
            <guid isPermaLink="false">5BC22A2D-9DF4-4F71-B58C-679D1CC9632C-1079-00000C5CEE8C5F9F-FFA</guid>
            <pubDate>Wed, 09 Oct 2013 13:53:25 -0400</pubDate>
        </item>

        <item>
            <title>Northwestern Mutual Is New Corporate Partner Of Coach To Cure MD</title>
            <description>In virtually every college stadium this weekend, more than 10,000 football coaches at more than 611 educational institutions will unite to support the Coach To Cure MD program, with the support of a new corporate sponsor, Northwestern Mutual, a leading financial security company.</description>
            <link>http://www.prnewswire.com/news-releases/northwestern-mutual-is-new-corporate-partner-of-coach-to-cure-md-225523252.html</link>
            <guid isPermaLink="false">A0F4D468-3DAC-475A-B6D1-B5B6DFFB0D02-692-00000A4B63E6D535-FFA</guid>
            <pubDate>Sun, 29 Sep 2013 23:05:31 -0400</pubDate>
        </item>

        <item>
            <title>GSK and Prosensa announce primary endpoint not met in Phase III study of drisapersen</title>
            <description>GSK has announced that its phase III study of the exon 51 skipping drug drisapersen failed to show a statistically significant improvement in the six-minute walk test compared to placebo. GSK will address the Duchenne community via Webinar on October 15th in collaboration with PPMD, CureDuchenne, Action Duchenne, and UPPMD. Details will be forthcoming and you will have the opportunity to submit your questions.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/gsk-and-prosensa-announce-primary-endpoint-not-met-in-phase-iii</link>
            <guid isPermaLink="false">A3D03501-1C6F-4FB6-A983-1F25B6213D37-476-000005F78187AF2E-FFA</guid>
            <pubDate>Fri, 20 Sep 2013 19:38:01 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Research &amp; Advocacy Efforts Will Tackle Duchenne</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews. Also meet our Featured Voice for September, 9-year-old TJ Clime.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=20081.0</link>
            <guid isPermaLink="false">DF78EB63-0AE4-4248-A00E-5664FB51D8A7-476-000005F25D753F42-FFA</guid>
            <pubDate>Tue, 17 Sep 2013 19:37:41 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Leadership on Patient-Focused Drug Development Nets Invitation to Present at Two Influential Meetings</title>
            <description>PPMD has been invited to present at two upcoming stakeholder meetings. On September 10, PPMD Founding President &amp; CEO Pat Furlong will speak at the FDA's Patient Network. The following day, Pat will present at the plenary session of the NINDS Nonprofit Forum. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-leadership-on-patient-focused-drug-development-nets-invitati?xg_source=activity</link>
            <guid isPermaLink="false">B60440ED-8B37-41AA-8CE7-3A5A95D37BBE-491-0000082EC4D7BCC0-FFA</guid>
            <pubDate>Wed, 11 Sep 2013 11:45:12 -0400</pubDate>
        </item>

        <item>
            <title>Prosensa Webinar Replay</title>
            <description>Thank you to Giles Campion for addressing the questions of our community.</description>
            <link>http://www.youtube.com/watch?v=a_QPQUbvVVs</link>
            <guid isPermaLink="false">DF8F1BE2-BE7C-4739-A1DC-C79C3FC2B75D-491-000008290236E840-FFA</guid>
            <pubDate>Wed, 11 Sep 2013 11:45:00 -0400</pubDate>
        </item>

        <item>
            <title>PPMD to Fund $1 Million in Exon Skipping Projects</title>
            <description>PPMD has announced that it will fund up to $1 million in projects by mid-2014 focused on the development of antisense oligonucleotides or other techniques to skip exons that are not currently in clinical development, or for multi-exon skipping projects, including the skipping of duplications. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-to-fund-1-million-in-exon-skipping-projects</link>
            <guid isPermaLink="false">6BBB1242-9A84-4E65-A8D6-2D71044CE791-491-0000082396ADCC51-FFA</guid>
            <pubDate>Wed, 11 Sep 2013 11:44:35 -0400</pubDate>
        </item>

        <item>
            <title>MD-CARE Act: Is your member in a target state or district?</title>
            <description>Your representative may be on a crucial committee that is next to take action on the MD-CARE Act. We need your help to move this legislation into the next phase. Contact your representatives today &amp; ask them to help extend the lives of those living with ‪#‎Duchenne‬ by cosponsoring the MD-CARE Act‬ (S. 315 / H.R 594)</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/late-summer-push-for-md-care-act-is-your-member-in-a-target-state?xg_source=homepage</link>
            <guid isPermaLink="false">E6973843-46F5-4F9D-8591-D1A8F5DB29E9-909-00000D3D3D721F37-FFA</guid>
            <pubDate>Wed, 31 Jul 2013 14:10:51 -0400</pubDate>
        </item>

        <item>
            <title>Sarepta Therapeutics announces plans to submit New Drug Application to FDA for Eteplirsen – A significant step for the Duchenne community</title>
            <description>Today is a landmark day for the entire Duchenne community. Not too long ago, the Duchenne therapy landscape was a barren field with little to no life. Thanks to a commitment to our patients and the field by the U.S. government, international governments, the venture community and industry, this landscape has changed markedly to the point where today we have the announcement for a planned first-ever filing of an NDA for Duchenne.&lt;br /&gt;
 &lt;br /&gt;
PPMD applauds Sarepta Therapeutics for moving forward to file its application for eteplirsen, a potential therapy intended to skip Exon-51, and to seek Accelerated Review for this candidate therapy from the Food and Drug Administration (FDA) based on the results of its Phase IIb clinical trial. PPMD advocated for stronger Accelerated Review tools that more fully account for the needs of the rare disease community as part of last year’s debate on the FDA Safety &amp; Innovation Act, and we urge FDA to use every tool at its disposal to conduct a swift and thorough evaluation.&lt;br /&gt;
 &lt;br /&gt;
Most recently, PPMD had a meeting with Dr. Janet Woodcock, head of the Center for Drug Evaluation and Research (CDER), during which we shared with her the results of our landmark benefit/risk survey of Duchenne parents to ensure the views of our patients and families are accounted for during the review of eteplirsen and other potential Duchenne therapies.&lt;br /&gt;
 &lt;br /&gt;
PPMD looks forward to continuing to work with leaders in government, industry and elsewhere to advance valuable Duchenne research, lengthen and improve the quality of life for every patient and to accelerate FDA review of potential therapies to deliver safe, effective and accessible to patients as quickly as possible.&lt;br /&gt;
 &lt;br /&gt;
This is a great day for the Duchenne community. Where at one time we saw nothing but a hopeless end, now we see nothing but endless hope. We are thankful to this community for all the work it has done together to raise awareness about the urgency to find treatments for all patients.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/sarepta-therapeutics-announces-plans-to-submit-new-drug?xg_source=activity</link>
            <guid isPermaLink="false">40146FA1-5D2A-4076-B6AA-6E6CD83E2B8A-678-0000039C14990A3D-FFA</guid>
            <pubDate>Wed, 24 Jul 2013 11:56:36 -0400</pubDate>
        </item>

        <item>
            <title>Connect Conference Recap</title>
            <description>This year's Connect Conference in Baltimore was incredibly informative and quite extensive. We packed our three days with the top experts in the Duchenne community. But, we know that some of you might not have been able to attend. Relive the Baltimore Connect Conference through PPMD's Storify project.</description>
            <link>http://storify.com/ParentProjectMD/ppmd-s-2013-connect-conference</link>
            <guid isPermaLink="false">F837B4D1-7A3C-4DF4-BEBF-DE79AC5A0E91-517-00000152C3390265-FFA</guid>
            <pubDate>Tue, 16 Jul 2013 16:54:26 -0400</pubDate>
        </item>

        <item>
            <title>Update from PPMD/FDA Meeting</title>
            <description><![CDATA[PPMD met with Dr. Janet Woodcock and leadership from the Office of New Drugs, Medical Policy and the Division of Neurology Products, as well as, staff from the Office of Strategic Programs, Office of Health and Constituent Affairs.   The purpose of the meeting was to continue our efforts to provide the agency relevant information and data about Duchenne that will encourage/enable them to be flexible in their review process.  <br />
We discussed PPMD’s views about regulatory strategy, initiated in 2012 with the Board Policy, previous interactions with the agency,  PPMD’s White Paper – Putting Patients First: Recommendations to Speed Responsible Access to Therapies for Duchenne muscular dystrophy, and Emil Kakkis’ White Paper focused on Accelerated Approval.   We briefly mentioned the EMA draft guidance and our (Treat NMD, PPMD, UPPMD, MDC) official response, as well as, the recent Treat NMD/EMA meeting in London.   <br />
 <br />
This primary objective of the meeting was to focus on PPMD’s Benefit Risk Survey and Analysis, as well as, to update the FDA with regard to Natural History Data.<br />
 <br />
In previous meetings with the agency, we discussed the need for BETTER data related to benefit/risk (B/R).  While we all agreed, B/R factors often are different in rare disease compared to common disease, concrete data to serve as reliable reference points for Duchenne did not exist. The agency suggested this data would be helpful and PPMD’s Holly Peay in collaboration with John Bridges developed a methodology and survey instrument to assess B/R in Duchenne. Holly presented data from PPMD’s survey using this instrument, showing that parents, above all else prioritized muscle function, and suggesting that parents equated this to quality of life (QOL). Dr. Woodcock stated she was impressed with this work and suggested she had hoped advocacy organizations would be willing to do the heavy lifting in this area. After some discussion, it was recommended we expand the survey to a more diverse group of parents and another survey for the adolescents/young adults.  Dr. Woodcock suggested Holly connect directly with one of her colleagues for advice about survey details of interest to the Agency.  In a meeting later that day, Dr. Woodcock said:<br />
PPMD is doing truly impressive work. This is what we need and we were really excited to think about where this will lead.<br />
 <br />
Craig McDonald presented natural history data, suggesting its predictive ability and the domino effect of functional decline over time. The loss of the ability to stand predicts loss of ambulation, loss of ambulation predicts loss of the ability to feed oneself, and the loss of the ability to feed, predicts the need for ventilation. Colleagues from CDER neurology were very engaged in this discussion and the concordance of these data sets (CINRG, PTC placebo, Goemans).  <br />
 <br />
The meeting ended with next steps and a plan to meet again to engage the community in an open forum to discuss a range of important topics. We are very optimistic about the opportunity to build on these important survey methods and findings to improve the drug development climate for all Duchenne stakeholders. <br />
PPMD’s regulatory team continues to meet regularly to develop those next steps and I will continue to report on any developments.]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/7-9-13-update-from-ppmd-fda-meeting?xg_source=PPMDhomepage</link>
            <guid isPermaLink="false">A551EAAC-0954-4E00-BE1B-D715937F314A-517-0000014BEF57135A-FFA</guid>
            <pubDate>Tue, 16 Jul 2013 16:54:10 -0400</pubDate>
        </item>

        <item>
            <title>Update from Congressional Briefing</title>
            <description><![CDATA[A big day for Duchenne – Take action to help make it even more impactful!<br />
 <br />
I had the pleasure to join other Duchenne advocates in Washington this week in an effort to bring attention to the need to accelerate treatments for Duchenne, highlighting eteplirsen as a prime example of a promising potential treatment for a subset of the Duchenne population.<br />
A briefing was held at the Rayburn House Office Building, sponsored by Congressman Keating and organized by the Jett Foundation.  The patient voice was front and center, the room was filled to the max with members and staffers, and the message was: time is our enemy, doing nothing is doing harm, the patients are waiting.<br />
 <br />
Take Action<br />
 <br />
Please consider contacting your member of Congress and ask them to sign onto a letter of support to the FDA being circulated by Congressman Keating urging the FDA to move expeditiously with respect to a request for the approval of the accelerated marketing application for eteplirsen.<br />
Ask to speak to the Health LA in their office, explain to them why this is important to you and your family, and if they have questions they can reach out to Sonya Spery in Congressman Keatings office by email sonya.spery@mail.house.gov or call 202-225-3111.<br />
 <br />
www.parentprojectmd.org/findrep<br />
 <br />
At the same time as the briefing, 20 miles away, PPMD and patient representatives held a meeting at the FDA with leadership that included Dr. Janet Woodcock. It was a productive and promising exchange regarding the urgency of getting Duchenne therapies to patients and what we’ve learned to date from patient families regarding benefit/risk.<br />
 <br />
Be sure to check out Pat’s summary of what came out of the meeting.<br />
We continue to be the most effective when we work as one, consistent voice with one mission:<br />
End Duchenne.]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/7-9-13-update-from-congressional-briefing-take-action?xg_source=shorten_twitter</link>
            <guid isPermaLink="false">FEA25E79-F024-47B6-AC12-8EDA374EF02A-517-0000014343BF7DB2-FFA</guid>
            <pubDate>Tue, 16 Jul 2013 16:53:54 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Urges HHS Secretary to Update Organ Transplantation Policies to Ensure Pediatric Patients Have Access</title>
            <description>PPMD is urging the Secretary of Health and Human Services to update the nation's organ transplantation polices to ensure pediatric patients with rare diseases are not negatively impacted by outdated regulations. In the letter, PPMD urged HHS Secretary Kathleen Sebelius to initiate a dialogue around the equitable distribution of available organs to individuals for whom they are appropriate, an issue of importance to patients and families battling Duchenne and who may need transplant organs one day.</description>
            <link>http://online.wsj.com/article/PR-CO-20130621-906037.html?mod=googlenews_wsj</link>
            <guid isPermaLink="false">BEB5FFE2-9630-4C00-A48A-9A3FA0E18AC2-517-00000138F892854C-FFA</guid>
            <pubDate>Tue, 16 Jul 2013 16:53:08 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Appreciating Parents</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews. Also meet our Featured Voice for May, 12-year-old Jack Knight.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=19461.0</link>
            <guid isPermaLink="false">2DB44338-9A80-4136-A445-6690DDAD3B48-388-000000CE9F996508-FFA</guid>
            <pubDate>Mon, 20 May 2013 09:20:46 -0400</pubDate>
        </item>

        <item>
            <title>2013 Connect Conference Agenda</title>
            <description>PPMD’s Annual Connect Conference will be here before you know it! This summer we return to Baltimore, Maryland at the beautiful Marriott Waterfront with our most exciting and important agenda yet focusing on Duchenne: Better, Faster, Now!. Check out who is presenting when.</description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_2013</link>
            <guid isPermaLink="false">1375FDA3-88D9-4B7D-887A-453167B29D4C-388-000000C5A2C401FF-FFA</guid>
            <pubDate>Mon, 20 May 2013 09:20:30 -0400</pubDate>
        </item>

        <item>
            <title>Drisapersen Update webinar with GSK</title>
            <description>The purpose of the webinar is to update the Duchenne community about Phase II clinical trial results for GSK’s drisapersen drug for the treatment of Duchenne. GSK investigator John Kraus will present and answer submitted questions. PPMD, CureDuchenne, and MDA will co-sponsor this webinar.</description>
            <link>http://community.parentprojectmd.org/events/webinar-may-6</link>
            <guid isPermaLink="false">03821020-5B31-46D0-9487-601580229189-610-000005A165D26616-FFA</guid>
            <pubDate>Wed, 08 May 2013 11:46:54 -0400</pubDate>
        </item>

        <item>
            <title>DuchenneConnect Year-End Report</title>
            <description>We had a busy and exciting year as we continue to expand our services to patients and families, as well as to researchers and clinicians. A big “thank you” to everyone who registered on DuchenneConnect in March - we had 92 new patient registrations, our highest month ever!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/duchenneconnect-presents-2012-data-2013-update</link>
            <guid isPermaLink="false">A505433E-5004-4531-BDC5-DCC8EE15409E-610-0000059E3BC76A9B-FFA</guid>
            <pubDate>Wed, 08 May 2013 11:46:44 -0400</pubDate>
        </item>

        <item>
            <title>New Mobile App - Locate Duchenne Clinical Trials</title>
            <description>PPMD is thrilled to launch Duchenne Central! This new app for your smartphone allows you to search for Duchenne clinical trials and clinics near you or near a specific location. You can also keep track of the latest news, bookmark items, and share with family and friends. Keep your family in the know in real time.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/introducing-duchenne-central?xg_source=activity</link>
            <guid isPermaLink="false">9B072739-A855-42E8-A1F3-A73EC7B9C45E-610-000005974ADE215C-FFA</guid>
            <pubDate>Wed, 08 May 2013 11:46:19 -0400</pubDate>
        </item>

        <item>
            <title>New PPMD White Paper</title>
            <description>PPMD is proud to share an advance copy of Putting Patients First: Recommendations to speed responsible access to new therapies for Duchenne, a white paper outlining recommendations to speed responsible access to new therapies for Duchenne. We are optimistic that Putting Patients First will provide guidance for the FDA and other regulatory agencies as they continue to understand Duchenne and this community’s need for accelerated approval.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/putting-patients-first</link>
            <guid isPermaLink="false">F727352B-9747-40E7-B292-8345B41921C4-610-000005955D901E09-FFA</guid>
            <pubDate>Wed, 08 May 2013 11:46:02 -0400</pubDate>
        </item>

        <item>
            <title>DOD will provide $3.2 million to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP)</title>
            <description>The Department of Defense just announced that the Defense Appropriations Act will provide $3.2 million to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP). In these tightening fiscal times, the continuation of this program is a testament to the advocacy of the Duchenne community on Capitol Hill. PPMD is thrilled by the announcement and proud of PPMD’s President Pat Furlong who serves as Chair of Congressionally Directed Medical Research Program in Duchenne.</description>
            <link>http://cdmrp.army.mil/pubs/press/2013/13dmdrppreann.shtml</link>
            <guid isPermaLink="false">6C3FCCCB-96D5-4C50-B4EC-5B565AEA3A66-610-000005928E82661B-FFA</guid>
            <pubDate>Wed, 08 May 2013 11:45:53 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: A Rich Drug Development Pipeline</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews. Also meet our Featured Voice for April, 17-year-old Matt Scheivert.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=19221.0</link>
            <guid isPermaLink="false">972443D6-7268-4073-8D80-6E5A22BDC7CF-610-0000058F18B6C7DA-FFA</guid>
            <pubDate>Wed, 08 May 2013 11:45:41 -0400</pubDate>
        </item>

        <item>
            <title>GSK's Drisapersen Reaches Primary Objective in Study</title>
            <description>GlaxoSmithKline Plc (GSK)’s drisapersen achieved the primary objective of a mid-stage study. Patients taking drisapersen showed a clinically meaningful difference from those on placebo after 48 weeks of treatment. </description>
            <link>http://www.bloomberg.com/news/2013-04-10/glaxo-muscular-dystrophy-drug-reaches-primary-objective-in-study.html</link>
            <guid isPermaLink="false">0A0B4A01-2665-4DBD-BE3C-B8327E83CBDC-3976-000008617F35F8F5-FFA</guid>
            <pubDate>Tue, 16 Apr 2013 11:39:44 -0400</pubDate>
        </item>

        <item>
            <title>Drug Development Prospects for Duchenne: The Pipeline is rich and deep, with lots of forward momentum</title>
            <description>This spring brings news of progress to the Duchenne community. PPMD's Vice President Research, Sharon Hesterlee, Ph.D. updates us on the promising prospects for treatment that are continuing to move forward.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/drug-development-prospects-for-duchenne-the-pipeline-is-rich-and</link>
            <guid isPermaLink="false">D6747934-C89A-48CE-831C-B87B6EB636AC-3976-0000083613E9777C-FFA</guid>
            <pubDate>Tue, 16 Apr 2013 11:39:31 -0400</pubDate>
        </item>

        <item>
            <title>Register for the 2013 Annual Connect Conference</title>
            <description>Summer is just around the corner and with that comes PPMD’s Annual Connect Conference. We are excited to be back in Baltimore, Maryland this year and really excited about this year’s program. In 2013, PPMD’s Annual Connect Conference will focus on Duchenne: Better, Faster, Now!</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=19101.0</link>
            <guid isPermaLink="false">C4144E00-1EDA-4680-BAC4-C7AF2AE5B773-3976-0000082FF3E36BF3-FFA</guid>
            <pubDate>Tue, 16 Apr 2013 11:36:26 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Funds Investigator to Build New Muscle from Skin Cells to Treat Duchenne</title>
            <description>PPMD has awarded University of Minnesota researcher Dr. Rita Perlingeiro a grant for $220,000 to develop a therapeutic approach for Duchenne using a new type of &quot;adult-derived&quot; stem cell called &quot;iPSCs.&quot;</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-funds-investigator-to-build-new-muscle-from-skin-cells-to-tr</link>
            <guid isPermaLink="false">41894594-5A3E-495D-9A3B-3E81BEC368CE-3976-0000082D33564C7D-FFA</guid>
            <pubDate>Tue, 16 Apr 2013 11:35:59 -0400</pubDate>
        </item>

        <item>
            <title>Summit outlines clinical development plans for Utrophin modulator program for Duchenne</title>
            <description>Summit has announced their proposed plans for the first patient trials of their lead utrophin drug SMT C1100, as well as other supporting work that will happen in parallel.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/pipeline-update-summit-outlines-clinical-development-plans-for-ut</link>
            <guid isPermaLink="false">56A74553-418A-4F81-92C7-7AE0DD99CED2-3976-000007DADA13E91E-FFA</guid>
            <pubDate>Tue, 16 Apr 2013 11:35:46 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Connecting you to Clinical Trials</title>
            <description>Catch up on the latest research and community updates in this month's End Duchenne eNews. Also meet our Featured Voice for March, 11-year-old Christopher Cameron.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=18821.0</link>
            <guid isPermaLink="false">9BDF459B-DE52-49BC-BB85-8EAC45C32BA9-3976-000007D7D2852C20-FFA</guid>
            <pubDate>Tue, 16 Apr 2013 11:29:54 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Adult Cardiac Care</title>
            <description>Cardiac care remains a major area of focus and concern for all those affected by Duchenne. PPMD held the fourth in our series of four cardiac webinars on Wednesday, March 6. This webinar was be dedicated to the subject of cardiac care for adults living with Duchenne. </description>
            <link>http://community.parentprojectmd.org/video/webinar-cardiac-care-for-adults-with-duchenne</link>
            <guid isPermaLink="false">6510341E-3238-4C38-84D6-06549C48964E-3976-0000062A880759E3-FFA</guid>
            <pubDate>Tue, 16 Apr 2013 11:29:41 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Funds Investigator to Build New Muscle from Skin Cells to Treat Duchenne</title>
            <description><![CDATA[<p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Parent Project Muscular Dystrophy (PPMD) has awarded&nbsp;<strong>University of Minnesota researcher Dr. Rita Perlingeiro a grant for $220,000</strong>&nbsp;to develop a therapeutic approach for Duchenne using a new type of "adult-derived" stem cell called "induced pluripotent stem cells" or "iPSCs." iPSCs can be created from non-controversial sources like skin, have the ability to multiply indefinitely, and can be coaxed to become many different kinds of tissue types.<br><br>Previously, Dr. Perlingeiro's group demonstrated that skin cells from donor mice that lack dystrophin could be converted into iPSCs, and then converted again into muscle stem cells with the mutation corrected using a modified viral carrier. When these corrected mouse stem cells were transplanted into recipient mice that lacked dystrophin, the mice showed improved muscle strength.&nbsp;<br><br>Now Dr. Perlingeiro will repeat this process with funding from PPMD, this time using human skin cells from donors with Duchenne and using a safer method of correcting the dystrophin deficiency that does not rely upon random integration. The goal is to start laying the groundwork for an FDA-approved stem cell treatment for Duchenne.</p><blockquote style="margin: 2em 0px; padding: 0px 0px 0px 1em; line-height: 1.8em; border-left-width: 2px; border-left-style: solid; border-left-color: rgb(204, 204, 204); font-style: italic; text-overflow: ellipsis; overflow: hidden; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><p style="margin: 0px; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">"Translating results in mice to treatments in humans is never straightforward. Support from the Parent Project will be tremendously beneficial at this stage in the development of stem cell therapies for muscular dystrophy."</p></blockquote><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important;"><strong><em>- Dr. Perlingeiro</em></strong></span></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><br>Since the mid-1990s, researchers have investigated repairing muscle lost to muscular dystrophy with various types of cells, usually from an unaffected donor whose cells have a normal supply of dystrophin. Key challenges have included producing and purifying enough stem cells to transplant, getting cells to migrate into the diseased muscle, and then getting the donor cells to survive long enough to engraft and build healthy new muscle without being attacked by the immune system. By using iPSCs, Dr. Perlingeiro's approach should theoretically allow an infinite supply of healthy muscle stem cells to be generated from a single small skin sample from a person with Duchenne. And because a person's own cells, corrected for the dystrophin mutation, would ultimately be used for treatment, the potential for the recipient's immune system to reject the new cells is reduced.<br><br>In addition to solving production issues and immune rejection issues, it also appears that some of the cells created by Dr. Perlingeiro's technique do not immediately become converted into mature muscle, but are rather maintained as muscle stem cells and continue to produce new, healthy mature muscle cells within the donor muscle. This means that as diseased muscle is lost over time, it may gradually become replaced with new muscle produced from the healthy transplanted stem cells.</p><blockquote style="margin: 2em 0px; padding: 0px 0px 0px 1em; line-height: 1.8em; border-left-width: 2px; border-left-style: solid; border-left-color: rgb(204, 204, 204); font-style: italic; text-overflow: ellipsis; overflow: hidden; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><p style="margin: 0px; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">"While the field has seen amazing potential in technology like exon-skipping designed to treat specific mutations, we have lacked a more general approach that could rebuild muscle in any person with a genetic muscle disease, regardless of the type of mutation. As the technology to produce stem cells has matured, we are thrilled that Dr. Perlingeiro is applying these new techniques to the problem of rebuilding lost muscle, which has the potential of helping all people with Duchenne."</p></blockquote><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important;"><em>- Pat Furlong, Founding President and CEO of PPMD</em></span></strong></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-2" style="font-size: 10pt !important; line-height: 1.2 !important;"><span>For more about Parent Project Muscular Dystrophy's&nbsp;</span><a href="http://www.parentprojectmd.org/site/PageServer?pagename=Advance_grantees" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">grant program</a><span>, as well as a comprehensive list of&nbsp;</span><a href="http://www.parentprojectmd.org/site/PageServer?pagename=Advance_funding_portfolio" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">what we are funding</a><span>, please visit&nbsp;</span><a href="http://www.parentprojectmd.org/site/PageServer?pagename=Advance_funding" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">ParentProjectMD.org/Research</a><span>.</span></span></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><a href="http://www.parentprojectmd.org/site/PageServer?pagename=Advance_funding" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);"><img src="http://www.parentprojectmd.org/images/content/pagebuilder/button_fundresearch.jpg" class="align-center" style="border: 0px none; text-align: center; margin: 4px 0px; clear: both !important; display: block !important; max-width: 721px; height: auto;"></a></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><a href="http://www.parentprojectmd.org/site/PageServer?pagename=Advance_research_pipeline" target="_blank" style="text-decoration: underline; color: rgb(238, 30, 58);"><img src="http://api.ning.com/files/iJ3pY5RsFseXXcZ0PuQNWVNg2GpXq4g07iYQhhq0NxKas6-6XIIUgvijrJutvluIzWFQdTo-riw3SKSzDkoOfGfo*M*PH-X-/button_viewpipeline.jpg" width="318" class="align-center" style="border: 0px none; text-align: center; margin: 4px 0px; clear: both !important; display: block !important; max-width: 721px; height: auto;"></a></p><div><br></div>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-funds-investigator-to-build-new-muscle-from-skin-cells-to-tr</link>
            <guid isPermaLink="false">07D9E0E8-3003-4D32-AFC2-B0F3ACC3862A-496-000003E99D2D57FD-FFA</guid>
            <pubDate>Fri, 22 Mar 2013 10:22:17 -0400</pubDate>
        </item>

        <item>
            <title>West Coast Connect!</title>
            <description><![CDATA[<p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">I am so excited that in just 6 weeks, Parent Project Muscular Dystrophy will be hosting our second&nbsp;<strong><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_west" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">West Coast Connect Meeting in San Diego, CA, April 26-28, 2013</a></strong>. This meeting will be hosted&nbsp;at&nbsp;the San Diego Marriott Mission Valley. &nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">The agenda is just days away from being finalized, but I can share with you that this year’s meeting will cover:<br><br></p><ul style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Natural history data</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Talks regarding biomarkers</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Numerous Duchenne research presentations</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Care discussions to include topics such as cardiology, bone health and transition care</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Hands on PT sessions</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Discussions related to behaviors in Duchenne and accommodations</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">A panel presentation from some of our Industry partners to discuss and update us on clinical trials</li></ul><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><br>And we are excited to be putting in place an&nbsp;<strong>Expert Panel of young men living with Duchenne</strong>&nbsp;who will be presenting on all topics Duchenne.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">We hope you can join us for this meeting. We are sure you will find the topics and speakers informative and inspiring.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Registration details can be found at&nbsp;<strong><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_west" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">ParentProjectMD.org/WestCoastConnect</a></strong>. And remember, if you need hotel accommodations while at the meeting, please make sure to&nbsp;<strong>book your reservation prior to April 4</strong>&nbsp;to receive our group rate.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Looking forward to seeing you in sunny California!<br><br><br><a href="http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_west" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);"><img src="http://api.ning.com/files/rRUWEC*XQHxMhVyWz37CZwa4F6QV-epY2fVDrfe7ZbGucFzYy3gE9Eal6cyTGRsk-2Dt49DaNpfk8VOtWrCAfurhDOnnf2D*/RegisterNow_02.jpg" width="152" class="align-center" style="border: 0px none; text-align: center; margin: 4px 0px; clear: both !important; display: block !important; max-width: 721px; height: auto;"></a><br><br><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important;">Related links</span></p><ul style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;"><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_west" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">Register for the West Coast Connect Meeting</a></li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;"><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">Learn more about the&nbsp;Annual Connect Conference &amp; Meetings</a></li></ul>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/west-coast-connect</link>
            <guid isPermaLink="false">5718497C-49F6-40DE-89B1-C0DEBACD77A1-2600-00001120087E0235-FFA</guid>
            <pubDate>Wed, 13 Mar 2013 14:12:54 -0400</pubDate>
        </item>

        <item>
            <title>Tree of Hearts</title>
            <description><![CDATA[<p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">I wish we had a&nbsp;<i>Tree of Hearts.&nbsp;</i>Healthy new hearts would hang on the high branches and devices on the lower branches – low hanging fruit! Established guidelines about who, what, in what circumstances, and where, accompanied by a simple set of instructions for physicians all over the world to understand, adapt, and provide appropriate care for these technologies. A handbook for parents and their physicians with a simple statement – The Heart is a Muscle Too –&nbsp;Duchenne Hearts Matter.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">There would be no need for donors. Parents would never have to sit at the bedside of their sick child, without options or limited expertise. They would not be asked to make impossible choices. There would be no waiting for a device or a new heart. No parent would carry the burden that a new heart for one means another life ends. &nbsp;&nbsp;&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">My&nbsp;<i>Tree of Hearts</i>&nbsp;would come with guarantees, an assurance of more time, even if it felt like borrowed time.<br><br></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">My&nbsp;<i>Tree of Hearts</i>&nbsp;would have generic hearts, beating in rhythm, ready and available for anyone in need. The transplant team would call the&nbsp;<i>Tree of Hearts</i>&nbsp;nursery to make the request. Within seconds, the new, healthy heart would be on its way to the center. The patient would be prepared for the surgical procedure, chest opened and ready as the surgeon, heart in hand, would remove the broken heart and gently lay this new, healthy heart in its place. Gingerly, the surgeon would attach all of the vessels and in a single instant, the heart would take on the genetic characteristics of the recipient and beat strong and steady. No immune suppression required. Lub dub, lub dub. Lub dub. Music to the heart and to the ears of the family waiting in the wings. The surgical procedure would be easy, no complications. Joyful parents, tears in their eyes, would see their smiling son, the cloud of his broken heart a forgotten memory. Each day of recovery would be better than the last until the patient would leave the hospital, eager and excited about this new life.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">The ICDs and VADs would come a list of instructions, the ‘how to’s” and essential steps for use. Standards established, proactively intervening. No waiting. None at all. The set of instructions for use would ensure optimal care and instill confidence where the device feels like new, unfamiliar territory.&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Some weeks back you may have watched&nbsp;<a rel="nofollow" href="http://community.parentprojectmd.org/profiles/blogs/webinar-q-a-ventricular-assist-device-vad-use-in-duchenne" target="_self" style="text-decoration: none; color: rgb(238, 30, 58);">PPMD’s Webinar on Ventricular Assist Devices</a>&nbsp;or VADS for short. Cardiac surgeons from different institutions discussed VADS and the first US experience, a 26-year-old man with Duchenne performed at Cincinnati Children’s Hospital. The discussion was interesting, frightening, exciting, and humbling. &nbsp;Another possibility. An opportunity for Duchenne – destination therapy for individuals in severe heart failure, now a potential for our sons. We listened, we learned, and parked the information away in the ‘just in case’ section of our brain.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">And then one day, we woke up, signed on to our Facebook account and were heartbroken to learn that&nbsp;<a rel="nofollow" href="https://www.facebook.com/mitchellsjourney?ref=ts&amp;fref=ts" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">one of our own&nbsp;was in severe failure</a>. All of us pushed the emergency button in our brain. How could this happen. So young. So unfair. So heartbreaking. So wrong. And we reached out to others, to anyone willing to listen, calling and begging for help.<br>One more time, the community raised their voices in protest. NO! NO HOPE AND NO HELP – words we have heard in the course of our journey and thrown out as impossible, intolerable, unacceptable, and unethical. The word rolled off of our tongues. NO!</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">In the last weeks we have learned more about VADS than we ever wanted to know.&nbsp;<br><br></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">The idea of an artificial heart and assist devices started long ago. In 1982, Barney Clark received the first artificial heart, called the Jarvick. In 1982, (the dark ages of cardiac surgery) Barney Clark did not expect to live more than a few days, but hoped that Dr. Jarvick and future doctors might learn to save the lives of others someday. Thirty years later, the technology has improved and evolved, and currently there are several FDA approved devices.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">A VAD is an implantable mechanical pump that helps pump blood from the lower chambers of the heart (the ventricles) to the rest of your body. VADs are used in people who have weakened hearts or heart failure. Although VADs can be placed in the left, right, or both ventricles of your heart, they are most frequently used in the left ventricle. When placed in the left ventricle they are called left ventricular assist devices (LVADs). The procedure to implant a VAD requires open-heart surgery and has serious risks. However, a VAD can be lifesaving if a patient is in severe heart failure.&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Here’s the hard part. Not every center has a pediatric VAD program. Not every insurance will allow patients to go outside their state in order to receive a VAD. And there are several types of these devices, each one is a bit different, requiring specific expertise, experience, tools, and management. Physicians are typically trained on one particular type. They become familiar, develop experience, and a certain comfort level with a certain device. Like all of us, we go with what we know, what we can rely on, what is familiar. Physicians at other institutions may prefer a different device. There is no ‘one size fits all’ in terms of devices and physicians are not ‘jack of all trades’, able to adapt and feel confident in procedures and devices that are unfamiliar.&nbsp;&nbsp;&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Management of the VAD has serious challenges. ERs have to be alerted in case of an emergency. They have to have tools and knowledge in the event of an emergency. As you might imagine, the local physicians – all of them: cardiac surgeon, cardiologist, neurologist, pulmonologist, nurse practitioner, ER physicians – have to know what to do when, have to have familiar tools, significant expertise and ability, and more than a little experience if the patient is to survive.&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">At the end of the day, VADs will be useful in Duchenne at certain times and in certain circumstances.&nbsp;<br>Here are our marching orders:<br><br></p><ol style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><li style="margin: 0px 0px 0.4em 2.5em; padding: 0px; line-height: inherit; font-size: 1em;">Convene interested centers/surgeons to begin to develop guidelines and standards</li><li style="margin: 0px 0px 0.4em 2.5em; padding: 0px; line-height: inherit; font-size: 1em;">Publish and ensure the community has access to the standards (transparency)</li><li style="margin: 0px 0px 0.4em 2.5em; padding: 0px; line-height: inherit; font-size: 1em;">Educational information for physicians and families</li><li style="margin: 0px 0px 0.4em 2.5em; padding: 0px; line-height: inherit; font-size: 1em;">Contact information – questions, information and soon, a helpline</li></ol><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">While my&nbsp;<i>Tree of Hearts</i>&nbsp;sounds like wishful thinking at the moment, we will convene leaders in the field to begin to develop standards for the use of devices such as ICD and VADs, and expand our understanding of the policies and practice of heart transplantation. &nbsp;&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><a rel="nofollow" href="http://community.parentprojectmd.org/profiles/blogs/early-morning-calls" target="_self" style="text-decoration: none; color: rgb(238, 30, 58);">For Matthew.</a></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><a rel="nofollow" href="https://www.facebook.com/mitchellsjourney" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">For Mitchell.</a></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong>For all of our sons.</strong></p>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/tree-of-hearts</link>
            <guid isPermaLink="false">DEBBC13B-E28D-4236-8987-0A5E35738DB2-3629-000006725BFEA8FD-FFA</guid>
            <pubDate>Wed, 06 Mar 2013 11:20:18 -0500</pubDate>
        </item>

        <item>
            <title>The MD-CARE Act: Update on Reauthorization Efforts</title>
            <description><![CDATA[<p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">We continue to make progress on the&nbsp;<a rel="nofollow" href="https://secure2.convio.net/ppmd/site/Advocacy?pagename=homepage&amp;id=171" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">Reauthorization of the MD-CARE Act</a>. Thanks to you, we have already collected a number of cosponsors for the legislation. It’s a strong start and we must continue to tell our story to congress and explain why renewing this critical legislation is paramount to all those living with Duchenne and all those diagnosed tomorrow and beyond.&nbsp;<a rel="nofollow" href="https://secure2.convio.net/ppmd/site/Advocacy?pagename=homepage&amp;id=171" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">Please continue to send the message to friends and</a>&nbsp;<a rel="nofollow" href="https://secure2.convio.net/ppmd/site/Advocacy?pagename=homepage&amp;id=171" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">family and ask them to take action</a>.&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><a href="https://secure2.convio.net/ppmd/site/Advocacy?pagename=homepage&amp;id=171" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);"><img src="http://api.ning.com/files/kpPDTkb*yUas0Z-8g-v25cdbduiwu7UWeAvJxiAypB-EpxUkUZGEF*Krn*bNx-45XshEQmMA*lnoDN8vFn2PBgLtzbX2So3U/TakeAction.jpg?width=152" width="152" class="align-center" style="border: 0px none; text-align: center; margin: 4px 0px; clear: both !important; display: block !important; max-width: 721px; height: auto;"></a></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; color: rgb(229, 25, 55);"><span style="color: rgb(0, 0, 0); font-size: 13px;">Since we left DC, we are happy to report</span>&nbsp;<strong style="color: rgb(0, 0, 0); font-size: 13px;">36 members</strong>&nbsp;<span style="color: rgb(0, 0, 0); font-size: 13px;">have already signed on as cosponsors.<br><br></span></span></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; color: rgb(229, 25, 55);"><span style="color: rgb(0, 0, 0); font-size: 13px;"><strong>Please send a thank you note</strong>&nbsp;to those members listed below. A hand written thank you goes a long way to creating and maintaining champions for our cause.&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Advocate_representatives" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">Find out who your members are and how to send them a thank you message.<br><br></a></span></span></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; color: rgb(229, 25, 55);">House (Bill number - H.R.594)<br><br></span></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong>Sponsor:</strong>&nbsp;Rep Burgess, Michael C. [TX-26] (introduced 2/8/2013)</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong>Cosponsors</strong>&nbsp;<strong>(26)</strong></p><ul style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Andrews, Robert E. [NJ-1] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Bachus, Spencer [AL-6] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Bishop, Sanford D., Jr. [GA-2] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Brownley, Julia [CA-26] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Ellison, Keith [MN-5] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Engel, Eliot L. [NY-16] - 2/8/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Graves, Sam [MO-6] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Green, Gene [TX-29] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Hall, Ralph M. [TX-4] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Holt, Rush [NJ-12] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Kilmer, Derek [WA-6] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep King, Peter T. [NY-2] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Lowey, Nita M. [NY-17] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Maloney, Carolyn B. [NY-12] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Markey, Edward J. [MA-5] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Matsui, Doris O. [CA-6] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Owens, William L. [NY-21] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Peterson, Collin C. [MN-7] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Poe, Ted [TX-2] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Runyan, Jon [NJ-3] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Rush, Bobby L. [IL-1] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Schwartz, Allyson Y. [PA-13] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Sessions, Pete [TX-32] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Shea-Porter, Carol [NH-1] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Slaughter, Louise McIntosh [NY-25] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Rep Welch, Peter [VT] - 2/25/2013</li></ul><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong>Related Bills:</strong>&nbsp;S.315</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; color: rgb(229, 25, 55);">Senate (Bill number - S.315)<br><br></span></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong>Sponsor:</strong>&nbsp;Sen Klobuchar, Amy [MN] (introduced 2/13/2013)</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong>Cosponsors (10)</strong></p><ul style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Sen Collins, Susan M. [ME] - 2/13/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Sen Isakson, Johnny [GA] - 2/13/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Sen Lautenberg, Frank R. [NJ] - 2/13/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Sen Leahy, Patrick J. [VT] - 2/13/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Sen Menendez, Robert [NJ] - 2/13/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Sen Mikulski, Barbara A. [MD] - 2/13/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Sen Nelson, Bill [FL] - 2/13/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Sen Sanders, Bernard [VT] - 2/13/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Sen Schumer, Charles E. [NY] - 2/25/2013</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Sen Wicker, Roger F. [MS] - 2/13/2013</li></ul><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong>Related Bills:</strong>&nbsp;H.R.594</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; color: rgb(229, 25, 55);">Related Links</span></p><ul style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;"><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Advocate_representatives" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">Find out who your members are and how to send them a thank you message</a></li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;"><a rel="nofollow" href="https://secure2.convio.net/ppmd/site/Advocacy?pagename=homepage&amp;id=171" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">Ask your friends and family to support the MD-CARE Act Reauthorization</a></li></ul>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-md-care-act-update-on-reauthorization-efforts?xg_source=rss</link>
            <guid isPermaLink="false">B2260E20-1433-4E4B-B330-D7CCC1378107-2886-0000170BB2362300-FFA</guid>
            <pubDate>Tue, 05 Mar 2013 16:01:14 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Funds UCLA Project to Identify Genetic Changes that Affect the Severity of Duchenne</title>
            <description><![CDATA[<p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">PPMD will provide&nbsp;<span class="xn-money">$100,000</span>&nbsp;to Dr.&nbsp;<span class="xn-person">Stanley Nelson&nbsp;</span>of the&nbsp;<span class="xn-org">University of California, Los Angeles</span>, to examine the genomes of 40 boys with&nbsp;Duchenne who are either very mildly affected or very severely affected. The goal is to identify changes in genes other than dystrophin that may affect the course of the disease.</p><blockquote style="margin: 2em 0px; padding: 0px 0px 0px 1em; line-height: 1.8em; border-left-width: 2px; border-left-style: solid; border-left-color: rgb(204, 204, 204); font-style: italic; text-overflow: ellipsis; overflow: hidden; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><p style="margin: 0px; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">"We know that even boys who have exactly the same mutation in the dystrophin gene can have different disease courses. It is very likely that other mutations or DNA variants in different genes may play a role in addition to dystrophin."</p></blockquote><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important;"><em><strong>-- Dr. Nelson</strong></em></span></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><br>Dr. Nelson will use a relatively new technique known as "exome sequencing" to look only at the parts of the genetic code that spell out the recipe for proteins, known individually as "exons."&nbsp; Because the exons of the genome make up less than 1% of the total genetic material, this method provides a far more practical way to look at the coding regions (genes) for the about 20,000 human proteins without having to sequence the participants' entire genome.<br><br></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">For this project, Dr. Nelson will obtain blood samples primarily from boys and men participating in registries and other studies who have out-of-frame deletions or know they have Duchenne from a muscle biopsy data and have been identified as "outliers" for the speed at which the disease is progressing in the skeletal muscles—that is, they have very mild disease or very severe disease based on the age that the ability to walk was lost. The work will be conducted within the Center for Duchenne Muscular Dystrophy at&nbsp;<span class="xn-org">UCLA</span>&nbsp;with additional analyses supported by the Genomics and Bioinformatics Core of the NIAMS-funded UCLA Muscular Dystrophy Core Center.<br><br></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Information generated from this project may serve a number of important functions, including providing critical insight into biological functions that affect Duchenne progression; allowing clinical trial sponsors to select participants with more similar disease courses based on genetic data (to design smaller, faster, and more powerful trials); and identifying new targets for drug development. It is also likely that some of the changes identified will be relevant to other forms of muscular dystrophy and muscle disease.</p><blockquote style="margin: 2em 0px; padding: 0px 0px 0px 1em; line-height: 1.8em; border-left-width: 2px; border-left-style: solid; border-left-color: rgb(204, 204, 204); font-style: italic; text-overflow: ellipsis; overflow: hidden; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><p style="margin: 0px; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">"The need to identify genetic modifiers is part of our strategic plan for research. We know this information may greatly speed the conduct of clinical trials by reducing the variability among participants in relation to other benefits. We are pleased to be able to fund Dr. Nelson's work."</p></blockquote><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important;"><em><strong><span>-- Sharon Hesterlee</span>, PPMD's Vice President for Research</strong></em></span></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><br>For more about Parent Project Muscular Dystrophy's&nbsp;<a href="http://www.parentprojectmd.org/site/PageServer?pagename=Advance_grantees" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">grant program</a>, as well as a comprehensive list of&nbsp;<a href="http://www.parentprojectmd.org/site/PageServer?pagename=Advance_funding_portfolio" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">what we are funding</a>, please visit&nbsp;<a href="http://www.parentprojectmd.org/site/PageServer?pagename=Advance_funding" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">ParentProjectMD.org/Research</a>.<br><br></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">To inquire about participating in this research, please contact Dr. Nelson's office by calling 310-983-3402 or emailing at<a href="https://mail.google.com/mail/?view=cm&amp;fs=1&amp;tf=1&amp;to=cdmd@ucla.edu" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);">cdmd@ucla.edu</a>.<br><br><br><br></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><a href="http://www.parentprojectmd.org/site/PageServer?pagename=Advance_funding" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);"><img src="http://www.parentprojectmd.org/images/content/pagebuilder/button_fundresearch.jpg" class="align-center" style="border: 0px none; text-align: center; margin: 4px 0px; clear: both !important; display: block !important; max-width: 721px; height: auto;"></a></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><a href="http://www.parentprojectmd.org/site/PageServer?pagename=Advance_research_pipeline" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58);"><img src="http://api.ning.com/files/iJ3pY5RsFseXXcZ0PuQNWVNg2GpXq4g07iYQhhq0NxKas6-6XIIUgvijrJutvluIzWFQdTo-riw3SKSzDkoOfGfo*M*PH-X-/button_viewpipeline.jpg" width="318" class="align-center" style="border: 0px none; text-align: center; margin: 4px 0px; clear: both !important; display: block !important; max-width: 721px; height: auto;"></a></p><div><br></div>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-funds-ucla-project-to-identify-genetic-changes-that-affect-t</link>
            <guid isPermaLink="false">CF0E3F14-004F-43C2-871C-19B8A6FD461C-627-000006C435590F66-FFA</guid>
            <pubDate>Tue, 05 Mar 2013 11:02:46 -0500</pubDate>
        </item>

        <item>
            <title>Run For Our Sons - Winter Newsletter</title>
            <description><![CDATA[<table width="630" border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; color: rgb(35, 31, 32); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 20px; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#FFFFFF" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; border: none; padding-bottom: 0px;"><table border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 18px; line-height: 22px; color: rgb(243, 83, 83); padding-top: 10px;"><table width="630" border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td width="630" align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 11px; line-height: 20px; color: rgb(136, 136, 136);"><table width="630" border="0" cellspacing="0" cellpadding="5" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 28px; line-height: 32px; color: rgb(229, 25, 55); padding-bottom: 0px;">Going the distance to&nbsp;<i>make it possible!</i></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 12px; color: rgb(39, 39, 39); line-height: 20px; padding-bottom: 20px;"><p style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; margin-top: 0px;"><img src="http://www.parentprojectmd.org/images/content/pagebuilder/rfos_winter_firstimage2.jpg" border="no" align="right" style="margin: 0px; padding: 15px;">January was a phenomenal month for&nbsp;<a href="http://www.runforoursons.org/" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Run For Our Sons</a>&nbsp;and the PPMD community. In one extraordinary weekend, 270 runners participated in 2 races and&nbsp;<strong>raised more than $350,000 to end Duchenne</strong>. Our runners, walkers, and rollers in the Walt Disney World Marathon Weekend and the Chevron Houston Marathon kicked off what is sure to be one of the best years yet for Run For Our Sons.</p><p style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; margin-top: 0px;"><strong>In 2012, Run For Our Sons raised more than $1.3 million</strong>&nbsp;– a record-breaking year for our endurance program! Run For Our Sons began nine years ago, with one race and a determined group of runners at Disney World. Today, we have expanded into&nbsp;<strong>15+ races across the country</strong>&nbsp;and thousands of participants. We added new races last year in Baltimore, New Orleans, Cleveland and Grand Rapids, and expanded our program to include the prestigious New York City Triathlon and Conquer the Canyon, a Grand Canyon hiking adventure. This incredible year was all thanks to you – our runners and cheerleaders!</p><p style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; margin-top: 0px;"><span style="color: rgb(219, 32, 61);"><strong>Your Impact</strong></span><br>The funds raised from all Run For Our Sons events continue to push PPMD’s programs forward, and&nbsp;<strong>every step taken and every dollar raised is critical in our fight to end Duchenne.</strong></p><p style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; margin-top: 0px;">See a full recap of all of our&nbsp;<a href="http://www.parentprojectmd.org/site/PageNavigator/Run%20For%20Our%20Sons/run_RaceRecaps_Results_2012.html" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">2012</a>&nbsp;and early&nbsp;<a href="http://www.parentprojectmd.org/site/PageServer?pagename=run_RaceRecaps_Results" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">2013</a>&nbsp;races.</p><img src="http://ppmd.convio.net/images/content/pagebuilder/Nicole_Herring_Sig.jpg" alt="Nicole herring" width="150" border="no" style="margin: 0px; padding: 0px; display: block;">Nicole Herring<br>Endurance Program Manager<br></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#FFFFFF" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; border: none; padding-bottom: 20px;"><img src="https://secure2.convio.net/ppmd/images/content/pagebuilder/splitted-gray-thin.jpg" alt="" border="no" style="margin: 0px; padding: 0px; display: block;"></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td valign="top" bgcolor="#FFFFFF" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 5px; border: none;"><table border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-bottom: 0px; border: none;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 15px; line-height: 22px; color: rgb(219, 32, 61); padding-bottom: 0px;"><strong>Tri For Our Sons in NYC</strong></td></tr></tbody></table></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#FFFFFF" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; border: none; padding-bottom: 0px;"><table width="630" border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td width="414" align="left" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><table width="414" border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 18px; line-height: 22px; color: rgb(243, 83, 83); padding-bottom: 20px;"><img src="http://www.parentprojectmd.org/images/content/pagebuilder/rfos_winter_tri.jpg" alt="Tri For Our Sons" border="no" style="margin: 0px; padding: 0px; display: block;"></td></tr></tbody></table></td><td width="20" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"></td><td width="196" align="left" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><table width="196" border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 12px; line-height: 20px; color: rgb(68, 68, 68); padding-bottom: 10px;"><strong>Swim, bike, and run</strong>&nbsp;through the Big Apple in the&nbsp;<a href="http://www.parentprojectmd.org/site/TR?fr_id=2670&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Aquaphor New York City Triathlon</a>&nbsp;with the Tri For Our Sons team. This challenging race will have you swimming in the<strong>Hudson Rive</strong>r, biking along the<strong>West Side of Manhattan</strong>, and running through NYC’s famed<strong>Central Park</strong>, all before most people get out of bed!<br><br><a href="http://www.parentprojectmd.org/site/TR?fr_id=2670&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Join Tri For Our Sons</a>&nbsp;on July 14th for this memorable experience.</td></tr></tbody></table></td></tr></tbody></table></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#FFFFFF" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; border: none; padding-bottom: 20px;"><img src="https://secure2.convio.net/ppmd/images/content/pagebuilder/splitted-gray-thin.jpg" alt="" border="no" style="margin: 0px; padding: 0px; display: block;"></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td valign="top" bgcolor="#FFFFFF" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 15px; border: none;"><table border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-bottom: 5px; border: none;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 15px; line-height: 22px; color: rgb(219, 32, 61); padding-bottom: 5px;"><strong>Tell Us What You Think!</strong></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 12px; line-height: 20px; color: rgb(77, 88, 82); padding-bottom: 5px;">If you ran a race with us in the past year, we’d love to hear your feedback! Tell us what you think about your experience with the Run For Our Sons team and help us make our program even better.<br><a href="http://www.parentprojectmd.org/site/Survey?ACTION_REQUIRED=URI_ACTION_USER_REQUESTS&amp;SURVEY_ID=8060" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Take the Run For Our Sons feedback survey.</a></td></tr></tbody></table></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#FFFFFF" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; border: none; padding-bottom: 20px;"><img src="https://secure2.convio.net/ppmd/images/content/pagebuilder/splitted-gray-thin.jpg" alt="" border="no" style="margin: 0px; padding: 0px; display: block;"></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td valign="top" bgcolor="#FFFFFF" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 15px; border: none;"><table border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-bottom: 5px; border: none;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 15px; line-height: 22px; color: rgb(219, 32, 61); padding-bottom: 5px;"><strong>Runners in the Spotlight</strong></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 12px; line-height: 20px; color: rgb(77, 88, 82); padding-bottom: 5px;">Meet some of our recent Runners in the Spotlight and learn why they run. Their stories may be just the inspiration you need to run with Run For Our Sons!</td></tr></tbody></table></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#FFFFFF" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; border: none; padding-bottom: 0px;"><table width="630" border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td width="305" align="left" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><table width="305" border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 10px;"><table border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#e51937" align="left" valign="middle" style="font-family: Arial, Helvetica, sans-serif; font-size: 11px; color: rgb(255, 255, 241); padding: 6px 8px;"><a href="http://www.parentprojectmd.org/site/News2?page=NewsArticle&amp;id=10602&amp;security=2121&amp;news_iv_ctrl=0" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;">Maria McDonald is one of 9 children, all of whom run for their youngest brother, Mark.</a></td></tr></tbody></table></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 11px; color: rgb(39, 39, 39); line-height: 1.4em; padding-bottom: 20px;"><a href="http://www.parentprojectmd.org/site/News2?page=NewsArticle&amp;id=10602&amp;security=2121&amp;news_iv_ctrl=0" target="_blank" style="color: rgb(153, 153, 102); text-decoration: none;"><img alt="Maria" src="http://www.parentprojectmd.org/images/content/pagebuilder/rfos_winter_spotlight_maria.jpg" border="no" style="border: 0px none; margin: 0px; padding: 0px; display: block;"></a></td></tr></tbody></table></td><td width="20" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"></td><td width="305" align="left" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><table width="305" border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 10px;"><table border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#e51937" align="left" valign="middle" style="font-family: Arial, Helvetica, sans-serif; font-size: 11px; color: rgb(255, 255, 241); padding: 6px 8px;"><a href="http://www.parentprojectmd.org/site/PageServer?pagename=run_RunnerSpotlight" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;">Meet Matt Dague, who has run 4 marathons for his nephew Alec and looks forward to running many more!</a></td></tr></tbody></table></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 11px; color: rgb(39, 39, 39); line-height: 1.4em; padding-bottom: 20px;"><a href="http://www.parentprojectmd.org/site/PageServer?pagename=run_RunnerSpotlight" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;"><img src="http://www.parentprojectmd.org/images/content/pagebuilder/rfos_winter_spotlight_mattdague.jpg" border="no" style="border: 0px none; margin: 0px; padding: 0px; display: block;"></a></td></tr></tbody></table></td></tr></tbody></table></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#FFFFFF" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; border: none; padding-bottom: 0px;"><table width="630" border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td width="305" align="left" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><table width="305" border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 10px;"><table border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#e51937" align="left" valign="middle" style="font-family: Arial, Helvetica, sans-serif; font-size: 11px; color: rgb(255, 255, 241); padding: 6px 8px;"><a href="http://www.parentprojectmd.org/site/PageServer?pagename=run_RunnerSpotlight" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;">Leeandra Archdeacon is mom to Nicholas, her inspiration for running. She has participated in 9 half marathons and is training for at least 4 more!</a></td></tr></tbody></table></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 11px; color: rgb(39, 39, 39); line-height: 1.4em; padding-bottom: 20px;"><a href="http://www.parentprojectmd.org/site/PageServer?pagename=run_RunnerSpotlight" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;"><img src="http://www.parentprojectmd.org/images/content/pagebuilder/rfos_winter_spotlight_leeandra.jpg" border="no" style="border: 0px none; margin: 0px; padding: 0px; display: block;"></a></td></tr></tbody></table></td><td width="20" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"></td><td width="305" align="left" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><table width="305" border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 10px;"><table border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#e51937" align="left" valign="middle" style="font-family: Arial, Helvetica, sans-serif; font-size: 11px; color: rgb(255, 255, 241); padding: 6px 8px;"><a href="http://www.parentprojectmd.org/site/PageServer?pagename=run_RunnerSpotlight" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;">Patrick Rownd has competed in several half marathons over the past year in honor of his son Wyatt, his biggest inspiration and the reason he runs every mile.</a></td></tr></tbody></table></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 11px; color: rgb(39, 39, 39); line-height: 1.4em; padding-bottom: 20px;"><a href="http://www.parentprojectmd.org/site/PageServer?pagename=run_RunnerSpotlight" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;"><img src="http://www.parentprojectmd.org/images/content/pagebuilder/rfos_winter_spotlight_rownd.jpg" border="no" style="border: 0px none; margin: 0px; padding: 0px; display: block;"></a></td></tr></tbody></table></td></tr></tbody></table></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td bgcolor="#FFFFFF" valign="top" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; border: none; padding-bottom: 20px;"><img src="https://secure2.convio.net/ppmd/images/content/pagebuilder/splitted-gray-thin.jpg" alt="" border="no" style="margin: 0px; padding: 0px; display: block;"></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td valign="top" bgcolor="#FFFFFF" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 15px; border: none;"><table border="0" cellspacing="0" cellpadding="0" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-bottom: 5px; border: none;"><tbody><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 15px; line-height: 22px; color: rgb(219, 32, 61); padding-bottom: 5px;"><strong>Now Recruiting For…</strong></td></tr><tr style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><td align="left" valign="top" style="font-family: Arial, Helvetica, sans-serif; font-size: 12px; line-height: 20px; color: rgb(77, 88, 82); padding-bottom: 5px;">Our calendar is jam-packed with races across the country, including some brand new additions! Sign up today and go the distance to end Duchenne!<ul style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><a href="http://www.parentprojectmd.org/site/TR?fr_id=2640&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Flying Pig Marathon, Half Marathon &amp; 10K</a>&nbsp;– May 5th</li><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><a href="http://www.parentprojectmd.org/site/TR?fr_id=2630&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Rite-Aid Cleveland Marathon, Half Marathon, 10K &amp; 5K</a>&nbsp;– May 19th</li><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><a href="http://www.parentprojectmd.org/site/TR?fr_id=2700&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Rock ‘n’ Roll Seattle Marathon &amp; Half Marathon</a>&nbsp;– June 22nd</li><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><a href="http://www.parentprojectmd.org/site/TR?fr_id=2670&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Aquaphor New York City Triathlon</a>&nbsp;– July 14th</li><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><a href="http://www.parentprojectmd.org/site/TR?fr_id=2740&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Disneyland Half Marathon Weekend</a>&nbsp;– August 30th &amp; September 1st</li><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><strong>**NEW**</strong>&nbsp;<a href="http://www.parentprojectmd.org/site/TR?fr_id=2780&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Medtronic Twin Cities Marathon</a>&nbsp;– October 6th</li><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><a href="http://www.parentprojectmd.org/site/TR?fr_id=2790&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Under Armour Baltimore Running Festival</a>&nbsp;– October 12th</li><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><a href="http://www.parentprojectmd.org/site/TR?fr_id=2750&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Bank of America Chicago Marathon</a>&nbsp;– October 13th</li><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><a href="http://www.parentprojectmd.org/denver2013" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Rock ‘n’ Roll Denver Marathon &amp; Half Marathon</a>&nbsp;– October 20th</li><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><strong>**NEW**</strong>&nbsp;<a href="http://www.parentprojectmd.org/site/TR?fr_id=2770&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Marine Corps Marathon</a>&nbsp;– October 27th</li></ul><strong>And Save the Date for these popular 2014 races!</strong><ul style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;"><a href="http://www.parentprojectmd.org/site/TR?fr_id=2860&amp;pg=entry" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Walt Disney World Marathon Weekend</a>&nbsp;– January 9-12, 2014</li><li style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 10pt;">Chevron Houston Marathon &amp; Aramco Houston Half Marathon – January 19, 2014</li></ul>For information about how you can join the Run For Our Sons team,&nbsp;<a href="http://www.parentprojectmd.org/site/PageServer?pagename=rfos_homepage" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">visit our website</a>&nbsp;or email<a href="https://mail.google.com/mail/?view=cm&amp;fs=1&amp;tf=1&amp;to=info@runforoursons.org" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">info@runforoursons.org</a>.<br><br><em><strong>Like Run For Our Sons on&nbsp;<a href="https://www.facebook.com/RunForOurSons?ref=ts&amp;fref=ts" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Facebook</a>&nbsp;and follow us on&nbsp;<a href="https://twitter.com/runforoursons" target="_blank" style="color: rgb(219, 32, 61); text-decoration: none;">Twitter</a>&nbsp;to get the latest news, fundraising and training tips, and to connect with other runners.</strong></em></td></tr></tbody></table></td></tr></tbody></table>]]></description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=18721.0</link>
            <guid isPermaLink="false">0A47C969-A9BB-4229-8F23-7DE13150390C-6371-0000126B6B533EFD-FFA</guid>
            <pubDate>Mon, 04 Mar 2013 14:37:27 -0500</pubDate>
        </item>

        <item>
            <title>LAST CALL: Risk/Benefit in Duchenne Therapies Survey</title>
            <description>This is our last call for participants for the survey. If you have already done the survey, thanks so much! If you haven’t done the survey, or are in the middle of completing it, please do so before 9:00 PM Eastern time on Wednesday, Feb 20th. We are still in need of a few more participants.&lt;br /&gt;
&lt;br /&gt;
We especially need parents OR guardians of:&lt;br /&gt;
&lt;br /&gt;
Very young children, especially age 4 and under&lt;br /&gt;
Children who are able to walk some, but who are having a lot of difficulty&lt;br /&gt;
Adults who have lost the ability to power their own wheelchair&lt;br /&gt;
 &lt;br /&gt;
Take the treatment priorities survey now.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/last-call-phase-1-survey-risk-benefit-in-duchenne-therapies?xg_source=activity</link>
            <guid isPermaLink="false">A7A7FCC2-9A1F-4E17-B859-B605E5AB48D4-2155-0000162BF20898CA-FFA</guid>
            <pubDate>Tue, 19 Feb 2013 15:56:09 -0500</pubDate>
        </item>

        <item>
            <title>Action Alert: Help Reauthorization from Home</title>
            <description><![CDATA[We recognize that not everyone is able to travel to Washington for our Advocacy conference. While our advocates continue to visit offices on Capitol Hill, you can make a difference from home. You are just a couple of clicks away from helping!<br />
<br />
Many of you already submitted your information for our packet drop off – here is one more simple step you can take to help to solidify your message to Congress. <br />
<br />
Help make our voice heard this week in Washington...<br />
<br />
 <br />
<br />
Make a Phone Call and Send an Email<br />
<br />
PPMD families from across the country need your help urging Senators, Congressmen and/or their staff to co-sponsor the Paul D. Wellstone MD-CARE Act reauthorization. <br />
<br />
You can help reinforce our message by sending emails and make phone calls. This can be with just a few easy clicks or five minutes on the phone. ]]></description>
            <link>https://secure2.convio.net/ppmd/site/Advocacy?pagename=homepage&amp;page=SplashPage&amp;id=171&amp;JServSessionIdr004=kkecdyr464.app202b</link>
            <guid isPermaLink="false">8111A550-035A-460E-9B65-C9C7A91B8A02-2155-0000162769BE5077-FFA</guid>
            <pubDate>Tue, 19 Feb 2013 15:55:45 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Funds Collection and Analysis of Imaging Data from Eteplirsen Study</title>
            <description><![CDATA[Parent Project Muscular Dystrophy (PPMD) announced that it has funded $59,000 to Krista Vandenborne, PhD  of the University of Florida in Gainesville to test the ability of magnetic resonance imaging  (MRI) to detect changes in the muscles of  those living with Duchenne muscular dystrophy (Duchenne) who participated in the Sarepta phase II trial of Eteplirsen.<br />
"This supplemental funding from PPMD allowed us to very quickly take advantage of a trial in progress to see if MRI can detect changes in the amount and quality of muscle in response to an experimental treatment," said Dr. Vandenborne.<br />
<br />
Eteplirsen is an antisense oligonucleotide-based drug that allows skipping of exon 51 in the dystrophin gene.  For approximately 13% of those with Duchenne, skipping exon 51 may lead to the production of a shorter, but functional dystrophin protein.  Sarepta Therapeutics recently completed a phase II study of the drug in 12 participants and found evidence of dystrophin production and some improvement in the distance walked in six minutes.<br />
<br />
Although the six minute walk test has been used as a primary outcome in almost all of the current clinical trials for Duchenne, study sponsors are also interested in identifying "biomarkers" or other types of measurements that might indirectly predict which study participants are responding to a therapeutic intervention.  If such biomarkers can be identified and demonstrated to be linked to functional benefits, such as walking ability, they may one day be used in place of functional tests or to add supporting evidence to those tests.<br />
<br />
Dr. Vandenborne's group has been using a technique known as "magnetic resonance imaging" or "MRI" to generate pictures of the muscles to demonstrate how much tissue is there, differentiating it from fatty scar tissue.  Due to pilot data generated from an earlier End Duchenne award from PPMD, Dr. Vandenborne received a $7 million grant from the National Institutes of Health to test the ability of MRI to accurately predict the loss of muscle function in boys not undergoing treatment trials. <br />
<br />
Now PPMD has provided an additional $59,000 to Dr. Vandenborne to test the ability of MRI to detect changes in the muscle in response to a treatment – in this case Sarepta's Eteplirsen. The investigators have collected data from the active phase of the study and will continue collecting data as the original study participants stay on the drug in the extended access program.  Results of the MRI analysis from the phase II Eteplirsen study will be submitted for publication as soon as the data is compiled.<br />
<br />
"Developing accurate, reliable ways to detect when new drugs are working has become increasingly important, as more drugs enter clinical testing for Duchenne," said PPMD's Founding President and CEO Patricia Furlong .  "This study is part of our ongoing effort to provide tools that will give each new experimental drug the very best chance for success."<br />
<br />
This grant was made possible as a result of PPMD's recent holiday campaign which focused on raising funds for projects aimed at identifying biomarkers and genetic modifiers, which will help to unlock better and faster ways of advancing clinical trials.<br />
<br />
For more about Parent Project Muscular Dystrophy's grant program, as well as a comprehensive list of what we are funding, please visit ParentProjectMD.org/Research.]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-funds-collection-and-analysis-of-imaging-data-from-eteplirse</link>
            <guid isPermaLink="false">93DF2E75-ED2A-4147-81C8-A155F004D4C8-657-000007EB18D1E76E-FFA</guid>
            <pubDate>Mon, 04 Feb 2013 11:43:00 -0500</pubDate>
        </item>

        <item>
            <title>Webinar Recording: Cardiac Series - LVAD in Duchenne</title>
            <description>On January 24, PPMD hosted the third in our series of four cardiac webinars. This webinar was dedicated to the subject of LVAD use in patients with Duchenne. We were pleased to be joined by a panel of four outstanding surgeons who are all experts in the field of cardiothoracic surgery. The recording is now available online. </description>
            <link>http://community.parentprojectmd.org/video/cardiac-webinar-series-part-3-the-use-of-ventricular-assist-devic</link>
            <guid isPermaLink="false">C58F8855-7354-441A-9797-8B06AD455A1D-4777-000027985D2AD654-FFA</guid>
            <pubDate>Wed, 30 Jan 2013 12:36:37 -0500</pubDate>
        </item>

        <item>
            <title>Is Your District Represented?</title>
            <description>As you know, we head into an important year of Advocacy with the muscular dystrophy community determined to Reauthorize the MD-CARE Act. We issued a 50 state challenge in the hopes of getting representation from Duchenne advocates in each district and every state. You heard the call to action and you responded! We compiled a list of coverage by state and district to date. Please make sure YOU are represented!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/is-your-district-represented</link>
            <guid isPermaLink="false">D5DE8F1D-E0FE-474C-90F0-DBE588F5F7C1-2021-00000C3A91C88170-FFA</guid>
            <pubDate>Tue, 29 Jan 2013 12:47:03 -0500</pubDate>
        </item>

        <item>
            <title>Important Reminder: Cardiac Webinar Series Continues 1/24/13</title>
            <description><![CDATA[Cardiac Series Part 3:<br>
The Use of Ventricular Assist Devices (VAD)<br>
On Thursday, January 24 at 1pm eastern, PPMD will be hosting the third in our series of four cardiac webinars. This webinar will be dedicated to the subject of LVAD use in patients with Duchenne.<br>
<br>
We are pleased to be joined by a panel of four outstanding surgeons who are all experts in the field of cardiothoracic surgery:<br>
Dr. Pirooz Eghtesady - cardiothoracic surgery, St. Louis Children’s Hospital<br>
Dr. David Morales - Chief of Cardiovascular surgery, executive co-director of the Heart Institute, Cincinnati Children's Hosptial Medical Center<br>
Dr. Robert “Jake” Jaquiss - Chief of Pediatric Cardiothoracic Surgery, Duke University<br>
Dr. Patrick McConnell - Cardiothoracic Surgery, Nationwide Children’s Hospital<br><br><div>
The topics they will cover will include:<br>
What is a VAD/LVAD?<br>
When might a VAD be considered?<br>
Who might be considered as a candidate?<br>
Pros and cons of VAD implantation<br>
Post-VAD life; lessons learned from the first 3 recipients</div><div><br>
To Participate<br>
Visit ReadyTalk.com and use participant code 9449985. (Be sure to test your computer beforehand)</div><div><br>
Audio Dial-In Information:<br>
U.S. &amp; Canada: Dial 866.740.1260 and use the Access Code 9449985<br>
Outside the U.S. and Canada: Lookup your number</div><div><br>
As always, if you are unable to attend or want to listen again, a link to download this webinar will be posted as soon as it is available.</div>]]></description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=18381.0</link>
            <guid isPermaLink="false">ECC78C80-EB57-4168-B38A-B6D502150B7E-388-000001CCF48EFA2F-FFA</guid>
            <pubDate>Tue, 22 Jan 2013 09:29:14 -0500</pubDate>
        </item>

        <item>
            <title>Parent Project Muscular Dystrophy Grants $175,000 for Biomarkers, Non-Ambulatory Endpoints in Duchenne Muscular Dystrophy</title>
            <description><![CDATA[Parent Project Muscular Dystrophy (PPMD) has awarded Dr. Craig McDonald of the University of California, Davis (UC Davis) $175,000 in supplemental funds to expand his ongoing study through the 20 CINRG (Cooperative International Neuromuscular Research Group) centers to better understand the progression of Duchenne muscular dystrophy (Duchenne) and determine the impact of the Duchenne standards of care established by the Centers for Disease Control (CDC).  Related studies will focus on developing new endpoints in boys who are still walking and those who can no longer walk, and identifying blood markers that track the progression of the disease.  The PPMD funding will allow Dr. McDonald to recruit 100 additional subjects into the study.<br />
(Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO )<br />
"Funding from PPMD will make a critical difference in the development of new outcome measures and the overall quality of the data we collect in this study," said McDonald who is a professor and chair of the UC Davis Department of Physical Medicine and Rehabilitation. "These studies have already impacted the development of endpoints for trials in Duchenne and the new funding will allow us to extend the research into younger boys and boys who have not yet started taking steroids."<br />
This research is critical because companies developing therapies for Duchenne, the Food and Drug Administration, and academic investigators have all expressed a need to develop additional "endpoints," or ways to measure the effectiveness of experimental drugs in clinical trials.  Although the six minute timed walk has been used in many clinical trials to date, new endpoints that can be used for wider ranges of ability so that more boys will be eligible to participate in drug trials could improve investigators' ability to recruit for clinical trials.  For example, Dr. McDonald's group is developing an "upper extremity function test" that could be used in clinical trials for subjects who have lost the ability to walk.<br />
In addition to developing new endpoints, the investigators will also be taking blood samples from participants to look for proteins in the blood or "biomarkers" that could indicate quickly whether or not a drug is working.  The group has already identified several prospective biomarker candidates and now needs to test those markers in a larger group of participants.<br />
"We are pleased to provide funding to enhance this project," said Pat Furlong , Founding President and CEO of Parent Project Muscular Dystrophy.  "As the pipeline of new drugs for Duchenne continues to mature, we are committed to making sure that investigators and companies have all the tools they need to approve drugs efficiently."<br />
This grant was made possible as a result of PPMD's recent holiday campaign which focused on raising funds for projects aimed at identifying biomarkers and genetic modifiers, which will help to unlock better and faster ways of advancing clinical trials.<br />
For more about Parent Project Muscular Dystrophy's grant program, as well as a comprehensive list of what we are funding, please visit ParentProjectMD.org/Research.<br />
<br />
PR Newswire (http://s.tt/1yDpV)]]></description>
            <link>http://www.prnewswire.com/news-releases/parent-project-muscular-dystrophy-grants-175000-for-biomarkers-non-ambulatory-endpoints-in-duchenne-muscular-dystrophy-187436771.html</link>
            <guid isPermaLink="false">3FBE0AEE-2979-48D4-B2AC-832DDB79AF9C-519-000001BE80E65E7C-FFA</guid>
            <pubDate>Fri, 18 Jan 2013 10:16:30 -0500</pubDate>
        </item>

        <item>
            <title>Help PPMD make twice the impact on important research</title>
            <description>We’re so close to reaching our goal of $300,000. Thanks to Ellen Wagner and her family, if you give by the 31st, your donation will go twice as far!&lt;br /&gt;
&lt;br /&gt;
Sharon, our Vice President for Research, wrote to you last week, explaining how important it is to support projects that create meaningful outcome measures for Duchenne therapies. Many people in our community have responded with generous donations.&lt;br /&gt;
&lt;br /&gt;
Please take a minute to share this with anyone in your life who knows what Duchenne is and has asked how they can help us end it. Remember: All online donations up to $50,000 will be matched 100%!&lt;br /&gt;
&lt;br /&gt;
The new year is approaching, and there’s no better way to end 2012 than by reaching our ambitious fundraising goal. Thank you for helping to make it all possible!&lt;br /&gt;
&lt;br /&gt;
Enjoy a bountiful 2013!&lt;br /&gt;
</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=18144.0</link>
            <guid isPermaLink="false">A1888397-A744-40F8-9D28-D51685756B6E-2053-00000F8C07A1A23C-FFA</guid>
            <pubDate>Thu, 27 Dec 2012 14:11:28 -0500</pubDate>
        </item>

        <item>
            <title>Vote for PPMD in Houston Marathon’s Run For a Reason Charity Contest</title>
            <description><![CDATA[<p class="MsoNormal" style="margin-top: 0in; margin-right: 0in; margin-left: 0in; margin-bottom: 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif; "><a href="http://houstonmarathon.wordpress.com/2012/12/19/vote-for-your-favorite-chevron-houston-marathon-run-for-a-reason-charity/" style="color: blue; text-decoration: underline; ">Vote for Parent Project Muscular Dystrophy</a>&nbsp;and help us win $50,000!<o:p></o:p></p><p class="MsoNormal" style="margin-top: 0in; margin-right: 0in; margin-left: 0in; margin-bottom: 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif; "><o:p>&nbsp;</o:p></p><p class="MsoNormal" style="margin-top: 0in; margin-right: 0in; margin-left: 0in; margin-bottom: 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif; ">Chevron is donating $50,000 to the Houston Marathon’s Run For a Reason Charity that receives the most votes between now and January 8<sup>th</sup>. Just&nbsp;<a href="http://houstonmarathon.wordpress.com/2012/12/19/vote-for-your-favorite-chevron-houston-marathon-run-for-a-reason-charity/" style="color: blue; text-decoration: underline; ">click this link</a>, select Parent Project Muscular Dystrophy, hit Vote, and you’re done! It’s that easy.<o:p></o:p></p><p class="MsoNormal" style="margin-top: 0in; margin-right: 0in; margin-left: 0in; margin-bottom: 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif; "><o:p>&nbsp;</o:p></p><p class="MsoNormal" style="margin-top: 0in; margin-right: 0in; margin-left: 0in; margin-bottom: 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif; "><a href="http://houstonmarathon.wordpress.com/2012/12/19/vote-for-your-favorite-chevron-houston-marathon-run-for-a-reason-charity/" style="color: blue; text-decoration: underline; ">Vote now</a>, then share this with everyone you know and ask them to vote too! The charity with the most votes wins.<o:p></o:p></p><p class="MsoNormal" style="margin-top: 0in; margin-right: 0in; margin-left: 0in; margin-bottom: 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif; "><span style="color: rgb(31, 73, 125); "><o:p>&nbsp;</o:p></span></p><p class="MsoNormal" style="margin-top: 0in; margin-right: 0in; margin-left: 0in; margin-bottom: 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif; "><span style="color: rgb(31, 73, 125); "><o:p>&nbsp;</o:p></span></p><p class="MsoNormal" style="margin-top: 0in; margin-right: 0in; margin-left: 0in; margin-bottom: 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif; "><i>Votes verified by an independent agency. Chevron, the Houston Marathon Committee and the Houston Marathon Foundation are not responsible for votes not received due to computer/internet malfunctions.<o:p></o:p></i></p><p class="MsoNormal" style="margin-top: 0in; margin-right: 0in; margin-left: 0in; margin-bottom: 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif; "><span style="color: rgb(31, 73, 125); "><o:p>&nbsp;</o:p></span></p>]]></description>
            <link>http://houstonmarathon.wordpress.com/2012/12/19/vote-for-your-favorite-chevron-houston-marathon-run-for-a-reason-charity/</link>
            <guid isPermaLink="false">B4B32BA1-A48F-44C4-922B-83185DC03C6B-353-0000047607897720-FFA</guid>
            <pubDate>Thu, 20 Dec 2012 16:19:42 -0500</pubDate>
        </item>

        <item>
            <title>Webinar: Ataluren Update with PTC</title>
            <description><![CDATA[<p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow: hidden; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">January 17 at noon EST</p><p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow: hidden; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><br>Dr. Jay Barth, Vice President for Clinical Development at PTC Therapeutics will present information about the study design and timeline for the upcoming Phase 3 confirmatory study of ataluren in Duchenne muscular dystrophy.</p><p class="p2" style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow: hidden; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"></p><p class="p2" style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow: hidden; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong>Additional Information:</strong></p><ul style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1.2em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Questions can be submitted until noon on Monday, January 14, by emailing&nbsp;<a href="https://mail.google.com/mail/?view=cm&amp;fs=1&amp;tf=1&amp;to=info@parentprojectmd.org" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">info@ParentProjectMD.org</a><span>&nbsp;(please put "Ataluren Webinar” as the subject line).</span></li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">The webinar will be recorded and available for replay shortly after.</li></ul><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow: hidden; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-2" style="font-size: 10pt !important; line-height: 1.2 !important;"><strong><br>To Participate:</strong></span></p><ol style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1.2em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><li style="margin: 0px 0px 0.4em 2.5em; padding: 0px; line-height: inherit; font-size: 1em;">Visit&nbsp;<a href="http://www.readytalk.com/" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">ReadyTalk.com</a>&nbsp;and use participant code 9449985.&nbsp;(Be sure to&nbsp;<a href="https://core.readytalk.com/interface/participantTest.jsp?host=readytalk" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">test your computer beforehand</a>)</li><li style="margin: 0px 0px 0.4em 2.5em; padding: 0px; line-height: inherit; font-size: 1em;">Audio Dial-In Information:<ul style="margin: 0.2em 0px 0px; padding: 0px; line-height: inherit; font-size: 1em;"><li style="margin: 0px 0px 0.4em 2.5em; padding: 0px; line-height: inherit; font-size: 13px; list-style: square;">U.S. &amp; Canada: Dial 866.740.1260 and use the Access Code 9449985</li><li style="margin: 0px 0px 0.4em 2.5em; padding: 0px; line-height: inherit; font-size: 13px; list-style: square;">Outside the U.S. and Canada:&nbsp;<a href="http://www.readytalk.com/account-administration/international-numbers" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">Lookup your number</a></li></ul></li></ol>]]></description>
            <link>http://community.parentprojectmd.org/events/webinar-ataluren-update-with-ptc</link>
            <guid isPermaLink="false">E1A997FB-3CE1-4ABB-B886-F41DCDBDB50A-397-000001CAC52A6F9C-FFA</guid>
            <pubDate>Thu, 20 Dec 2012 12:55:05 -0500</pubDate>
        </item>

        <item>
            <title>Exon Skipping &amp; Improving Industry Communications</title>
            <description>The 194th workshop of the European Neuro Muscular Centre (ENMC) met in Naarden, The Netherlands, December 7-9, 2012. The title of the workshop was, “Towards Clinical Application of Antisense-mediated Exon Skipping for Duchenne Muscular Dystrophy – Opportunities and Challenges.”  25 representatives of industry, research, care and advocacy from around the world attended the workshop. &lt;br /&gt;
 &lt;br /&gt;
Industry and research presented the current state of the science of exon skipping: where trials stand and result so far.   Future directions, including the challenges of developing additional antisense oligonucleotides (AO’s), detecting and improving delivery of AO’s, responses to treatment were discussed. Potential outcome measures and initiatives for clinical trails in smaller subpopulations were discussed. Finally, the importance of affecting the cardiac muscle was stressed.&lt;br /&gt;
 &lt;br /&gt;
Parent and patient representatives from the US, The Netherlands and Italy discussed the importance of communication – accurate, precise, timely and transparent communication. The impact of social media, and the responsibility of all parties to be aware of messages that are given and received online was stressed. Everyone agreed that we are indeed in a new era of communication. Social media may not be recognized by industry and research as credible, but the ability of sites such as Facebook to impact a huge portion of the community in a very brief amount of time was recognized. The take home message was that parents and patients appreciate regular communication, both when there is and where there is not something new to report.&lt;br /&gt;
 &lt;br /&gt;
As a result of this meeting, a working group addressing communication was formed. The working group was charged with the task of developing a method for industry to give regular (quarterly) reports to patient/parent organization, which will then publish them for the Duchenne and Becker community. This will enable the Duchenne and Becker community to have available, timely access to accurate information, which comes straight from industry and is delivered in a consistent manner to the entire community. The working group will keep us updated as to their progress and hopes to have a working method of information in place within the next few months.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/exon-skipping-improving-industry-communications?xg_source=shorten_status</link>
            <guid isPermaLink="false">9D1EC9EC-9674-463A-9C71-C5ABE1E9BCAE-397-000001C3F1286870-FFA</guid>
            <pubDate>Thu, 20 Dec 2012 10:00:33 -0500</pubDate>
        </item>

        <item>
            <title>Two Moms, Co-Blogging: The Greatest of These</title>
            <description><![CDATA[<p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important;"><strong>12 months of IVY blogs</strong></span></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><a rel="nofollow" href="http://community.parentprojectmd.org/profile/PatFurlong" target="_self" style="text-decoration: initial; color: rgb(238, 30, 58);">by Pat Furlong</a></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">For the last 12 months, we have all enjoyed Ivy’s blogs. I have had the pleasure of introducing Ivy’s words, wrapping my words around hers, almost as if wrapping a gift, finding the perfect box, filling it with tissue paper, or laying the words on piece of black velvet, like an exquisite piece of jewelry. Some of the time, I thought her words should be on a soft pillow and carried as if in a procession for all to see. This month’s particular one, beamed from earth and posted on the moon to light up the night sky.&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Sometimes I thought about them as comfort food, hot chocolate and blueberry muffins or warm potato soup on days when sadness seemed to surround me.&nbsp; Often, a few words or a phrase recycled in my brain as delicious morsels, a bag of chocolate chips to savor for the day, a gentle reboot for my thoughts. And there were times when I imagined myself back in school, imagining classes such as ‘Wisdom 101’ or ‘Learnings from Rain’ as I read and re-read Ivy’s blogs.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Like all of you, tis the season for thinking about Miracles, Magic, and Meaning. Duchenne has taught me many things and perhaps the most important is to give, to be part of something much, so much greater than the sum of its parts – a community that is willing to: bear all things, believe all things, hope all things, endure all things in the persistent pursuit of a cure.&nbsp;&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">God Bless Us Everyone.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><i><em>Pat Furlong is the Founder and President of Parent Project Muscular Dystrophy.&nbsp;<a rel="nofollow" target="_blank" href="http://community.parentprojectmd.org/profiles/blogs/list?user=syv5r11hhapz" style="text-decoration: initial; color: rgb(238, 30, 58);">Follow Pat at her blog.</a></em></i></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><i><em><br><br></em></i></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important;"><b><a href="http://www.livingduchenne.blogspot.com/" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);"><img src="http://api.ning.com/files/D*Jf-S9oW6SP0pEWv6PF4UcyTZQwNltK2jpRZZUm7KJyH4InEURBquUnv2xo5Ltctog5V170jRnSlbNKg7pcFnUJRAEfR*9h/Blog_Ivy.jpg?width=163" width="163" class="align-right" style="border: 0px none; text-align: right; margin: 4px 0px; float: right !important; display: inline !important; max-width: 721px; height: auto;"></a>The Greatest of These&nbsp;</b></span><b>&nbsp;</b></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><a rel="nofollow" href="http://www.livingduchenne.blogspot.com/" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">by Ivy Scherbarth</a></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Nearly everyone, nearly everywhere is celebrating something at this time of year, whether you call it Diwali or the Day of Ashura, Hanukkah, Kwanzaa, Yule or Christmas or something else entirely. Here's what I love: the mingled smells of snow and latkes and gingerbread, fresh oranges and fir needles and peppermint candy. The feel of wool scarves and velvet and polar fleece. The sight of rosy cheeked smiles popping out from the thin visible sliver between hoods and parkas.&nbsp;<a rel="nofollow" href="http://www.youtube.com/watch?v=qM4q2p-Nml0" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">How about a favorite Christmas song performed by some Romani</a>&nbsp;<a rel="nofollow" href="http://www.youtube.com/watch?v=qM4q2p-Nml0" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">from France, as a flamenco version translated</a>&nbsp;<a rel="nofollow" href="http://www.youtube.com/watch?v=qM4q2p-Nml0" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">into Spanish, which was originally written by a</a><a rel="nofollow" href="http://www.youtube.com/watch?v=qM4q2p-Nml0" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">Russian Jewish immigrant to America?</a>&nbsp;Whether we see our modern society as a melting pot or a mosaic or even a tossed salad, most of us agree on certain virtues that we think about at this time of year. I am thinking about Peace. I am thinking about Joy. I am thinking about Love. I am thinking about Miracles and Magic and Meaning. I am thinking about Beauty, Truth and Goodness. I am thinking about Faith, Hope and Charity.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">I am thinking about what traditions I want to pass down to my children. I want my kids to know that I believe we live in an amazing world, full of beauty that goes far beyond mere prettiness, a kind of immanent beauty that may lead us toward the Something More. I want my children to have a personal experience of peace and to care about what it really means to say to one another, "Peace on Earth." I want my children to understand and to cultivate a deep sense of compassion, to care about the welfare of those who are less fortunate than we are. I want my children to understand true generosity. I want my children to have a deeply nuanced, well-educated and well-rounded appreciation of where we come from and where we would like to be going. I want my children to know that I believe in goodness, the true human goodness we see embodied in the world's many shared traditional virtues.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Though the words are specific, the imperative is, I believe, universal:</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><blockquote style="margin: 2em 0px; padding: 0px 0px 0px 1em; line-height: 1.8em; border-left-width: 2px; border-left-style: solid; border-left-color: rgb(204, 204, 204); font-style: italic; text-overflow: ellipsis; overflow: hidden; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;"4 Charity suffereth long, and is kind; charity envieth not; charity vaunteth not itself, is not puffed up, 5 Doth not behave itself unseemly, seeketh not her own, is not easily</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; provoked, thinketh no evil; 6 Rejoiceth not in iniquity, but rejoiceth in the truth; 7 Beareth all things, believeth all things, hopeth all things, endureth all things. 8 Charity never</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; faileth: but whether there be prophecies, they shall fail; whether there be tongues, they shall cease; whether there be knowledge, it shall vanish away. 9 For we know in part,</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and we prophesy in part. 10 But when that which is perfect is come, then that which is in part shall be done away. 11 When I was a child, I spake as a child, I understood as a</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; child, I thought as a child: but when I became a man, I put away childish things. 12 For now we see through a glass, darkly; but then face to face: now I know in part; but then</p><p style="margin: 0px; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shall I know even as also I am known. 13 And now abideth faith, hope, charity, these three; but the greatest of these is charity." (King James Version<i>, 1 Corinthians 13: 4-13)</i></p></blockquote><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Or, as most modern versions have it translated: "faith, hope and love." (New International Version)</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">I believe that parenthood itself requires me to express Faith, Hope and Love continuously in my relationship with my children. I owe them these things by definition. Parenting a child with Duchenne is not quantitatively different. Yet, our families are different, if only because of the awareness that Duchenne brings on its heels. Duchenne forces us to confront the unconfrontable. It forces us to do the very things listed above: to "suffer long" and be patient, to "bear all things, believe all things, hope all things, endure all things" in the persistent pursuit of a cure. And yet I believe that Duchenne is unsatisfied with us merely&nbsp;<i>loving&nbsp;</i>our sons. Duchenne requires us to work much harder if we want to see a cure. Duchenne requires a translation of our lives that includes Charity as well as Love. Charity is love in action.</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Go back to the beginning of the chapter:</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><blockquote style="margin: 2em 0px; padding: 0px 0px 0px 1em; line-height: 1.8em; border-left-width: 2px; border-left-style: solid; border-left-color: rgb(204, 204, 204); font-style: italic; text-overflow: ellipsis; overflow: hidden; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;"1 Though I speak with the tongues of men and of angels, and have not charity, I am become as sounding brass, or a tinkling cymbal. 2 And though I have the gift of prophecy,</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and understand all mysteries, and all knowledge; and though I have all faith, so that I could remove mountains, and have not charity, I am nothing. 3 And though I bestow all</p><p style="margin: 0px; padding: 0px; line-height: inherit; font-size: 1em; min-height: 1em;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; my goods to feed the poor, and though I give my body to be burned, and have not charity, it profiteth me nothing." (King James Version,&nbsp;<i>1 Corinthians 13: 1-3</i>)</p></blockquote><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">I don't want my faith, my hope, my love and my work for my son to go unrequited. I want my persistence to pay off in the form of a cure.&nbsp;<i>The greatest of these is Charity.</i>&nbsp;Nothing I pass down to my children will have a bigger impact. No holiday gift or symbol could possibly mean more. In fact, it doesn't matter how we translate it, whether we call our action "love" or "charity" as long as we take action. Charity is the way in which we bring all of our personal love, faith and hope into a public form. Charity is the sum of our virtues, embodied and working.&nbsp;<i>Charity never faileth.</i></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">&nbsp;</p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">No one can do everything, but Everyone Can Do Something.&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Connect_pledge_action" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">Put your money and your time where your heart is.</a></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><i><em><br></em></i></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><em><br>Ivy Scherbarth is a Colorado/Wyoming FACES Coordinator for PPMD.&nbsp;<a rel="nofollow" href="http://www.livingduchenne.blogspot.com/" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">Follow Ivy at her blog, Living Duchenne.</a></em></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><em><br><br></em></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important;"><b>What action will you take in 2013?</b></span></p><p style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important;"><span class="font-size-2" style="font-size: 10pt !important; line-height: 1.2 !important;"><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Connect_pledge_action" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">Sign the pledge.</a></span><b><br></b></span></p><div><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important;"><br></span></div>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-greatest-of-these?xg_source=feed</link>
            <guid isPermaLink="false">08439ED3-60E0-40DE-9C71-7393A9C9F88C-397-000001BD6401FD13-FFA</guid>
            <pubDate>Thu, 20 Dec 2012 10:00:03 -0500</pubDate>
        </item>

        <item>
            <title>End Duchenne Gala: 12.6.12 - Recap &amp; Photos</title>
            <description>On December 6, 2012, PPMD held its inaugural End Duchenne Gala in New York City. It was a truly remarkable evening thanks in large part to the organizing committee (Catherine Collins, Anessa Fehsenfeld, Janelle Hester, Vicki Singh, and Paula Zenobio) and a room full of compassionate, generous guests...including acclaimed author, Mary-Lou Weisman. Mary-Lou and her husband Larry are founders of Fund for Pete's Sake and she was kind enough to recap the evening for those of you who couldn't join.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/end-duchenne-gala-12-6-12?xg_source=activity</link>
            <guid isPermaLink="false">B1BFF455-A268-4386-9A64-D473EAA0CF67-878-0000056BCF24DC85-FFA</guid>
            <pubDate>Mon, 17 Dec 2012 15:25:10 -0500</pubDate>
        </item>

        <item>
            <title>Orphan Drug Designation for Myostatin Inhibitor for Muscular Dystrophy</title>
            <description>Milo Biotechnology announced that AAV1-FS344 has been granted Orphan Drug designation from the FDA for the treatment of Becker and Duchenne muscular dystrophy. AAV1-FS344 is a gene therapy-delivered myostatin inhibitor that increases muscle strength.&lt;br /&gt;
&lt;br /&gt;
The program is currently in a Phase 1/2 trial in adult patients with Becker muscular dystrophy and inclusion body myositis.&lt;br /&gt;
&lt;br /&gt;
Duchenne muscular dystrophy is the most common inherited myopathy, caused by the absence of dystrophin protein. Becker muscular dystrophy, a less severe form of Duchenne muscular dystrophy, is caused by reduced levels of dystrophin protein. With both types, patients experience progressive muscle weakness, and cardiac and respiratory complications.&lt;br /&gt;
&lt;br /&gt;
For more information visit www.milobiotechnology.com.</description>
            <link>http://www.empr.com/orphan-drug-designation-for-myostatin-inhibitor-for-muscular-dystrophy/article/272287/</link>
            <guid isPermaLink="false">AEDDF2B7-EF32-4F73-8B82-1DBD28BB006D-878-00000563A1EF01ED-FFA</guid>
            <pubDate>Mon, 17 Dec 2012 13:03:45 -0500</pubDate>
        </item>

        <item>
            <title>Henri Termeer joins Prosensa as Strategic Advisor</title>
            <description>Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has appointed industry leader and former Genzyme CEO, Mr. Henri Termeer as Strategic Advisor. His role at Prosensa will be to provide input on the company’s corporate strategy and growth plans.&lt;br /&gt;
Commenting on his appointment, Mr. Termeer said: “Prosensa has the key ingredients of a successful company in the rare disease community: breakthrough science, a highly motivated workforce and a passionate commitment to improving the lives of patients. I am very much looking forward to working with the Prosensa team.”&lt;br /&gt;
&lt;br /&gt;
Prosensa’s CEO, Hans Schikan, commented: “We are very pleased that Henri is joining the team as a Strategic Advisor. Under his leadership, Genzyme became a world-leading biotech company and a pioneer in rare diseases and orphan drugs. His expertise will be invaluable to use as we drive our products and technology forward.”&lt;br /&gt;
&lt;br /&gt;
Henri Termeer served as Chairman, President and CEO of Genzyme Corporation for nearly three decades. Under his leadership, the company evolved from a mid-sized biomedical company to one of the world’s leading biopharmaceutical companies, especially in the field of rare diseases and orphan drugs. He retired from Genzyme in 2011 following its acquisition by Sanofi in a transaction valued at more than $20 billion.  Mr. Termer is also involved in a number of other companies and not-for-profit organizations.&lt;br /&gt;
&lt;br /&gt;
Commenting on the appointment, Mr. Daan Ellens, Chairman of Prosensa’s Supervisory Board, said: “Henri is a luminary in the biotech world, and an expert in rare diseases and orphan drugs. His expertise will be crucial in supporting our goal of developing and commercialising oligonucleotide treatments for rare neuromuscular disorders. We welcome him on board.”</description>
            <link>http://www.prosensa.eu/press-release/henri-termeer-joins-prosensa-strategic-advisor</link>
            <guid isPermaLink="false">F01FBA0C-0AA5-4520-9D77-B4B0DD1D0BB0-878-00000560B314161A-FFA</guid>
            <pubDate>Mon, 17 Dec 2012 13:03:09 -0500</pubDate>
        </item>

        <item>
            <title>Help us Reauthorize the MD-CARE Act</title>
            <description><![CDATA[<p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="s1">I am</span>&nbsp;often asked<span class="s2">:</span>&nbsp;"<span class="s2">H</span>ow can I help in the fight to end Duchenne?" and "What are things I can do to make a difference?" My answer is always&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Advocate" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">Advocacy</a>.<br><br></p><p class="p3" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong>You are already natural advocates<span class="s2">.</span></strong>&nbsp;<span class="s2">Y</span>ou began advocating the day you received the diagnosis, or found out someone you cared about was affected by Duchenne. Advocacy take<span class="s2">s</span>many forms<span class="s2">. One</span>&nbsp;of the most important ways is the interaction between citizens and those elected to represent them in Congress to change the status quo. For our community<span class="s2">,</span>&nbsp;we advocate in the hope of improving the lives of those you love by advancing research, improving care standards, and ensuring the proper resources exist to expedite treatments for Duchenne. A small group of Duchenne advocates have made such a tremendous difference in the lives of so many Duchenne patients and families by telling their stories to those who represent them in&nbsp;<span class="s2">C</span>ongress.<br><br></p><p class="p4" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">The cornerstone of our&nbsp;<span class="s2">a</span>dvocacy efforts in Washington has been the&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Advocate_conference_options" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">MD-CARE Act</a>. First passed in 2001, this banner legislation has been a pivotal piece of the successes we’ve had in advancing the fields of research and care. This bill laid the foundation for the successes we have seen in the last decade, and was reauthorized in 2008 after the community worked hard with members of Congress to ensure its passage.<br><br></p><p class="p3" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">Here is what has been yielded from our efforts:<br><br></p><ul style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;"><strong>Over $400&nbsp;<span class="s2">m</span>illion</strong>&nbsp;has gone into muscular dystrophy research, leveraging additional millions in private investment.</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;"><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Care_elements_considerations" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">Care Standards</a>&nbsp;have been established and published and are in the process of being disseminated. These standard<span class="s2">s</span>&nbsp;have<strong>added 10 years to the lives of those living with Duchenne</strong>.</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">The&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Care_resources_links_MDStar" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">MD STARnet program</a>&nbsp;has yielded important data on incidence prevalence and burden of cost for those living with Duchenne.</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">Six (rotating) cooperative MD research&nbsp;<a rel="nofollow" href="http://www.wellstonemdcenters.nih.gov/index.htm" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">Centers of Excellence</a>&nbsp;were established by the National Institutes of Health (NIH). The centers work individually and collaboratively. Each has both&nbsp;<strong>basic and clinical research projects</strong>, and one or more core facilities to support them.</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square;">The public-private&nbsp;<a rel="nofollow" href="http://www.ninds.nih.gov/find_people/groups/mdcc/" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">Muscular Dystrophy Coordinating Committee</a>, established under the bill, has worked to expand, intensify, and coordinate research activities related to muscular dystrophy.</li></ul><p class="p4" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><br>None of these accomplishments would be possible without the power of your voice.&nbsp;<span class="s2">From c</span>onstituents telling their stories to members of congress&nbsp;<span class="s2">to</span>&nbsp;advocating for more money for research, care, and improvements in regulatory processes&nbsp;<span class="s2">– patient</span>advocacy has made a tremendous difference in the fight to end Duchenne. Over the last decade you spoke up and Congress listened.&nbsp;<b>We must continue to raise our voices.&nbsp;</b>We compete with so many others trying to be heard, and in order to remain on the radar of the federal government we must remain vigilant with a consistent message.<br><br></p><p class="p4" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; color: rgb(229, 25, 55);">Take Action -&nbsp;Tell Congress to Reauthorize the MD-Care Act!</span></strong></p><p class="p4" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);">All authorizing legislation must be reauthorized every&nbsp;<span class="s2">five&nbsp;</span>years. We are embarking upon another reauthorization year for our bill and&nbsp;<strong><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Advocate_conference_options" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">need your voice</a></strong>.<br><br></p><p class="p4" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><b>How can you help?</b>&nbsp;We’ve put together a&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Advocate_conference_options" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">landing page that you can share</a>&nbsp;with your family, friends, and neighbors—really anyone who cares about changing the course of Duchenne. Join us in Washington, Add your name to our packet drop, sign up for advocacy alerts&nbsp;<span class="s2">– lend</span>&nbsp;your voice to ours!<br><br></p><p class="p4" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Advocate_conference_options" target="_blank" style="text-decoration: initial; color: rgb(238, 30, 58);">Please visit our Get Active page</a>&nbsp;page to learn more how you can get involved.</p><p class="p5" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><span class="s3"><a rel="nofollow" href="http://www.parentprojectmd.org/getactive" style="text-decoration: initial; color: rgb(238, 30, 58);">&nbsp;</a></span></p><p style="margin: 0px; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-align: right;"><a href="http://community.parentprojectmd.org/profile/RyanFischer" target="_self" style="text-decoration: initial; color: rgb(238, 30, 58);"><img src="http://api.ning.com/files/pbAD1vT8NrGS1km1ZVeYeRpnTnzer2U2ksCHVXysYku-Ds14wPCN6SUZ9WnT*omG7HVZuSHBm8cgEAKK0G1M6yf4FTrR3d7o/ryan.jpeg" width="64" class="align-right" style="border: 0px none; text-align: right; margin: 4px 0px; float: right !important; display: inline !important; max-width: 721px; height: auto;"></a></p><div><br></div>
]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/help-us-reauthorize-the-md-care-act?xg_source=shorten_status</link>
            <guid isPermaLink="false">5DF2E861-6BFA-4C7E-ACA3-B46F773BCADE-2661-00001453D38D8D41-FFA</guid>
            <pubDate>Wed, 12 Dec 2012 16:49:50 -0500</pubDate>
        </item>

        <item>
            <title>Help us advance clinical trials - faster</title>
            <description>This holiday season, PPMD will be funding three projects totaling just over $300,000 to help unlock better and faster ways of advancing clinical trials. Donate today to help make new breakthroughs possible, and your gift will be matched dollar for dollar due to the generosity of the Wagner family!</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=17941.0</link>
            <guid isPermaLink="false">01843BB2-4C9C-4D5C-A862-D15CDB2BEBFB-3031-00001BFD090AAF5A-FFA</guid>
            <pubDate>Thu, 06 Dec 2012 17:01:11 -0500</pubDate>
        </item>

        <item>
            <title>Webinar Q&amp;A: Cardiac Interventions</title>
            <description><![CDATA[Parent Project Muscular Dystrophy recently hosted the second part of our Cardiac Webinar Seriers with Dr. Larry Markham (Children’s Hospital Vanderbilt, Vanderbilt, TN) and Dr. J. Lynn Jefferies (Cincinnati Children's Hosptial, Cincinnati, OH) to discuss cardiac interventions. <br />
 <br />
Topics included:<br />
When to intervene (parameters for intervening, pros/cons to early intervention)<br />
What meds to use and why (ACE, ARB, Beta blockers, aldactone)<br />
 <br />
Dr. Markham discussed medical interventions, including beta blockers, ACE inhibitors, angiotensin receptor blockers, diuretics, heart failure medications: what to start, when to start, why to start, actions of the medications, side effects, follow up.<br />
<br />
Dr. Jefferies discussied mechanical interventions, including internal cardiac defibrillators (ICD's), ventricular assist devices (VAD's), pacemakers: what are they, when to consider their use, why to consider their use, who should insert the device, pros/cons of each.<br /><br />There were some great questions asked, but unfortunately we were not able to get to all of them during the webinar. The remaining questions have been addressed below!<br />
<br />
Make sure to join us for Cardiac webinar series, Part 3 - The use of Ventricular Assist Devices in Patients with Duchenne in January.<br />
 ]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/webinar-q-a-cardiac-interventions?xg_source=activity</link>
            <guid isPermaLink="false">79BBED09-DDD2-4535-8989-AB40FB381F38-3031-00001BF66ACBAC11-FFA</guid>
            <pubDate>Thu, 06 Dec 2012 17:00:30 -0500</pubDate>
        </item>

        <item>
            <title>Pat Furlong to speak at Institute Of Medicine Roundtable</title>
            <description>PPMD founding president and CEO Pat Furlong, has been invited to speak today at the Institute of Medicine's (IOM) Roundtable on Translating Genomic-Based Research for Health. IOM is holding a public workshop today in Irvine, CA titled &quot;Improving the Efficiency and Effectiveness of Genomic Science Translation.&quot; Pat is a member of IOM's Committee on Pediatric Studies and is thrilled to be participating in the discussion &quot;The Role of Advocacy in Facilitating Basic Scientific Research&quot; at this important roundtable.</description>
            <link>http://www.prnewswire.com/news-releases/parent-project-muscular-dystrophy-founder-pat-furlong-to-speak-at-institute-of-medicines-roundtable-on-translating-genomic-based-research-for-health-181814241.html</link>
            <guid isPermaLink="false">8F1A8F3A-DE85-4396-A01E-C45FD8CA6737-1093-00000D671FE69EC5-FFA</guid>
            <pubDate>Mon, 03 Dec 2012 14:42:18 -0500</pubDate>
        </item>

        <item>
            <title>Upcoming Webinar: Summit, SMT C1100</title>
            <description>PPMD is hosting a webinar with Summit plc on Tuesday, December 11 from 1pm to 2pm. The webinar will discuss the Phase 1 Clinical Trial results on SMT C1100 for the treatment of Duchenne as well as outlining the next steps for this utrophin upregulator program. Jon Tinsley, Senior Director of R&amp;D and Richard Pye, Head of Communications at Summit plc will give a presentation and answer questions that have been submitted.</description>
            <link>http://community.parentprojectmd.org/events/webinar-smt-c1100-phase-1-trial-results</link>
            <guid isPermaLink="false">C43EF84A-FC8C-4F65-A0D2-59745276369C-1093-00000D5E85376F19-FFA</guid>
            <pubDate>Mon, 03 Dec 2012 14:42:02 -0500</pubDate>
        </item>

        <item>
            <title>Giving Thanks, Looking Forward</title>
            <description><![CDATA[Every Thanksgiving, I find myself with a lot to be thankful for: my family’s love and support, our Duchenne community, and your tireless efforts.<br />
<br />
This year is no exception. We’ve accomplished so much together. When I think of all that our community has made possible over the years, all that we’ve done in 2012, and all that we’re doing today, my heart fills with appreciation and gratitude for each and every one of you—for your passion and commitment.<br />
<br />
More often than not, the difference between the impossible and the possible is sheer determination. That’s especially true for our community.<br />
<br />
Through our hard work and dedication, we’re finally seeing all the moments we never thought we would see. Our sons are walking longer than ever before, they’re graduating from college, they’re getting married, and they’re starting careers and families of their own.<br />
<br />
And we’re still going. In 2012 alone, we’ve seen a number of unbelievable achievements. We’ve expanded our partnership with the FDA, holding two important meetings in 2012 to help provide them with the information about Duchenne that they need—about both the disease and the community—to exercise flexibility in the review process. We’ve seen not only a record number of clinical trials but also trials that are showing signs of efficacy and moving forward in the drug approval process. And we have built an unprecedented network of experts in research, drug development, regulatory compliance, and advocacy that are dedicated to helping us achieve our research goals.<br />
<br />
Behind this amazing progress are the families and friends like you who roll up your sleeves and do anything and everything you can for people with Duchenne. There are so many ways that we can make a difference for the Duchenne community: from taking part in our advocacy efforts to completing surveys and connecting with others through our FACES groups. And it’s been the combination of all those actions that has gotten us this far.<br />
<br />
I know that we can go even further. That’s why I’m asking you—and every member of our wonderful, dedicated community—to join me in a resolution. None of us can do everything, but we can all do something. So pledge to do something in 2013, one small action that will make even more incredible things possible.<br />
<br />
Years from now when we look back, I know that we’ll always consider 2012 a year of significant achievements. And with your continued commitment to this community and PPMD’s work, we’ll have even more to be proud of in 2013.<br />
<br />
Enjoy a bountiful and healthy Thanksgiving, and thank you for being part of the PPMD family!]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/giving-thanks-looking-forward?xg_source=activity</link>
            <guid isPermaLink="false">DF14B4C2-A246-448A-936D-E88D621E268C-2408-00001BB1B300DA3F-FFA</guid>
            <pubDate>Tue, 20 Nov 2012 16:53:39 -0500</pubDate>
        </item>

        <item>
            <title>Help Protect Federal Spending on Rare Diseases like Duchenne</title>
            <description><![CDATA[PPMD Taking Action to Avert Sequestration<br />
<br />
<br />
<br />
Those engaged in federal advocacy probably thought the Prescription Drug User Fee Act and its acronym PDUFA would take the cake in terms of policy jargon. But as the nation's eyes are fixed on Washington to see whether or not the nation will careen over the "fiscal cliff," the term sequester and sequestration is invading the American lexicon.<br />
<br />
According to Webster, sequester traces its roots to the 14th Century and is derived from the Latin "sequestrare" which means "to hand over to a trustee."  After centuries of obscurity, the term gained new prominence beginning in the summer of 2011, when Congress reached a deal to increase the nation's debt that forced a set of across-the-board spending cuts – or a sequester of such funds – if a committee of a dozen members of Congress – dubbed the "Super Committee" failed to come up with another way to cut between $1.2 to $1.5 trillion in spending over the next decade.<br />
<br />
After a few months of work, the Super Committee fizzled and shortly before Thanksgiving last year failed to meet their deadline and find a way to reduce spending by $1.2 to $1.5 trillion. The basic divide was between those opposed to any increases in taxes and those opposed to any cuts in spending, resulting in a chasm that could not be overcome and leaving the nation with the sequester scheduled to take effect in January 2013. In recent months, the number of warnings that the impact of such cuts – divided between defense spending and domestic discretionary or non-entitlement spending – would be devastating to our still fragile economy, have increased as we near the implementation date.<br />
<br />
Most importantly to our community, projections estimate that the National Institutes of Health would see its 2013 budget reduced by $2.5 billion, a cut that would result in about 2,400 fewer grants to support research aimed at discovering treatments and cures for a host of conditions like Duchenne.<br />
<br />
Other agencies of importance to Duchenne families like the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) would be similarly impacted. All the work our community did to ensure the rare disease provisions were included in the final FDA PDUFA bill would be stalled due to these cuts. The only bright spot of the sequester and its current terms are that Medicaid funding is not on the table.<br />
<br />
PPMD is working hard with organizations such as NORD and Research!America to urge lawmakers to take action before Congress adjourns this year to protect vital biomedical research, public health and medical innovation programs vital to continued progress in medical innovation from devastating across-the-board cuts. Over the coming days and weeks, we will continue to closely follow developments on Capitol Hill and take additional actions as necessary to keep our nation from going over the fiscal cliff and to relegate the term sequester back to the history books.<br />
<br />
Take Action<br />
Now is your chance to tell Congress that their inaction on a deal could potentially have an enormous negative impact on the lives of you and your family!<br />
<br />
JOIN US in telling Congress that they must work together with the President to achieve a balanced approach to deficit reduction.<br />
<br />
]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/help-protect-federal-spending-on-rare-diseases-like-duchenne</link>
            <guid isPermaLink="false">5302405D-76EF-45D7-B2E6-9901F9372006-2408-00001BAE246AA486-FFA</guid>
            <pubDate>Tue, 20 Nov 2012 16:53:11 -0500</pubDate>
        </item>

        <item>
            <title>EndDuchenne eNews: Weathering the Storm</title>
            <description>What you'll see in this month's EndDuchenne eNews:&lt;br /&gt;
&lt;br /&gt;
--More research progress as we continue to pursue a mantra of &quot;Better, Faster, Now.&quot; &lt;br /&gt;
&lt;br /&gt;
--The groundwork we are laying in Washington, DC, with the FDA with the hopes that promising treatments are understood by federal agencies and accelerated approvals are considered. &lt;br /&gt;
&lt;br /&gt;
--Our commitment to care, making sure parents are armed with the tools they need to help their child.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=17741.0</link>
            <guid isPermaLink="false">E1F340FC-420D-45A7-85F0-64A3401FB223-2685-000011A75FEF630D-FFA</guid>
            <pubDate>Thu, 15 Nov 2012 16:40:49 -0500</pubDate>
        </item>

        <item>
            <title>Representing Duchenne at the Congressional Rare Disease Caucus Briefing</title>
            <description><![CDATA[Today, Parent Advocate and Founder of Two Smiles One Hope Foundation, Alison Willis and I represented the Duchenne community at the Congressional Rare Disease Caucus Briefing in Washington, DC. Alison did a remarkable job speaking on behalf of PPMD regarding the Patient Participation in Medical Product Discussions Provision within the newly passed Food and Drug Administration Safety and Innovation Act (FDASIA or PDUFA V).<br />
<br />
Thank you, Alison, for lending your voice to ours and representing the Duchenne community!<br />
<br />
Remarks by Alison Willis at the Congressional Rare Disease Caucus Briefing<br />
Thank you very much to Congressmen Leonard Lance and Joe Crowley, the co-chairs of the Congressional Rare Disease Caucus, for hosting this important briefing. Also thank you very much to Rare Disease Legislative Advocates (RDLA), the National Health Council, and Shire for organizing this event.<br />
<br />
And thank you to all of the staff for taking time out of your busy schedule to attend this session during what we all know is a most eventful week here on Capitol Hill.<br />
<br />
As a parent of two boys living with Duchenne Muscular Dystrophy, I am very grateful for the number of provisions contained within the recently enacted FDA Safety and Innovation Act or FDASIA that empower the agency with the authority and tools it needs to more expeditiously review potential therapies for serious and life-threatening conditions, particularly when no other alternative treatments exist.<br />
<br />
From provisions to strengthen and enhance existing Fast Track and Accelerated Review authorities to establishment of a new Breakthrough Therapies category to deeper and more robust engagement of outside scientific experts and patients, Congress should be commended for your efforts.<br />
<br />
But as you all know, while enacting a bill into law is critical, the devil is in the regulation, particularly on complex FDA topics that will require a host of new guidance.<br />
<br />
Before I touch on this key point, I want to first make it abundantly clear what has driven me to commit to advocacy and come to Washington today.<br />
<br />
I am a resident of Fayetteville which is a small town in central New York. I am a pharmacist by profession, and my husband Matt and I are the proud parents of three wonderful boys – Caleb, age 13 and 11-year-old twins Nolan and Jack, both of whom have Duchenne.<br />
<br />
In addition to advocating with Parent Project Muscular Dystrophy, we have founded a small foundation called Two Smiles One Hope that funds groundbreaking research in the pursuit of treatments and therapies for Duchenne.<br />
<br />
Duchenne is the most common form of Muscular Dystrophy, a form that affects almost entirely boys because it impacts the X chromosome. The disease keeps muscles from producing the Dystrophin protein that is essential for building strong muscles. And when muscles cannot rebuild, they slowly atrophy, leading to loss of ambulation and eventually loss of all use.<br />
<br />
For years, the only therapy for patients with Duchenne has been steroids,which are not effective for long-lasting improvement and which result in a number of side effects.<br />
<br />
While no therapy has yet to be approved for Duchenne, the community and our family is full of hope as nearly 20 potential therapies are in various stages of clinical testing and evaluation, and a number of additional potential therapies are in early stages of development.<br />
<br />
This past fall has been a particularly hopeful time, with multiple companies including Summit, Prosensa and Sarepta all announcing promising news.<br />
<br />
Perhaps most encouraging is the news from Sarepta that its candidate therapy, Eteplirsen, had produced statistically significant levels of Dystrophin in patients participating in the Phase IIb clinical trial. In addition to showing increased levels of Dystrophin, the study also found a significant clinical improvement as measured by the 6-minute walk test standard.<br />
<br />
Both Jack and Nolan participated in this trial. I would love to discuss the details of our experiences during the trial with anyone who is interested after this briefing. The main point I would like to drive home about Eteplirsen is that there is a finite window of opportunity here for these boys. For maximum benefit, it is imperative that these boys receive the drug as early as deemed necessary. As illustrated quite clearly by my own sons' results at the end of the first 24 weeks, there is a tipping point before which Eteplirsen should be dosed. Although Jack and Nolan qualified without issue for this trial, they showed the most deterioration from the start, therefore; their loss of ambulation during the trial came to no great surprise. The progress that the other 10 participants are achieving is phenomenal. They continue to progress to this day.<br />
<br />
As you can imagine, this news has left many of us in the Duchenne campaign quite eager and optimistic, particularly as Sarepta prepares to move forward as quickly as possible in submitting its data to the FDA, which brings us right back to the reforms Congress included in the FDASIA law.<br />
<br />
While the ball is presently in Sarepta's court as it prepares for the filing, once their application arrives at FDA, it is critical that it be reviewed as expeditiously as possible because no alternative treatments or therapies exist and the disease is 100% fatal. The drug should therefore qualify as a breakthrough therapy. Our community is counting on FDA's "patient-focused drug development" initiative to move these interests forward.<br />
<br />
In addition to prompt review, we trust FDA will take into account the views of patients and/or their parents/guardians, in the case of minors, particularly when it comes to the all-important issue of assessing levels of benefit and risk offered by a therapy.<br />
<br />
To help better inform FDA on this most important issue, PPMD is developing a survey tool to gather the input from the Duchenne community as to how we see this benefit/risk issue and what levels of risk we would be willing to accept. The findings will in turn be presented to FDA to help inform how they consider reviews of potential therapies by providing a natural history "yardstick" for later comparisons.]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/speaking-at-the-congressional-rare-disease-caucus-briefing?xg_source=rss</link>
            <guid isPermaLink="false">FE9471B4-41EF-4D2A-B103-D879C1B08A9A-2820-0000132548F00F77-FFA</guid>
            <pubDate>Wed, 14 Nov 2012 16:18:16 -0500</pubDate>
        </item>

        <item>
            <title>What is Duchenne? (Two Moms, Co-Blogging)</title>
            <description><![CDATA[What IS Duchenne?<br />
by Pat Furlong<br />
 <br />
Last year, Ivy and I agreed to write a co-blog. I would introduce Ivy’s or wrap something around what she writes. It was selfish really. I love reading and in my next lifetime, am considering a writing career or maybe a singing career, I have not decided. Don’t laugh. I realize there are a number of things that I will need to include in the ‘ask’, in order to prepare for the next lifetime: things like a talent for storytelling and creativity, a singing voice (my brother Jack asked that I not sing ever… not even Happy Birthday), and that natural musical ability that comes from somewhere deep in the soul.  <br />
 <br />
But in this lifetime, I love reading – especially Ivy’s blogs about Rain, about home, about life, about hope. And while I realized that my writing skills are different than Ivy’s, I love her use of words, her definitions, and the wonderful way she explains the use of a certain word, giving each word a specific purpose and place in our lives. I have long admired her sense of self, her selflessness, and her creativity. She has the ability to make sense of a world in which she is both a new member and one with history. I love how she is able to capture our imagination and talk about things and situations we all have in common, as if we are all sitting around the fireplace, barefoot and comfortable; the room filled with the smell of warm chocolate chip cookies and fresh flowers; sharing our stories, our worries, our dreams. In so many ways, I see Ivy as the teacher, the person guiding the discussion, a visual image of the therapeutic dose of hope.<br />
<br />
I agree that Duchenne is not to be framed as a disease (see Ivy’s blog which follows). Our children are not sick in the sense of feeling awful, lying on the couch with symptoms of flu or of some contagious disease. Rather Duchenne is a misprint of the genetic map for muscle which results in weakness of muscle – all of it – skeletal, smooth, and cardiac. Our sons need assistance (some more, some less) depending on the degree to which their muscles have responded and interpreted the misprint. Granted, it is no small misprint, but Duchenne is better represented as a condition or a disorder. It makes it no less serious, but perhaps more understandable, or even somehow gentler, especially when explaining the term to our sons and daughters.<br />
 <br />
I could not say the word ‘dying’ in reference to my sons. That word rattled around my brain once Duchenne entered my home. But I just could not form the word, would not form that word, especially not around Chris and Patrick. One day, long ago, one of Patrick’s friends, Johnny asked me about an article he read about Duchenne. He commented that the article said Chris and Patrick were dying. He looked at me, tears in his eyes, and said ‘I didn’t know they were sick.’ I closed my eyes, fighting back tears as well, and realized how much I loved my children’s friends, how much I took for granted, the way they understood Duchenne. I loved the fact that they knew Duchenne was a part of Chris and Patrick’s lives, an unwelcome participant for sure, but they refused to allow Duchenne to interfere or interrupt their lives. <br />
 <br />
Duchenne is a GIANT word to be sure. It crashes into our homes, our hearts, and changes to some degree the map of the life that was supposed to be. But it does not change our sons. They are exactly who they should be.<br />
 <br />
And our collective energy is spent around End(ing)Duchenne: to accelerate treatments, to do whatever is necessary to ensure that they have a toolbox at their disposal (a fistful of prescriptions, capable physicians, and local resources). To give them a future – the opportunity to grow into middle age and beyond.<br />
 <br />
Thank you Ivy! If there is anyone in the world I would like to write a book, it is you.<br />
 <br />
Pat Furlong is the Founder and President of Parent Project Muscular Dystrophy. Follow Pat at her blog.<br />
<br />
<br />
Duchenne: Disease or Disability?  <br />
by Ivy Scherbarth<br />
 <br />
Sometimes the way in which we define a word can change our whole perspective on life. Without resorting to the dictionary or the internet, how do you define Duchenne? Is it a disease or a disability?<br />
 <br />
The word "disability" implies for me a chronic condition, either lifelong or acquired, which cannot be eliminated, only compensated for. A disability is part of a person's identity. It is a thing that you live with, a thing you work around but do not escape. It is integral to the person who has it; it's in our deepest layers of being, literally in the very makeup of our bodies. A disability is a different way of doing things. It is a different way of moving in the world, or thinking, or functioning, or feeling. It is something that contributes to what makes you special and unique. A disability is something to be confronted, manipulated, dealt with, but ultimately, accepted.<br />
 <br />
To my mind, a disease is something else entirely. A disease is something that happens to you. A disease means that something has gone wrong. We have been attacked from the outside. When you have a disease, you're sick. People say to you, "you're not looking yourself today, sweetie. You'd better go lie down and I'll bring you some tea." A disease has symptoms that make you feel bad. When you're sick, people send you flowers and get well cards, and then you do get well and you're fine again, just like you were before you got sick. A disease is something that, if you do the right things, will someday go away. It is a transient overlay on top of the self, something to be transcended and vanquished. A disease is something from which to be recovered. A disease is meant to be cured.<br />
 <br />
To me, Duchenne is a disability. There is no separation between my son and Duchenne. There was no "before Duchenne" for Rain. Not only was he born this way, he has been this way since my egg developed in my womb before I was born. In fact, Rain's body is functioning perfectly according to the set of instructions that he has in his unique DNA. It's just that his DNA is a tiny bit different from the other boys in our neighborhood. There's nothing wrong with him when you compare him only to himself, rather than comparing him to other people. And who wants to be compared to other people? It's not Rain's fault that he has Duchenne. It isn't something that happened to him. He didn't contract it. It isn't contagious. Duchenne is a part of our family history, just like brown eyes and dimples. Just like myopia and crooked teeth. Maybe Rain will need to compensate for some of his genetic heritage by wearing eyeglasses when he's older. Maybe he'll need a wheelchair and a lift and a special van and an IEP.<br />
 <br />
These are ways to compensate for parts of us that we would find more convenient if assisted. None of this is meant to change fundamentally who we are. Rather, these compensatory devices exist merely to make our challenges easier to cope with. I love my glasses and I am very grateful to be able to see things but when I take my glasses off I'm still me. Putting my glasses on does not restore me to a previous self that existed before my eyes went blurry. Rain's wheelchair gives him a lift when he needs one but it doesn't take away his Duchenne.<br />
 <br />
This is not to say that I don't hope for a cure for Duchenne. I do. But when I think "cure," I'm not thinking of a magic pill that will make Duchenne disappear forever. Perhaps I lack imagination. Rather, I am hoping for a wonderful toolbox, a drug and assistive technology regime that will keep our boys on their feet, moving around, hearts beating and lungs working easily, hugging their families, enjoying middle age and beyond. I'm hoping that someday, when a kid gets his new diagnosis, which will always happen just because of the nature of genes and life on earth, that his family will be given some information on local accessibility resources and fistful of prescriptions. His family will know that, with careful maintenance, this chronic condition can be mitigated and life can go on, maybe not in exactly the way it did before, but with limited disruption, for a long time. Whether Duchenne is ultimately a disease or a disability, our boys, perfect just the way they are, deserve nothing less.<br />
<br />
Ivy Scherbarth is a Colorado/Wyoming FACES Coordinator for PPMD. Follow Ivy at her blog, Living Duchenne.<br />
<br />
<br />
What's your perspective?<br />
How do you define Duchenne? Share your thoughts in the comments!]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/what-is-duchenne-two-moms-co-blogging</link>
            <guid isPermaLink="false">024F86EE-6473-4773-BCAD-1675E18B3437-1897-00000C1171C079F4-FFA</guid>
            <pubDate>Tue, 13 Nov 2012 12:04:25 -0500</pubDate>
        </item>

        <item>
            <title>Cedars-Sinai research: Preclinical muscular dystrophy data shows promise</title>
            <description><![CDATA[LOS ANGELES — Nov. 7, 2012 – Cedars-Sinai Heart Institute researchers have found that an experimental compound may help stem the debilitating effects of muscular dystrophy by restoring normal blood flow to muscles affected by the genetic disorder.<br />
<br />
The researchers studied HCT 1026, a new type of molecule in which nitric oxide is chemically attached to a standard anti-inflammatory agent, in a preclinical model of muscular dystrophy. Results suggest HCT 1026 may be beneficial for the treatment of Duchenne muscular dystrophy, which begins in early childhood, and Becker muscular dystrophy, which often occurs later in adulthood.<br />
<br />
Preliminary results were presented in April 2012 at the experimental Biology meeting and now the full study is published in the Public Library of Science (PLOS ONE) and is available online.   <br />
<br />
Both forms of muscular dystrophy are caused by problems with a protein called dystrophin, which helps maintain healthy muscles. If patients have less dystrophin protein or if their body manufactures dystrophin protein that does not function correctly, their muscles cannot work properly and eventually become permanently damaged. As diseased muscles weaken over time, patients gradually can lose their ability to walk, sit or use their muscles in other ways. There is no cure now for either form of the disease.  <br />
<br />
“There is an urgent unmet need for effective therapeutic options for this devastating disease,” said Ronald G. Victor, MD, director of the Cedars-Sinai Center for Hypertension in the Cedars-Sinai Heart Institute and the Burns and Allen Chair in Cardiology Research. “If we can improve blood flow in muscular dystrophy patients, we may be able to preserve some muscle function over a longer period of time.”<br />
<br />
HCT 1026 dramatically improved blood flow in muscles used during exercise by dystrophin-deficient laboratory mice who share the same genetic defect as humans, Cedars-Sinai researchers found. The compound may have accomplished this by delivering nitric oxide, a key molecule involved in many physiological functions and found at reduced levels in dystrophic muscles.<br />
<br />
The compound fully restored blood flow to affected muscles within the first month of treatment and the impact was completely sustained for three months without any noticeable adverse side effects.<br />
<br />
Authors of the study said the results represent a step in the quest to find an effective treatment for muscular dystrophy that will reduce muscle wasting as well as slow the progression of the disease.  <br />
<br />
“Based on our previous work, we think the ability of HCT 1026 to release nitric oxide is the key to restoring muscle blood flow in dystrophin-deficient mice,” said Gail Thomas, PhD, a lead author of the Cedars-Sinai study. “HCT 1026 is an interesting prototype which allowed us to investigate the potential of this family of molecules in muscular dystrophies. While we do not expect these nitric oxide-donating compounds to cure the disease, our hope is that the improved blood flow could reduce muscle fatigue and injury, allowing patients to be more active while slowing down the loss of vital muscle.”    <br />
<br />
The study was performed in collaboration with scientists at Nicox in Bresso (Italy) and Sophia Antipolis (France).  <br />
<br />
The work was supported by grants from the National Center for Advancing Translational Sciences in the National Institutes of Health (Grant #UL1TR000124), the Center for Duchenne Muscular Dystrophy, UCLA Muscular Dystrophy Core Center (Grant # P30AR05723) and Nicox Research Institute.  ]]></description>
            <link>http://www.cedars-sinai.edu/About-Us/News/News-Releases-2012/Cedars-Sinai-research-Preclinical-muscular-dystrophy-data-shows-promise.aspx</link>
            <guid isPermaLink="false">CE332F58-B1E6-4CB3-A137-3762FDD81801-1897-00000BFE8D82E317-FFA</guid>
            <pubDate>Tue, 13 Nov 2012 12:03:07 -0500</pubDate>
        </item>

        <item>
            <title>You're Invited - End Duchenne Gala</title>
            <description>Please join us for the first annual End Duchenne Gala on December 6, 2012 from 7:00 pm - 12:00 am at the Metropolitan Club in New York City, NY.&lt;br /&gt;
&lt;br /&gt;
When a child is diagnosed with Duchenne muscular dystrophy the family is devastated. The news is overwhelming and seemingly without hope. Their first question is, &quot;What’s next?”&lt;br /&gt;
&lt;br /&gt;
Parent Project Muscular Dystrophy knows there is no simple answer to the questions, but we also know the Duchenne field is ripe with opportunity – ready for investment – and primed for results. Parent Project Muscular Dystrophy knows there is hope.&lt;br /&gt;
&lt;br /&gt;
The End Duchenne Gala will celebrate current research advancements and help raise funds for upcoming research that will help us change the future for those living with Duchenne.&lt;br /&gt;
&lt;br /&gt;
Cocktails • Dinner • Silent &amp; Live Auction • Special Entertainment</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=17641.0</link>
            <guid isPermaLink="false">A8F73352-0550-462C-9935-0EB9CDC081A9-5640-00001567C649AC99-FFA</guid>
            <pubDate>Tue, 06 Nov 2012 15:59:09 -0500</pubDate>
        </item>

        <item>
            <title>Partnering with the FDA to accelerate approvals- The question of risk tolerance in the Duchenne community</title>
            <description><![CDATA[Background <br />
Friends, we have been actively pursuing a regulatory strategy and have had two meetings with the neurology division at the FDA. We are currently working on the 'to do' list for the community and are trying to understand barriers/obstacles to approval from the FDA side, as well as, from the sponsor side of the issue. We are working a smart, targeted call to action. We have learned through years of advocacy that the most successful approach is to make sure what we are asking is consistent throughout the community.<br />
 <br />
During the FDA rare disease open meeting in May, Janet Woodcock said - FDA weighs the evidence presented, but at the end of the day, it is often a value judgment about benefit to the patient with a high unmet medical need. During a round table conversation with Dr. Katz, he was asked about the perception that he was 'risk adverse.’ He explained that he views risk on a scale and used a cancer example at one end and migraine headache at the other end. Basically, he said that when someone is dying within a period of six months, he would accept a 50/50 risk. At the other end of the scale, where there is a chronic condition and no imminent threat of death, he would be risk adverse. So that said, in this last meeting we had a similar conversation where our goal was to make sure the neurology division understood that Duchenne, while not exactly in the same category as a stage 4c cancer diagnosis, causes boys to peak in function at age 7–10 (depending on steroid response) and then lose function, so that each loss, each small negative change should be viewed as a 'little death,' from the boy's perspective as well as the increasing burden in terms of required care. A degenerative disease is not at all the same as a chronic disease and should be much closer to the cancer end of the scale than to the migraine end.<br />
 <br />
Taking Action<br />
The first step is for this community to weigh in on this benefit/risk equation. As we speak, PPMD is setting up a survey that is in development and will be posted next week. YOU will have the opportunity to weigh in on risk/benefit and include your own personal story about your situation.Presenting this data to FDA will provide compelling arguments and rationale for the FDA to grant accelerated approval to compounds that demonstrate safety and efficacy.<br />
 <br />
We have learned, success with our advocacy is the result of a single, compelling message. While every family wants and needs treatment for their son, our message is about successfully navigating the regulatory process in order to get drugs approved – these first candidates currently in trial and all others to come. We are consulting with experts from communities that have been effective in getting drugs approved, as well as, combination therapies.   <br />
 <br />
We are exploring opportunities with our regulatory advisors and consultants. We are currently organizing meetings with companies to ensure we adequately understand the barriers they face and will come to all of you with an overall strategy and plan for discussion and opinion. In November, we will collect risk/benefit and personal stories –either text or video.  In December, we will lay out a comprehensive strategy for review and discussion. This may also involve contacting your members of Congress.<br />
 <br />
We have to be measured, strategic, and effective. We can do this. This community has gotten legislation passed and reauthorized, $500 million federal dollars which galvanized research, incentivized industry, and brought us to this moment. Our conversation has changed and we are now focused on a regulatory strategy. We must work together. Our sons are worth it.<br />
 <br />
This Thursday, October 25, PPMD will participate in the FDA open meeting, this time to respond to a call for public comment. This is part of the PDUFA V reauthorization that PPMD worked so hard to pass in 2012.  <br />
 <br />
The FDA's notice invites public comments on the preliminary list of disease areas and requests that those who propose additional disease areas for consideration describe how they applied the criteria identified by the FDA. On first glance, we might suggest Duchenne should be at the top of this list, as it certainly fits the criteria outlined below. If you think about it, you might imagine FDA has more than 1,000 disease specific advocacy organizations making the same request. It seems to make more sense to potentially achieve the same goal by focusing on pediatric muscle disease which exactly fits the criteria and provides FDA the ability to accomplish the stated objectives of the patient-focused drug development initiative. We are working with other rare disease groups in order to have the same message to the FDA. They have agreed to review 20 diseases within the 5-year authorization period. That will not be sufficient time to review the many disease indications that exist, thus the reasoning for combining similar diseases that all have similar characteristics. <br />
 <br />
Those key targets are made clear in the FDA's public notice – a thorough understanding of the severity of the treated condition and the unmet medical needs so as to set the context of regulatory decision making in regards to benefit and risk. <br />
 <br />
Disease areas that are chronic, symptomatic, or affect functioning and activities of daily living<br />
Disease areas that reflect a range of severity – While the patients with each of these life-shortening disorders are very severely affected, the individual patients with each of them experience a range of severity in such factors as age of onset of symptoms, rate of progression, age at which full-time assistance is needed for activities of daily living, and age at death – those ‘little deaths’ that occur with loss of function<br />
Disease areas for which aspects of the disease are not formally captured in clinical trials<br />
Disease areas that have a severe impact on identifiable subpopulations (such as children or the elderly)<br />
Disease areas that represent a broad range in terms of size of the affected population<br />
Disease areas for which there are currently no therapies or very few therapies, or the available therapies do not directly affect how a patient feels, functions, or survives<br />
 <br />
We feel that this is the best strategy to move the needle for the disease in order to properly educate the FDA on the risk benefit analysis. At the same time we will be analyzing our own study of the community. Please continue to stay engaged. PPMD will be keeping you informed – in the next week we will be contacting you with the survey we mentioned, as well as, requesting your personal stories to better educate those who make decisions on therapies for Duchenne within the FDA. We will then lay out the plan moving forward.<br />
 <br />
We are excited for the progress made to date with our community, we must continue this momentum, and with your help, we will do what it takes to end Duchenne.  <br />
 <br />
Learn more<br />
Sign up for Action Alerts<br />
Connect with PPMD: Facebook, Twitter, and Community site<br />
<br />
<br />
<br />
<br />
Pat Furlong, Founding President, CEO<br />
Read more PPMD Staff Blogs]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/partnering-with-the-fda-to-accelerate-approvals-the-question-of</link>
            <guid isPermaLink="false">40398DF2-FA2E-4298-A538-4E72A56B17EA-1634-00000E987C88CD54-FFA</guid>
            <pubDate>Wed, 24 Oct 2012 14:41:48 -0400</pubDate>
        </item>

        <item>
            <title>Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne</title>
            <description>Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.&lt;br /&gt;
 &lt;br /&gt;
Prosensa identified suitable oligonucleotide candidates for PRO052 and PRO055, designed for the skipping of exons 52 and 55 of the dystrophin gene. PRO052 and PRO055 are currently in pre-clinical development and will be moved to clinical trials as soon as possible.&lt;br /&gt;
 &lt;br /&gt;
Prosensa has also received orphan drug designation by the European Commission for PRO045 and PRO053. These compounds are designed to skip exons 45 and 53 of the dystrophin gene and are expected to enter clinical development within the next 6 months. In parallel, Prosensa and GSK have initiated a large global natural history study in order to generate important data on the progress of DMD that will help to facilitate the development pathways for these compounds.&lt;br /&gt;
 &lt;br /&gt;
Together with drisapersen (PRO051/GSK2402968) and PRO044, already in clinical development, the Prosensa portfolio of six DMD compounds has the potential to treat more than 40% of all DMD patients.&lt;br /&gt;
 &lt;br /&gt;
Hans Schikan, CEO of Prosensa, commented: “Achieving orphan drug status for PRO045 and PRO053 is an important milestone that we believe will allow us to accelerate development of these compounds and initiate clinical trials within the next half year. While GSK has an option to license one compound, PRO045 or PRO053, the other compound will be developed and eventually commercialized by Prosensa in our ambition to become a fully integrated biopharmaceutical player in rare diseases. Together with PRO052 and PRO055, where the same principle applies, Prosensa will be in a position to target rare mutations in specific DMD subpopulations and may provide treatment to more patients with this debilitating disease.”&lt;br /&gt;
 &lt;br /&gt;
Prosensa has the most advanced portfolio of drug candidates for the treatment of DMD, and has also preclinical compounds for Myotonic Dystrophy and Huntington’s Disease. Prosensa’s DMD compounds are based on its proprietary exon-skipping technology that uses antisense oligonucleotides to restore expression of a functional dystrophin protein and to provide potential treatment for patients affected by this progressively debilitating neuromuscular disease.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/prosensa-announces-progress-on-exon-skipping-compounds-for-the-tr</link>
            <guid isPermaLink="false">6CC2770D-7181-4511-A950-C5910BFDA012-4103-00001CCF94F9A8D1-FFA</guid>
            <pubDate>Tue, 23 Oct 2012 17:07:25 -0400</pubDate>
        </item>

        <item>
            <title>October End Duchenne eNews</title>
            <description>Catch up on the latest research and community updates, including what PPMD has been up to lately, in this month's End Duchenne eNews. Also meet our Featured Voice for October, 20-year-old Ryan &quot;Wheelz&quot; Schmidt.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=17501.0</link>
            <guid isPermaLink="false">5C4D4A5F-A15E-4495-92E2-2B4D36B00A8F-4103-00001CC8FC8C5FA1-FFA</guid>
            <pubDate>Tue, 23 Oct 2012 17:07:00 -0400</pubDate>
        </item>

        <item>
            <title>ImagingDMD: Making muscle biopsies a thing of the past</title>
            <description><![CDATA[In the clinical trial world, there are some things that divide us these days- most specifically, what mutation type your son has. However, we are united in wanting better ways to look for the benefits of potential drugs; who isn’t hoping for a day when the muscle biopsy is a relic from the past? <br />
<br />
There are several dedicated research teams doing exciting work to evaluate different ways of measuring changes to muscles. At PPMD, we’ll work hard to keep the community up-to-date about these efforts as results become available. We are also working hard to encourage sponsors of clinical trials to measure changes to muscles by means OTHER than the muscle biopsy, whenever possible.<br />
<br />
Your family can help us move closer to a goal of no more muscle biopsies, as well as learning a lot about muscles in Duchenne. The ImagingDMD study is looking for a few more good “men;” specifically, they are looking for males between 5 and 14 with Duchenne. At their first visit, participants must be able to walk roughly the length of a football field by themselves. Boys in the study can be on steroids, or not. The study sites are at the University of Florida, Children's Hospital of Philadelphia, Oregon Health and Science University, Shriners Hospital for Children-Portland, and the University of Pennsylvania. PPMD has provided financial support for this important study.<br />
<br />
At our 2012 Connect Conference, we heard from a panel of children and teens about participating in research. One thing uniting these guys was that they were all in the ImagingDMD study. You may remember their positive comments about being in this trial. As the moderator, I was impressed by their enthusiasm for the study and the study teams—the word “fun” was even mentioned more than once!<br />
<br />
Please visit the study website at ImagingDMD.org to learn more, or to contact the research teams at each site. The “about” section has a clear explanation of what your son would do if he was in the study.<br />
Learn More<br />
ImagingDMD Recruitment Ad (via DuchenneConnect)<br />
ImagingDMD.org<br />
<br />
]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/imagingdmd-making-muscle-biopsies-a-thing-of-the-past</link>
            <guid isPermaLink="false">309F3014-9924-4BE0-8873-6981C3A2C363-944-00000454737350CC-FFA</guid>
            <pubDate>Tue, 16 Oct 2012 10:03:05 -0400</pubDate>
        </item>

        <item>
            <title>Management of End Stage Heart Failure: Ventricular Assist Devices (VAD)</title>
            <description><![CDATA[In light of PPMD’s Cardiac Webinar Series, our Director of Care, Kathi Kinnett answers questions/concerns about Ventricular Assist Devices (VAD).<br />
 <br />
There has been recent discussion worldwide regarding the use of ventricular assist device therapy in patients with Duchenne/Becker muscular dystrophy (Duchenne/Becker). This discussion is in its infancy; very few patients to date have had a device inserted. Ventricular assist device therapy has potential benefit in a select group of people, including patients with Duchenne/Becker, but it is not without significant risk.<br />
 <br />
A “ventricular assist device (VAD)” is a mechanical pump that is connected to the heart in order to support its function. The type of device that would be considered in individuals with Duchenne/Becker is a “left ventricular assist device (LVAD)”. It works by assisting the ill heart in pumping blood from the left ventricle to the body. <br />
 <br />
Generally VAD therapy is used as a “bridge to transplant” (after the heart is too weak to support the body and until a donor heart for transplant is found). In some patients, a VAD could be used as “destination therapy.” What this means is that the device is implanted in an individual who is not a transplant candidate with the intent that the device will be in place for the remainder of their life. Not all people are good candidates for a device. Previous abdominal surgery, liver, kidney, or lung disease may be contraindications. Given the risks associated with the use of the device (outlined below) this option should only be considered when the individual is experiencing significant symptoms and only after all other options (such as medications) have been thoroughly exhausted.<br />
 <br />
Insertion of a VAD is a major surgical procedure requiring general anesthesia and requires recovery in the intensive care unit. The patient and the family will need significant education as to how to care for the device once it is in place. <br />
 <br />
VAD therapy remains associated with significant risks. Complications of VAD placement may include:<br />
Bleeding – this may require re-operation and is a common occurrence<br />
Stroke (both hemorrhagic and ischemic)<br />
Infection<br />
Arrhythmia<br />
Respiratory failure<br />
Kidney failure<br />
Liver failure<br />
Hemolysis (break down of red blood vessels)<br />
Blood clots within the pump<br />
Re-hospitalizations<br />
Development of right sided heart failure or air embolism during surgery<br />
 <br />
Following VAD placement, the patient will be managed on numerous medications. These medications will help support heart function and help reduce clotting.<br />
 <br />
There may be unique issues regarding VAD use in the patient with Duchenne/Becker that are currently unknown. Both the upcoming cardiology webinars and the cardiology workshop will address the use of VAD therapy in Duchenne, as well as many other issues. We will keep the community informed as more information becomes available. <br />
]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/management-of-end-stage-heart-failure-ventricular-assist-devices</link>
            <guid isPermaLink="false">EF506381-E987-4CC4-92E3-E55ACEEC56AC-944-0000044CB698CB58-FFA</guid>
            <pubDate>Tue, 16 Oct 2012 10:03:22 -0400</pubDate>
        </item>

        <item>
            <title>Full 48-week Phase IIb data from eteplirsen study in Duchenne presented at World Muscle Society</title>
            <description><![CDATA[Dr. Jerry Mendell, Director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital and principal investigator of the Phase IIb eteplirsen study, presented the full set of 48-week data from Sarepta at the World Muscle Society (WMS) Congress in Perth, Australia on Friday, October 13. This presentation  includes greater detail around the full Phase IIb study results.<br />
<br />
Additional data presented at WMS included:<br />
<br />
Individual patient data on the primary endpoint of change in dystrophin-positive fibers from baseline;<br />
Additional biochemical findings including RT-PCR and western blot images from selected patients;<br />
Additional information on the two patients in the 30 mg/kg cohort who showed a rapidly progressive decline on the 6-minute walk test and were excluded from the analysis; and<br />
A summary of treatment-emergent adverse events comparing eteplirsen-treated patients versus placebo, which demonstrated that eteplirsen was well-tolerated through 48 weeks of treatment. No treatment-related adverse events, serious adverse events, or treatment discontinuations related to eteplirsen were observed.  In addition, no treatment-related changes were detected on any safety laboratory parameters, including several biomarkers for renal function.<br />
<br />
We look forward to the Sarepta webinar on October 23, where your questions will be answered by the Sarepta team. Learn more about the upcoming webinar.<br />
<br />
<br />
Learn more<br />
Read the full presentation of 48-week data from Dr. Mendell<br />
Read Holly Peay’s blog about what this data may mean for the community.<br />
Read Sharon Hesterlee’s blog about what exon skipping success means for those with Duchenne unaffected by exon skipping.<br />
]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/full-48-week-phase-iib-data-from-eteplirsen-study-in-duchenne-pre?xg_source=twitter</link>
            <guid isPermaLink="false">CA7C3273-ACAB-4540-B4C1-D1CD4F2B4998-944-00000448382A635D-FFA</guid>
            <pubDate>Tue, 16 Oct 2012 10:01:47 -0400</pubDate>
        </item>

        <item>
            <title>Better, Faster, Now!</title>
            <description><![CDATA[These are the words that best describe PPMD’s research plan. We aim to put better drugs into development for clinical trials because we can’t afford the failures, we apply funding strategically to increase the speed of testing new drugs, and we prioritize and fund the testing in Duchenne of drugs that are already approved for other purposes. Everything we do goes through this filter to make sure that we are achieving one of these aims and our actions and funding history demonstrate this commitment. <br />
 <br />
Better: For example, in the interest of putting better drugs into clinical development, I recently took part in a meeting sponsored by the National Institutes of Neurological Disorders and Stroke to address the reasons why animal data was not translating efficiently into good drug candidates for various diseases. The group concluded that many studies are not conducted with the appropriate degree of rigor and that replication of studies is important. That report, of which I am one of the authors, includes recommendations for increasing the rigor of preclinical animal studies—it appears in today’s issue of Nature. As I write this blog we are also in the process of adapting PPMD’s grant applications to request that applicants address the issues highlighted in this report even more explicitly than they have done in the past.<br />
<br />
In addition to increasing the rigor of our reviews to improve the quality of drug candidates, we’ve used a multi-pronged strategy that includes collaborating with the TREAT-NMD TACT expert committee for review, a strategy that we’ve been invited to present at the upcoming FasterCures partnering meeting. And we continue to fund the laboratory of PPMD Scientific Advisory Committee Chair Dr. Lee Sweeney to replicate findings published in the scientific literature by others. This strategy has proved increasingly important as more and more groups are reporting that the vast majority of studies published in the scientific literature cannot be replicated and should not be relied upon as the basis for human clinical trials (see Believe it or not: how much can we rely on published data on potential drug targets? and Drug development: Raise standards for preclinical cancer research).<br />
<br />
<br />
Faster: We also want to see better drugs approved faster. To increase the efficiency of clinical trials we have provided travel awards to sites involved in both the Shire/Acceleron study and the Sarepta Eteplirsen study to help cover costs, such as childcare, that may not be allowed by institutional review boards. We also developed the DuchenneConnect patient registry, which sends out notifications to those eligible for clinical trials at the request of companies and academic investigators.  <br />
 <br />
Now: Finally, to take advantage of the potential of drugs that are already approved, we have vigorously investigated the possiblity of repurposing drugs approved for other uses by directly supporting clinical trials of approved drugs Cialis/Viagra and Eplerenone, based on animal studies funded by PPMD that showed these drugs were promising (see our Investigator grant to Stan Froehner, Ph.D. and Bridge grant to Jill Rafael-Fortney, Ph.D.), and by forming a working group with the purpose of reviewing all the data on Duchenne published to date to prioritize other approved drugs for testing in Duchenne.<br />
<br />
<br />
We know that the fight to end Duchenne is a race against time. But we also understand that there is little to no room for error in this journey to treat people with Duchenne. That is why we will continue to instill this philosophy of Better, Faster, Now any time we consider supporting potential therapies.<br />
<br />
<br />
]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/better-faster-now?xg_source=rss</link>
            <guid isPermaLink="false">7C99039D-D13F-4052-9664-6229A1F3E699-2097-00001044CE22FB62-FFA</guid>
            <pubDate>Thu, 11 Oct 2012 13:19:19 -0400</pubDate>
        </item>

        <item>
            <title>PPMD’s Sharon Hesterlee Featured in Nature Magazine</title>
            <description>In an article published in the most recent issue of Nature magazine called, “A call for transparent reporting to optimize the predictive value of preclinical research, “ PPMD’s Senior Director of Research, Dr. Sharon Hesterlee helps take a look at reasons why animal data was not translating efficiently into good drug candidates for various diseases. </description>
            <link>http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html</link>
            <guid isPermaLink="false">327DC46A-6134-4C27-B81A-371DECE7B895-2097-00000FBD2F41EBA7-FFA</guid>
            <pubDate>Thu, 11 Oct 2012 13:09:35 -0400</pubDate>
        </item>

        <item>
            <title>Webinar Q&amp;A: Monitoring Heart Disease in Duchenne and Carrier Moms/Daughters</title>
            <description>Parent Project Muscular Dystrophy recently hosted the first part of our Cardiac Webinar Seriers with Dr. Linda Cripe (Nationwide Children’s Hospital, Columbus, OH) and Dr. Kan Hor (Cincinnati Children's Hosptial, Cincinnati, OH) to discuss monitoring heart disease in Duchenne and carrier moms/daughters. There were some great questions asked, but unfortunately we were not able to get to all of them during the webinar. The remaining questions have been addressed below!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/webinar-q-a-monitoring-heart-disease-in-duchenne-and-carrier-moms</link>
            <guid isPermaLink="false">7F284028-2F6B-42B7-A884-D28D7FBADD19-2090-00001478EBD043FA-FFA</guid>
            <pubDate>Wed, 10 Oct 2012 16:59:24 -0400</pubDate>
        </item>

        <item>
            <title>Positive Phase 1 trial results for SMT C1100 (Summit PLC)</title>
            <description>Following closely on the heels of the good news about Sarepta’s exon 51 skipping strategy, PPMD is pleased to report that Summit PLC has been able to achieve sufficient plasma levels of its reformulated utrophin-upregulating drug to justify a phase I/II trial in Duchenne (Read Summit's Press Release). At PPMD we have always believed in “hedging our bets” and investing widely in different therapies, some of which are mutation specific and some of which are not. Unlike exon-skipping strategies, upregulating utrophin is not a mutation specific strategy and, if effective, could potentially benefit anyone with Duchenne. To date we have funded the screening and identification of a utrophin upregulating compound at PTC Therapeutics, which is now in the preclinical validation stage; Tivorsan’s biglycan compound which seems to work by concentrating utrophin at the muscle cell membrane; and we contributed $250,000 to Summit PLC to fund the manufacture of its reformulated utrophin-upregulating compound SMT-C1100. Some of you may recall that the SMT-C1100 had been acquired by Biomarin who gave the drug back after they were unable to achieve high enough plasma levels of the drug with the original formulation and Summit struggled to find support to reformulate the drug and try again.&lt;br /&gt;
 &lt;br /&gt;
The Summit PLC project is unique in that so many different funders in the Duchenne world came together to support it and we all worked together to share our reviews and information (with full permission from the company). Other significant funders of this project included Charley’s Fund, Cure Duchenne, the Foundation to Eradicate Duchenne, the Muscular Dystrophy Association, and the Nash Avery Foundation. Never doubt that this community can make a difference—a phase I/II Duchenne trial with this drug is only possible due to the support of the community. &lt;br /&gt;
Learn more&lt;br /&gt;
Summit's News Release&lt;br /&gt;
</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/summit-announces-positive-phase-1-trial-results-for-smt-c1100</link>
            <guid isPermaLink="false">31257DB0-E097-4AEB-8798-4829E051FBAC-2090-00000D60A4CDE0F1-FFA</guid>
            <pubDate>Wed, 10 Oct 2012 14:49:10 -0400</pubDate>
        </item>

        <item>
            <title>Medical Alert Bracelets for Duchenne</title>
            <description><![CDATA[For several years now, there has been the question of, “Where is the best place to get medical bracelets” and “what should they say?”  Finally, I think we have an answer.<br />
 <br />
“Lauren’s Hope” started out as “You Name It,” and began as a fun little business making personalized gifts for women and children. They were approached by Lauren’s Hope for A Cure to make medical ID bracelets. The medical alert line became so popular, that they changed the name of the company to “Lauren’s Hope.”  While they started out focusing on diabetes, Lauren’s Hope quickly learned of the tremendous need for medical alert bracelets for all medical conditions. Today, their products are available for men, women and children of all ages and diagnoses, and their product line consists of everything from bracelets to dog tags to temporary tattoos.<br />
 <br />
Several PPMD parents strongly endorsed Lauren’s Hope, saying that the company was responsive and easy to work with, the products are durable and the engraving is deep enough to last. We contacted Lauren’s Hope and they have generously agreed to work with our community. <br />
 <br />
There was much discussion regarding what is most important to engrave. Please keep in mind that the information on the jewelry is primarily for “first responders” (fire department, EMT, etc.) We are recommending that the following information is engraved:<br />
 <br />
Name, birthdate<br />
Phone number, allergies and medications:<br />
This will indicate that there are either No Known Drug Allergies (NKDA) or that there are Known Drug Allergies (+KDA), and that the patient is on medication (+MEDS)<br />
No inhaled anesthesia<br />
 <br />
The engraving will look like this:<br />
JOE SMITH 05/23/99<br />
3215609880  NKDA (or +KDA)  +MEDS<br />
NO INHALED ANESTHESIA<br />
 <br />
To order visit LaurensHope.com. The company has generously offered to give our community a 10% discount on all merchandise. The discount code is “DUCHENNE.” <br />
 <br />
Thanks to Doug Biggar and Ivy Scherbarth for all of their help and expertise!]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/medical-alert-bracelets-for-duchenne</link>
            <guid isPermaLink="false">FED8EC2A-C0F4-442D-9EC5-D2FC0BB49679-1290-00000E43F4C40A09-FFA</guid>
            <pubDate>Tue, 09 Oct 2012 12:50:42 -0400</pubDate>
        </item>

        <item>
            <title>Understanding Accelerated Approval</title>
            <description><![CDATA[With the recent news of Sarepta's promising 48-week data, many have asked how accelerated approval may play into the FDA review of eteplirsen. Let's first define what accelerated approval means.<br />
 <br />
Because it often takes years to assess whether patients truly benefit/improve from a particular drug or if the drug shows a "meaningful clinical outcome", in 1992 the FDA instituted accelerated approval allowing approval based on a surrogate end point. This applies to diseases with an unmet medical need, like Duchenne. Approval of a drug based on such endpoints is given on the condition that post marketing clinical trials verify the anticipated clinical benefit.<br />
 <br />
FDA rules state that accelerated approval indicates that acceptable/validated clinical endpoints have been met, that the trial(s) was adequate/well controlled, that FDA has received NDA application/reviewed it/agreed with sponsor analysis, AND that sponsor has agreed to post approval trial to confirm outcome (not just repeating surrogate findings).<br />
 <br />
Questions obviously remain. How will the newest version of PDUFA (Prescription Drug User Fee Act) factor into this review? The reauthorized bill (an important piece of FDA legislation that the community rallied behind this year) contained provisions strengthening accelerated review. It also contained a provision to work on speeding up the development of "breakthrough therapies" that demonstrate early promise. How these are applied remains to be seen. PPMD and others in the community are wanting answers and will work tirelessly to get them so we have as much clarity as possible on the path forward.<br />
 <br />
*Be sure to check out our upcoming webinar with Serepta where participants have the opportunity to ask questions directly with the company. We encourage you to submit questions prior to the webinar via email (info@parentprojectmd.org).<br />
This is an exciting time for the Duchenne community. On their recent call with investors on October 3, Sarepta's CEO Chris Garabedian stated their intent to discuss accelerated approval with the FDA at their meeting later this year. Though the community is anxious to move things along faster, much of this will depend on that meeting and how the FDA views the data.<br />
 <br />
We all eagerly await the results from the full data presentation by Sarepta at World Muscle Society next week. And we will make sure you stay abreast of the role you can play.<br />
 <br />
Learn More:<br />
FDA.gov: About the Accelerated Approval Program<br />
PPMD’s Board Approved FDA Policy<br />
Webinar explaining PDUFA legislation<br />
Blog explaining all provisions PPMD endorsed within PDUFA]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/understanding-accelerated-approval</link>
            <guid isPermaLink="false">FFC04CC2-7DF8-4249-BE3F-F9D0B265D813-1290-00000E36C3BF0C72-FFA</guid>
            <pubDate>Tue, 09 Oct 2012 12:50:05 -0400</pubDate>
        </item>

        <item>
            <title>Save the Date: Q&amp;A Webinar with Sarepta</title>
            <description>Sarepta Therapeutics has asked PPMD to host a webinar on Tuesday, October 23 at 1pm eastern to discuss the 48-week results from their ongoing Phase IIb clinical trial of eteplirsen with the Duchenne community. This comes after early results were released yesterday.</description>
            <link>http://community.parentprojectmd.org/events/webinar-eteplirsen-sarepta?xg_source=homepage</link>
            <guid isPermaLink="false">8D03210F-2953-4205-9E62-9B1B84A12A4C-1290-00000E319243A863-FFA</guid>
            <pubDate>Tue, 09 Oct 2012 12:49:32 -0400</pubDate>
        </item>

        <item>
            <title>Promising News from Sarepta on Exon 51 Skipping Trial</title>
            <description><![CDATA[The much-anticipated 48-week results on eteplirsen, a drug designed to skip exon 51, were presented today by Sarepta Therapeutics on a webinar and press release. On the webinar, Sarepta’s Chief Executive Chris Garabedian presented data about the dystrophin found in study participants’ muscle biopsies and the 6-minute walk results.<br />
 <br />
To read some background about this clinical trial, click here.<br />
 <br />
An overview of the data reported today:<br />
Chris presented results from the phase IIb study, which continued into an open-label extension study. The data that they presented included:<br />
the change in dystrophin positive fibers, which was the primary endpoint for the clinical trial, and<br />
the change in the 6-minute walk test, which was the primary clinical endpoint for the open-label extension part of the clinical trial.<br />
<br />
There are 12 people with Duchenne in this clinical trial. For the first 24 weeks, they were randomly chosen to get 50mg/kg of eteplirsen, 30mg/kg of eteplirsen, or to be on placebo. They are now all in the open-label extension study, and all 12 are now getting either 50 or 30mg/kg of the drug.<br />
<br />
The 48-week data shows that:<br />
The children treated with eteplirsen have significantly more dystrophin-positive fibers in their muscles (with an average 47% increase for those who have been on drug for 48 weeks), and the number of dystrophin-positive fibers has increased over time as the children are on the drug longer. Children who started out on placebo and who are now on the active drug also show improvement in the number of dystrophin-positive fibers.<br />
<br />
Children on the drug also improved in the 6-minute walk test. Children on drug had an average 21 meter improvement in their walk test, while children on placebo had a decline of 68 meters.<br />
<br />
The data don’t yet tell us clearly whether 50mg/kg is better than 30mg/kg.<br />
<br />
Children who were younger when the trial started, as well as those who had better walk test scores when the trial started, seemed to have more benefit from the drug. The two children who lost the ability to walk during the trial also had more dystrophin-positive fibers over time. However, this is a very small study and not all of the data has been analyzed, so it is too early to say who is most likely to benefit and how.<br />
<br />
There were not any treatment-related adverse events during the study, which adds important information about the safety of the drug.<br />
<br />
What's next?<br />
Sarepta is still working on the analysis of this data and will present more information at the World Muscle Society meeting. They will also be presenting their information to the PPMD community on October 23rd at 1:00 pm Eastern- come learn more and ask your questions!<br />
<br />
In the meantime, Sarepta is getting prepared to talk to the FDA about the results and discuss next steps. They are hoping to make a case for accelerated approval of Eteplersen. (PPMD continues to be in constant communication with our partners in Washington about the role of patient advocacy in this process. We will alert the community about actions that should be taken. Make sure you're signed up for our action alerts!) They are also starting to plan for a phase III/confirmatory trial. They understand that the community is likely to be negative about a trial that includes a placebo group after such promising results from this phase II study, and are trying to come up with trial designs that do not include a placebo group and that are acceptable to the FDA. They are also working on another important issue, which is scaling up their production so they can make enough of the drug to give to people in the confirmatory clinical trial (and hopefully, later to any person with Duchenne who would benefit from skipping exon 51).<br />
<br />
For more details about the findings, read Sarepta's news release.<br />
<br />
Also read Beyond Exon 51, a blog from PPMD's Senior Research Director, Sharon Hesterlee, explaining how an exon 51 success can benefit all people with Duchenne, regardless of mutation.<br />
<br />
We are hopeful and very enthusiastic about these promising findings. We will keep you updated on what we learn at the World Muscle Society meeting, and please tune in for PPMD’s webinar with Sarepta on October 23rd at 1:00 pm EST.<br />
Learn more: <br />
Sarepta's Press Release<br />
Attend our webinar with Sarepta on October 23rd at 1:00 pm EST<br />
In A First, An Experimental Drug May Help Boys With Muscular Dystrophy (Forbes article, quoting PPMD's Scientific Advisor, Dr. Lee Sweeney)<br />
Beyond Exon 51<br />
2011 Webinar (Sarepta was previously known as AVI BioPharma)<br />
Sign up for Action Alerts]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/sarepta-on-exon-51-skipping-trial-eteplirsen?xg_source=rss</link>
            <guid isPermaLink="false">55481DB4-75B2-49F1-B6F7-C416DEB5213D-878-000003BE74229E8C-FFA</guid>
            <pubDate>Wed, 03 Oct 2012 19:03:08 -0400</pubDate>
        </item>

        <item>
            <title>The Global Genes Project</title>
            <description><![CDATA[Jeans. Genes. Thursday night, I changed from jeans into a blue dress – as in blue jean blue. The recommended color for the R.A.R.E. Gala. The focus was genes, rare genetic disorders. While most of my days are focused on Duchenne, I am very aware that Duchenne is 1 of 7,000 rare diseases.<br />
<br />
R.A.R.E. includes more than 30 million Americans and 85% of those 30 million are children. Just outside the ballroom were photographs of people with rare diseases. Some of the names of the diseases were familiar, as I have met many families over the years: moms, dads, sisters, brothers, uncles, aunts, friends who love a person with a rare disease. They all remember the exact date and time when this new word, this diagnosis, broke down the door of their home, and interrupted the life they were planning to live.<br />
<br />
There was a little girl, about 2, SMA type 1, immobile and in a vent. Another little girl of about 7, mobile, but unable to communicate, Phelan-McDermid Syndrome, suggested to be the genetic cause of autism. A boy with Fragile X Syndrome. And so many more.<br />
<br />
The photographs and the people told the story of unmet needs, of parents and families feeling isolated and alone, and of HOPE – the belief in biomedical research, scientific opportunity, and treatment. And also, the HOPE of connection.<br />
<br />
I stood staring at the pictures, watching the families, in tears. The mantra in my head... Children should not be sick. They should have opportunities and dreams. And every child I met was smiling, happy, deeply loved. It was quite an evening.<br />
<br />
I accepted an award for advocacy, but the award does not belong to me. It belongs to all of us and especially to our children. They smile in the face of a diagnosis that brings us to our knees. They teach us about hope, about living each day, about appreciating the gifts we have. They teach us the real definition of strength.<br />
<br />
I walked up to the podium, humbled by the evening… I started off saying:<br />
I am very grateful and honored to be part of this amazing celebration. It is an honor to be in the presence of my personal hero’s such as Dr. Emil Kakkis, Brad Margus, and John Crowley and so many of you sitting in this audience.<br />
<br />
Duchenne muscular dystrophy is a RARE disease. Perhaps medium rare…<br />
<br />
Approximately 250,000 individuals in the world are diagnosed as having Duchenne muscular dystrophy.<br />
<br />
Approximately 12,000 of those individuals live in the United States.<br />
<br />
To be honest, Duchenne affects millions of people – the diagnosis of Duchenne or any RARE disease refers to an individual, but the impact of that diagnosis ripples through families, neighborhoods, schools, and communities. Everyone in the world is touched by a RARE disease.<br />
<br />
Duchenne muscular dystrophy is x-linked, which means that Duchenne primarily affects boys and young men. Women can be carriers (I am one of them) and some of them are symptomatic.<br />
<br />
My sons Christopher and Patrick were diagnosed with Duchenne in 1984. They died on September 29 and April 29, in 1995 and 1996, 7 months apart-to the day and to the hour.<br />
<br />
The ‘Duchenne gene’ is the largest gene in the human genome, with 79 exons and 2.5 million base pairs. Mutations occur across the gene and result in the loss of a structural protein called dystrophin. Dystrophin plays a critical role in muscle. It acts as a shock absorber, an organizer, and a regulator. Without this protein, muscle cells are unable to survive.<br />
<br />
As babies, most parents would never recognize signs or symptoms of Duchenne as they are subtle. These wonderful boys gain skills such as sitting upright and walking as anticipated, though sometimes there are slight delays. Most of the time, if mom or dad expresses concern, the delays are dismissed by pediatricians and family doctors.<br />
<br />
Once diagnosed (and even before) the clock starts. Over the next 20 years, they will lose the skills they worked so hard to gain. At 16, when their peers think about driving, young men with Duchenne are typically unable to walk even a step. Soon after, they will be unable to throw their arms around someone they love. By their 20s, most of the everyday things we take for granted (feeding, personal needs, scratching our nose) will take extraordinary effort or become impossible. Keep in mind, the heart is a muscle too and by the age of 30, it will fail.<br />
<br />
Because all of us are RARE, we face the same challenges.<br />
<br />
Finding our gene. Understanding the pathophysiology of the condition – what is missing because of the genetic mutation? Identifying targets for potential intervention and repurposing drugs or developing new drugs. We have to think about addressing clinical variability and standardizing care. Understanding progression and collecting natural history studies with sufficient rigor for FDA. Developing clinical trials in small populations and thinking ‘out of the box’ about adaptive designs to include patients across the spectrum of the condition (in Duchenne – ambulatory and non). And progress may be slowed and difficult because of absence of biomarkers and validated outcome measures, the recognition that success or failure of clinical trials depends on primary outcomes or surrogate measures, and data statistically relevant for approval.<br />
<br />
We need and advocate for regulatory authority – for the FDA to understand that RARE is complicated and flexibility will be required- that it is may sometimes be difficult to ‘tease’ out benefit in the context of a clinical trial and that vehicles such as conditional approval (Europe) and accelerated approval (US) need to be in embraced and post marketing studies required if we are to understand benefit from a given compound. This year, in particular, we, the RARE disease community, worked on this legislatively with PDUFA5 and FDASIA.<br />
<br />
And for all of us to discuss benefit /risk in the context of rare disease – what is the risk tolerance and where do we set the ‘bar’ for benefit. I would have been grateful for 5 additional minutes with my sons.<br />
<br />
And approvals, TREATMENTS: the holy grail and the recognition that our work is not complete until we are able to ensure ACCESS for all who may benefit from a given therapeutic intervention.<br />
<br />
I cannot imagine how it would feel to know about a therapy, something that might change the predicted outcome for someone you love and to be denied access – for whatever reason.<br />
<br />
This is why we are here. This is why we need each other and depend upon each other.  WE are RARE and together, we are louder, stronger, more visible, more effective.<br />
<br />
I’m often reminded of the story Horton Hears a Who. Horton, the elephant knows that size doesn't matter – whether you're as big as an Horton or as small as a speck, RARE is all of us. We ARE the people of Whoville and we may be tiny but if you will remember the story of WHOVILLE:<br />
<br />
Their voices were heard. They rang out loud and clean.<br />
And the elephant smiled, “Do you see what I mean?”<br />
They proved they ARE persons, no matter how small (rare).<br />
And THE whole world will be saved by the smallest of all.<br />
<br />
My deepest thanks for this wonderful award.<br />
<br />
A person’s a person, no matter how small…or how RARE. Thank you. God bless and Godspeed to all of us.<br />
<br />
And as I walked off that podium, I whispered a prayer to Chris and Patrick, thanking them again and again for the journey.<br />
 <br />
]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-global-genes-project</link>
            <guid isPermaLink="false">A6C7D7D6-19B6-45D8-92A1-92EB039A74DE-878-000003B070D7FA41-FFA</guid>
            <pubDate>Wed, 03 Oct 2012 19:02:23 -0400</pubDate>
        </item>

        <item>
            <title>PPMD awards $50,000 to multi-exon skipping project</title>
            <description>We are so happy to support the work of Dr. Toshifumi Yokota at the University of Alberta, in Canada. Exon skipping looks promising as a viable therapeutic for Duchenne. Dr. Yokota is taking the process several steps forward by experimenting with skipping multiple exons. If successful, a large percentage of the Duchenne population could be effectively treated. PPMD has long supported the development of exon skipping and this project will lay the groundwork for the next generation of exon-skipping. Congratulations to Dr. Yokota, and thank you!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/parent-project-muscular-dystrophy-awards-50-000-for-multi-exon</link>
            <guid isPermaLink="false">A638C318-FF84-47BF-A7A3-2DED14BDE302-878-000003A0F7176C71-FFA</guid>
            <pubDate>Wed, 03 Oct 2012 19:01:34 -0400</pubDate>
        </item>

        <item>
            <title>Implementing PDUFA</title>
            <description><![CDATA[With Congress decamping from Washington and not expected to return until after the November election, we thought we'd revisit one of the few bright spots of bipartisanship this Congress – the enactment of the latest FDA user fee law (PDUFA), known as the FDA Safety and Innovation Act or FDASIA. (Washington loves a good acronym).<br />
<br />
Earlier this year PPMD helped lead an effort supported by a number of other organizations like Genetic Alliance, National Down Syndrome Society, and the Everylife Foundation for Rare Diseases to include within FDASIA key rare disease provisions intended to expedite review of potential treatments.<br />
<br />
These provisions:<br />
Modify and improve the FDA's Accelerated Review and Fast Track programs to enhance their use and provide clearer guidance on the use of surrogate endpoints; (surrogate endpoint (or marker) is a measure of effect of a certain treatment that may correlate with a  clinical endpoint)<br />
<br />
Provide FDA with greater ability to engage medical and scientific experts who posses knowledge and expertise the agency may lack internally;<br />
<br />
A path forward to enhance direct patient engagement with FDA in key medical product review discussions and to better understand and recognize concerns, particularly from rare diseases advocates, regarding the balance between potential benefits and risks; and<br />
<br />
Establish a new Breakthrough Therapy designation designed to further expedite review of potential therapies.<br />
<br />
PPMD is grateful that Congress included all of these rare provisions. But as all of you know, while enacting an idea into law is a major accomplishment, it's far from the end of the road, particularly on complex regulatory topics like this. Over the coming months and even years, FDA will be tasked with drafting guidance and other proposed regulations that will provide the specific details of how these provisions will be implemented.<br />
<br />
In comparing the process to constructing a building, the provisions of the law lay out the key elements – how tall the building will be, what it will look like, etc., but the regulations and guidance will stipulate the details – floor plans, critical infrastructure, and the like – that are essential to the project.<br />
<br />
PPMD will be working with our champions in Congress and fellow patient advocacy organizations to engage throughout the process. This work will include ensuring FDA meets its deadlines, meeting with senior agency officials, reviewing and commenting on draft documents and, ultimately, ensuring the provisions are implemented as Congress and the advocacy community intended them to be.]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/implementing-pdufa?xg_source=rss</link>
            <guid isPermaLink="false">6590F4BE-1684-43D5-A411-67344F2C3633-878-000003996EB7BF41-FFA</guid>
            <pubDate>Wed, 03 Oct 2012 19:00:30 -0400</pubDate>
        </item>

        <item>
            <title>Parent Project Muscular Dystrophy awards $280,000 for cardiac gene therapy to University of Missouri</title>
            <description><![CDATA[Yesterday, we announced that the University of Missouri’s Dongsheng Duan, Ph.D. was awarded a grant of $280,000 by PPMD to continue his work with SERCA2a. <br />
<br />
We all know how important a healthy heart is, especially in Duchenne. And because you thought with your heart and cheered on Olympic hero Ryan Lochte by giving to the Go for the Gold campaign this summer, we were able to continue our support of Dr. Duan’s important work. So thank you…Together, we went for the gold and made it happen!<br />
<br />
About the project<br />
The heart is a muscle too. This is something we stress over and over again in our fight to end Duchenne. Talented researchers like Dr. Duan understand that the best therapies in the world will do patients no good if their hearts can't handle the therapy. Therefore, this research will give us the building blocks we need to eventually create wholly successful therapeutics that patients can withstand.<br />
 <br />
Dr. Duan and his team at the University of Missouri want to determine if delivering the gene for the calcium-handling protein SERCA2a is sufficient to correct cardiac disease in mdx mice or if the dystrophin gene must be delivered as well. This is important information since SERCA2a gene therapy is in human testing now for non-Duchenne related cardiomyopathy.<br />
<br />
Heart failure is a leading cause of death in people with advanced Duchenne. Through the course of the disease, heart function is progressively compromised by calcium overload and inadequate transport, which leads to cell imbalance, dysfunction, and death. SERCA2a is a calcium ion pump that may be able to reduce the damage caused by calcium overload.<br />
<br />
Learn more<br />
Press release<br />
PPMD's Funding Portfolio<br />
Donate Now]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/parent-project-muscular-dystrophy-awards-280-000-for-cardiac-gene</link>
            <guid isPermaLink="false">1182DA50-9267-4E5F-9014-EC70E9211E0B-3528-000017AAECBFE5E2-FFA</guid>
            <pubDate>Tue, 18 Sep 2012 15:29:42 -0400</pubDate>
        </item>

        <item>
            <title>Dispatch Article about Serepta Trial</title>
            <description>New article from The Columbus Dispatch about Serepta's eteplirsen trial.</description>
            <link>http://www.dispatch.com/content/stories/local/2012/09/16/drug-could-help-boys-walk.html</link>
            <guid isPermaLink="false">6849BCC8-D623-4CC2-A54D-9A548E740999-3528-000017A7DD002E80-FFA</guid>
            <pubDate>Tue, 18 Sep 2012 15:28:51 -0400</pubDate>
        </item>

        <item>
            <title>September End Duchenne eNews</title>
            <description>With school back in session, we have some important information for you on flu vaccinations, medical alert bracelets, and a downloadable webinar on IEPs. We are also launching a three-part webinar series on cardiac issues featuring the most knowledgeable cardiologists in the Duchenne space. </description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=17221.0</link>
            <guid isPermaLink="false">047AE8C5-AB49-47BA-84D0-CEEC5213C0EF-3528-000017A4C8ABDED7-FFA</guid>
            <pubDate>Tue, 18 Sep 2012 15:28:38 -0400</pubDate>
        </item>

        <item>
            <title>AgeView Press names PPMD President Pat Furlong a 'Belle of Steel'</title>
            <description><![CDATA[In 1969, a young, single Catholic woman graduated from college with a double major, nursing and education.   She was bubbly and vivacious with her curly brown locks.   It was remarkable to the nuns of the all-girls Catholic college who had told her she would never make a nurse.    Her social priorities overshadowed her academic prowness.   At her graduation party, her parents asked her what she wanted for her present.   She looked over at her fiancé, directly.   “More than anything else, I want not to be engaged.”     She stunned the room to silence.<br />
<br />
This is just one example of the  “I dare you to say no” dogged tenacity of Pat Furlong.    Motivated by a German mother who was a silent feminist before her time,  Pat moved out of her parent’s home in Cincinnati, Ohio shortly after.  She moved to Columbus, got her first job as a nurse in the Medical Intensive Care Unit and started graduate school at Ohio State.   She just had to learn more about this fascinating thing called the body.   She wanted to know how each cell worked implicitly with the others.    For the first time, Pat felt free and independent.   And it was liberating!<br />
<br />
Pat Furlong is now the Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), now the largest nonprofit organization in the United States solely focused on Duchenne muscular dystrophy.   Its mission is to improve the treatment, quality of life, overall care and outlook through research for all individuals affected by this monstrously degenerative, childhood disorder.   Duchenne is the most common fatal, genetic disease which affects 1 out every 3,500 boys each year worldwide.   It currently has no cure.<br />
<br />
But Pat Furlong and her team are working to change all that.    In 1984, when both of her boys were diagnosed with Duchenne,  Pat simply could not accept as a mother and as a nurse, the physician’s “there’s no hope and little help. . .they’ll lose the ability to walk, then lose their upper arm strength, then. . lose their life by age 20.”   She wasn’t afraid to tell any doctor just what she thought.  Their answers were not good enough.<br />
<br />
Pat’s nursing journey had taken her from the bedside, to patient educator and advocate.   Garnering her gumption Pat immersed herself in learning everything there was to learn about Duchenne.   There was no internet, she physically went to medical libraries and ordered articles and copies of research studies.     She presented herself, not as the teary-eyed mother of two dying boys looking for a miracle.  She knew better.   No, Pat got her foot in many doors, by selling her advocacy as a post-graduate student on a mission of research.   Sadly, there seemed to be no general concensus or standard of care about just what were the best treatment options.  Everyone seemed to be doing their own thing.   It was appalling.  Funding for research was minimal.  No one wanted to hear about a rare genetic disorder.<br />
<br />
But for Pat, it wasn’t rare, it was destroying her boy’s muscles, one cell at a time.   And time was running out.   Tragically, both her boys lost their battle with Duchenne in their early teens.   But that didn’t stop Pat.   In fact, standing over their graves, she decided there and then she would not stop until there was a cure.    She remembered her boys telling her, “don’t do it for us, do it for the many.  Miracles aren’t just for one.”<br />
<br />
Pat began gathering people around her to ask the tough questions.    With each visit to each expert she asked, “What do we know?   What do we need to know?  What’s the standard of care?  Who’s doing something about it?   And most importantly . . . who’s investing?”   At point in time, the Muscular Dystrophy Association was only investing about a one million a year.   That simply wasn’t enough to fund a cure.  Many feds, the movers and shakers in DC had never even heard of the disease.  It wasn’t on the National Institute of Health’s radar screen because it was a rare disorder.    There were many that told her “just go home.”<br />
<br />
But Pat wouldn’t give up.  She had to do it.  She promised her boys.   The defective gene had been isolated back in 1987, but yet there still was no cure.  Pat transformed all of the pain and anger that resulted from profound grief into an unrivaled, energized force.    A DC lobbyist had contacted her; his son was diagnosed with Duchenne’s.    Pat turned to him for advice on how to get Washington to notice.    Gathering a group of other parents of young men with Duchenne, Pat founded PPMD to change to course of this disease.<br />
<br />
In 1996, they put on the first-ever  NIH workshop on Duchenne, harnessing a consortium of experts from around the world.   Earning seed funds, they hired a powerful team of DC lobbyists.   There was legislation needed to garner increased funding for research.   In 2001, Senator Arlen Specter took note.   PPMD drafted the MD Care Act, laying out plans for Centers of Excellence to establish standards of care across the nation.<br />
<br />
<br />
One of our Texas DMD boys, advocate Sam Killian.<br />
<br />
Pat’s perseverance for her sons paid off.   The legislation passed in Feb of 2001 infusing over 400 million dollars in pivotal Duchenne research.   The NIH took notice which gave researchers a credibility factor.  The moment was literally life changing for many.    In 2010, in the medical journal The Lancet, 180 physicians published a consensus of care considerations for Duchenne.   But the work still is not done.   Pat has bigger plans.   During the next few crucial years of research, as drugs are developed to genetically re-engineer the destructive forces of Duchenne, Pat hopes to see herself smiling.   Her goal is to see more development in combined therapies for Duchenne, more early diagnosis and thus earlier intervention.  She dreams to see boys still walking at 17 and 18.   More extension of life expectancy into the middle thirties, maybe forties.The New Yorker named Pat a World Changer in 2010.  WebMD designated her as a World Health Hero the same year.   She is a top leader at the Institute of Medicine and the FDA.<br />
<br />
When asked what makes her successful, Pat describes, “I’m a consummate pest!  If I want something and I know it’s right, I just will not give up.  The pain of losing your children has a ripple effect that lasts forever.  Not a day goes by that I don’t miss my boys.    I channel that pain into productivity.”<br />
<br />
For Pat, indeed the mission and the message aren’t over.   For her unbridled passion and stoic, gutsiness to move mountains in a sea of bureaucracy . . . all to save our boys, AgeView Press is proud to honor Belle of Steel number four – the truly amazing Pat Furlong.]]></description>
            <link>http://jeanettevaughan.wordpress.com/2012/08/31/world-changer-and-world-health-hero-pat-furlong-belle-of-steel-4/</link>
            <guid isPermaLink="false">BB979B78-FCEF-4C1B-85D6-054EFB27CEEF-3528-0000179E556CC1C7-FFA</guid>
            <pubDate>Tue, 18 Sep 2012 15:28:25 -0400</pubDate>
        </item>

        <item>
            <title>Update from Summit on their Duchenne drug development strategy</title>
            <description><![CDATA[Biotechnology group Summit’s (LON:SUMM) new strategic focus on commercial development rather than early-stage research will increase the chance of success at its flagship drug programmes, according to Singer Capital.<br />
The firm is to focus its attention on the development of two drugs – one for Duchenne Muscular Dystrophy, the other for C. difficile infections.<br />
It will end discovery-stage research, which will affect around half the company’s workforce.<br />
House broker Singer said the Summit had a very busy first half with the appointment of a new chief executive and considerable scientific and commercial progress as SMT C1100 (DMD) entered Phase-I trials and SMT 19969 (C. difficile) moved towards the start of Phase-I trials by the end of 2012.<br />
Chief executive Glyn Edwards said: “Summit has two promising clinical stage programmes targeting areas of high unmet medical need and this change in strategy is intended to provide the company with greater focus and resources to accelerate their development.<br />
“Our aim is to provide best value for our shareholders by developing high-value franchises in the DMD and C. difficile therapy areas and seeking to maximise the therapeutic and commercial potential of these two programmes.”<br />
Summit said it “remains enthusiastic” about the potential of second generation immunosugars, or Seglins for short, and in particular the OGA inhibitor programme.<br />
OGA, or O-linked N-acetylglucosaminidase, segues very neatly into the latest research on Alzheimer’s. <br />
Two new studies seem to show it spreads like an infection from brain cell to brain cell. <br />
But instead of viruses or bacteria, what is being propagated is a distorted protein known as tau.<br />
“The OGA programme will continue to progress as planned through to an important technical milestone after which the company will evaluate its options for taking this forward,” the company said this morning. <br />
“Summit will however be unable to sustain the general development of Seglin technology or other programmes and will seek alternative ways for realising value from these assets.”<br />
The most advanced of Summit’s portfolio is SMT C1100 for DMD, a fatal and thankfully rare genetic muscle wasting disorder that affects boys.<br />
Today Summit said it will “seek to expand partnerships with leading academics, clinicians and community advocacy foundations” to support the development of SMT C1100. <br />
This potentially first-in-class utrophin upregulator is currently in a Phase I clinical trial.<br />
Results are expected by the end of the year.  Its highly potent anti-biotic SMT 19969, meanwhile, is expected to enter clinical trials by the end of the year.<br />
As would be expected of a company at this stage in its development, Summit posted a loss for the half year to July 31. The shortfall was £1.7 million.<br />
It had cash of £4.8 million at the period-end following a £5 million fundraising.<br />
This money provides a ‘cash runway’ for the company through to third quarter of its 2013 and possibly into 2014 following the restructuring, said Singer.<br />
The broker added it maintained its positive view on the stock and awaits further progress]]></description>
            <link>http://www.proactiveinvestors.co.uk/companies/news/47762/update-summit-corp-reveals-new-sharper-strategic-focus-47762.html</link>
            <guid isPermaLink="false">E9A777AD-C6E9-44AF-B9C8-E77BD7ACFD45-3546-00001C9551CD57DF-FFA</guid>
            <pubDate>Thu, 06 Sep 2012 16:58:50 -0400</pubDate>
        </item>

        <item>
            <title>Why should you join our team?</title>
            <description>With the 5th annual Coach To Cure MD right around the corner, we wanted to tell you why you should make this the year to show your support for one of the biggest national awareness campaigns in the Duchenne community. And we wanted you to hear it from families that have participated since the beginning...</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=17141.0</link>
            <guid isPermaLink="false">02CC1A71-FFF4-4DD4-B676-2CD2B29EC587-3546-000015BABE00D1CD-FFA</guid>
            <pubDate>Thu, 06 Sep 2012 14:52:52 -0400</pubDate>
        </item>

        <item>
            <title>The flu vaccine and Duchenne: What you need to know</title>
            <description><![CDATA[Yes, summer is winding down, and the welcoming of fall brings many things – cooler weather, wonderful fall colors, the beginning of school and, unfortunately, the start of flu season. Every year, thousands of people get the flu. While it can be an inconvenience for some, the flu has resulted in thousands of deaths. A recent study shows that children with underlying neurologic disorders, like Duchenne, are at especially high risk of pulmonary complications and death from the flu.<br />
 <br />
The CDC (Center for Disease Control and Prevention) has joined with The  American Academy of Pediatrics, Families Fighting Flu and Family Voices to spread the message about the importance of influenza vaccination to protect our children.<br />
 <br />
The influenza vaccine, or “flu shot,” is an injection into the muscle, usually given in the upper arm or thigh. The flu shot contains inactivated (dead) virus and is recommended for patients with neuromuscular diseases and patients taking chronic steroids. Because the virus is dead, there is no risk of getting the flu from the flu shot. (The “nasal spray flu vaccine” contains living virus, and is NOT recommended for people with neuromuscular diseases.) <br />
 <br />
The flu shot for 2012-2013 will protect against 3 kinds of viruses: influenza B, influenza A (H1N1) and influenza A (H3N2). The most common side effects from the flu shot are pain at the injection site, low-grade fever, slight tiredness, and mild generalized muscle soreness. These side effects are most common in children getting their first flu shot, and will go away on their own within 1-2 days.<br />
 <br />
The best time to get vaccinated is as soon as it is available in your community. It takes about 14 days for the body to build up antibodies for the 3 viruses in the vaccine. Those antibodies will protect against those 3 flu viruses. <br />
 <br />
PPMD wants to keep both you and your family safe and healthy. So you can enjoy the good parts of fall!<br />
 <br />
Links<br />
CDC Press Release: Children with neurologic disorders at high risk of death from flu<br />
HealthMap Vaccine Finder<br />
Sign up for PPMD's eNews]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-flu-vaccine-and-duchenne-what-you-need-to-know</link>
            <guid isPermaLink="false">2E3303E1-DFAF-4E6C-BB8A-7F6DF4C13D0C-3546-000015B407B64577-FFA</guid>
            <pubDate>Thu, 06 Sep 2012 14:52:34 -0400</pubDate>
        </item>

        <item>
            <title>Tackle Duchenne</title>
            <description>We are one month away from the fifth annual Coach To Cure MD! Over the past four years, you have helped us reach the $1 million mark, as well as raise awareness about our fight to end Duchenne. We want to make 2012 another milestone year. Join the Coach To Cure MD team in one of three easy ways.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=17083.0</link>
            <guid isPermaLink="false">0CD48513-5AA2-4BA6-9DFC-A68076F3FE95-1256-000006C2A97D2B8E-FFA</guid>
            <pubDate>Thu, 30 Aug 2012 14:48:16 -0400</pubDate>
        </item>

        <item>
            <title>Low oxygen boosts stem cell survival in Duchenne therapy</title>
            <description>One approach to improving muscle strength in Duchenne is to replace unhealthy muscle cells that lack dystrophin with donor stem cells that have normal levels of dystrophin. These cells might come from a relative unaffected by Duchenne or even a person with Duchenne’s own cell, after dystrophin is restored though a technique like gene therapy.&lt;br /&gt;
 &lt;br /&gt;
Although we’ve heard much more in recent years about drug approaches to therapy, work continues to better understand how to use stem cells to restore muscle tissue. In a new article from Purdue, Dr. Shihuan Kuang describes how stem cell therapy would work for Duchenne and his discovery that mimicking the environment in the muscle is the best way to grow healthy muscle stem cells in culture dishes.&lt;br /&gt;
</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/increasing-stem-cell-survival-in-duchenne-therapy/</link>
            <guid isPermaLink="false">7018F1C6-366D-4220-985B-9CE2C825DCA7-2847-00001A072C188B13-FFA</guid>
            <pubDate>Wed, 29 Aug 2012 17:16:05 -0400</pubDate>
        </item>

        <item>
            <title>An open letter from Chris Garabedian, president and CEO of Sarepta Therapeutics</title>
            <description>An open letter from Chris Garabedian, president and CEO of Sarepta Therapeutics with an update on their clinical program for eteplirsen.</description>
            <link>http://www.parentprojectmd.org/site/DocServer/Sarepta_Letter_to_Patient_Community_082812.pdf?docID=13303</link>
            <guid isPermaLink="false">EA2D2889-783C-4408-9A79-02224FACB85C-4097-0000181103884A1B-FFA</guid>
            <pubDate>Tue, 28 Aug 2012 16:39:35 -0400</pubDate>
        </item>

        <item>
            <title>Clinical Trial Update: GSK2402968 (drisapersen) for Exon 51 Skipping</title>
            <description>GlaxoSmithKline (GSK) recently announced that one of their clinical trials (Study DMD114044) for exon 51 skipping has completed recruitment. This trial is a phase 3, randomized, double blind, placebo-controlled study to assess the efficacy and safety of GSK2402968 in patients with Duchenne. GSK is currently conducting four clinical trials to investigate the efficacy and safety of GSK2402968. Two of these studies have sites in the United States (DMD114876 and DMD114118). DMD114876 is currently recruiting patients at 14 different sites across the United States. </description>
            <link>https://www.duchenneconnect.org/index.php?option=com_content&amp;view=article&amp;id=418%3Aclinical-trial-update-from-gsk-regarding-gsk2402968-drisapersen-for-exon-51-skipping&amp;catid=69%3Aclinical-trials-news&amp;lang=en</link>
            <guid isPermaLink="false">6A98175D-A4EB-4F7D-8AFC-29A135CBC0BD-5615-0000165C6D89C236-FFA</guid>
            <pubDate>Tue, 21 Aug 2012 16:10:00 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews: Go for the Gold</title>
            <description>Catch up on the latest research and community updates, including what PPMD has been up to lately, in this month's End Duchenne eNews. Also meet our Featured Voice for August, 18-year-old Sean Quigg, founder of Spaghetti Arms.</description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=nws_index</link>
            <guid isPermaLink="false">79CDDA86-7999-46D5-95A6-E7E76332576A-5615-00001658186BE373-FFA</guid>
            <pubDate>Tue, 21 Aug 2012 16:09:44 -0400</pubDate>
        </item>

        <item>
            <title>Beyond Exon 51</title>
            <description>As Sarepta (formely AVI) announces promising results from its phase II interim data and GSK follows up its promising phase II data with a phase III study, things are looking good for an exon-skipping based therapy for Duchenne…if you happen to be in the 13% of those with Duchenne who have a mutation that can be improved by skipping exon 51. But for the other 77% of families out there dealing with other types of mutations including other deletions, duplications or point mutations, what does an exon 51 success mean? PPMD's Senior Research Director, Sharon Hesterlee, explains how these studies can benefit all people with Duchenne, regardless of mutation.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/beyond-exon-51</link>
            <guid isPermaLink="false">5BE08AE3-9DE3-4755-BE4E-AC98C6830750-5615-000016557937B73C-FFA</guid>
            <pubDate>Tue, 21 Aug 2012 16:09:29 -0400</pubDate>
        </item>

        <item>
            <title>Standardizing Duchenne care</title>
            <description>Standards of care are critical for ensuring that everyone with Duchenne receives a similar baseline level of care. PPMD's Director of Clinical Care, Kathi Kinnett provides an update on our efforts to establish a clear, consistent message of care for parents, providers and industry.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/transforming-duchenne-care-update?xg_source=RSS</link>
            <guid isPermaLink="false">B0BAC5F0-298F-42C3-95E4-A81C991F000C-895-00000D2F04E0CD14-FFA</guid>
            <pubDate>Wed, 08 Aug 2012 13:22:51 -0400</pubDate>
        </item>

        <item>
            <title>Progress on Duchenne via antisense exon region skipping</title>
            <description>A different approach to exon skipping: Editing out a whole stretch of exons (45 to 55) could improve genetic function in any patients with mutations in the stretch. </description>
            <link>http://www.nctimes.com/blogsnew/business/scitech/progress-on-duchenne-muscular-dystrophy-via-antisense-exon-region-skipping/article_6093e17a-3801-50ce-b3dd-40771b395f1e.html</link>
            <guid isPermaLink="false">C5F0D1BB-5EFE-4B5D-A920-FF63D026A887-895-00000D2BDA0EA061-FFA</guid>
            <pubDate>Wed, 08 Aug 2012 13:22:01 -0400</pubDate>
        </item>

        <item>
            <title>Pat Furlong named one of the PharmaVOICE 100</title>
            <description>Congratulations to PPMD President &amp; Founder Pat Furlong for being named one of the PharmaVOICE 100! This is an incredible honor and we are so proud of Pat for being recognized as an inspiring part of the healthcare industry and one of the biggest forces in the global Duchenne community. </description>
            <link>http://www.pharmavoice.com/content/digitaledition.html?pg=96</link>
            <guid isPermaLink="false">23BFD3F7-C9B8-4BD0-8B61-972E10FCD0AD-4879-00001AEC154CF684-FFA</guid>
            <pubDate>Thu, 02 Aug 2012 17:29:27 -0400</pubDate>
        </item>

        <item>
            <title>Join us for Walt Disney World Marathon Weekend!</title>
            <description>Registration is now open for the 2013 Walt Disney World Marathon Weekend Run For Our Sons team! 2013 marks the 20th anniversary of the Full Marathon, which means a new race course and a very special commemorative medal. We'll have teams racing in the Half Marathon, Goofy Challenge and 5K race as well. The 5K includes a Stroller Division, which is open to runners and walkers pushing strollers and wheelchairs!</description>
            <link>http://www.parentprojectmd.org/site/TR?fr_id=2420&amp;pg=entry</link>
            <guid isPermaLink="false">BD76B4CA-8936-4EA1-9400-15B079D515DD-4879-00001AE7B3659E6C-FFA</guid>
            <pubDate>Thu, 02 Aug 2012 17:29:12 -0400</pubDate>
        </item>

        <item>
            <title>Celebrating Our Olympic Hero</title>
            <description><![CDATA[<p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">If you asked me if I could swim, I might say ‘more or less’. Translated, that means that somewhere long ago I took some lessons, that are now lost to memory and in some strange way in my ‘muscle memory’ and adapted for the few times I have access to a pool. For some of us, the ‘more or less’ approach is what we do. Paddle around the shallow end, jump or dive off the board with sufficient confidence that we can manage some to resurface and rotate our arms, randomly kick our legs until we reach the edge of the pool. In my head, that’s called swimming. But my definition of swimming and Ryan Lochte’s definition of SWIMMING are worlds apart.</p><p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">In 2008, I spent some time with Ryan Lochte, who then was a six-time Olympic medalist with three gold, two silver and one bronze. Ryan, the swimming champion was in Washington as a champion of the re-authorization of the MD CARE Act. And he did just that, used his strength for Duchenne.</p><p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Friday is Ryan’s birthday. He’s already struck Olympic gold – the first gold medal for the US actually! – and in our hearts he will forever be a hero of this community. Help celebrate Ryan’s birthday by:</p><ul style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square; "><a rel="nofollow" href="https://secure2.convio.net/ppmd/site/Donation2?df_id=3620&amp;3620.donation=form1" target="_blank" data-bitly-type="bitly_hover_card" style="text-decoration: none; color: rgb(238, 30, 58); ">Making a donation to his</a>&nbsp;<a rel="nofollow" href="https://secure2.convio.net/ppmd/site/Donation2?df_id=3620&amp;3620.donation=form1" target="_blank" data-bitly-type="bitly_hover_card" style="text-decoration: none; color: rgb(238, 30, 58); ">Go for the Gold fundraising page</a></li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square; ">Texting JEAH to 90999 to make a $5 donation</li><li style="margin: 0px 0px 0.4em 1.5em; padding: 0px; line-height: inherit; font-size: 1em; list-style: square; ">Leaving a thank you message on&nbsp;<a rel="nofollow" href="https://www.facebook.com/parentprojectmd" target="_blank" data-bitly-type="bitly_hover_card" style="text-decoration: none; color: rgb(238, 30, 58); ">PPMD’s Facebook page</a>. We’ll pass them on to Ryan on Friday. &nbsp;&nbsp;</li></ul><p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">In a recent interview, Matt Lauer asked Ryan to write the headlines. Ryan smiled and said “Ryan Lochte takes over’.&nbsp;&nbsp; I’m adding my voice to his – TAKE OVER RYAN, win the Gold. Thanks for making a difference in the world of swimming and in our world of Duchenne.</p><p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "></p><p class="p1" style="margin: 0px 0px 0.4em; padding: 0px; line-height: 17px; font-size: 13px; min-height: 1em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><a href="https://secure2.convio.net/ppmd/site/Donation2?df_id=3620&amp;3620.donation=form1" target="_blank" data-bitly-type="bitly_hover_card" style="text-decoration: none; color: rgb(238, 30, 58); "><img src="http://api.ning.com/files/A1s0dQf7WLx96LGzYRRWRVAW8I-VWc0J0R7-m7pv7GEWh7BG0iyql1ri2Ib1e5QnlsoFJGyarzIeKNO4lhFUUnfolxqm0MJ*/PatsBlog_RyanLochte.jpg?width=600" width="600" class="align-center" style="border: 0px none; text-align: center; margin: 4px 0px; clear: both !important; display: block !important; max-width: 721px; height: auto; "></a></p>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/celebrating-our-olympic-hero</link>
            <guid isPermaLink="false">5E835C7F-995B-4A9E-8EFD-FFA6EDD52CCE-4025-00000647BBAA4837-FFA</guid>
            <pubDate>Wed, 01 Aug 2012 11:14:37 -0400</pubDate>
        </item>

        <item>
            <title>Expected Ryan Lochte Events &amp; TV Coverage on NBC</title>
            <description>We compiled a list of expected Ryan Lochte events &amp; TV coverage on NBC. Cheer Ryan on and thank him for supporting the fight to end Duchenne... Text JEAH to 90999 to make a $5 donation.</description>
            <link>http://issuu.com/parentprojectmd/docs/ryan_lochte?mode=window&amp;viewMode=singlePage&amp;backgroundColor#222222</link>
            <guid isPermaLink="false">FD4D60DA-F636-4E94-A908-673E7EF64DA3-4268-000019FADD074E3B-FFA</guid>
            <pubDate>Mon, 30 Jul 2012 17:17:09 -0400</pubDate>
        </item>

        <item>
            <title>Request for Applications for the next competitive round of the Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers</title>
            <description>&lt;br /&gt;
	See all News	&lt;br /&gt;
&lt;br /&gt;
Expected Ryan Lochte Events &amp; TV Coverage on NBC&lt;br /&gt;
We compiled a list of expected Ryan Lochte events &amp; TV coverage on NBC. Cheer Ryan on and thank him for supporting the fight to end Duchenne... Text JEAH to 90999 to make a $5 donation.&lt;br /&gt;
July 30, 2012 | Read more&lt;br /&gt;
&lt;br /&gt;
Request for Applications for the next competitive round of the Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers&lt;br /&gt;
The purpose of this Funding Opportunity Announcement (FOA) is to publicize the re-competition of Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (MDCRCs). These Centers promote collaborative basic, translational and clinical research and provide important resources that can be used by the national muscular dystrophy research communities.</description>
            <link>http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-13-012.html</link>
            <guid isPermaLink="false">790AFB57-5A78-43F1-8183-775470B81C62-4268-000019F7E1DC8FCF-FFA</guid>
            <pubDate>Mon, 30 Jul 2012 17:16:44 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews July 2012</title>
            <description>In this month's newsletter, you'll find several highlights from the 2012 Connect Conference. We also feature Jack and Nolan Willis, 10 year old twins with Duchenne who participated in our panel about clinical trials from the patients perspective. </description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=16881.0</link>
            <guid isPermaLink="false">6B7C3FE3-1996-46F3-95BD-0679BD928373-577-0000016A03F054AA-FFA</guid>
            <pubDate>Thu, 19 Jul 2012 09:37:52 -0400</pubDate>
        </item>

        <item>
            <title>Go for the Gold with Ryan Lochte</title>
            <description>Olympic star Ryan Lochte lost a member of his family to Duchenne muscular dystrophy. Ryan is dedicated to the fight to end Duchenne and hopes wants you to join him. This summer, as he swims for us in the 2012 Olympic Games, Ryan is challenging us to &quot;Go for the Gold” and raise money for research projects (SERCA2a and tamoxifen) that we believe will help all of our sons dream Olympic dreams, and one day see those dreams come true.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=16862.0</link>
            <guid isPermaLink="false">3EBACAE3-29DC-44AB-9A94-3D4F77C6A3EF-577-000001668D1EDB4D-FFA</guid>
            <pubDate>Thu, 19 Jul 2012 09:37:37 -0400</pubDate>
        </item>

        <item>
            <title>Action Alert! Contact your Senators to help save vital Duchenne programs at the CDC</title>
            <description>We need your voice to help save critical Duchenne related programs at the CDC! Efforts to consolidate these activities threaten to slow down the gains we have made in treating Duchenne. In May we asked everyone to reach out to their member in the House of Representatives on this issue. Now it's time to contact your two Senators! Deadline: Friday, July 13</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/action-alert-contact-your-senators-to-help-save-vital-duchenne?xg_source=shorten_twitter</link>
            <guid isPermaLink="false">5B265603-87B5-4486-AFD8-15F045FE848D-861-00000705535CE52E-FFA</guid>
            <pubDate>Tue, 10 Jul 2012 11:31:32 -0400</pubDate>
        </item>

        <item>
            <title>Landmark FDA legislation becomes law</title>
            <description>PPMD applauds the President for signing into law the Prescription Drug User Fee Act (PDUFA) also known as The Food and Drug Administration Safety and Innovation Act. This is a major win for the Duchenne community as well as the rare disease community as a whole. We are grateful to everyone who helped by contacting your members of Congress to educate them on the importance of the provisions we championed. Your voice made all the difference!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/landmark-fda-legislation-becomes-law</link>
            <guid isPermaLink="false">93DCDB10-6ABC-427E-8DEC-BA2394B1C28B-861-000006FFAA27FE2A-FFA</guid>
            <pubDate>Tue, 10 Jul 2012 11:31:19 -0400</pubDate>
        </item>

        <item>
            <title>NIH and NCATS Accepting Proposals for TRND Program</title>
            <description>The National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation, intends to publish an opportunity for research on the following: The NCATS Therapeutics for Rare and Neglected Diseases (TRND) program performs preclinical and early clinical development of new drugs for rare and neglected diseases, and develops new technologies and paradigms to improve the efficiency of therapeutic development for these diseases. Learn more about applying: http://grants.nih.gov/grants/guide/notice-files/NOT-TR-12-007.html</description>
            <link>http://grants.nih.gov/grants/guide/notice-files/NOT-TR-12-007.html</link>
            <guid isPermaLink="false">DC71276F-F3B5-41AB-A2F0-14079AF300CE-570-000002C85650604A-FFA</guid>
            <pubDate>Mon, 09 Jul 2012 10:12:52 -0400</pubDate>
        </item>

        <item>
            <title>AVI BioPharma and PPMD team up for Rock 'n' Roll Seattle Marathon</title>
            <description><![CDATA[<p class="p1" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; "><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=rfos_homepage" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">Run For Our Sons</a>&nbsp;(PPMD's endurance program) is teaming up with<a rel="nofollow" href="http://www.avibio.com/" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">AVI BioPharma</a>&nbsp;in Saturday's&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/TR?fr_id=2260&amp;pg=entry" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">Rock 'n' Roll Seattle Marathon</a>&nbsp;t<span>o raise money and awareness to help end Duchenne!</span></p><p class="p1" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; "><span>&nbsp;</span></p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; ">AVI and PPMD have a long history of working together to develop treatments that may help to prolong the lives of those living with Duchenne. We have always been grateful to the dedication AVI has shown to the Duchenne community as they continue to work on treatments that will help our sons live longer, stronger lives. Now they are taking that dedication a step further by lacing up their running shoes and pounding the streets of Seattle to help raise awareness and end Duchenne.</p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; "></p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; ">Participating alongside the AVI team are 20 other runners, including<strong>Conrad Reynoldson, a 25-year-old man living with Duchenne (pictured right)</strong>. Conrad is the only person to have participated in the Rock 'n' Roll Seattle Marathon &amp; Half Marathon in a power wheelchair. 2012 will mark his second year competing in the race.</p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; "></p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; ">"I am always looking for new and innovative ways to raise awareness and funds for PPMD as well as the broader disability community," said Conrad. "Last year when I heard that no one in a power chair had ever participated in this race, I realized this was a perfect opportunity."</p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; "></p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; ">The Run For Our Sons&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/TR?fr_id=2260&amp;pg=entry" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">team fundraising goal</a>&nbsp;for the Rock 'n' Roll Seattle Marathon &amp; Half Marathon is $25,000.</p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; "></p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; ">"Perhaps over time Run For Our Sons can become&nbsp;<strong>Run With Our Sons&nbsp;</strong>as more of us adults and young men with Duchenne take charge of our futures," said Conrad.</p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; "></p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; "><span class="s1"><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=rfos_homepage" style="text-decoration: none; color: rgb(238, 30, 58); ">Run For Our Sons</a></span>&nbsp;began in 2005 with 80 runners at the Walt Disney World Marathon. Since then the program has grown to encompass most&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=run_RaceCalendar" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">major marathons around the country</a>, with hundreds of runners participating each year. Since its founding, the Run For Our Sons program has raised more than $6 million to fund PPMD's work.</p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; "></p><p class="p3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; min-height: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; "><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; "><strong>Learn more</strong></span></p><ul style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; "><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; "><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=run_RaceCalendar" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">Find a race near you or start a team</a></li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; "><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=rfos_homepage" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">Visit RunForOurSons.org for more information</a></li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; "><a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=rfos_homepage" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); "></a><a rel="nofollow" href="http://www.prnewswire.com/news-releases/avi-biopharma-and-parent-project-muscular-dystrophy-team-up-to-run-seattle-marathon--raise-money-to-end-duchenne-159758665.html" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">Read the press release</a></li></ul>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/teaming-up-with-avi-biopharma-in-saturday-s-rock-n-roll-seattle</link>
            <guid isPermaLink="false">AF59E304-8D08-4B35-8503-DB5E59A2816C-321-00000079C58D818C-FFA</guid>
            <pubDate>Thu, 21 Jun 2012 09:57:20 -0400</pubDate>
        </item>

        <item>
            <title>Patients driving direction of new drug research</title>
            <description>PPMD President Pat Furlong spoke at this week’s Biotechnology Industry Organization (BIO) convention in Boston this week, which allows patients and patient groups the opportunity to meet with pharmaceutical companies and regulators. Pat was featured in this front page article in the Boston Globe.</description>
            <link>http://www.bostonglobe.com/business/2012/06/19/patients-driving-direction-new-drug-research/TjWu74aFVH2g4wNPhUbfQL/story.html</link>
            <guid isPermaLink="false">BB070295-3128-4576-B64C-9692A8E0B3D3-321-000000734747586C-FFA</guid>
            <pubDate>Thu, 21 Jun 2012 09:56:39 -0400</pubDate>
        </item>

        <item>
            <title>End Duchenne eNews - June 2012</title>
            <description>It's time to connect! Catch up on the latest research and community updates, including what PPMD has been up to lately, in this month's End Duchenne eNews. Also meet our Featured Voice, Elizabeth Heller. Elizabeth is the rarest of the rare - a woman with Duchenne. She's telling her story and using her voice so that people know that while Duchenne tends to predominantly affect men, women can be affected as well.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=16721.0</link>
            <guid isPermaLink="false">980A48D0-F4F8-486A-9C0C-32721315E87D-1126-000004EE8FEA4B89-FFA</guid>
            <pubDate>Fri, 15 Jun 2012 11:03:01 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Leads Critical Letter for Rare Disease Community</title>
            <description>Parent Project Muscular Dystrophy (PPMD) has teamed up with EveryLife Foundation for Rare Diseases and Genetic Alliance to galvanize the rare disease community and send a strong message to Congress to ensure the most important provisions for the rare disease community were included in the final Prescription Drug User Fee Act (PDUFA) legislation. The provisions are aimed at accelerating Food and Drug Administration (FDA) review of therapies to treat rare diseases and to enable FDA to more aggressively engage external experts in reviewing candidate therapies.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-leads-critical-letter-for-rare-disease-community</link>
            <guid isPermaLink="false">08C2BB8C-705D-4E8E-972F-F58B02BE2EA5-1126-000004DE9C935227-FFA</guid>
            <pubDate>Fri, 15 Jun 2012 11:02:26 -0400</pubDate>
        </item>

        <item>
            <title>New Cardiomyopathy Study for Duchenne Recruiting in Ohio</title>
            <description>This study is taking place at two sites in Ohio: The Ohio State University (OSU) in Columbus and Cincinnati Children's Hospital Medical Center (CCHMC). Three visits to the study site will be necessary, at baseline, 6 months and 12 months. Interim blood draws at 1, 3, and 9 months can be done at any convenient lab. There is funding to help cover travel costs. Approximately 40 males with Duchenne will be enrolled in this study. Participants will be randomized to receive either the study drug, an aldosterone antagonist called eplerenone, or a placebo. Both will be taken by mouth, once a day for 12 months. Cardiac magnetic resonance imaging and blood tests will be performed to assess clinical outcome measures.</description>
            <link>https://www.duchenneconnect.org/index.php?option=com_content&amp;view=article&amp;id=414%3Anew-cardiomyopathy-study-for-dmd-recruiting-in-ohio&amp;catid=69%3Aclinical-trials-news&amp;lang=en</link>
            <guid isPermaLink="false">DB7AC024-D59F-42D9-8B1E-534FFB0BA962-413-0000020D7F2C7395-FFA</guid>
            <pubDate>Wed, 13 Jun 2012 09:50:46 -0400</pubDate>
        </item>

        <item>
            <title>Summit achieves SMT C1100 Phase 1 dosing milestone</title>
            <description>Summit today announced that it has successfully passed a milestone in the Phase 1 trial of SMT C1100 for the treatment of Duchenne Muscular Dystrophy, which triggered the final payment from a $1.5 million funding agreement with US-based DMD organizations, including Parent Project Muscular Dystrophy. SMT C1100, an oral small molecule compound, is a potential disease-modifying drug that works by increasing, or upregulating, the amount of a naturally occurring protein called utrophin. The Phase 1 dose-escalation study in healthy volunteers was initiated in May 2012 and will now progress to the stage where participants receive multiple doses. </description>
            <link>http://www.summitplc.com/uploads/12_rns_14smtc1100phase1milestonefinal.pdf</link>
            <guid isPermaLink="false">15D03025-E4A3-4A3E-A9FF-CA67DB115498-413-00000208DCED129E-FFA</guid>
            <pubDate>Wed, 13 Jun 2012 09:50:24 -0400</pubDate>
        </item>

        <item>
            <title>2012 Connect Conference: Last Day to Book Hotel!</title>
            <description>Today - Friday, June 8 - is the last day to take advantage of PPMD's hotel room block for the Annual Connect Conference in Ft. Lauderdale, FL, June 28 - July 1, 2012. Today is the day to book your room for this important event...and save some money! There will be no further extensions granted by the hotel and no guarantee that you will get a room at our hotel if you do not book TODAY. </description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_2012</link>
            <guid isPermaLink="false">CFE32E94-0A2B-44BB-9916-2140B95B5A20-292-000000392BBCD06D-FFA</guid>
            <pubDate>Fri, 08 Jun 2012 12:10:02 -0400</pubDate>
        </item>

        <item>
            <title>All Sites Now Recruiting for GSK Exon 51 Skipping Trial</title>
            <description>The purpose of this study is to determine if GSK2402968 is effective in the treatment of ambulant boys with Duchenne resulting from a mutation thought to be corrected by exon 51 skipping. Two doses of GSK2402968 and placebo will be used in this study. This study is sponsored by GlaxoSmithKline (GSK). </description>
            <link>https://www.duchenneconnect.org/index.php?option=com_content&amp;view=article&amp;id=402%3Aclinical-trial-announcement-from-gsk-for-exon-51-skipping&amp;catid=69%3Aclinical-trials-news&amp;lang=en</link>
            <guid isPermaLink="false">A674D258-ADA2-4D73-9101-DDCAA58FE0E4-6130-000057404D310EF8-FFA</guid>
            <pubDate>Thu, 07 Jun 2012 15:34:53 -0400</pubDate>
        </item>

        <item>
            <title>Webinar: New approaches to treating inflammation</title>
            <description>Parent Project Muscular Dystrophy welcomes Dr. Michael Jirousek from Catabasis as our guest for a webinar on June 6, 2012 at 1pm eastern. This presentation will describe the science and rationale behind CAT-1004, a novel, anti-inflammatory agent being developed by Catabasis as a potential treatment for patients with Duchenne. Please note: Unfortunately we will not be able to record this webinar, so make sure to join us LIVE.</description>
            <link>http://community.parentprojectmd.org/events/webinar-new-approaches-to-treating-inflammation-in-duchenne</link>
            <guid isPermaLink="false">7DABEFF6-E663-4132-9AD0-26250EA20E7D-299-000001B444623C26-FFA</guid>
            <pubDate>Mon, 04 Jun 2012 11:38:55 -0400</pubDate>
        </item>

        <item>
            <title>Upcoming Webinar: New approaches to treating inflammation</title>
            <description>Parent Project Muscular Dystrophy welcomes Dr. Michael Jirousek from Catabasis as our guest for a webinar on June 6, 2012 at 1pm eastern. This presentation will describe the science and rationale behind CAT-1004, a novel, anti-inflammatory agent being developed by Catabasis as a potential treatment for patients with Duchenne. Please note: Unfortunately we will not be able to record this webinar, so make sure to join us LIVE.</description>
            <link>http://community.parentprojectmd.org/events/webinar-new-approaches-to-treating-inflammation-in-duchenne</link>
            <guid isPermaLink="false">F1FCA1CF-74B9-4E34-986B-7BD5B01BCF72-870-000007C41B8A1C22-FFA</guid>
            <pubDate>Thu, 31 May 2012 11:40:10 -0400</pubDate>
        </item>

        <item>
            <title>Summit initiates Phase 1 trial of SMT C1100</title>
            <description>Summit has officially initiated the Phase 1 trial of SMT C1100, a small molecule that increases the production of a protein called utrophin that studies suggest can compensate for the loss of dystrophin when present in greater than normal amounts. PPMD is proud to support this trial.</description>
            <link>http://www.marketwire.com/press-release/summit-corporation-plc-summit-announces-initiation-phase-1-trial-treatment-duchenne-aim-summ-1661655.htm</link>
            <guid isPermaLink="false">E302B9CC-E25B-43D5-B07D-DAAF19934A08-870-000007BFCEF5F988-FFA</guid>
            <pubDate>Thu, 31 May 2012 11:39:47 -0400</pubDate>
        </item>

        <item>
            <title>PPMD endorses Senate version of Prescription Drug User Fee Act (PDUFA) after patient voice strengthened</title>
            <description><![CDATA[As the U.S. Senate continues debate on legislation that seeks to accelerate delivery of safe and effective therapies to patients and to increase the patient voice as part of the therapy review process, PPMD is pleased to offer our enthusiastic endorsement of the legislation.<br />
 <br />
Over the past several months, PPMD has fought to include several key provisions included in the Senate version of the Food and Drug Administration Safety and Innovation Act, commonly referred to as the Prescription Drug User Fee Act or PDUFA. A number of similar provisions are also included in a House bill expected to be voted on by that chamber next week.<br />
 <br />
The provisions included in the Senate user fee bill will help expand the patient voice when key decisions are being made, an issue of grave importance to our community and to the larger rare disease community. The provisions will also provide the FDA with additional tools to more quickly review potential therapies for life-threatening conditions, including Duchenne.<br />
 <br />
PPMD has also supported expanded external expert engagement on key issues such as benefit/risk and trial design, and has urged the FDA to accelerate the timing of various rare disease-focused activities.<br />
 <br />
As Congress works to finalize the user fee legislation, PPMD calls upon the U.S. House of Representatives to amend their version of the user fee bill to mirror the patient representative provisions contained in the Senate legislation.<br />
 <br />
The legislative provisions that strengthen the patient voice throughout the FDA review process parallel the FDA Policy position statement adopted by the PPMD Board of Directors in February, and align with the Congressional request made by the PPMD community during the 2012 Advocacy Conference in Washington, DC.<br />
]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/ppmd-endorses-senate-version-of-prescription-drug-user-fee-act</link>
            <guid isPermaLink="false">A730B0EB-2589-4762-8C03-1DF8618A454D-6012-0000154D0E44ECA6-FFA</guid>
            <pubDate>Thu, 24 May 2012 15:54:45 -0400</pubDate>
        </item>

        <item>
            <title>Connect with us!</title>
            <description>The clock is ticking and the  Annual Connect Conference in Ft. Lauderdale, FL, June 28 - July 1, 2012 will be here before you know. Register today to participate in the most comprehensive and important annual meeting in the Duchenne community, and take advantage of our Early Bird Special, now through May 21!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/register-for-the-2012-annual-connect-conference</link>
            <guid isPermaLink="false">1868C4FE-B8A9-4145-95CC-3F51E17A7483-9279-00004CB15B166A63-FFA</guid>
            <pubDate>Thu, 17 May 2012 16:38:10 -0400</pubDate>
        </item>

        <item>
            <title>Scientists Discover Clues to Muscle Stem Cell Functions</title>
            <description>A study conducted by Children’s Hospital &amp; Research Center Oakland scientists identifies how skeletal muscle stem cells respond to muscle injury and may be stimulated to improve muscle repair in Duchenne. The study, led by Julie D. Saba, MD, PhD, senior scientist at Children’s Hospital Oakland Research Institute (CHORI), shows that a lipid signaling molecule called sphingosine-1-phosphate or “S1P” can trigger an inflammatory response that stimulates the muscle stem cells to proliferate and assist in muscle repair.</description>
            <link>http://www.newswise.com/articles/children-s-hospital-research-center-oakland-scientists-discover-clues-to-muscle-stem-cell-functions-study-reveals-a-potential-key-to-new-treatment-strategies-for-muscular-dystrophy?ret=/articles/list&amp;category=medicine&amp;page=1&amp;search%5bstatus%5d=3&amp;search%5bsort%5d=date+desc&amp;search%5bsection%5d=10&amp;search%5bhas_multimedia</link>
            <guid isPermaLink="false">848887F3-2DA2-4E4F-92F4-294CCDFF1C8D-9279-00004CA9EF07A975-FFA</guid>
            <pubDate>Thu, 17 May 2012 16:37:43 -0400</pubDate>
        </item>

        <item>
            <title>Researchers develop new muscular dystrophy treatment approach using human stem cells</title>
            <description><![CDATA[Researchers from the University of Minnesota's Lillehei Heart Institute have effectively treated muscular dystrophy in mice using human stem cells derived from a new process that – for the first time – makes the production of human muscle cells from stem cells efficient and effective.<br />
<br />
The research, published today in Cell Stem Cell, outlines the strategy for the development of a rapidly dividing population of skeletal myogenic progenitor cells (muscle-forming cells) derived from induced pluripotent (iPS) cells. iPS cells have all of the potential of embryonic stem (ES) cells, but are derived by reprogramming skin cells. They can be patient-specific, which renders them unlikely to be rejected, and do not involve the destruction of embryos.<br />
<br />
This is the first time that human stem cells have been shown to be effective in the treatment of muscular dystrophy.<br />
<br />
According to U of M researchers – who were also the first to use ES cells from mice to treat muscular dystrophy – there has been a significant lag in translating studies using mouse stem cells into therapeutically relevant studies involving human stem cells. This lag has dramatically limited the development of cell therapies or clinical trials for human patients.<br />
<br />
The latest research from the U of M provides the proof-of-principle for treating muscular dystrophy with human iPS cells, setting the stage for future human clinical trials.<br />
<br />
"One of the biggest barriers to the development of cell-based therapies for neuromuscular disorders like muscular dystrophy has been obtaining sufficient muscle progenitor cells to produce a therapeutically effective response," said principal investigator Rita Perlingeiro, Ph.D., associate professor of medicine in the Medical School's Division of Cardiology. "Up until now, deriving engraftable skeletal muscle stem cells from human pluripotent stem cells hasn't been possible. Our results demonstrate that it is indeed possible and sets the stage for the development of a clinically meaningful treatment approach."<br />
<br />
Upon transplantation into mice suffering from muscular dystrophy, human skeletal myogenic progenitor cells provided both extensive and long-term muscle regeneration which resulted in improved muscle function.<br />
<br />
To achieve their results, U of M researchers genetically modified two well-characterized human iPS cell lines and an existing human ES cell line with the PAX7 gene. This allowed them to regulate levels of the Pax7 protein, which is essential for the regeneration of skeletal muscle tissue after damage. The researchers found this regulation could prompt naïve ES and iPS cells to differentiate into muscle-forming cells.<br />
<br />
Up until this point, researchers had struggled to make muscle efficiently from ES and iPS cells. PAX7 – induced at exactly the right time – helped determine the fate of human ES and iPS cells, pushing them into becoming human muscle progenitor cells.<br />
<br />
Once Dr. Perlingeiro's team was able to pinpoint the optimal timing of differentiation, the cells were well suited to the regrowth needed to treat conditions such as muscular dystrophy. In fact, Pax7-induced muscle progenitors were far more effective than human myoblasts at improving muscle function. Myoblasts, which are cell cultures derived from adult muscle biopsies, had previously been tested in clinical trials for muscular dystrophy, however the myoblasts did not persist after transplantation.<br />
<br />
"Seeing long-term maintenance of these cells without major adverse side effects is exciting," said Perlingeiro. "Our research proves that these differentiated stem cells have real staying power in the fight against muscular dystrophy."<br />
<br />
According to John Wagner, M.D., scientific director of clinical research at the University's Stem Cell Institute and renowned blood and marrow transplant expert, "This research is a phenomenal breakthrough. Dr. Perlingeiro and her collaborators have overcome one of the most significant obstacles to moving stem cell therapies into the treatment of children with devastating and life threatening muscular dystrophies."<br />
<br />
The U of M researchers say alternative methods of Pax7 induction will need to be investigated before this study can be turned into a human clinical trial. Their method of delivering the Pax7 protein involved genetic modification of cells with viruses and because viruses sometimes cause mutations, they add risk to a clinical trial. But the U of M researchers are committed to developing a safe and effective clinical protocol, and are actively testing alternate methods of delivering Pax7.<br />
<br />
Source: University of Minnesota Academic Health Center]]></description>
            <link>http://www.sciencecodex.com/u_of_m_researchers_develop_new_muscular_dystrophy_treatment_approach_using_human_stem_cells-91005</link>
            <guid isPermaLink="false">14113182-6BEE-4511-AD7B-4E74CDFEEFD2-363-000001BDB61A7F50-FFA</guid>
            <pubDate>Sat, 05 May 2012 16:33:06 -0400</pubDate>
        </item>

        <item>
            <title>PPMD holds landmark meeting with FDA leaders</title>
            <description>PPMD convened a high-impact meeting with leaders of the U.S. Food and Drug Administration (FDA) drug review center to seek ways to accelerate the review process and to ensure the patient voice is included when key decisions are being made. The session represented a landmark meeting between high-level FDA leaders, and included the leader of the agency’s Center for Drug Evaluation and Research as well as the head of its neurology products division. Read the press release to learn more about next steps!</description>
            <link>http://www.prnewswire.com/news-releases/ppmd-holds-landmark-meeting-with-fda-leaders-to-address-trial-design-endpoint-and-other-issues-150024505.html</link>
            <guid isPermaLink="false">6C35DE74-1ABF-4737-8E16-AB1BC44C913E-363-000001B919337022-FFA</guid>
            <pubDate>Sat, 05 May 2012 16:32:24 -0400</pubDate>
        </item>

        <item>
            <title>Results from DuchenneConnect study - Webinar follow up</title>
            <description>Many of you asked questions during last week's webinar that we were unfortunately unable to get to within the hour. We have done our best to answer all questions submitted. Click the link below for the list of Q&amp;A's, and let us know if you have any additional follow up questions!</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/results-from-duchenneconnect-study-webinar-follow-up?xg_source=activity</link>
            <guid isPermaLink="false">FAAA9E7B-FB6B-4FA3-B1E0-4B6E849F0644-363-000001B4D36D40A4-FFA</guid>
            <pubDate>Sat, 05 May 2012 16:32:05 -0400</pubDate>
        </item>

        <item>
            <title>Kitchen Table Conversations: Mothers &amp; Daughters</title>
            <description>In honor of Mother’s Day, the latest HerSelf First podcast features special guests Kris Hersom from Florida and Christine Piacentino from Rochester, NY discussing the complexities of the mother-daughter relationship, including what their daughters are teaching them about taking risks, living fearlessly, and staying connected to their sense of self.</description>
            <link>http://herselffirst.com/2012/05/02/kitchen-table-conversations-ep-05-mothers-daughters/</link>
            <guid isPermaLink="false">9A9046A3-F0DC-496F-8A67-766658133C07-363-000001AFCE5C8801-FFA</guid>
            <pubDate>Sat, 05 May 2012 16:31:46 -0400</pubDate>
        </item>

        <item>
            <title>Webinar: Results from DuchenneConnect Study</title>
            <description>In our latest webinar, Dr. Stanley Nelson, Professor of Human Genetics at the David Geffen School of Medicine at the University of California, Los Angeles discusses his study of the DuchenneConnect data. His research team investigated several associations, including associations between corticosteroid use, supplement use, and ambulation, and they had some very interesting results to share.</description>
            <link>http://community.parentprojectmd.org/video/duchenneconnect-results-webinar</link>
            <guid isPermaLink="false">93E4181D-135F-47B2-8ED7-C698E4A0EF55-363-000001A669F64D58-FFA</guid>
            <pubDate>Sat, 05 May 2012 16:31:25 -0400</pubDate>
        </item>

        <item>
            <title>Upcoming Webinar: Results from DuchenneConnect Study</title>
            <description><![CDATA[<p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow-x: hidden; overflow-y: hidden; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font size="3" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; "><b>Results from DuchenneConnect Study</b></font></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow-x: hidden; overflow-y: hidden; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><a href="https://www.duchenneconnect.org/index.php" style="text-decoration: none; color: rgb(238, 30, 58); ">DuchenneConnect</a><span>&nbsp;and&nbsp;</span><a href="http://www.parentprojectmd.org/" style="text-decoration: none; color: rgb(238, 30, 58); ">Parent Project Muscular Dystrophy</a><span>&nbsp;are proud to present the next in our ongoing&nbsp;</span><a href="https://www.duchenneconnect.org/index.php?option=com_content&amp;view=article&amp;id=408%3Aapril-25-2012-webinar-review-of-the-duchenneconnect-data-by-stanley-nelson-md&amp;catid=3%3Anewsflash&amp;lang=en" style="text-decoration: none; color: rgb(238, 30, 58); ">Direct Access Webinar Series</a><span>&nbsp;on&nbsp;Wednesday, April 25 at 1pm eastern.<br>&nbsp;</span></p><ul style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1.2em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; "><strong>Topic:</strong>&nbsp;Results from DuchenneConnect Study</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; "><strong>When:</strong>&nbsp;Wednesday, April 25 at 1pm eastern</li></ul><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow-x: hidden; overflow-y: hidden; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><br>Have you ever wondered if anyone is&nbsp;examining all the data entered into DuchenneConnect? Would you like to hear the results from a study focusing on the registry data? If so, you must listen to the&nbsp;<a href="https://www.duchenneconnect.org/index.php?option=com_content&amp;view=article&amp;id=408%3Aapril-25-2012-webinar-review-of-the-duchenneconnect-data-by-stanley-nelson-md&amp;catid=3%3Anewsflash&amp;lang=en" style="text-decoration: none; color: rgb(238, 30, 58); ">webinar on April 25 at 1pm eastern</a>. Dr. Stanley Nelson, Professor of Human Genetics at the David Geffen School of Medicine at the University of California, Los Angeles, will be discussing his study of the DuchenneConnect data. His research focused on analyzing the registry data from the start of the registry in 2007 through June, 2011. His research team investigated several associations, including associations between corticosteroid use, supplement use, and ambulation, and they have some very interesting results to share.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow-x: hidden; overflow-y: hidden; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow-x: hidden; overflow-y: hidden; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><span class="font-size-2" style="font-size: 10pt !important; line-height: 1.2 !important; "><strong>To Participate</strong></span></p><ul style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1.2em; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">Visit&nbsp;<a href="http://www.readytalk.com/" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">ReadyTalk.com</a>&nbsp;and use participant code 9449985.&nbsp;(Be sure to&nbsp;<a href="https://core.readytalk.com/interface/participantTest.jsp?host=readytalk" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">test your computer beforehand</a>)</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">Audio Dial-In Information:<ul style="margin-top: 0.2em; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; "><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 13px; list-style-type: square; list-style-position: initial; list-style-image: initial; ">U.S. &amp; Canada: Dial 866.740.1260 and use the Access Code 9449985</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 13px; list-style-type: square; list-style-position: initial; list-style-image: initial; ">Outside the U.S. and Canada:&nbsp;<a href="http://www.readytalk.com/account-administration/international-numbers" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">Lookup your number<br>&nbsp;</a></li></ul></li></ul><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow-x: hidden; overflow-y: hidden; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">If you are unable to attend this webinar, a link will be provided and posted on&nbsp;<a href="http://www.parentprojectmd.org/" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">our website</a>&nbsp;afterwards that will allow you to download the entire presentation.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow-x: hidden; overflow-y: hidden; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><b><br></b></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1.2em; text-overflow: ellipsis; overflow-x: hidden; overflow-y: hidden; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><b><span class="font-size-2" style="font-size: 10pt !important; line-height: 1.2 !important; ">DuchenneConnect's Direct Access Webinar Series</span></b><br>DuchenneConnect's Direct Access Webinar Series allows you direct access to key figures in the fight to end Duchenne. Whether it's a researcher offering updates on a developing therapy, or industry providing clinical trial information, this series will be your resource to find out what is going on in the community from the people making it happen. Please continue to visit<a href="http://www.duchenneconnect.org/" target="_self" style="text-decoration: none; color: rgb(238, 30, 58); ">DuchenneConnect.org</a>&nbsp;to learn about upcoming webinars.</p>]]></description>
            <link>http://community.parentprojectmd.org/events/webinar-results-from-duchenneconnect-study</link>
            <guid isPermaLink="false">77C43F4B-1FBB-4642-A015-E2D7D96A9AC4-410-0000015C68292DED-FFA</guid>
            <pubDate>Thu, 19 Apr 2012 23:45:34 -0400</pubDate>
        </item>

        <item>
            <title>Pat's Blog: The 2012 West Coast Connect Meeting</title>
            <description><![CDATA[<p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">How many times have you explained something that happened, but in the retelling, the moment lost its punch?<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><a href="http://api.ning.com/files/vo5tffOixBFRcwPIqGL8Nb7IjPVxIaDnekgqs9Si2B4d9sHBeJhzPXAU9BCnKLrUSq4xzcTXq7ZXKOWH3psPl5GO7HKjev6Z/Chartv04_white.jpg" target="_self" style="text-decoration: none; color: rgb(238, 30, 58); "><img src="http://api.ning.com/files/UaXybx*6-MkYKIf0Vwmzwd-rcx2bzQw*YGr032ZLuHS80Hld2S6b9kgzKrWr9OrMFa4OECofxJAzabGgxy1kPEJEWLU-mC7x/Chartv04.jpg?width=400" width="400" class="align-center" style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-top-style: none; border-right-style: none; border-bottom-style: none; border-left-style: none; border-color: initial; border-image: initial; text-align: center; margin-top: 4px; margin-right: 0px; margin-bottom: 4px; margin-left: 0px; clear: both !important; display: block !important; max-width: 721px; height: auto; padding-top: 5px; padding-right: 5px; padding-bottom: 5px; padding-left: 5px; "><br></a></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">I’m a fan of technology. Really. I love it that we are able to participate in meetings and conferences in real time, from anywhere in the world. It encourages, incentivizes, stimulates conversation on community and social networking sites. In fact, many of you streamed during our West Coast Connect Meeting on Saturday. But while all of that is fantastic, there is something significant about&nbsp;<em>being there</em>. Something happens when the community gathers. There is an exchange that occurs, science and medicine aside…the connecting part of the West Coast Connect Meeting.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">You had to be present during the reception when a new mom walked tentatively into the room. It was pretty clear she was new, the diagnosis raw. She had that look in her eye, tears welling in the corners, the weight on her shoulders obvious. We have all been there. Within minutes, people gathered around her, introduced themselves, asked questions, listened and then gently and tenderly brought her into the room, introducing her to researchers, clinicians, and other families. Her shoulders relaxed and after a few minutes, there was a smile.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">We have all said time and time again, that we wish we had never heard the word Duchenne. But there is a lining… bronze, silver, gold… call it what you will. The Duchenne community is a family and when members of the family gather, there is a synergy, a spirit of kind-heartedness, helpfulness, empathy, hope. There is something to be said about connecting, not only with the families, but with researchers, clinicians and industry partners. There is something transferred in the conversation, that is not captured on-line – the intense desire to change the predicted outcome, clarification on timelines, what we can do now, optimal medical care across the spectrum, trials in progress or in development…and hope.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">We will be posting presentations from our West Coast Connect Meeting in the coming week. Thank you to everyone who attended, presented, and watched us online. We hope everyone who can will join us at the&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/PageServer?pagename=Connect_conference_2012" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">Annual Connect Conference in Fort Lauderdale on June 28 – July 1</a>&nbsp;for more great presentations, critical information, and connecting.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-align: right; ">&nbsp;<a target="_self" href="http://community.parentprojectmd.org/profiles/blog/list?user=syv5r11hhapz" style="text-decoration: none; color: rgb(238, 30, 58); "><br class="Apple-interchange-newline"><img class="align-right" src="http://api.ning.com/files/BZ2ZZqiffDKEbBEr1SIzKO0Sh8ycWPNr4majDmGS6DxsPiMQkbhpgOL-WhyRCJeDR8iOQDdgwRUezybgrydMC2RC1-tK8qgj/Pat2.jpg?width=75" width="75" style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-top-style: none; border-right-style: none; border-bottom-style: none; border-left-style: none; border-color: initial; border-image: initial; text-align: right; margin-top: 4px; margin-right: 0px; margin-bottom: 4px; margin-left: 0px; float: right !important; display: inline !important; max-width: 721px; height: auto; "></a><br><span>Pat Furlong, Founding President, CEO</span><br><a rel="nofollow" target="_self" href="http://community.parentprojectmd.org/profiles/blog/list?tag=Staff" style="text-decoration: none; color: rgb(238, 30, 58); ">Read more PPMD Staff Blogs</a></p>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/the-2012-west-coast-connect-meeting</link>
            <guid isPermaLink="false">2C1BBF0C-E5FF-412E-B1D9-CCE6B5258A98-410-00000152F235F25A-FFA</guid>
            <pubDate>Thu, 19 Apr 2012 23:44:51 -0400</pubDate>
        </item>

        <item>
            <title>Watch Live: 2012 West Coast Connect Meeting</title>
            <description>Not able to join us at the 2012 West Coast Connect Meeting in San Diego, CA this weekend? Tune in from home to listen to this amazing lineup of presenters online! PPMD will be live streaming sessions on Saturday, April 14 from 8:15 am to 6:00 pm Pacific Time.</description>
            <link>http://community.parentprojectmd.org/page/live-stream</link>
            <guid isPermaLink="false">BE03AD48-E3DB-444A-AAB3-3215FE48AA5D-643-000009A8F7D33926-FFA</guid>
            <pubDate>Fri, 13 Apr 2012 15:18:15 -0400</pubDate>
        </item>

        <item>
            <title>Pat's Blog: Getting It All Done (Co-blog)</title>
            <description><![CDATA[<p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><em>Everyone is in a race against the clock these days. Nowhere is that more the case though, than in this community. Dealing with Duchenne, on top of everything else life throws at you, can leave you feeling overwhelmed, inadequate, and exhausted. In their monthly co-blog, PPMD President Pat Furlong and Colorado FACES coordinator, Ivy Scherbarth discuss the ways we cope with this ticking clock while keeping our families happy, our son’s healthy, and our sanity in check. Read this month’s co-blog and share your thoughts.</em></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><b><br></b></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><span style="font-size: 19px; "><b>The Duchenne Box</b></span></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><a rel="nofollow" href="http://community.parentprojectmd.org/profiles/blog/list?user=syv5r11hhapz" target="_self" style="text-decoration: none; color: rgb(238, 30, 58); ">by Pat</a>&nbsp;<a rel="nofollow" href="http://community.parentprojectmd.org/profiles/blog/list?user=syv5r11hhapz" target="_self" style="text-decoration: none; color: rgb(238, 30, 58); ">Fu</a><a rel="nofollow" href="http://community.parentprojectmd.org/profiles/blog/list?user=syv5r11hhapz" target="_self" style="text-decoration: none; color: rgb(238, 30, 58); ">rlong</a></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">The Duchenne Box. The invisible pieces of our lives. The place where worries live, where the map of our life is designed, modified, changed, scaled up or down, the secrets hidden from others because they are impossible to explain, impossible for others to fully comprehend – the definition of Duchenne and all the strings that come along with it.&nbsp;&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">We all have such a box. It lives somewhere in the depths of our soul, the place we go to every day, every moment, the place we live once the word Duchenne enters our house.&nbsp;&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">There are days when the Duchenne box is impossible to conceal: &nbsp;an arbitrary visit to school, the children all running and your son behind (by what feels like miles), the clinic visit where changes are discussed and your knees shake uncontrollably, the kind neighbor with 'how are you?' and the expected response 'I'm fine' when you aren't.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Life feels heavy carrying around the burden of Duchenne, trying to manage the ordinary things, regular things, the things of life that have to happen in order to get through the day: breakfast, lunch, dinner, snacks, groceries, laundry, shopping, homework, errands and all that's attached to those activities, caring for, caring about, taking time, playing, smiling, drying tears, tenderness, making peace.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">And in fulfilling all of the needs and wants of life, trying to find a safe place to tuck away that Duchenne box now and again, that place in your heart and mind, where you are able to let it rest, hide it, if only for a few seconds or minutes.&nbsp; Where you can see around or over the box and see the "sun,"&nbsp;<i>your</i>son that brightens your day – when he giggles for no reason at all, finds joy in a puddle left after a rainstorm, and loves with his whole heart.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><i><br></i></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><i><span><em>Pat Furlong is the Founder and President of Parent Project Muscular Dystrophy.&nbsp;<a rel="nofollow" target="_blank" href="http://community.parentprojectmd.org/profiles/blogs/list?user=syv5r11hhapz" style="text-decoration: none; color: rgb(238, 30, 58); ">Follow Pat at her blog.</a></em></span><br></i></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><br><span style="font-size: 19px; "><b>Getting It All Done</b></span></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><a rel="nofollow" href="http://www.livingduchenne.blogspot.com/" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">by Ivy Scherbarth</a></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">I know that it is not just me:</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">How is it that I cannot find time to take care of the basic needs of my family like grocery shopping, laundry, washing the dishes, and cleaning the house? How is it possible that I don't have time to do a five minute, once a week job like watering the plants? How is it possible to be this busy and yet still be constantly behindhand on everything I have to do?</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">In the old days, four years ago, before I knew the word Duchenne, I used to feel like I had plenty of time. I used to really believe in the virtues of taking a long view of things. I used to say, "Don't worry about this small thing that has happened to you. You could live to be 100 and you won't even remember this little disappointment." I used to expect to have grandchildren who would inherit the benefits of the hard work I do today. I was satisfied to be planting the seeds of great trees for them.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Time is not a thing I think of as being abundant anymore. I see our time as being sharply limited, horribly pinched by Duchenne. Nowadays, looking very far into the future means next month. I don't really expect to have any grandchildren. I don't want to think about living to be 100 because I don't want to think about how very many of those years will be&nbsp;<i>after</i>. You know,<i>after</i>, as in, you know.… I don't want to face a single minute of life on earth without my son being here to share in it! I am afraid to think about my kids growing up because nowadays I just don't have the old constant and unshakeable faith in that possible reality-- the reality where my son grows up and gets married and has kids of his own. A taking-the-future-for-granted life is over for me. I can't put a brave face on the deepest chambers of my heart so easily. And I can't just forget about all that angst and fear either. All I can do is kind of set it aside, in a special mental box labeled "Duchenne" and try to walk away from it for a while.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">And that takes work. It takes time and energy and effort. You just can't see it happening from the outside. Moving on from the trauma of diagnosis is the kind of work that wears me out even though it is almost impossible to articulate why. Maybe trying to explain it is part of the reason it is so exhausting. It can be very hard to talk about the burden of the invisible, the deeply personal, and the cosmological. After the catastrophe of a Duchenne diagnosis, you have to reinvent the nature of the universe and the meaning of life for your new self. It can be very difficult to explain to an outsider why you're still having such a hard time pulling yourself together after years of working on it every day.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">We are survivors of a completely invisible natural disaster. The moment of diagnosis is like the touch down of a tornado, destroying everything that sits directly in its path. Our dreams, our goals, our plans, our very selves are gone. But somehow it hasn't actually killed us, and so we have to find ways to rebuild. But rebuilding isn't quite it because we actually have to build anew. We are starting all over again from scratch. Like immigrants who have landed on a foreign shore, we have to learn a new language and customs, learn a new history, learn to advocate for ourselves, learn to accept ourselves as permanently separate or assimilate. Oh, and, I believe that I mentioned this important factor already? Our "immigration" process is completely secret because it all happens inside of our own heads. Our parents, childhood friends, neighbors, etc. have no idea that this has even happened to us unless it has also somehow happened to them. I cannot overstate the vast significance of the fact that no one can&nbsp;<i>see</i>&nbsp;what is happening inside of us. Somehow, having it be invisible makes the people around us, and even our own selves, want to dismiss it as insignificant. It's all in our heads, to be sure, but that doesn't mean it isn't really happening or somehow isn't very important.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">That's an awful lot to think about while the business of life continues on around you, not only without pause, but in a horribly speeded up kind of way. Suddenly, we have a lot more incomprehensible draws on our precious time and energy while we simultaneously take on a tremendous amount of new practical work. We still have young children when we get the diagnosis. They didn't change at all. They still need us to reassure them and love them and tuck them in at night and make their lunches and remind them to put on a coat, for crying out loud. It makes me feel that not only am I Late(!) all the time but I am on the strictest and most horrible of literal deadlines. I have so much of the world to show to my son in so very, very little time! How can I give him the very best life when we all expect that life to be so short? And if you're like me, and feel compelled to finish your work before you play, the crisis of getting the groceries in becomes a reason to panic in itself. If I can't play with my son until I do the shopping and I can't shop until I write the list and I can't write the list until I have the mental space and I can't clear out the mental space until I have a solid cosmology and philosophical/spiritual basis for human existence in the face of Duchenne…!?!!</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">I feel like I am not only panicking, but I am also constantly distracted. Do people whose faith in God/life/reality remains steady in the face of Duchenne manage to get their houseplants watered before they are fatally desiccated? Are there people whose faith in God/life/reality remains steady in the face of Duchenne?</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">And what about those days when I just naturally wake up in the morning and I've somehow managed to get enough sleep and the sun is shining and I have nothing scheduled for the day and there are fresh strawberries waiting for my breakfast? Because those days happen too, just not as often as they used to. Those are days that take another kind of mental discipline altogether. Those are the days when our "Duchenne" box has to be shoved into a deeper, dustier corner in the attic of our minds. Those are days when we have to push ourselves to remember that our kids are still kids and they need us. Those are days when we have to make play a priority or we are robbing our children of what childhood is all about. Those are the days when we throw on some dirty clothes, pack the strawberries into a basket, squeeze our growing boy into the bike trailer and ride down to the river and sit under the new-leafed willows and get sand between our toes and in our sandwiches, and appear for a few hours in public to be relaxed, unhurried, and happy. If we're really lucky, we may actually even feel relaxed, unhurried, and happy for a while. Those are the days that we can give to our children as a gift, right now, wrapped in the ephemeral beauty and luxury of having plenty of time-- time to be, time to play, time to dream and grow, time to really&nbsp;<i>live</i>.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">But then we have to come home again and make supper, and feed the cat, and wash the dishes, and bathe the kids, and throw a load of just underwear and socks into the washing machine (because we still haven't gotten the laundry done properly), and find the school lunch boxes, and look at the calendar, and write the grocery list, and be ready for the week to come, and collapse into bed at 10 or 11pm and hope against hope that we all wake up on Monday morning healthy and well rested enough to keep on keeping on the daily grind.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Looking at the calendar was in that list. What am I doing with my time besides worrying about the inchoate and ultimately unknowable? When I'm down at the river ignoring it all, just what am I taking a break from anyway? My calendar does not look like a cheerful Mother Goose rhyme, with a single task for each day (Monday wash, Tuesday iron, Wednesday mend, etc.) My calendar is full of things like doctor's appointments, PT, OT, swimming therapy, massage (for my Duchenne boy only-- never for me!), horseback riding therapy, marriage counselor, school psychologist. There's also all the "normal" stuff we do like work, school, music lessons, dance class, volunteer. And then there are those things that we just can't say no to doing just this once like look after my sister's pets for a few weeks while she's out of town, go to that informational evening about raising kids with disabilities, participate in that once-a-month friendly meet up group, spend a few minutes on a beloved hobby, attend that fundraiser for our local charity serving people with disabilities (they're serving us, after all), welcome a house guest for the weekend.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">And then on top of those things, there are a few other projects we do relating to Duchenne. Do these sound familiar? Buy gear (like a wheelchair) and have it fitted for your son. Buy a van. Convert the van for accessibility. Design and build an accessible house or remodel an existing home. Move to the new, accessible house and/or live with construction guys in your remodel for 6 - 12 months. (Or, gasp, do the remodel, piecemeal, yourself!) Travel a couple of hours each way to the Neuromuscular Clinic 2 - 4 times a year. Participate in a clinical trial. Go to the PPMD Annual Conference. Organize and/or participate in at least one Run for Our Sons/Coach to Cure/MDA walkathon/Fill the Boot Campaign. Go to the PPMD Advocacy Conference. Lobby Congress. Participate in other fundraising events like wine tastings, golf tournaments, silent auctions. Go to FACES events. Nurse at least one child through major surgery and recovery, often more than one child and more than one surgery. Set up and/or update an IEP. Agitate for at least one public place you have to go to a lot to add accessibility features. Go on a Make-a-Wish trip. Make your own Make-a-Wish trip and go on that one too…</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">I'm not even going to write about our daily caregiving duties. Let's just discount for a minute all the time we spend with helping our sons get up, get dressed, get toileted, get clean, get stretched, get medicated, get fed. Let's not factor in how much time we spend organizing outside-of-the-family caregivers. Let's not even go into how long it takes to deal with irresponsible caregivers or gear that breaks down. And let's also put aside how much time we spend on researching DBMD issues or trying to find support on Facebook. And for pity's sake let's not talk about how much time we spend driving around town or who is looking after grandma.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">So, how is it possible to be this busy and yet still be constantly behindhand on everything I have to do? Oh, wait. Maybe all that stuff we do because of Duchenne really is an unmanageable amount and I'm not just "mooning about" trying to figure out the meaning of life all the time. Maybe I'm in a panic because there really is too much going on.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Maybe this is the also partly the result of nothing feeling optional anymore. We used to talk about the differences between needs and wants; we could prioritize our lives to meet our needs and occasionally accommodate some of our wants. But with our Duchenne colored glasses on, we see all of the things we do as being necessary and essential, don't we? We are now in the untenable position of having to prioritize and make choices between needs and needs. Of course when everything is a need and our time and energies are limited, needs will slip through the cracks and go unmet. We are living our whole lives in crisis mode.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Different disability communities react to their situations in different ways. It is interesting to me to see that the DBMD trend is to grab life by the horns, hold on tight, and ride this monster to as many fun, exciting, life-affirming, and service oriented places we can make it go. This is a choice we are making as a community, this lifestyle of working and playing as hard as we can. I admire this choice in general but we could make other choices, and of course, some of us do. Maybe it is a matter of tweaking the schedule so that we can satisfy our need to make sense of it all, breathe, and then go get those groceries, not in a panic, but in a calm and efficient manner. Maybe, from time to time, we can make a quiet moment in which to contemplate. Or maybe sometimes it just all comes together in a great big mishmash, and we have one of those "aha" moments that give deeper meaning and a sense of belonging to our lives even in the midst of everything else that is going on. Maybe there's a reason why some grocery stores are open 24 hours a day and cactus makes such an attractive houseplant.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><em>Ivy Scherbarth is a Colorado/Wyoming FACES Coordinator for PPMD.&nbsp;<a rel="nofollow" target="_blank" href="http://www.livingduchenne.blogspot.com/" style="text-decoration: none; color: rgb(238, 30, 58); ">Follow Ivy at her blog, My Son, My Rain: A personal, biased account</a>&nbsp;<a rel="nofollow" target="_blank" href="http://www.livingduchenne.blogspot.com/" style="text-decoration: none; color: rgb(238, 30, 58); ">of one family living with Duchenne Muscular Dystrophy.</a></em></p>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/getting-it-all-done-two-moms-co-blogging?xg_source=rss</link>
            <guid isPermaLink="false">2E66E330-F9A5-40C7-8390-8E0AB62F2CA1-2055-00000B0C1B831B4A-FFA</guid>
            <pubDate>Wed, 11 Apr 2012 12:35:58 -0400</pubDate>
        </item>

        <item>
            <title>For Caregivers: The Power of Female Friendship</title>
            <description>In the latest HerSelf First podcast, PPMD Northern California FACES coordinators, Rebecca Saulsbury and Christina Adamson discuss the importance of cultivating lasting, strong female friendships, and how having a child with a chronic illness alters the terrain of female social relationships.</description>
            <link>http://herselffirst.com/2012/04/10/kitchen-table-conversations-ep-04-get-your-gayle-the-power-of-female-friendship/</link>
            <guid isPermaLink="false">DB728005-6707-424E-BABE-B8B2E67EFB19-2055-00000B073DCA27D8-FFA</guid>
            <pubDate>Wed, 11 Apr 2012 12:35:18 -0400</pubDate>
        </item>

        <item>
            <title>April end Duchenne eNews</title>
            <description>We are a community of voices. Voices that share stories. Voices that want to scream, and sometimes may. Voices that want to soothe, but sometimes can’t. And as overwhelming as all of this can be, we think you’ll see from this month’s newsletter…We are all making it happen.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=16241.0</link>
            <guid isPermaLink="false">CC8B1326-0D2B-4D54-A426-038690329AB5-2055-00000B03A3F5C1E8-FFA</guid>
            <pubDate>Wed, 11 Apr 2012 12:34:57 -0400</pubDate>
        </item>

        <item>
            <title>PPMD Blog: AVI Summary Announcement</title>
            <description><![CDATA[This morning, AVI BioPharma released information discussing their findings thus far in their Phase IIb study of Eteplirsen.<br />
<br />
About Eteplirsen<br />
Eteplirsen uses AVI’s phosphorodiamidate morpholino oligomer (PMO)-based chemistry to skip exon 51 of the dystrophin gene. By skipping exon 51, eteplirsen may restore the gene’s ability to make a shorter, functional form of dystrophin.<br />
<br />
The Study<br />
The Eteplirsen Phase IIb Study is being conducted at Nationwide Children's Hospital in Columbus, Ohio. Twelve boys between 7 and 13 years of age eligible for treatment with an exon-51 skipping drug received either IV infusions of placebo (n=4), 30 mg/kg of eteplirsen (n=4), or 50 mg/kg ofeteplirsen once weekly for 24 weeks (n=4). Muscle biopsies for evaluation of dystrophin were obtained at baseline for all subjects, after 12 weeks for patients in the 50 mg/kg cohort and after 24 weeks for patients in the 30 mg/kg cohort. Following the placebo trial, all patients were placed into the open label study.<br />
<br />
In the open label study, two placebo patients were randomized to the 30 mg/kg cohort (now n=6) and two placebo patients were randomized to the 50 mg/kg cohort. The open label trial extension trial is ongoing. An extension has just been added to the study, which includes muscle biopsies at 24 weeks and 40 weeks in both the 30 mg and 50 mg cohorts.<br />
<br />
Results<br />
Results have demonstrated the following:<br />
 <br />
The group receiving Eteplirsen 30 mg/kg/week over 24 weeks resulted in a 22.5% increase in dystrophin on muscle biopsy, exceeding the company’s expectations. There was no increase in dystrophin in the placebo group.<br />
The group receiving Eteplirsen 50mg/kg/week did not show an increase in dystrophin at 12 weeks, despite the higher dose.<br />
The dystrophin produced appears to be new, novel dystrophin producing muscle fibers of normal length and consistency. The dystrophin appears to be diffusely distributed throughout the muscle biopsy.<br />
There was no change in the clinical outcomes (6 minute walk test, Gower’s maneuver, 10 meter run) in the treatment group at 12 or 24 weeks.<br />
Doses were well tolerated and there were no serious side effects to the drug at either doses.<br />
<br />
Implications<br />
These findings show that:<br />
 <br />
Shorter duration of treatment with eteplirsen (12 week) did not increase novel dystrophin production<br />
Longer duration of dosing (at least longer than 12 weeks) is required before meaningful levels of dystrophin are produced<br />
Although the amount of dystrophin was increased, the extension study will demonstrate whether or not longer treatment improves clinical outcomes (6 minute walk test, Gower’s maneuver, 10 meter run)<br />
The extension study and additional biopsies will also demonstrate whether the amount of dystrophin in the muscle reaches a steady state (for example, does not go beyond 22.5% increase) or if it continues to accumulate and increase<br />
<br />
Summary<br />
AVI is to be commended for their dedication to Duchenne research and to be congratulated on their current findings.  We are pleased to be partners in their continued research. Eteplirsen is the first DMD specific drug to demonstrate production of new, novel dystrophin consistently throughout the muscle. This extremely important finding supports the need for a pivotal trial. AVI is in the process of producing a brief for the FDA, collating the remainder of their data and presenting the need for next steps. A comprehensive summary of their findings will also be presented at the annual American Association of Neurology meeting in New Orleans, April 25, 2010, during the Emerging Science.]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/avi-summary-announcement</link>
            <guid isPermaLink="false">D40AEED2-AC77-46AC-A9F3-9972171F7AEB-4180-0000193C1DD951DE-FFA</guid>
            <pubDate>Mon, 02 Apr 2012 17:08:16 -0400</pubDate>
        </item>

        <item>
            <title>AVI BioPharma Announces Eteplirsen Meets Primary Endpoint, Demonstrating a Significant Increase in Dystrophin at 24 Weeks Compared to Placebo in Phase IIb Trial for the Treatment of Duchenne Muscular Dystrophy</title>
            <description><![CDATA[BOTHELL, WA, Apr 02, 2012 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy (DMD). Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant (p ≤ 0.002) increase in novel dystrophin (22.5% dystrophin-positive fibers as a percentage of normal) compared to no increase in the placebo group.<br />
"This study represents a major advance in the field of DMD research as the results indicate that eteplirsen is producing consistent levels of dystrophin, which is the essential protein that these patients need," said Jerry Mendell, M.D., Director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital and principal investigator of the Phase IIb study. Dr. Mendell added, "We anticipate that these levels of dystrophin could lead to significant clinical benefit if maintained over a longer course of treatment."<br />
In the study, a shorter duration of eteplirsen treatment, 12 weeks, did not show a significant increase in novel dystrophin (0.79% dystrophin-positive fibers as a percentage of normal; p-value NS), despite administration of the drug at a higher dose (50mg/kg once weekly). This finding suggests that a longer duration of dosing is required before meaningful levels of dystrophin are produced. There were no significant improvements in clinical outcomes in the treated groups compared to placebo. Performance on the 6-minute walk test and other outcome measures were generally stable across most of the patients, including the placebo patients, suggesting that a longer period of observation will be required to demonstrate clinical effects of eteplirsen versus a placebo control.<br />
Eteplirsen was well tolerated at both dose levels through 24 weeks of treatment. There were no treatment-related adverse events, no serious adverse events, and no treatment discontinuations related to eteplirsen. Furthermore, no treatment related changes were detected on any safety laboratory parameters, including several biomarkers for renal function.<br />
"We are very encouraged by the results of this first placebo-controlled study investigating exon-skipping technology in DMD," said Chris Garabedian, President and CEO of AVI BioPharma. "Eteplirsen represents the first drug candidate for DMD to demonstrate the production of novel dystrophin in a robust and consistent manner and these study results support advancing eteplirsen into a pivotal study."<br />
Conference Call AVI BioPharma, Inc. will hold a conference call to discuss these results today at 8:00 a.m. EDT (5:00 a.m. PDT). The conference call may be accessed by dialing 800.561.2718 for domestic callers and 617.614.3525 for international callers. The passcode for the call is 99858553. Please specify to the operator that you would like to join the "AVI BioPharma Phase IIb Top-Line Data Results Call." The conference call will be webcast live under the events section of AVI's website at www.avibio.com and will be archived there following the call for 90 days. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. An audio replay will be available through April 9, 2012 by calling 888.286.8010 or 617.801.6888 and entering access code 16040637.<br />
About Study 201 (Eteplirsen Phase IIb Study) Study 4658-US-201 was conducted at Nationwide Children's Hospital in Columbus, Ohio. Twelve boys meeting the inclusion criteria being between 7 and 13 years of age with appropriate deletions of the dystrophin gene that confirm eligibility for treatment with an exon-51 skipping drug received double-blind IV infusions of placebo (n=4), 30 mg/kg of eteplirsen (n=4), or 50 mg/kg of eteplirsen once weekly for 24 weeks (n=4). Muscle biopsies for evaluation of dystrophin were obtained at baseline for all subjects and after 12 weeks for patients in the 50 mg/kg cohort and after 24 weeks for patients in the 30 mg/kg cohort. Two placebo patients were randomized to the 30 mg/kg cohort and two placebo patients were randomized to the 50 mg/kg cohort. This study design allowed AVI to investigate the relationship of dose and duration of eteplirsen treatment on the production of dystrophin over the course of the 24 week study.<br />
About Eteplirsen Eteplirsen is AVI's lead drug candidate that is systemically delivered for the treatment of a substantial subgroup of patients with DMD. Data from clinical studies of eteplirsen in DMD patients have demonstrated a broadly favorable safety and tolerability profile and restoration of dystrophin protein expression.<br />
Eteplirsen uses AVI's novel phosphorodiamidate morpholino oligomer (PMO)-based chemistry and proprietary exon-skipping technology to skip exon 51 of the dystrophin gene. By skipping exon 51, eteplirsen may restore the gene's ability to make a shorter, but still functional, form of dystrophin from mRNA. Promoting the synthesis of a truncated dystrophin protein is intended to improve, stabilize or significantly slow the disease process and prolong and improve the quality of life for patients with DMD.<br />
AVI is also developing other PMO-based exon-skipping drug candidates intended to treat additional patients with DMD.<br />
About AVI BioPharma AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging its highly differentiated RNA-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including eteplirsen, which is in clinical development for the treatment of Duchenne muscular dystrophy, and multiple drug candidates that are in clinical development for the treatment of infectious diseases. For more information, visit www.avibio.com.<br />
Forward-Looking Statements and Information In order to provide AVI's investors with an understanding of its current results and future prospects, this press release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements about the development of eteplirsen and its efficacy, potency and utility in the treatment of DMD and the potential for the creation of novel dystrophin to lead to significant clinical benefit over a longer course of treatment.<br />
These forward-looking statements involve risks and uncertainties, many of which are beyond AVI's control. Known risk factors include, among others: clinical trials may not demonstrate the safety and efficacy of eteplirsen and/or AVI's antisense-based technology platform; treatment of patients with DMD using eteplirsen over a longer duration may not lead to significant clinical benefit; and any of AVI's drug candidates, including eteplirsen, may fail in development, may not receive required regulatory approvals, or be delayed to a point where they do not become commercially viable.<br />
Any of the foregoing risks could materially and adversely affect AVI's business, results of operations and the trading price of AVI's common stock. For a detailed description of risks and uncertainties AVI faces, you are encouraged to review the official corporate documents filed with the Securities and Exchange Commission. AVI does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.<br />
AVI Investor and Media Contact:<br />
Erin Cox<br />
425.354.5140<br />
Email Contact<br />
<br />
AVI Media Contact:<br />
David Schull<br />
858.717.2310 or 212.845.4271<br />
Email Contact<br />
<br />
<br />
SOURCE: AVI BioPharma, Inc.<br />
http://www2.marketwire.com/mw/emailprcntct?id=92FD1C6728CCA146<br />
http://www2.marketwire.com/mw/emailprcntct?id=538ABDB1A62880F6<br />
<br />
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward–looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.]]></description>
            <link>http://investorrelations.avibio.com/phoenix.zhtml?c=64231&amp;p=irol-newsArticle&amp;ID=1678924&amp;highlight</link>
            <guid isPermaLink="false">9F760C0B-5E0C-4A62-9B38-71D0037E84C4-425-0000028498AED17F-FFA</guid>
            <pubDate>Mon, 02 Apr 2012 10:11:32 -0400</pubDate>
        </item>

        <item>
            <title>Ask Your Representative to Co-Sponsor FAST Act</title>
            <description><![CDATA[<p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">We are coming to you today to ask that you devote your attention and energy towards legislation that seeks to expedite the process FDA uses to review drug applications.&nbsp;<a rel="nofollow" href="http://www.prnewswire.com/news-releases/parent-project-muscular-dystrophy-endorses-fast-act-legislation-to-expedite-fda-review-of-life-saving-therapies-144942995.html" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">PPMD has officially endorsed</a>&nbsp;<strong>HR. 4132</strong>, the&nbsp;<strong>Faster Access to Specialized Treatments (FAST) Act</strong>, bipartisan legislation that was recently introduced in the House of Representatives.<br><br><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; color: rgb(229, 25, 55); ">How you can take action</span></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">The FAST Act is consistent with the FDA proposal the PPMD board adopted earlier this year. As such, we are requesting that you – our advocates – contact your members of Congress and urge them to co-sponsor the FAST Act.<br><br>We have prepared an&nbsp;<a rel="nofollow" href="https://secure2.convio.net/ppmd/site/Advocacy?pagename=homepage&amp;page=SplashPage&amp;id=152" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">email template for you to send to Representatives</a>&nbsp;and a&nbsp;<a rel="nofollow" href="https://secure2.convio.net/ppmd/site/Advocacy?pagename=homepage&amp;page=SplashPage&amp;id=152" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">phone script for additional follow-up</a>.<br><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; color: rgb(229, 25, 55); "><br>Background</span></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Introduced by Reps. Stearns (R-FL) and Towns (D-NY), FAST puts into law an "accelerated approval" pathway for drugs that are in clinical trials with FDA and that are targeted to serious and life-threatening conditions, like Duchenne, that lack existing treatment options. Among other things, the bill would enable drug sponsors to request that their drug receive Fast Track designation by the FDA, and it would provide greater flexibility in designing clinical trials involving rare disease population. Given the challenges in finding a sizeable population with Duchenne to design an effective trial, this proposal holds promise for the development of drugs to treat the disease.<br><br>Portions of the FAST Act are included in the House's draft version of the Prescription Drug User Fee Act (PDUFA). PPMD will advocate that the FAST Act remain in the final user fee package that passes the Congress.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><br>Thank you for all of your hard work and for&nbsp;<a rel="nofollow" href="https://secure2.convio.net/ppmd/site/Advocacy?pagename=homepage&amp;page=SplashPage&amp;id=152" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">joining us in this important &amp; simple action</a>.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Let’s keep up the outstanding advocacy!</p>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/take-action-ask-your-representative-to-co-sponsor-fast-act</link>
            <guid isPermaLink="false">A1CE81CD-2F05-4E9F-9BFA-3F78FE1AE08A-425-0000021633C8A787-FFA</guid>
            <pubDate>Mon, 02 Apr 2012 10:10:54 -0400</pubDate>
        </item>

        <item>
            <title>Parent Project Muscular Dystrophy Endorses FAST Act Legislation to Expedite FDA Review of Life-Saving Therapies</title>
            <description><![CDATA[<p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Leading Duchenne-Specific Nonprofit Urges Congress to Enact as Part of User Fee Bill</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><span class="xn-location" style="font-family: Helvetica, Arial, sans-serif; ">HACKENSACK, N.J.</span>,&nbsp;<span class="xn-chron" style="font-family: Helvetica, Arial, sans-serif; ">March 29, 2012</span>&nbsp;/PRNewswire-USNewswire/ --&nbsp;<a href="http://www.parentprojectmd.org/" target="_blank" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; color: rgb(153, 51, 153); text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; ">Parent Project Muscular Dystrophy (PPMD)</a>&nbsp;– the leading advocacy organization fighting to end&nbsp;<a href="http://www.parentprojectmd.org/site/PageServer?pagename=Understand_about" target="_blank" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; color: rgb(153, 51, 153); text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; ">Duchenne muscular dystrophy</a>&nbsp;– has endorsed legislation that would shorten the amount of time the Food and Drug Administration (FDA) takes to review candidate therapies for life-threatening conditions like Duchenne that lack other treatment options.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">(Logo:&nbsp;<a href="http://photos.prnewswire.com/prnh/20100119/DC39975LOGO" target="_blank" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; color: rgb(153, 51, 153); text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; ">http://photos.prnewswire.com/prnh/20100119/DC39975LOGO</a>)</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">The bill, known as the Faster Access to Specialized Treatments or FAST Act, is bipartisan legislation sponsored by Rep.&nbsp;<span class="xn-person" style="font-family: Helvetica, Arial, sans-serif; ">Cliff Stearns</span>&nbsp;of&nbsp;<span class="xn-location" style="font-family: Helvetica, Arial, sans-serif; ">Florida</span>&nbsp;and Rep.&nbsp;<span class="xn-person" style="font-family: Helvetica, Arial, sans-serif; ">Edolphus Towns</span>&nbsp;of&nbsp;<span class="xn-location" style="font-family: Helvetica, Arial, sans-serif; ">New York</span>.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">"For 20 years, FDA has had tools at its disposal to accelerate the agency's review of therapies targeted to treat life-threatening conditions that lack any other therapeutic options. Unfortunately, these tools have not yielded optimal advances despite the significant need that exists for patients and families living with Duchenne and other conditions,"&nbsp;<a href="http://www.parentprojectmd.org/site/PageServer?pagename=About_media_presidentsbio" target="_blank" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; color: rgb(153, 51, 153); text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; ">Pat Furlong, Founding President and CEO of PPMD</a>, said.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">"The FAST Act is commonsense legislation that would leverage the Fast Track and Accelerated Review options at FDA's disposal. It would allow sponsors of candidate drugs to petition FDA to designate their product as being eligible for Fast Track review. It would also allow for approval of therapies on the condition of surrogate endpoints or intermediate markers used to gauge the trajectory of a disease," Furlong added.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Surrogate endpoints are a particularly important issue to the Duchenne community given the course of the disease and the need to more quickly determine whether or not a therapy is having its intended effect.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">The legislation also seeks to more appropriately balance the benefits of a therapy with the potential risks. It would revoke accelerated approval if a sponsor fails to adequately study and monitor the therapy in patients or if further studies fail to verify clinical benefit.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">"With nearly 20 potential therapies in clinical testing, it is a very exciting time for the Duchenne community, but a time in which we must make sure the FDA is equipped with the tools and laws it needs to evaluate these therapies as quickly as possible to save our sons," Furlong said.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">"I commend Congressmen Stearns and Towns for introducing this legislation, and I urge other members to cosponsor it today so it can become law this year," she added.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">The FAST Act is consistent with the&nbsp;<a href="http://www.parentprojectmd.org/site/DocServer/PPMD__FDA_Policy_Statement_Final.pdf?docID=12503" target="_blank" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; color: rgb(153, 51, 153); text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; ">FDA policy position</a>&nbsp;the PPMD Board of Directors adopted earlier this year, that seeks to address critical issues impacting the Duchenne and rare disease communities. PPMD is evaluating other FDA-related legislative proposals and engaging with Members of Congress on issues unaddressed to date, including the importance of making sure the voices of rare disease patients are heard when critical decisions, such as those about clinical trial design and appropriate levels of benefit and risk, are being made.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><b><u>About Duchenne<br></u></b><a href="http://www.parentprojectmd.org/site/PageServer?pagename=Understand_about" target="_blank" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; color: rgb(153, 51, 153); text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; ">Duchenne</a>, the most common form of childhood muscular dystrophy, is a progressive and fatal muscle disorder affecting boys and young men that causes the loss of muscle function, wheelchair dependency and a decline in respiratory and cardiac function.&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><b><u>About Parent Project Muscular Dystrophy<br></u></b><a href="http://www.parentprojectmd.org/" target="_blank" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; color: rgb(153, 51, 153); text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; ">Parent Project Muscular Dystrophy (PPMD)</a>&nbsp;is a national not-for-profit organization founded in 1994 by parents of children with Duchenne and Becker muscular dystrophy.&nbsp; Our mission is to end Duchenne. We accelerate research, raise our voices in<span class="xn-location" style="font-family: Helvetica, Arial, sans-serif; ">Washington</span>, demand optimal care for all young men, and educate the global community. PPMD is headquartered in<span class="xn-location" style="font-family: Helvetica, Arial, sans-serif; ">Middletown, Ohio</span>&nbsp;with offices in&nbsp;<span class="xn-location" style="font-family: Helvetica, Arial, sans-serif; ">Fort Lee</span>, New Jersey.&nbsp; For more information, visit&nbsp;<a href="http://www.parentprojectmd.org/" target="_blank" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; color: rgb(153, 51, 153); text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; ">www.ParentProjectMD.org</a>.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">SOURCE Parent Project Muscular Dystrophy</p><a href="http://www.prnewswire.com/news-releases/parent-project-muscular-dystrophy-endorses-fast-act-legislation-to-expedite-fda-review-of-life-saving-therapies-144942995.html#linktopagetop" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; color: rgb(153, 51, 153); text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 12px; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Back to top</a><span style="color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 12px; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none; "></span><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; line-height: 1.333em; padding-top: 0px; padding-right: 0px; padding-bottom: 10px; padding-left: 0px; word-wrap: break-word; color: rgb(70, 70, 70); font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">RELATED LINKS<br><a title="Link to http://www.parentprojectmd.org" href="http://www.parentprojectmd.org/" target="_blank" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; color: rgb(153, 51, 153); text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; ">http://www.parentprojectmd.org</a></p>]]></description>
            <link>http://www.prnewswire.com/news-releases/parent-project-muscular-dystrophy-endorses-fast-act-legislation-to-expedite-fda-review-of-life-saving-therapies-144942995.html</link>
            <guid isPermaLink="false">A0F684CD-5849-44DE-8F15-D2559DC534C9-5007-0000149D08246A8C-FFA</guid>
            <pubDate>Thu, 29 Mar 2012 15:35:15 -0400</pubDate>
        </item>

        <item>
            <title>Pat's Blog: Bikram Yoga meets the Grand Canyon</title>
            <description><![CDATA[<p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Bikram yoga. Michelle had just been home talking about her Bikram practice. We talked about it a lot over the holidays. Michelle had been practicing for nearly 5 years. I wondered if I could survive 90 minutes in 105 degree heat. I had a range of readily available excuses; the easiest one was that there was no Bikram in Cincinnati, Ohio. And my unspoken reason was that I hesitated because I was quite sure the class would be filled with shapely 30 something’s in bikinis and there I’d be, let’s just say, a mature woman and definitely not in a bikini.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Shortly after Michelle left for London, I decided I needed to learn about Bikram. Now, it is true, that if I decide to learn about something, I don’t stop until I feel convinced that I have learned what I needed to learn. My family and friends can attest to that fact as I often drive everyone to their wits end, &nbsp;with my endless searches and questions. I started with the ‘Bikram class locator’, plugging in 45042, my zip code just for fun, assuring myself that there was no Bikram nearby. &nbsp;I am convinced, sometimes the universe sends a message and there it was…. Cincinnati Bikram Yoga. Opened mid-December and just 35 minutes south.&nbsp; &nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">The next day I had a meeting at Cincinnati Children’s Hospital. I gathered my courage and decided that I would head to Bikram just after.&nbsp; After all, I was in the neighborhood. How bad could it be? Just as the meeting was ending, I asked Kathi Kinnett about Bikram, assuring myself she would add to my long list of reasons against the idea.<br><br>And then&nbsp;<strong>THE BRIBE</strong>. Kathi offered to go with me, to help offset my worries about 30 year olds and bikinis. She agreed to partner the Bikram if I agreed to&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/TR?fr_id=2200&amp;pg=entry" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">Conquer the Canyon</a>. She agreed to call 911 if I fainted or worse. She agreed not to laugh if I was unable to do the first position.&nbsp; She agreed to secrecy, never to talk about my first Bikram. &nbsp;Without hesitation, I accepted the bribe, clearly used to bribes from raising my children.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">For me, the first Bikram was a ‘near death’ experience. I attempted some of the poses, the heat taking its toll. For some of the poses, I sat, wishing the 90 minutes away. And strangely enough, after those first 90 minutes, I was hooked. There was something there, something that was helpful, something serene, something that I needed and something peaceful about those 90 minutes, staring in a mirror, attempting to stretch and balance all at the same time. The ‘universe’ was right. Silently and privately, I signed onto the Bikram and admittedly much less sure about fulfilling my part of the agreement, hiking the Canyon.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><strong>Why would I want to Conquer the Canyon?</strong>&nbsp;I had never been to the Grand Canyon, never thought about it really; my focus –Run for our Sons.&nbsp; But… then, the Canyon is scheduled for &nbsp;April, a month I both love and hate, always looking forward to signs of spring, but on the other side bittersweet. Jenny, Michelle, and Chris have April birthday 11, 14, and 27. Patrick died on April 29. The month is full of remembering: wonderful and tender moments, heartbreaking/gut wrenching moments, and each day recalling the day before or the day after moments, memories, and time. There are thoughts unspoken, unspeakable, about precious times filled with tears of sorrow, pride, and love. And as I thought about the Canyon and about April, I mentally committed to the bribe, to be on the team to Conquer the Canyon.&nbsp;&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Chris and Patrick would never see the Grand Canyon from earth, but I decided I would take this journey and with each step, paint each color, each view of the amazing landscape, the grandeur of the Canyon on my heart, and send it to heaven via the universe with love, with remembering, &nbsp;with longing.&nbsp;&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">It is April after all…Spring, a new beginning, as well as a time for remembering, a time to celebrate, a time to participate with others – actually a perfect time for this journey.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">And as you might imagine, part of the deal is that I am&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/TR?fr_id=2200&amp;pg=entry" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">raising money for research</a>. I realize we all have precious few dollars to spare and decisions around donations are done thoughtfully, carefully, and with purpose. I’m asking for your help. I am asking you to support this journey.&nbsp;And I, in return, promise to Conquer the Canyon for every boy and every family where Duchenne, the uninvited visitor, has entered.&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><a rel="nofollow" href="http://www.parentprojectmd.org/site/TR?fr_id=2200&amp;pg=entry" style="text-decoration: none; color: rgb(238, 30, 58); ">I would be grateful, thankful, and thrilled if you would join our team</a>. I can promise that every dollar you give will be leveraged to accelerate therapies and to change the predicted outcome for all of our sons. Because it is important, because it matters to me and I know to you. Duchenne is a complex multi-system condition and it will take all of us, together.&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Give what you can and if you are able.&nbsp;Send me your thoughts, your karma, your prayers, your silent commitment.&nbsp; Let’s End Duchenne.</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><div><br></div>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/bikram-yoga-meets-the-grand-canyon</link>
            <guid isPermaLink="false">53E1BDE8-34A5-44D4-881F-194FCF3DE045-423-0000024679CD2527-FFA</guid>
            <pubDate>Thu, 29 Mar 2012 09:59:17 -0400</pubDate>
        </item>

        <item>
            <title>Prosensa’s Clinical Development Plan Update – March 2012</title>
            <description>In parallel to the on-going development of the lead compound PRO051/GSK2402968, which is being developed by GSK with an active involvement of Prosensa, there are five more compounds for Duchenne in Prosensa’s pipeline.  Below you can find an update about the current state of development of these compounds.&lt;br /&gt;
&lt;br /&gt;
Prosensa is currently conducting a clinical study to investigate the effect of PRO044 in boys with Duchenne muscular dystrophy, who have a dystrophin gene mutation amenable to an exon 44 skip. This study is a phase I/IIa study that will assess the safety, tolerability, efficacy and pharmacokinetics of PRO044. The inclusion/exclusion criteria, as well as the endpoints and investigator locations are available on www.clinicaltrials.gov (search terms ‘Duchenne and Prosensa’ or ‘PRO044’).&lt;br /&gt;
 &lt;br /&gt;
Prosensa has four additional compounds in development that target exons 45, 53, 52 and 55 (PRO045, PRO053, PRO052 and PRO055). These programs currently are in the pre-clinical development phase. It is anticipated that the company will be able to progress PRO045 and PRO053 into the clinic in the second half of 2012. Discussions are on-going with the regulatory authorities to ensure optimum development. Each trial will be posted at the website www.clinicaltrials.gov as soon as the study design is finalized and all the required approvals of authorities and ethics committees are granted.&lt;br /&gt;
 &lt;br /&gt;
It is always difficult to predict timelines for drug development. Therefore, please keep in mind that expected start and end dates are based on predictions and could be delayed if unforeseen events occur.&lt;br /&gt;
 &lt;br /&gt;
Prosensa is very committed to developing safe and effective treatments and we will do our utmost to succeed herein. Our goal is to develop compounds for as many patients as feasible who may benefit from the exon skipping platform. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/prosensa-clinical-development-plan-update-march-2012?commentId=1187424%3AComment%3A150116&amp;xg_source=msg_com_blogpost</link>
            <guid isPermaLink="false">0273F100-2EAE-4416-8338-0778EB8C1FF4-2289-00000C99382A620F-FFA</guid>
            <pubDate>Mon, 26 Mar 2012 13:09:54 -0400</pubDate>
        </item>

        <item>
            <title>Pat's Blog: Steroids - A Certain Can of Worms (A Complicated State of Affairs)</title>
            <description><![CDATA[<p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Steroids. What regimen, what dose, for what individual? When to start? When to stop? A complicated question to be sure.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Steroids are a complicated story and have clearly changed the natural history of Duchenne. We know they work for some, for most in fact, but not all. We know they increase strength and prolong ambulation, and statistics back this up. Predicting ambulation is prolonged on average for 2+ years. But this is not the end of the story. Genetic modifiers have been identified that are thought to dramatically push out this timeline. Individuals with specific genetic modifiers continue walking into their mid- to late teens, often called outliers.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">It is clear that steroids have changed the natural history and we cannot forget about the impact of night splints and aggressive stretching. We can mention supplements, though there is scant data which is largely anecdotal. And hopefully there has been a general change in attitude, less therapeutic nihilism today than 10 years back – a therapeutic dose of hope. Physicians are less likely, today, to say ‘no hope and no help’ and send us on our way.<br><br></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><span style="color: rgb(229, 25, 55); "><strong><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; ">The Right Regimen</span></strong></span><br>Twenty-eight years of steroids, multiple publications, Cochrane Report, and significant unpublished data, and we still have no definitive answers about the RIGHT regimen and I’m guessing we never will. Some years back we surveyed families, inquiring about their son’s regimen and interestingly we learned about 20 or so regimens in our very informal survey.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">They included:</p><ul style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">10 days on and 10 days off</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">Daily Prednisone 0.35mg/kg</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">Daily Prednisone 0.75mg/kg</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">Daily Deflazacort 0.9 mg/kg</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">Alternate Day 0.75mg/kg</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">High Dose Weekend 0.75mg/kg X 14, divided into 2 doses</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">Low Dose Weekend 0.75mg/kg X 7, divided into 2 doses</li></ul><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><br>And variations on the theme:</p><ul style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">10 days on and 5 days off</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">10 days on and 2 days off</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">Daily with changing dosage</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 1.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; list-style-type: square; list-style-position: initial; list-style-image: initial; ">Random – modifications done along the way based on appetite (PM rather than AM dosing), behavior (every other day during the week, 2 consecutive days of the weekend)</li></ul><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><br>There will never be the perfect regimen that is best for all of the boys. Is there such a thing as the average boy with Duchenne? With genetic diagnosis and hopefully soon, expanded knowledge about genetic modifiers, we may have a more informed ways to discuss steroids. At the end of the day, it is up to the family, the individual, and the clinical team to discuss what makes most sense. Keep in mind, medicine is personalized. And one day, we are all hopeful to have a replacement... something that improves strength with fewer side effects.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; "><strong><span style="color: rgb(229, 25, 55); ">Spectrum of Responses</span></strong></span><br>Over the last 20 years, I have met more than 1,000 boys with Duchenne, most of them on steroids. For me, they fall into specific subsets.<br>&nbsp;</p><ol style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 2.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; ">No response to steroids – this is the minority, but there are clearly non-responders.</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 2.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; ">Increase in strength accompanied by severe changes in behavior, which do not lessen over time.</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 2.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; ">Increase in strength but dramatic increase in weight (insulin resistance, glycemic diet currently recommended by some clinics)</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 2.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; ">Increase in strength accompanied by changes in behavior (easier to push their buttons)</li><li style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 2.5em; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: inherit; font-size: 1em; ">Dramatic increase in strength, nearly a Becker like phenotype.</li></ol><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><br>Of course, it is important to keep in mind, this is a spectrum, with the lines blurring on each end. But, if you speak with parents you might hear these common themes.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; color: rgb(229, 25, 55); "><strong>When to Start? What Dose?</strong></span><br>And there is the ‘when to start steroids’ dilemma. There are some physicians who suggest that starting early (say 3 or 4 years old) minimizes behavior side effects. This may be true, but the side effects after 5-10 years old are pretty obvious and for some boys and their families, really hard to deal with.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Other physicians suggest starting steroids when the boys plateau and some, with signs of decline. The argument from the other side, is that the best medicine is preventative, initiating therapy to prevent decline.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Still others suggest that the boys start steroids when the parents are ready, having fully weighed risk and benefit.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">And there is the dose issue. Some physicians initiate therapy with 0.75mg/kg (or 0.9mg/kg Deflazacort) and never adjust the dose as the individual changes in height and weight. Others initiate therapy and adjust (increase) the dose over time as height and weight changes and consider 30-35mg/steroid day as the maximum permissible dose.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><span class="font-size-3" style="font-size: 12pt !important; line-height: 1.2 !important; color: rgb(229, 25, 55); "><strong>Continued Discussion</strong></span><br>Whatever the decision, the discussion continues – each visit, each year – evaluating benefit and risk and potentially modifying the plan.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">While there are suggested regimens and regimens favored by certain clinics, sometimes the side effects dictate that a change is necessary. This is where clinical judgment comes into play. Families must discuss their concerns with their physician, weighing benefit and risk, altering regimens and timing of the dose (from AM to PM).<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Steroids will hopefully be replaced in the near future with something better, more predictable, less toxic. But for today, there is no easy or simple solution as all boys need and deserve personalized medicine.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">Steroids are complicated. And it is important to remember, you know your son best. Consult with physicians, experts, other families in the community, and then make the decision as a family.</p>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/steroids-a-certain-can-of-worms-a-complicated-state-of-affairs</link>
            <guid isPermaLink="false">32A34FC7-BC13-4CE2-83E2-D582A6D4B82E-1235-00000FBB36DEC3E4-FFA</guid>
            <pubDate>Wed, 21 Mar 2012 16:29:14 -0400</pubDate>
        </item>

        <item>
            <title>Upcoming Webinar: AVI Trial Update</title>
            <description>Parent Project Muscular Dystrophy presents an AVI webinar on Wednesday, March 21 at 1pm eastern. The webinar will cover a pre-data update on AVI BioPharma's Phase IIb study evaluating eteplirsen for the treatment of Duchenne patients with mutations amenable to exon-51 skipping, and will be lead by Chris Garabedian, the CEO of AVI BioPharma. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/important-webinar-avi-clinical-trial-update</link>
            <guid isPermaLink="false">3BE56F72-5CE7-4F63-9539-0AF2A0718F70-1906-00001A4E4E67EC6F-FFA</guid>
            <pubDate>Mon, 19 Mar 2012 17:13:40 -0400</pubDate>
        </item>

        <item>
            <title>ImagingDMD MRI Study (DuchenneConnect Webinar Series)</title>
            <description>Dr. Krista Vandenborne and Claudia Senesac, PT, PhD, PCS, both from the University of Florida, discuss the ImagingDMD Study. This study focuses on developing Magnetic Resonance Imaging (MRI) as a tool to monitor disease progression in Duchenne and to serve as an outcome measure for clinical trials.</description>
            <link>http://community.parentprojectmd.org/video/imagingdmd-mri-study-webinar</link>
            <guid isPermaLink="false">49AAFCBC-2B06-42CC-B5A5-3BA7593C02F3-1906-00001A492557212F-FFA</guid>
            <pubDate>Mon, 19 Mar 2012 17:13:18 -0400</pubDate>
        </item>

        <item>
            <title>Pat's Blog: Our View</title>
            <description><![CDATA[<p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">So many times we view the world from the dark side, the part where we worry our sons (and daughters) may never see x or y, may never have this or that opportunity. I recall Kevin Smith standing up and telling us how he promised Zach there would be no limits on what he wanted to do or see, that if he wanted to see the top of a mountain, Kevin would put him on his back and show him the view. I think any of us would do that for our child or for our friend.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">This&nbsp;<a rel="nofollow" href="http://www.youtube.com/watch?v=0hG21VZ7D4k&amp;sns=fb" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">video</a>&nbsp;expresses loads of things, but one thing in particular, is that the view is still beautiful, even if you are carried.<br>&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;</p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><a href="http://www.youtube.com/watch?v=0hG21VZ7D4k&amp;sns=fb" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); "><img src="http://api.ning.com/files/Sojfs*bo6k04OkrUwcmhzmt8deTPLfDg62Y46w7NnGt2nlE1b9Vh12nqx0TkmyGW8K7KvZxXrsuD2owpFDQWEsK5ziwDynkH/PatHiking.jpg?width=403" width="403" class="align-center" style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-top-style: none; border-right-style: none; border-bottom-style: none; border-left-style: none; border-color: initial; border-image: initial; text-align: center; margin-top: 4px; margin-right: 0px; margin-bottom: 4px; margin-left: 0px; clear: both !important; display: block !important; max-width: 721px; height: auto; "></a></p><p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.4em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; line-height: 17px; font-size: 13px; color: rgb(0, 0, 0); font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); ">&nbsp;<br>I hope you’ll join me as we&nbsp;<a rel="nofollow" href="http://www.parentprojectmd.org/site/TR?fr_id=2200&amp;pg=entry" target="_blank" style="text-decoration: none; color: rgb(238, 30, 58); ">Conquer the Canyon to End Duchenne</a>, April&nbsp;20-23, 2012.</p>]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/our-view?xg_source=RSS</link>
            <guid isPermaLink="false">DA86DF8D-F464-4171-BAAB-33D8A7735C87-840-00000363B5E53B7D-FFA</guid>
            <pubDate>Wed, 14 Mar 2012 16:56:35 -0400</pubDate>
        </item>

        <item>
            <title>Volunteers needed to Dine Out for Duchenne!</title>
            <description><![CDATA[Do you love to go out to eat? Do you want to help fundraise, but don't have the time? Then this is the event for you!! You can participate whenever you visit a new restaurant without doing extra work! It's fast and easy!! <br />
 <br />
Dine Out for Duchenne is a week-long, online event where people can purchase gift certificates donated by restaurants throughout the United States. Supporters can click on an image map of states to find the listings, by city, in any state – for their own dining, as a gift, for when they travel, etc. Each restaurant will have a listing (multiple listings if more than one location) that includes a description of the restaurant, a link to their website, and the amount of the certificate. Press releases will be sent out to national and local media, focusing on the restaurants in local areas. The week before the event will be a preview week where people can look at the available certificates and target their purchases.<br />
 <br />
Here’s how it will work:<br />
PPMD volunteers will go to their favorite, local restaurants to seek gift certificates. [Note: Volunteers will be provided with a packet of information they can use when visiting the restaurants. One of our members has done this for a local fundraiser and tells us that restaurants are very willing to help out, making the volunteers’ jobs easy.]<br />
Gift certificates will then be displayed and sold on our Dine Out for Duchenne website during the week of May 13-20, 2012.<br />
 <br />
We’re aiming for at least 15 certificates of $25 each from each of the 50 states…but of course, more is better! Our first goal, however, is to get at least two volunteers from each state committed to get gift certificates. <br />
 <br />
Will you help?<br />
Email Judy Schneider at judygsch@comcast.net today to volunteer and help us make this fundraiser the incredible success we believe it can be! Let’s Dine Out for Duchenne. Together, we will end Duchenne.<br />
 <br />
Thanks and we look forward to working with you!]]></description>
            <link>http://community.parentprojectmd.org/profiles/blogs/dine-out-for-duchenne?xg_source=RSS</link>
            <guid isPermaLink="false">8DFFE084-CD92-4D0D-AD04-907E7778C49A-1991-00000E3261324D07-FFA</guid>
            <pubDate>Wed, 14 Mar 2012 13:33:25 -0400</pubDate>
        </item>

        <item>
            <title>Rare Disease Leaders’ Forum 2012</title>
            <description>Pat's Blog:&lt;br /&gt;
&lt;br /&gt;
This is my first visit to San Francisco, the city by the bay, home of the Golden Gate Bridge and Tony Bennett’s song “I Left My Heart in San Francisco,” a song from my younger days and one that, even today, sometimes gets in my head and repeats and repeats.&lt;br /&gt;
&lt;br /&gt;
Some time back I was invited to participate in the Rare Disease Leaders’ Forum, participating in a working group to discuss how the role and business model of patient groups is evolving, the funding models, de-risking specific programs or areas of drug development, building patient registries and natural history data and its relevance to Phase IV, post marketing surveillance, and what might be a recipe for success (and failure) in rare diseases. As the working groups for these discussions evolved, I was invited to chair a workshop on entering and collaborating with patient advocates, a discussion centered around piecing together an assembly line of information to make potential rare disease opportunities more tangible and to discuss lobbying for reimbursement and how we might ensure a sustainable model for price and access throughout the product lifecycle. These are complex issues but there are solutions and key reforms that need to take place to ensure access.&lt;br /&gt;
&lt;br /&gt;
I’m looking forward to these discussions and will report back what I learn.</description>
            <link>http://community.parentprojectmd.org/profiles/blogs/rare-disease-leaders-forum-2012?xg_source=feed</link>
            <guid isPermaLink="false">448AD3FF-8B57-420C-9862-65E23E7AA765-3223-000013B5866497B0-FFA</guid>
            <pubDate>Tue, 13 Mar 2012 15:17:43 -0400</pubDate>
        </item>

        <item>
            <title>Webinar on the ImagingDMD MRI Study on March 14</title>
            <description>Dr. Vandenborne will explain what “magnetic resonance imaging” is, what it may be able to tell you about your son, and how you can help develop this tool to aid in future therapy development trials. </description>
            <link>https://www.duchenneconnect.org/index.php?option=com_content&amp;view=article&amp;id=407%3Aimagingdmd-webinar-on-march-14-2012&amp;catid=3%3Anewsflash&amp;lang=en</link>
            <guid isPermaLink="false">1EC2882C-B9FD-4591-9C0B-4927E0615B07-3282-000002CEE8F3CEDA-FFA</guid>
            <pubDate>Mon, 12 Mar 2012 10:08:47 -0400</pubDate>
        </item>

        <item>
            <title>The March End Duchenne eNews is here!</title>
            <description>In our latest newsletter, we proudly present our 2012 educational series, the Connect Conference and West Coast Connect Meeting. We also fill you in on how you can experience a once-in-a-lifetime adventure, while helping end Duchenne at the same time. Plus, meet our Featured Voice, 30-year-old, Canadian author, Ricky Tsang. </description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=16021.0</link>
            <guid isPermaLink="false">88F3D6A9-3B49-41F7-81A3-8A2CBD7CE521-3282-000002CA3C44FDA0-FFA</guid>
            <pubDate>Mon, 12 Mar 2012 10:08:32 -0400</pubDate>
        </item>

        <item>
            <title>Reminder: Register Today for 2012 West Coast Connect Meeting</title>
            <description>By now we hope you have heard that Parent Project Muscular Dystrophy will be hosting our first West Coast Connect Meeting, April 13-15, 2012 in San Diego, CA at the San Diego Marriott Mission Valley. This will be a great opportunity to get the latest research updates on a variety of different therapies in the pipeline, as well as direct access to the people moving these projects along. We are very excited about the comprehensive agenda that we have put together, and the amazing assembly of speakers. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/first-west-coast-connect?xg_source=activity</link>
            <guid isPermaLink="false">8081AD7A-8927-4049-83BD-FD898FCCE237-4264-00001948A9970776-FFA</guid>
            <pubDate>Wed, 07 Mar 2012 17:01:17 -0500</pubDate>
        </item>

        <item>
            <title>AVI BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results and Recent Corporate Developments</title>
            <description>&quot;This past year at AVI was marked by significant advancements in our lead clinical program with our drug, eteplirsen, for the treatment of Duchenne muscular dystrophy and we are now poised to deliver results from these efforts in the coming months,&quot; said Chris Garabedian, president and CEO of AVI. &quot;We believe 2012 will be a transformative year for AVI, as we learn the clinical effects of eteplirsen in what will be the first reported placebo-controlled study assessing the disease-modifying effects of exon-skipping technology.&quot; </description>
            <link>http://investorrelations.avibio.com/phoenix.zhtml?c=64231&amp;p=irol-newsArticle&amp;ID=1668283&amp;highlight</link>
            <guid isPermaLink="false">EE29B564-DE41-4F94-B5BD-87E7F6C1E426-2280-0000193AA1DEAC2B-FFA</guid>
            <pubDate>Thu, 01 Mar 2012 17:02:56 -0500</pubDate>
        </item>

        <item>
            <title>Safe and Effective Medicines for Children</title>
            <description>The IOM has published a review of the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), policies that were designed to encourage more pediatric studies of drugs used for children. </description>
            <link>http://www.nap.edu/catalog.php?record_id=13311</link>
            <guid isPermaLink="false">8A9A6A6D-47E9-4B7C-9E80-B01DC9EEBFFE-2280-00001935AC47D11B-FFA</guid>
            <pubDate>Thu, 01 Mar 2012 17:02:37 -0500</pubDate>
        </item>

        <item>
            <title>Latest issue of BIO-NMD's Patient Newsletter</title>
            <description>BIO-NMD is a research project searching for biomarkers in people with Duchenne and Becker. By measuring and monitoring these biomarkers, the effect of drugs or other therapies on disease progression can be evaluated. Check out BIO-NMD's latest Patient Newsletter, which provides a project update and a collection of news &amp; events from related organizations </description>
            <link>http://www.bio-nmd.eu/userfiles/BIONMD03.2.pdf</link>
            <guid isPermaLink="false">C706390D-483A-4DB1-A381-E89C50052672-2280-0000193212770205-FFA</guid>
            <pubDate>Thu, 01 Mar 2012 17:02:16 -0500</pubDate>
        </item>

        <item>
            <title>TAKE ACTION! 2012 Advocacy Conference Action Alert</title>
            <description>We need your help in supporting PPMD's 2012 Advocacy Agenda. Whether or not you were able to join us in Washington, DC for our 2012 Advocacy Conference, now is the time to make your voice heard. As always, we aim to preserve critical funding for Duchenne research and education programs. You are just a few &quot;clicks&quot; away from sending your Senators and Representative an email message asking for their support. </description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=15921.0</link>
            <guid isPermaLink="false">7949CA05-A5F0-4E3E-A612-A725B34FEA7A-5040-00001862C48329CA-FFA</guid>
            <pubDate>Mon, 27 Feb 2012 16:49:02 -0500</pubDate>
        </item>

        <item>
            <title>Duchenne Advocates Take to the Hill</title>
            <description>Nearly 80 parents, grandparents, and relatives of boys with the most common form of muscular dystrophy will be on Capitol Hill today and tomorrow urging Members of Congress to support critical research and patient care initiatives. Advocates from 23 states are participating in the 13th annual advocacy event sponsored by Parent Project Muscular Dystrophy (PPMD), the largest Duchenne muscular dystrophy advocacy organization in the nation. </description>
            <link>http://www.prnewswire.com/news-releases/duchenne-muscular-dystrophy-advocates-take-to-the-hill-140578493.html</link>
            <guid isPermaLink="false">F478E7BF-8985-4847-89A8-5FC5903CA5D1-5040-0000185FC2B0BC0C-FFA</guid>
            <pubDate>Mon, 27 Feb 2012 16:48:48 -0500</pubDate>
        </item>

        <item>
            <title>AVI BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results and Corporate Update Conference Call</title>
            <description>AVI BioPharma, Inc., a developer of RNA-based therapeutics, will report fourth quarter and full year 2011 financial results after the NASDAQ Global Market closes on Thursday, March 1, 2012. Subsequently, at 5:00 p.m., Eastern Time (2:00 p.m., Pacific Time), Chris Garabedian, AVI's president and CEO, will host a conference call to discuss fourth quarter and full year 2011 financial results and to provide a corporate update. </description>
            <link>http://investorrelations.avibio.com/phoenix.zhtml?c=64231&amp;p=RssLanding&amp;cat=news&amp;id=1664416</link>
            <guid isPermaLink="false">140E3FA1-2A69-4F29-A80F-C05E577E3101-4898-00001A63864E9498-FFA</guid>
            <pubDate>Thu, 23 Feb 2012 17:19:01 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Awards $500,000 to Tivorsan Pharmaceuticals</title>
            <description>PPMD is proud to be able to award Dr. Fallon and Tivorsan this grant to continue their critical work with biglycan. This community came together during the holidays and made funding biglycan a priority, so that we could fulfill our pledge of $500,000. Thank you to everyone who not only sees a future without Duchenne but are making it happen. </description>
            <link>http://www.prnewswire.com/news-releases/parent-project-muscular-dystrophy-awards-500000-to-tivorsan-pharmaceuticals-139840393.html</link>
            <guid isPermaLink="false">674EE7C2-B9B9-409E-8BF4-6A25F45BC6F9-4356-000017627FF34E8B-FFA</guid>
            <pubDate>Wed, 22 Feb 2012 16:21:23 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Announces Board Approved FDA Policy</title>
            <description>At this time, Congress is working on writing a critical FDA related bill called the Prescription Drug User Fee Act (PDUFA), and PPMD is working with other rare disease advocates on provisions to benefit our sons. Earlier this year, the PPMD Board of Directors adopted a policy position that, among other things, seeks to ensure the potential benefits of a therapy are weighted appropriately against possible risks. </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/board-approved-fda-policy?xg_source=activity</link>
            <guid isPermaLink="false">F2977A4E-69B6-47A1-9606-8609D1B8A2A4-4356-0000175FFE3B38AC-FFA</guid>
            <pubDate>Wed, 22 Feb 2012 16:21:09 -0500</pubDate>
        </item>

        <item>
            <title>Summit Outlines Clinical Trial Plans for its Duchenne Program</title>
            <description>Summit today outlines its clinical trial plans for SMT C1100, a potential first-in-class disease modifying drug for the treatment of the fatal rare disease Duchenne Muscular Dystrophy. SMT C1100 is a small molecule that works by producing a naturally occurring protein called utrophin to substitute for the missing dystrophin. This is the only approach in development that continually makes new utrophin and has the potential to treat all Duchenne patients, regardless of their specific genetic mutation. </description>
            <link>http://www.parentprojectmd.org/site/DocServer/12_RNS_01_SMT_C1100_clinical_trial_update_FINAL.pdf?docID=12483</link>
            <guid isPermaLink="false">71D50B30-864C-4905-AA6C-FABE50135FDD-860-00000C32CE334F09-FFA</guid>
            <pubDate>Tue, 14 Feb 2012 12:57:58 -0500</pubDate>
        </item>

        <item>
            <title>JumpStart Invests $250,000 in Milo Biotechnology</title>
            <description>Milo Biotechnology will receive $250,000 from JumpStart Inc., a nonprofit investing intensive business assistance and some capital into early stage Northeast Ohio-based tech companies. Milo Biotechnology's lead product is an adeno-associated virus (AAV) delivered follistatin protein. The Phase I/II trial, funded by a grant from Parent Project Muscular Dystrophy, is enrolling patients with Becker muscular dystrophy and inclusion body myositis. </description>
            <link>http://www.prnewswire.com/news-releases/jumpstart-invests-250000-in-milo-biotechnology-139280013.html</link>
            <guid isPermaLink="false">7DDC2DAF-3060-45AB-ADBB-78CB4B729D6E-860-00000C23A3B80B04-FFA</guid>
            <pubDate>Tue, 14 Feb 2012 12:57:41 -0500</pubDate>
        </item>

        <item>
            <title>Trailer - A Life Worth Living: Pushing the Limits of Duchenne</title>
            <description>Available on DVD in April 2012.</description>
            <link>http://www.youtube.com/watch?v=nrOOe_xXFa4&amp;feature=player_embedded</link>
            <guid isPermaLink="false">2792524B-F91D-409A-9CB2-A17E92E0249E-860-000008927B3064DF-FFA</guid>
            <pubDate>Tue, 14 Feb 2012 11:51:46 -0500</pubDate>
        </item>

        <item>
            <title>West Coast Families: Join PPMD in a variety of events near you</title>
            <description>We are excited to announce a 2012 calendar full of events on the West Coast! From educational Connect Meetings, to Run For Our Sons events, to FACES support groups, we look forward to seeing you and your family at any or all of these great events! </description>
            <link>http://community.parentprojectmd.org/profiles/blogs/go-west-join-ppmd-in-a-variety-of-west-coast-events?xg_source=homepage</link>
            <guid isPermaLink="false">D6C5C958-DC30-4F71-BB3D-60EC46BDF2DD-860-0000088E3C5A7057-FFA</guid>
            <pubDate>Tue, 14 Feb 2012 11:51:11 -0500</pubDate>
        </item>

        <item>
            <title>The February End Duchenne eNews is here!</title>
            <description>February is arguably one of the most important months of the year for this community. Each winter, families gather in our nation’s capital to have their voices heard by lawmakers in the hopes of increasing funding for Duchenne-specific research. </description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=15781.0</link>
            <guid isPermaLink="false">AC4B764D-F1AF-4AD3-9E68-8E5C0D671F9D-860-0000088A77FFBBB0-FFA</guid>
            <pubDate>Tue, 14 Feb 2012 11:50:57 -0500</pubDate>
        </item>

        <item>
            <title>AVI BioPharma to Present Company Overview at the 14th Annual BIO CEO &amp; Investor Conference</title>
            <description>AVI BioPharma, a developer of RNA-based therapeutics, announced today that Chris Garabedian, AVI's president and CEO, will present a company overview at 9:30 a.m. EST on Tuesday, Feb. 14, at the 14th Annual BIO CEO &amp; Investor Conference at the Waldorf Astoria in New York City. The presentation will be webcast live under the events section of AVI's website at www.avibio.com and will be archived there following the presentation for 90 days. </description>
            <link>http://investorrelations.avibio.com/phoenix.zhtml?c=64231&amp;p=RssLanding&amp;cat=news&amp;id=1655896</link>
            <guid isPermaLink="false">61894618-E443-4BF8-8F52-C6C2BB4A826C-4891-000019AB374D210E-FFA</guid>
            <pubDate>Thu, 02 Feb 2012 17:00:08 -0500</pubDate>
        </item>

        <item>
            <title>Despite Flat Budget, NIH’s TRND Program Tries to Spark Interest in Rare and Neglected Diseases</title>
            <description>With 14 approved programs in total, TRND has progressed two into clinical development. For the past two years NIH has been trying to double its funds for developing orphan drugs. But the FY 2012 budget offered more of the same, as in the same $24 million of annual funding set aside for NIH’s Therapeutics for Rare and Neglected Diseases (TRND) program since its creation in 2009. The institute had sought $50 million for TRND this year and last. </description>
            <link>http://www.genengnews.com/keywordsandtools/print/3/25896/</link>
            <guid isPermaLink="false">4D9AB491-07B2-4697-A4A8-1301F69C8CC7-4891-000019A9032477E9-FFA</guid>
            <pubDate>Thu, 02 Feb 2012 16:59:50 -0500</pubDate>
        </item>

        <item>
            <title>Important Advocacy Webinar: PDUFA Reauthorization</title>
            <description>As PPMD heads into another year advocating in Washington, we encourage all members of our community to learn more about drug development and the FDA. </description>
            <link>http://www.youtube.com/watch?v=SNcBR_h_kpk</link>
            <guid isPermaLink="false">0A65A118-EA81-45CE-AFD7-6F404346DB2A-803-000008DCD0837E8D-FFA</guid>
            <pubDate>Tue, 31 Jan 2012 11:52:06 -0500</pubDate>
        </item>

        <item>
            <title>GSK's Clinical Development Plan for Duchenne</title>
            <description>GSK has released comprehensive details their four controlled clinical studies to evaluate the effect of the investigational medicine GSK2402968 (GSK’968), formerly known as PRO051, in boys with Duchenne, who have a dystrophin gene mutation amenable to an exon 51 skip.</description>
            <link>https://www.duchenneconnect.org/index.php?option=com_content&amp;view=article&amp;id=404%3Agsks-clinical-development-plan-for-dmd-12162011&amp;catid=69%3Aclinical-trials-news&amp;lang=en</link>
            <guid isPermaLink="false">A10475D5-2532-4A99-8F5C-065FA681BC68-2168-00000AEA121B20C4-FFA</guid>
            <pubDate>Thu, 26 Jan 2012 12:44:01 -0500</pubDate>
        </item>

        <item>
            <title>Prosensa Raises €23 Million in New Equity Financing</title>
            <description>Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised €23 million in new equity financing. This new investment gives additional stability to the company and allows Prosensa to keep advancing the Duchenne programs as fast as possible.</description>
            <link>http://www.prosensa.eu/press-release/prosensa-raises-%E2%82%AC23-million-new-equity-financing-led-new-enterprise-associates</link>
            <guid isPermaLink="false">22F864A2-1204-4FDA-9013-708EC62A13EF-2168-00000AE821EC57BB-FFA</guid>
            <pubDate>Thu, 26 Jan 2012 12:43:44 -0500</pubDate>
        </item>

        <item>
            <title>PPMD Awards Stanley Froehner, PhD, $132,322 Grant</title>
            <description>PPMD recently announced that it will award University of Washington’s Dr. Stanley Froehner a grant in the sum of $132,322 to continue his work with sildenafil (Viagra) and prednisone, as PDE5 inhibitors like sildenafil are brought to human clinical trials. According to Dr. Froehner’s research, studies of sildenafil, an FDA drug that amplifies the nNOS signaling pathway, demonstrate a marked improvement in heart and diaphragm function in the mdx mouse. In preparation for expanded clinical trials in Duchenne patients, his team will determine in mdx mice if sildenafil and prednisone have additive effects, or if prednisone can interfere with the positive effects of sildenafil. Since steroids are standard care in Duchenne, investigators want to understand how drugs will act when used in combination with steroids.</description>
            <link>http://www.parentprojectmd.org/site/PageServer?pagename=Advance_funding_portfolio_more#Froehner-investigator</link>
            <guid isPermaLink="false">E1841C6E-8B23-411D-8B8D-383FF51184B5-2833-0000162AC5B32DE8-FFA</guid>
            <pubDate>Wed, 18 Jan 2012 16:01:10 -0500</pubDate>
        </item>

        <item>
            <title>NORD's letter to Congressman Stearns</title>
            <description>The National Organization for Rare Disorders (NORD) believes that there are regulatory and legislative alternatives to the recent &quot;Unlocking Lifesaving Treatments for Rare Diseases Act&quot; (ULTRA) proposal that can more quickly advance the development of new drugs for rare diseases. </description>
            <link>http://rarediseases.org/docs/policy/ultra-response-2012</link>
            <guid isPermaLink="false">5D987BF2-6AD6-4E30-A435-A87DB3B8C5D8-2781-0000175481E7B76D-FFA</guid>
            <pubDate>Mon, 16 Jan 2012 16:27:15 -0500</pubDate>
        </item>

        <item>
            <title>The January eNewsletter is here!</title>
            <description>With the New Year, we are excited to bring you a revamped newsletter that gives you the inside scoop on the latest happenings in Duchenne research, advocacy, care, and the community. We will also bring you a new monthly feature, My Voice, featuring someone special living with Duchenne.</description>
            <link>http://www.parentprojectmd.org/site/MessageViewer?em_id=15421.0</link>
            <guid isPermaLink="false">716E3EB3-F860-434C-B850-7ACB28B09FBF-2781-000017511E180317-FFA</guid>
            <pubDate>Mon, 16 Jan 2012 16:26:59 -0500</pubDate>
        </item>

        <item>
            <title>Enzyme function may discover muscular dystrophy therapies</title>
            <description>The function of the glycosylating enzyme involved in muscular dystrophy, brain development and infection by arenaviruses could reveal new therapies. Researchers at the University of Iowa have mapped the function of the enzyme LARGE and believe that the knowledge could help to screen potential muscular dystrophy therapies. The LARGE enzyme is known to add a critical sugar chain onto an important membrane protein called dystroglycan.</description>
            <link>http://www.barchester.com/Healthcare-News/Enzyme-function-may-discover-muscular-dystrophy-therapies/376/5105</link>
            <guid isPermaLink="false">D23C30DA-7357-4E66-A80F-B313AF3AC4D1-2781-0000174A6590AF70-FFA</guid>
            <pubDate>Mon, 16 Jan 2012 16:26:46 -0500</pubDate>
        </item>

    </channel>
</rss>
